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Metabolic health 
Metabolism is a term that describes all the physical and chemical processes occurring within 
a living cell or organism that are necessary for the maintenance of life. To stay metabolically 
healthy, the body needs to adapt its metabolism in response to continuously changing external 
factors such as diet, fasting, exercise and temperature (1, 2). The liver is one of the largest 
organs of the human body and has a crucial role in metabolism. By producing bile acids, the 
liver facilitates the digestion and absorption of dietary lipids. Depending on the metabolic 
state, the liver can also convert carbohydrates, lipids and proteins into substrates to be used 
by other organs. For example, in the postprandial state glucose is converted into glycogen 
or into fatty acids when glycogen stores are replenished. These fatty acids are subsequently 
esterified with glycerol to form triglycerides and stored in the liver as such, or packaged and 
secreted into the circulation as very low-density lipoproteins. In the fasted state, glycogen 
will be converted back into glucose and released into the circulation to provide energy for 
extrahepatic tissues and to maintain blood glucose levels. Upon prolonged fasting when the 
glycogen stores are depleted, the liver will convert adipose tissue-derived fatty acids into 
ketone bodies to provide an alternative energy source for the brain (3). In addition to its role 
in energy metabolism, the liver also has a major role in the detoxification of toxic substances 
and the production of plasma proteins. 
Considering the various functions of the liver, dysfunction of the liver may cause or 
predispose to disease, including non-alcoholic fatty liver disease (NAFLD). NAFLD describes 
a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis, 
liver fibrosis and cirrhosis, and is often associated with impaired metabolic health. 
Non-alcoholic fatty liver disease
The prevalence of non-alcoholic fatty liver disease (NAFLD) is closely aligned with the 
increasing prevalence of obesity and related insulin resistance and has become one of the 
most common liver diseases worldwide (4). While the estimated prevalence of NAFLD is 
around 20-30% in the western population, the prevalence rises up to 70% in patients with 
type 2 diabetes (5) and up to 90% in morbidly obese individuals (6, 7). 
The earliest stage of NAFLD is hepatic steatosis and is characterized by intracytoplasmic 
lipid accumulation in the hepatocytes. The majority of these lipids derive from fatty acids 
released by the adipose tissue or from dietary fatty acids and sugars which will be turned 
into triglycerides in the liver (8). NAFLD is in general a benign condition, but about 25% 
of the patients with NAFLD progress to non-alcoholic steatohepatitis (NASH). NASH is 
characterized by inflammation, hepatocellular ballooning and often fibrosis, and may lead 
to cirrhosis. In this advanced form of liver fibrosis, healthy liver tissue is replaced by collagen 
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and may eventually result in liver failure, portal hypertension and hepatocellular carcinoma 
(9). 
Patients with NAFLD not only exhibit liver-related complications but also have an 
increased risk of developing cardiovascular disease (10). Importantly, cardiovascular disease 
is the most common cause of death in patients with NAFLD (11). As the exact pathogenesis 
of NAFLD is unknown and since NAFLD and cardiovascular disease have shared metabolic 
risk factors, it is difficult to dissect how NAFLD contributes to cardiovascular disease (10). 
Therefore, getting a better understanding of the underlying mechanisms of NAFLD may not 
only provide targets for treatment of NAFLD but also of cardiovascular disease.
In the past two decades several models have been proposed for the progression of steatosis 
to non-alcoholic steatohepatitis (12, 13). The current ‘multiple parallel hits’ hypothesis 
considers multiple factors acting together and thereby contributing to the progression of 
NAFLD, including genetic predisposition, lipid overload and inflammatory insults. Recently, 
factors deriving from the gastrointestinal tract are increasingly being recognized to play a 
role in the progression of steatosis to non-alcoholic steatohepatitis (13, 14) (see Figure 1 for 
further details). 
Gastrointestinal tract
The major functions of gastrointestinal tract are to digest food, to extract and absorb energy 
and nutrients, and to excrete the remaining waste as feces and urine. These functions are 
achieved by the different physiological roles of the different organs along the gastrointestinal 
tract. While the digestive process starts in the mouth and stomach, the majority of the 
food components will be digested and absorbed in the small intestine. Part of the food 
components that cannot be digested in the small intestine will reach the large intestine for 
further microbial fermentation. After the extraction of water and salts, the undigested food 
material will be excreted as feces (16).
Intestinal barrier
In addition to the primary function of the intestine to digest and absorb nutrients and fluids, 
the intestine also needs to protect the underlying tissues against harmful substances and 
pathogens from the external environment. The intestinal barrier is composed of several layers 
(Figure 2). The first line of defence is a layer of mucus that covers the intestinal epithelial 
cells. The mucus layer is a hydrated gel which is formed by mucins produced by the goblet 
cells located in the epithelium. The importance of the mucus layer has been shown in mice 
lacking the main constituent of the mucus layer, Muc2 mucin. These mice spontaneously 
develop colitis (17). In the intestine, the thickness of the mucus layer gradually increases from 
~150-300μm in the small intestine to ~700μm in the large intestine, reflecting the increase 
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Figure 1. Multiple parallel hits hypothesis in NAFLD
The ‘first hit’ of NAFLD consists of the accumulation of triglycerides in the liver and is thought to be 
primarily caused by insulin resistance, which is closely related to obesity. Consequently, hyperinsulinemia 
results in increased lipolysis in the adipose tissue concomitant with increased hepatic de novo lipogenesis 
which, together with increased dietary fat and sugar intake, will lead to triglyceride accumulation in the liver. 
Hepatic steatosis in turn is considered to enhance the susceptibility of the liver to multiple concurrent hits 
which may lead to hepatic injury and the progression from simple steatosis to nonalcoholic steatohepatitis 
(NASH). Such multiple factors may include pro-inflammatory cytokines from the adipose tissue, factors 
from the gut (e.g. endotoxins), mitochondrial dysfunction and ER stress (13). Moreover, also genetic factors, 
including a polymorphism in the patatin-like phospholipase domain-containing 3 gene (PNPLA3), have 
increasingly been recognized as a risk factor for NAFLD progression (15). NASH may eventually lead to 
cardiovascular disease (CVD), which is the most common cause of death in patients with NAFLD (11).
in microbial numbers along the intestinal tract (18). Based on histological observations, the 
mucus layer can be divided into two layers, an outer loose layer and a more dense inner layer 
(19). The outer mucus layer, also known as the non-adherent layer, is constantly degraded 
by the luminal microbiota and replenished by mucus from the inner layer (20). Whereas the 
outer mucus layer provides a habitat for commensal microbiota, the inner layer is nearly 
sterile (21). The inner dense mucus layer prevents penetration of the intestinal microbiota 
due to its dense polymeric network which is reinforced by a range of antimicrobial peptides 
produced by Paneth cells (for example α-defensins, RegIIIγ and lysozymes) or by enterocytes 
(RegIIIγ) (22) (Figure 2). Indeed, mice lacking RegIIIγ have increased numbers of bacteria 
penetrating the mucus layer resulting in low-grade inflammation (23, 24).
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The second physical barrier of defence is the epithelial layer and is composed of enterocytes, 
goblet cells, Paneth cells (located only in the small intestine) and enteroendocrine cells 
(Figure 2). To allow the uptake of nutrients and fluids while preventing the uptake of harmful 
substances, the passage of these molecules across the intestinal wall needs to be carefully 
regulated. The absorption of amino acids, sugars and fatty acids occurs via transcellular 
transport and is regulated by specific transporters at the apical and basolateral membrane 
of the enterocyte (25–27). To prevent leakage, the epithelial cells are sealed by a number 
of protein complexes, including tight junctions, adherens junctions and desmosomes. 
Whereas the desmosomes and adherens junctions are mainly involved in cell-cell adhesion 
and intracellular signaling respectively, tight junctions have a central role in regulating the 
permeability of the intestinal barrier (28). Tight junctions are located at the apical site of 
the endothelium and prevent passage of pathogens, bacteria and toxins, while providing 
a dynamic barrier for ions, water and other molecules in a size- and charge-dependent 
manner (29–31). The tight junctional complex is composed of various transmembrane 
proteins, including occludins and claudins, that are connected to the actin cytoskeleton 
of adjacent cells via intracellular scaffold proteins such as zonula occludens (28, 32). The 
structure of the tight junction is constantly remodelled in response to external stimuli and 
is closely associated with health and susceptibility to disease (31, 33). Disruption of the 
tight junction affects intestinal barrier function and may lead to increased translocation of 
pro-inflammatory molecules resulting in inflammation and tissue damage. For example, 
an increased intestinal permeability is thought to contribute to the pathogenesis of several 
gastrointestinal diseases, including inflammatory bowel disease and celiac disease (34, 35). 
Interestingly, disruption of the tight junction complexes have more recently also been linked 
to obesity and related metabolic disorders (36). Compared to lean mice, obese mice were 
shown to have reduced expression of occludin and claudin-1 in association with elevated 
levels of circulating endotoxins and pro-inflammatory cytokines, and increased adipose 
tissue inflammation (37). In addition to obesity, tight junction proteins have also been 
found to be reduced in a mouse model of NAFLD (38). Similar results have been observed 
in humans as patients with NAFLD displayed lower expression of the tight junctional 
protein zonula occludens 1 than healthy individuals, suggesting that patients with NAFLD 
have increased intestinal permeability. Intriguingly, it was also found that the degree of 
intestinal permeability in human subjects positively correlated with the degree of steatosis 
(39). However, whether aberrant expression of tight junction proteins is causally involved 
in obesity and related disorders or is a consequence of the disturbed metabolism remains 
unknown. 
The third layer of intestinal defence is composed of the immune cells located in the 
connective tissue below the epithelial layer called lamina propria and is referred to as the 
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gut-associated lymphoid tissue (GALT) (Figure 2). GALT is comprised of diffusely scattered 
lymphocytes in the lamina propria and in the epithelial layer, and organized lymphoid 
structures, including Peyer’s patches and isolated lymphoid follicles (40). These organized 
lymphoid structures are covered by a particular epithelium, called follicular-associated 
epithelium, which forms the interface between the GALT and intestinal lumen. Specialized 
microfold (M) cells, located in the follicular-associated epithelium, sample the intestinal 
lumen and are able to transport antigens to the underlying immune cells (40, 41). In addition 
to M cells, epithelial cells and dendritic cells also have a key role in initiating an immune 
response. 
Such an immune response can be immunogenic to pathogenic bacteria or tolerogenic to 
commensal microbes. A subset of dendritic cells is directly connected with the intestinal 
lumen via extensions through epithelial tight junctions (Figure 2). Epithelial cells and 
immune cells, such as dendritic cells, recognize microbes in the intestinal lumen through 
pattern recognition receptors. These receptors recognize common structures on microbial 
surfaces via so-called pathogen- or microbe-associated molecular patterns (42). The Toll-like 
receptor (TLR) family is the best characterized family of pattern recognition receptors. In 
humans, ten different toll-like receptors have been identified, thereby enabling the immune 
system to detect different microbial structures. For example, TLR4 recognizes the gram-
negative cell wall component lipopolysaccharide, whereas TLR3 recognizes viral double-
stranded RNA (43). Stimulation of these pattern recognition receptors result in activation 
of immune cells, which in turn regulate the adaptive immune response and enhance the 
production and secretion of cytokines, chemokines and antimicrobial peptides such as 
Immunoglobulin A (43–45). 
Taken together, the three layers of the intestinal barrier serve as a gatekeeper for harmful 
substances and pathogens from the external environment and control host defences to 
maintain intestinal homeostasis. 
Factors influencing metabolic health
As mentioned above, the liver and the intestine have an important role in mediating 
metabolic health but are also affected by changes in metabolic health. Over the last two 
decades three factors have increasingly been linked to metabolic health, which include the 
gut microbiota, bile acids and the glycoprotein ANGPTL4. 
Gut microbiota
The gastrointestinal tract harbours a large and complex community of microorganisms, 
collectively known as the gut microbiota. This community consist of approximately 1014 
microorganisms and includes fungi, archaea, viruses and protozoa but is by far dominated 
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by the presence of ~500-1000 different species of bacteria (46, 47). The gut microbiota lives 
in close relationship with the host and have an essential role in several aspects of host 
physiology. For example, the microbiota confers protection against invading pathogens 
(48), produce essential vitamins (49), maintain tissue homeostasis and are required for the 
full development of the immune system (50). Indeed, germ-free mice have an undeveloped 
mucosal immune system displaying smaller and fewer Peyer’s patches, mesenteric lymph 
nodes, goblet cells and IgA-secreting plasma cells than conventionally-raised mice (50–52). 
Intestinal microbes also benefit from the mutualistic relationship with the host, as the 
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Figure 2. Schematic figure of the intestinal barrier
The three layers of the intestinal barrier consist of the mucus layer, the epithelial layer and the underlying 
immune cells located in the lamina propria. The mucus layer is composed of mucins produced by goblet 
cells and consists of an inner dense layer and an outer loose layer. The outer mucus layer is constantly 
degraded by the luminal microbiota and replenished by mucus from the inner layer. The inner dense mucus 
layer is devoid of intestinal microbiota due to its dense polymeric network which is reinforced by a range 
of antimicrobial peptides (AMP) and immunoglobulin A (IgA) (18). The epithelial layer consists of a single 
layer of epithelial cells which physically separates the intestinal lumen from the underlying tissues of the 
body. The tight junctions located at the apical site of the endothelium seal adjacent cells and prevent passage 
of pathogens, bacteria and toxins (28). The gut-associated lymphoid tissue in the lamina propria contains 
various immune cells, including macrophages, dendritic cells, T cells, B cells and IgA producing plasma 
cells. These immune cells are diffusely scattered in the lamina propria or are located in organized lymphoid 
structures, such as Peyer’s patches. Microfold (M) cells located in the follicular-associated epithelium 
of Peyer’s patch sample together with dendritic cells and epithelial cells luminal antigens. The resulting 
immune response can be either immunogenic to pathogenic bacteria of tolerogenic to commensal bacteria 
(40).
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host provides a relatively stable habitat that is rich in energy. Whereas some bacterial species 
(e.g. Akkermansia muciniphila) can use mucins in the mucus layer as a source of energy 
(53), other bacteria (e.g. Bifidobacterium spp) obtain their energy from the degradation 
and fermentation of indigestible complex carbohydrates, such as dietary fibers (54). The 
fermentation of these carbohydrates liberate short-chain fatty acids (SCFAs), including 
acetate, propionate and butyrate, which can in turn be utilized by other bacterial species, 
a phenomenon called cross-feeding (55, 56), or absorbed by the host. Approximately 95% 
of the produced SCFAs is rapidly absorbed in the colon resulting in limited fecal SCFA loss 
(57). In the host, butyrate is mainly used as a fuel by the colonic epithelial cells and the 
remainder of the SCFAs is largely taken up by the liver, where butyrate and acetate can be 
used as precursors for lipogenesis and propionate can be used for gluconeogenesis (56, 58, 
59). 
The gut microbiota of a healthy individual is dominated by two phyla, namely Firmicutes 
and Bacteroidetes, which are complemented with many other minor phyla, including 
Actinobacteria, Proteobacteria and Verrucomicrobia (60, 61). Although the intraindividual 
microbiota composition has been reported to be relatively stable over time (62–64), the 
microbiota composition varies greatly between individuals (61, 65). The interindividual 
differences in gut microbiota composition are caused by both genetic and environmental 
factors, such as diet, exercise, medication use and hygiene but may also be influenced by 
specific diseases (66–68). Alterations in gut microbiota composition may be unfavourable 
and may in turn also predispose an individual to disease. Indeed, dysbiosis has been 
implicated in several gastrointestinal diseases, including inflammatory bowel disease and 
colorectal cancer (69, 70), but is also thought to contribute to metabolic disorders such 
as obesity, diabetes type 2, cardiovascular disease and NAFLD (71–75). For example, it 
has been demonstrated that germ-free mice are resistant to diet-induced obesity, hepatic 
steatosis and insulin resistance (71, 72, 76) and that transplantation of intestinal microbiota 
from conventionally-raised mice to germ-free mice induced obesity, hepatic steatosis and 
insulin resistance (71). Several mechanisms have been proposed to mediate the effects of the 
gut microbiota on metabolic health, including lipopolysaccharides, short-chain fatty acids, 
bile acids and angiopoietin-like protein 4 (75). In Chapter 2 and Chapter 3 of this thesis, the 
evidence related to the role of the gut microbiota in metabolic health, including potential 
underlying mechanisms, is more extensively described. 
Bile acids
In addition to the gut microbiota, bile acids have also been suggested to impact metabolic 
health. Bile acids are amphipathic steroids and are best known for their role in lipid 
absorption. Bile acids are synthesized in the liver from cholesterol via two pathways. 
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The main pathway, also known as the classical pathway, is initiated by the rate limiting 
enzyme CYP7A1 and results in the production of cholic acid (CA) and chenodeoxycholic 
acid (CDCA), whereas the alternative pathway is initiated by CYP27A1 and predominantly 
generates CDCA (77) (Figure 3). In the classical pathway, CYP8B1 is required for the 
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Figure 3. Bile acid synthesis pathways
Bile acids are synthesized in the liver from cholesterol via two pathways: the classical and the alternative 
pathway. The classical pathway is initiated by the rate-limiting enzyme CYP7A1 which converts cholesterol 
into 7α-hydroxycholesterol leading to the formation of cholic acid (CA) and chenodeoxycholic acid 
(CDCA) (77). The synthesis of CA is regulated by CYP8B1 (78). In the alternative pathway, cholesterol 
is first converted into 27α-hydroxycholesterol by the action of CYP27A1, eventually also leading to the 
formation of CDCA (77). In mouse liver, most of the CDCA is converted to α-muricholic acid (α-MCA) 
and β-muricholic acid (β-MCA) (79, 80). After the formation, these primary bile acids are predominantly 
conjugated to either glycine, in humans, or to taurine, in rodents, by the enzymes bile acid-CoA synthetase 
(BACS) and bile acid-CoA: amino acid N-acetyltransferase (BAT) and subsequently secreted into bile (77, 
81). In the intestine, the bacteria deconjugate the bile acids to their respective unconjugated free bile acids 
by bile salt hydrolases and then form secondary bile acids through 7α/7β-dehydroxylation, oxidation and 
epimerization (82). Bile acids are reabsorbed in the ileum and returned to the liver via the portal vein where 
the secondary bile acids can also be conjugated to taurine or glycine (83, 84). Bile acids formed in mouse 
liver and intestine are indicated in italics. 
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production of CA and therefore determines the relative production of CA and CDCA (78). 
In contrast to humans, rodents also produce muricholic acid (MCA) as primary bile acid, 
though the enzyme responsible for the conversion of CDCA into MCAs remains unknown 
(79, 80). After their formation, bile acids are conjugated predominantly to glycine, in 
humans, or to taurine, in rodents, which increases the hydrophilicity and thus the solubility 
of the bile acids (Figure 3). These bile acids are subsequently transported into the gall 
bladder via the bile salt exporter protein (BSEP; ABCB11) where they will be concentrated 
into bile together with phospholipids and cholesterol (85). Upon the ingestion of a meal, bile 
is released into the duodenum to facilitate the digestion and absorption of dietary lipids by 
pancreatic lipase (86). Approximately 95% of the bile acids are actively reabsorbed by the 
apical sodium-dependent bile acid transporter (ASBT; SLC10A2) in the distal ileum and 
returned to the liver via a process referred to as the enterohepatic cycle (83) (see Figure 4 for 
further details). However, intestinal microbiota possessing active bile salt hydrolase activity 
can deconjugate the primary bile acids and thereby limit the reabsorption of bile acids from 
the small intestine (82, 87). These deconjugated primary bile acids are subsequently further 
converted into more hydrophobic secondary bile acids through 7α/7β-dehydroxylation, 
epimerization and oxidation by the intestinal microbiota, of which only a minor part 
reaches the liver through passive reabsorption (82, 84, 87) (Figure 3). Taken together, the 
microbial metabolism of bile acids increases bile acid diversity but also contributes to a more 
hydrophobic and thus toxic bile acid pool (87).
To prevent accumulation of potentially cytotoxic bile acids, bile acid transport and 
metabolism are tightly regulated within the liver and intestine. When the bile acid pool 
increases, a negative feedback mechanism is activated to suppress bile acid synthesis. In the 
liver, bile acids can directly inhibit the expression of CYP7A1 via the activation of farnesoid 
X receptor (FXR) or indirect via the induction of FGF19 (or FGF15 in rodents) through 
intestinal FXR activation (77) (see Figure 4 for further details). FXR can thus be seen as a 
bile acid sensor controlling the bile acid pool. However, it is now increasingly recognized 
that beyond the role of regulating bile acid metabolism, FXR also influences lipid, glucose 
and energy metabolism. Consequently, bile acids have emerged as signaling molecules 
regulating metabolic homeostasis (91, 92). Indeed, activation of FXR by bile acids has been 
shown to lower plasma triglyceride levels (93–95), and to suppress gluconeogenesis and lower 
plasma glucose levels (96, 97). The effects of bile acids on glucose metabolism seem to occur 
not solely via FXR but may also be mediated via the G protein-coupled bile acid receptor 
TGR5. Activation of TGR5 by bile acids has been shown to stimulate GLP-1 secretion and 
enhance glucose tolerance (98, 99). In addition to the effects on glucose homeostasis, bile 
acid-mediated TGR5 activation is also suggested to affect energy expenditure (100) and 
inflammation (101). Although it is widely accepted that bile acids are important regulators 
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Figure 4. Enterohepatic circulation of bile acids
Bile acids are synthesized in the liver and transported across the bile canalicular membrane into the gall 
bladder via ABCB11 (BSEP) where they will be concentrated into bile together with phospholipids (PL) 
and cholesterol (CH) (83, 85). Upon the ingestion of a fatty meal, the gall bladder contracts and bile acids 
are released into the duodenum to facilitate the digestion and absorption of dietary lipids. Roughly 95% of 
the bile acids are reabsorbed in the ileum via SLC10A2 (ASBT) present on the enterocyte brush border (83, 
84). Within the enterocytes, bile acids activate FXR to induce the expression of FABP6 (I-BABP) and the 
transporters SLC51A (OSTα) and SLC51B (OSTβ) that facilitate the excretion of the bile acids into the portal 
blood (88, 89). Activation of FXR also induces the expression and secretion of FGF19 (FGF15 in rodents) 
which signals via the FGF receptor 4 (FGF4R) – β-Klotho receptor on the hepatocytes to limit bile acid 
synthesis through inhibition of CYP7A1 (88, 90). Bile acids are taken up in the hepatocytes via SLC10A1 
(NTCP). Binding of bile acids to FXR results in the expression of SHP, also leading to downregulation of 
CYP7A1 expression (83, 89). 
of metabolic homeostasis, the exact relationship between bile acids and metabolism remains 
unknown. So far it is well-established that the amount and type of reabsorbed bile acids 
varies as a result of diet, drugs, disease and microbiota. Furthermore, it is known that 
different bile acid species have a different potency to activate FXR and TGR5 and that the 
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expression and activity of FXR may be modulated depending on metabolic status e.g. during 
diabetes type 2 (91). 
Angiopoietin-like protein 4
Another important mediator of metabolic health is angiopoietin-like protein 4 (ANGPTL4). 
ANGPTL4 is a 50kDa glycosylated protein belonging to the angiopoietin-like protein family 
and is best known for regulating lipid metabolism via the inhibition of LPL activity. Indeed, 
ANGPTL4 knock-out mice display reduced plasma triglyceride levels (102). As all members 
of the ANGPTL family, the ANGPTL4 protein consists of a N-terminal coiled-coil domain, 
a linker region and a C-terminal fibrinogen-like domain. Only ANGPTL8 is an exception as 
it lacks the fibrinogen-like domain (103, 104). ANGPTL4 is subjected to posttranscriptional 
modifications including the cleavage of ANGPTL4 into a N-terminal and C-terminal 
fragment exerted by proprotein convertases (105). Of these two fragments, the N-terminal 
ANPGTL4 has been shown to inhibit LPL activity by converting active LPL dimers into 
inactive LPL monomers (106). However a mechanism by which ANGPTL4 noncompetitively 
inhibits LPL has also been suggested (107). The inactivation of LPL by ANGPTL4 has been 
suggested to occur in the interstitial space and on the endothelial surface (108) but has more 
recently also been shown to also occur inside the cell just after posttranslational processing 
of LPL in the ER (109). 
Angptl4 is ubiquitously expressed with the highest expression in the adipose tissue and 
liver followed by the intestine, heart and skeletal muscle (103, 110–112). The induction of 
Angpt4 is under transcriptional control by the peroxisome proliferator-activated receptors 
(PPARs) family of nuclear receptors that includes PPARα, PPARδ and PPARγ (110, 113–115). 
As fatty acids are potent inducers of PPARs, the elevation of free fatty acids during various 
physiological conditions stimulates the expression of Angptl4, subsequently leading to the 
inhibition of LPL. For example, during fasting, the lipolysis-mediated free fatty acid release 
induces the expression Angptl4 to inhibit LPL activity specifically in the white adipose tissue 
(116). Consequently, the hydrolysis of triglycerides by the white adipose tissue is prevented 
and triglyceride-rich lipoproteins are redirected to other tissues that are in demand of energy 
(110, 116). Similarly, the induction of Angptl4 in white adipose tissue upon cold exposure 
inhibits the activity of LPL to ensure the provision of energy to brown adipose tissue for 
the generation of heat (117). Also, during exercise, elevated circulating free fatty acid levels 
induce Angptl4 specifically in the non-exercising muscle to inhibit the activity of LPL and to 
direct VLDL-rich lipoproteins to the exercising muscle (111). 
As mentioned previously, the liver has a pivotal role in lipid metabolism and also 
abundantly expresses Angptl4 (110). However the expression of LPL in the liver is very low. 
Consequently, as opposed to the local inhibitory effect of ANGPTL4 on LPL in the adipose 
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tissue, muscle and heart, it has been suggested that ANPGTL4 in the liver may have an 
endocrine function. Indeed, mice with liver-specific overexpression of Angptl4 displayed 
reduced post-heparin plasma LPL activity and increased plasma triglyceride levels (102). 
Similar to the liver, Angptl4 is also well expressed in the intestine while LPL is not. 
Although it has been suggested that intestinal Angptl4 also functions in a endocrine fashion 
by inhibiting LPL activity in peripheral tissues (71), direct evidence is lacking. Recently, 
however it has been suggested that ANGPTL4 may act locally in the intestine by inhibiting 
pancreatic lipase, a structural homolog of LPL. Consequently, mice lacking Angptl4 have 
enhanced dietary lipid absorption, resulting in higher fat mass and bodyweight (112). The 
expression of intestinal Angptl4 has been found to be under transcriptional control of 
gut microbiota as mice devoid of any microbiota have relatively higher levels of intestinal 
Angptl4 mRNA than conventionally-raised mice (118). In apparent contrast, bacterial-
derived metabolites, such as short-chain fatty acids, were shown to induce Angptl4 (119, 
120). The exact mechanism by which the gut microbiota regulate the expression of intestinal 
Angptl4 is not fully understood. 
Outline of this thesis
As discussed above, there are many factors that may influence our metabolism. Since obesity 
and related metabolic disturbances such as NAFLD have become an immense global health 
problem, it is of utmost importance to understand the causes of these metabolic disorders. 
The main aim of this thesis was therefore to increase our understanding regarding the 
role of various mediators in metabolic health with a special focus on the gut microbiota, 
bile acids and ANGPTL4. This thesis is divided in three parts. In the first part, we focus 
on the role of the gut microbiota in metabolic health. Therefore, in Chapter 2, we provide 
an overview of the knowledge regarding the role of the gut microbiota in metabolic health. 
Subsequently, in Chapter 3, we more critically evaluate the evidence related to the causal role 
of the gut microbiota in metabolic diseases. In Chapter 4, the objective was to investigate the 
influence of changes in gut microbiota composition in NAFLD. We therefore first verified a 
diet-induced mouse model to study NAFLD and subsequently performed a study in which 
we modulated the gut microbiota using dietary fibers and antibiotics. We demonstrated 
that the gut microbiota have a marked impact on the development of NAFLD, which is 
likely mediated via changes in the portal delivery of bile acids. Accordingly, in Chapter 5 we 
investigated the therapeutic effect of the administration of the bacteria, A. muciniphila and 
B. thetaiotaomicron, on NAFLD. We found that in this experimental setup neither of the two 
bacterial species influences NAFLD. 
In the second part, the focus lies on the establishment of an ex vivo system to study the 
effects of microbial metabolites on human liver. In Chapter 6, we demonstrate the suitability 
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of precision-cut liver slices (PCLS) as a model to study human liver using the PPARα agonist 
Wy14643. Subsequently, in Chapter 7, we study the effect of the novel drug, obeticholic acid, a 
semi-synthetic bile acid that is now in phase 3 clinical trial for non-alcoholic steatohepatitis, 
on whole genome gene expression using human PCLS.
In the third part, we focus on the role of ANGPTL4 in metabolic health and reveal two 
novel functions of ANGPTL4. Using Anpgtl4-/- mice we show in Chapter 8 that ANGPTL4 
influences intestinal bile acid absorption while Chapter 9 describes an important new role 
of ANGPTL4 in the regulation of glucose metabolism in diet-induced obese mice. Finally, 
an overall evaluation and interpretation of the data is provided in Chapter 10. 
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Abstract
The global prevalence of obesity and related comorbidities has increased considerably over 
the last decades. In addition to an increase in food consumption and a reduction in physical 
activity, growing evidence implicates the microorganisms in our gastrointestinal tract, 
referred to as the gut microbiota, in obesity and related metabolic disturbances. 
The composition of the gut microbiota can fluctuate markedly within an individual 
and between individuals. Changes in gut microbial composition may be unfavorable and 
predispose an individual to disease. Studies in mice that are germfree, mice that are cohoused, 
and mice that are treated with antibiotics have provided some evidence that changes in gut 
microbiota may causally contribute to metabolic disorders. Several mechanisms have been 
proposed and explored that may mediate the effects of the gut microbiota on metabolic 
disorders. 
In this review, we carefully analyse the literature on the connection between the gut 
microbiota and metabolic health with a focus on studies demonstrating a causal relation and 
clarifying potential underlying mechanisms. Despite a growing appreciation for a role of the 
gut microbiota in metabolic health, more experimental evidence is needed to substantiate 
a cause and effect relationship. If a clear causal relationship between the gut microbiota 
and metabolic health can be established, dietary interventions may be targeted towards 
improving gut microbial composition in the prevention and possibly even treatment of 
metabolic diseases.
The role of the gut microbiota in metabolic health
31
2
Introduction
The global prevalence of obesity has increased substantially over the last decades (1). As a 
consequence, there has been a rise in obesity-related comorbidities such as diabetes mellitus, 
dyslipidemia, and hypertension, each of which serve as an independent risk factor for 
cardiovascular diseases (2-4).
The increase in obesity rates is believed to be the result of increased consumption of 
calorie- dense foods in combination with reduced levels of physical activity. Interestingly, 
growing evidence implicates the microorganisms residing within the gastrointestinal tract 
in obesity and its associated metabolic disturbances (5, 6). Initial studies indicated that 
diet-induced obesity (DIO) in mice is associated with changes in gut microbial composition 
(7-9). In addition, obese humans were shown to have an altered composition of their gut 
microbiota, as compared to lean individuals (10, 11). These early findings have fed the notion 
that the gut microbiota plays a role in obesity. Besides obesity, changes in the gut microbial 
community also have been found in patients with symptomatic atherosclerosis (12), in 
individuals with type 2 diabetes (13) and in patients with non-alcoholic fatty liver disease 
(NAFLD) (14, 15), suggesting that the gut microbiota has a role these diseases as well. 
However, these cross-sectional and correlative studies did not discriminate between 
the possibilities that the observed changes in gut microbiota causally contribute to obesity 
and associated diseases or occur as a consequence of the disturbed metabolism or immune 
system. Therefore, in this review, we examine the role of the gut microbiota in mediating 
the effects of diet on metabolic health, and explore the potential underlying mechanisms. In 
the first part, we describe the normal function of the gut microbiota in humans, and in the 
second part, we discuss the effect of diet on the gut microbiota and the potential relationship 
with metabolic diseases.
Human gut microbiota
All higher organisms live in an intimate relationship with microorganisms. Microorganisms 
that live in a particular environment such as the intestine are known collectively as a 
microbiota. A microbiota is composed of bacteria, viruses, fungi, archea, and protozoa. They 
reside at every surface that is in contact with the external environment, but in particular 
at mucosal surfaces of the gastro-intestinal tract (16-18). The advent of new molecular 
techniques such as 16S rRNA sequencing and dedicated DNA Chips, has made it possible 
to identify and study the composition of the human gut microbiome (19, 20). It is estimated 
that the number of bacteria in the human intestine easily reaches 1014 and is predominantly 
composed of Bacteroidetes and Firmicutes (90%), complemented with Actinobacteria, 
Proteobacteria and Verrucomicrobia (5, 21, 22).
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The gut microbiota live in a mutualistic relationship with its host that is beneficial to 
both organisms, and it is especially important in the development of the immune system. 
The complete absence of bacteria in the GI tract leads to large defects in the development of 
gut-associated lymph tissues, low levels of secretory IgA antibodies in the intestine, and less 
and smaller mesenteric lymph nodes. Furthermore, the gut microbiota has an important 
role in protecting the host against invasion of intestinal pathogens and in maintaining tissue 
homeostasis (18, 23, 24). Without the gut microbiota, dietary fibers such as inulin, pectin, 
xylans, and mannans would leave the body unaffected. Fermentation of dietary fiber by 
bacteria yields energy, which is important for the growth and maintenance of the microbial 
community. In addition, fermentation leads to the formation of metabolic end products that 
are beneficial to the host (25, 26). The principal end products of carbohydrate fermentation 
are the short chain fatty acids  (SCFAs) acetate, propionate and butyrate, as well as gases 
such as CO2, H2 and CH4 (26, 27). SCFAs are very effectively absorbed in the colon, giving 
rise to minimal loss in the feces. The host utilizes SCFAs for a variety of different purposes. 
Whereas butyrate is an important energy source for colonic epithelial cells, acetate and 
propionate can be utilized by the liver for lipogenesis and gluconeogenesis, respectively (5, 
25, 28).
Changes in gut microbial composition and metabolic health
The composition of the gut microbiota is not constant but differs between individuals and can 
fluctuate markedly within an individual. Interindividual variation in bacterial diversity is 
caused by differences in host genomes, but also by environmental factors, such as antibiotics 
use, lifestyle, hygiene, and diet. An altered gut microbial composition, defined as dysbiosis, 
may be unfavorable and may predispose an individual to disease (18, 29, 30). 
How diet affects gut microbiota
Wong et al. (25) proposed that the gut microbiota evolved in conjunction with the 
consumption of diets containing large amounts of nondigestible fibers and complex 
carbohydrates, which presumably was the diet of our prehistoric ancestors. They reasoned 
that modern diets that are low in dietary fibers malnourish the gut microbiota and thereby 
negatively influence the health of the host. De Filippo (31) examined to what extent 
consumption of a Western diet differentially affects human gut microbial composition 
as compared with diets from our ancestors, which was characterized by large amounts of 
starch, fiber, and plant polysaccharides, and low amounts of fat and animal protein. In 
this study, the fecal microbiota of 14 healthy children living in Burkina Faso, Africa, were 
compared with the fecal microbiota of 15 healthy children from Florence, Italy. Compared to 
the feces of children from Italy, the feces of the African children contained higher amounts 
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of Bacteroidetes and lower amounts of Firmicutes. However, not all studies that assessed 
microbial composition found similar associations. Wu et al. (32) showed that Bacteroidetes 
and Actinobacteria are positively associated with fat-rich diets and negatively associated 
with fiber-rich diets, whereas the opposite applied to Firmicutes and Proteobacteria. David 
et al. (33) found that an animal-based diet has a more pronounced impact on gut microbial 
clusters than does a plant-based diet. In addition, it has been found that Firmicutes 
associated negatively and Bacteroidetes associated positively with animal-based diets. 
In contrast, no effect of diet on any phyla was observed in a 10-week controlled-feeding 
study in which obese individuals successively received a control diet, a diet rich in resistant 
starch or nonstarch polysaccharides, and a reduced carbohydrate weight-loss diet. The diets’ 
effects were only observed at lower taxonomic levels (34). One of the possible reasons that 
changes in gut microbial composition differed in the various studies is the duration of the 
diet intervention. Gut microbial composition has been shown to be stable, even up to 10 
days after switching to a new diet (32). Besides the duration of the dietary intervention, the 
composition of an individual’s gut microbiota prior to the intervention may also influence 
the effect of diet on gut microbial composition (34, 35). This notion is supported by a recent 
mouse study that showed that the gut microbial composition is not only determined by the 
current diet but also partly depends on dietary history (35). Additionally, a study in human 
subjects concluded that a change in dietary fiber can produce marked changes in the gut 
microbiota, but these depend on the initial composition of an individual’s gut microbiota 
(34). In general, it can be concluded that diet markedly affects gut microbial composition 
at the phylum level and especially at lower taxonomic levels (32, 34, 36, 37), although not 
necessarily in a manner that is consistent between individuals. 
In addition to diet, host genetic makeup, and nondietary environmental factors, such as 
antibiotic use, lifestyle and hygiene, may also affect microbial composition (18). It has been 
found that the within-twin similarity in fecal microbial composition is comparable between 
adult monozygotic twin pairs and dizygotic twin pairs, indicating that environmental 
factors play a dominant role in determining gut microbial composition (38). Some of these 
environmental exposures may exert their effects early in life, such in the route of childbirth, 
feeding method (breast or bottle feeding), and weaning. For instance, the gut microbiota 
of babies delivered via caesarian sections more closely resembles the microbiota of the 
maternal skin, whereas in babies delivered vaginally the gut microbiota is derived primarily 
from the maternal birth canal and rectum, giving rise to an abundance of  Lactobacillus, 
Prevotella and Atopobium (39). Taken together, diet markedly influences intestinal microbial 
composition, but to date there is no evidence that particular dietary components have a 
specific and consistent effect on gut microbial composition, likely because of the major 
confounding effects of genetic makeup and various environmental factors. 
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To overcome the inherent limitations of cross-sectional studies and directly investigate the 
functional impact of the gut microbiota, investigators have performed studies in germfree 
mice. Germfree mice are bred and born without exposure to any microorganisms and can be 
colonized with specific microbial communities to create gnotobiotic mice. These gnotobiotic 
mice are a powerful tool for exploring the interaction between the gut microbiota and the 
host, because host genotype, diet, microbial composition and other environmental factors 
can be strictly controlled (40). A proof-of-principle study showed that the gut microbial 
composition of germfree C57BL/6 mice colonized with adult human fresh or frozen fecal 
microbiota largely resembled the microbial composition of the donor. Switching to a western 
diet with high levels of fat and sugar resulted in a significant decrease in Bacteroidetes and 
an increase in Erysipelotrichi, a class of bacteria from the phylum Firmicutes (41). A similar 
shift in microbial community was observed in another study in which germfree mice were 
cultured with human microbiota, followed by feeding a Western diet (42). Thus, studies with 
germ free mice are instrumental in dissecting the role of the gut microbiota in mediating the 
effects of diet on metabolic health without interference by potential confounders. 
Association between gut microbiota and metabolic health
As described above, diet markedly affects gut microbial composition. Diet also influences 
obesity, as seen in wild-type mice fed a high-fat diet rich in saturated fat, which is a frequently 
used model of DIO. An interesting finding is that, concurrent with enhanced weight gain, 
DIO mice have an altered gut microbial community, as compared with mice fed a low fat 
diet, suggesting that obesity is linked to the gut microbiota (7, 43). Alterations in microbial 
composition were also found in genetically obese mice, which exhibited increased levels 
of Firmicutes and reduced levels of Bacteroidetes in the cecum in comparison with their 
lean wild-type and heterozygous littermates (8). An increase in the ratio of Firmicutes to 
Bacteroidetes was also observed in obese rats (44) and pigs (45) when compared with animals 
in the lean state. The above studies suggest that obesity influences gut microbial composition 
or vice versa. In contrast, Hildebrandt et al. (46) reported that the intestinal microbial 
composition is primarily influenced by diet and not by the obese state. Using Resistin-like 
molecule β-knockout mice, which are resistant to DIO, they showed that switching from 
a chow to a high-fat diet changed gut microbial composition independently of the obese 
state. Furthermore, ob/ob mice, which are genetically altered obese mice characterized 
by a mutation in the leptin gene, showed no difference over time in the number of fecal 
Firmicutes, despite progressive obesity (47). It could thus be argued that high fat feeding per 
se, independent of obesity, may be the primary determinant of gut microbial composition 
in DIO studies. 
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Causal link between gut microbiota and metabolic health
The major limitation of the studies mentioned above is that they merely correlated microbial 
composition to obesity. Whether a relationship between the microbiota and obesity is in fact 
causal can be ascertained by performing studies with gnotobiotic animals, animals treated 
with antibiotics, or animals that are co-housed, allowing modulation of the gut microbial 
composition. The use of such approaches makes it possible to determine whether changes 
in gut microbial composition directly impact metabolic health or vice versa. Studies with 
germfree mice have supported a causal role for the gut microbiota in obesity. Whereas 
conventionally-raised mice develop DIO, germfree mice were protected against obesity 
development (48-50). Furthermore, it has been observed that transplantation of the gut 
microbial community from conventionally-raised obese mice to germfree or antibiotic-
treated mice causes more pronounced weight gain than colonization with microbiota from 
lean, conventionally-raised donors, indicating that the composition of gut microbiota can 
affect obesity (9, 51). 
To examine whether the human gut microbiota may affect weight gain, germfree mice 
were colonized with fecal microbiota from adult humans and placed on a Western diet, 
resulting in increased adiposity when compared to mice colonized with human microbiota 
followed by a low-fat, plant polysaccharide-rich diet. Strikingly, the feces from mice 
colonized with human microbiota and fed a Western diet caused higher levels of total body 
fat when introduced into germfree recipient mice by gavage, as compared with feces from 
mice colonized with human microbiota and fed a low-fat plant polysaccharide-rich diet (41). 
As an extension to the above findings, Ridaura et al. (52) transplanted fecal microbiota 
from adult female twin pairs that were discordant for obesity into germfree mice. An 
increase in adiposity and total body mass was found in the recipients of the gut microbiota 
transplanted from the obese twin, as compared to mice that received the lean twin’s gut 
microbiota. Of particular note, the obese state was transferable, as observed, by cohousing 
mice that received transplants of  either the obese or lean twin’s microbiota. Because mice 
are coprophagic, cohousing results in transfer of the gut microbiota via the ingestion of 
other animals’ feces.
Further suggesting a causal link between gut microbiota and obesity, treatment of 
mice with the antibiotic vancomycin, which caused a decrease in the relative amounts of 
Bacteroidetes and Firmicutes combined with an increase in the abundance of Proteobacteria, 
reduced weight gain in mice fed a high-fat diet (53). In a recent study, it was shown that 
antibiotic treatment early in life may set metabolic consequences in motion. Giving mice 
whose mothers were treated with penicillin before birth of their pups a low-dose penicillin 
during the weaning period increased DIO and visceral fat accumulation, and affected 
hepatic gene expression and metabolic hormone levels such as peptide YY (PYY). A causal 
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role for the microbiota was confirmed by transplanting gut microbiota from antibiotic-
treated mice to germfree mice. Remarkably, cessation of the antibiotic treatment induced a 
marked recovery of microbial composition but did not change the metabolic phenotype (54).
Taken together, the evidence from studies in mice suggest a causal link between gut 
microbiota and obesity. Complementing the animal studies mentioned above, several human 
studies support such a correlation between the gut microbiota and obesity. Specifically, 
humans with obesity were shown to have an increased ratio of Firmicutes/Bacteroidetes 
when compared with lean individuals (10). In addition, the abundance of Bacteroidetes 
increased upon weight loss, either by fat- or carbohydrate-restricted low-calorie diets (10) or 
after a gastric bypass (55). Because people who undergo gastric bypass surgery also have to 
make major adjustments in their diet, the latter study does not provide any information on 
whether the changes in microbial composition are dictated by the changes in diet or by the 
reduced adiposity. 
Although other studies have found changes in gut microbial composition in obese 
individuals, the increase in Firmicutes/Bacteroidetes ratio in obesity and the increase in 
the presence of Bacteroidetes upon weight loss have not been observed consistently (11, 38, 
56-58). Confounding factors such as diet, fasting (59), hygiene, lifestyle (18) and the use 
of antibiotics (60) affect gut microbial composition and might explain the discrepancies 
between these studies. These confounding factors, as well as species specific factors, may 
also explain why vancomycin treatment was associated with weight gain in adults subjects 
(61), whereas vancomycin reduced weight gain in mice (53). In conclusion, some human 
studies suggest that intestinal microbial composition is altered in obesity, although more 
studies are necessary to determine the direction and causality of the relationship.
In addition to obesity itself, the gut microbiota may also be associated with perturbations 
that are coupled to obesity, including systemic inflammation, insulin resistance and 
NAFLD (14, 62, 63). Cohousing experiments revealed that the gut microbiota may have 
an important role in NAFLD. Numerous studies have demonstrated that activation of the 
inflammasome by endogenous danger signals, such as reactive oxygen species, are involved 
in the progression of NAFLD. Activation of the inflammasome causes cleavage and thereby 
activation of the pro-inflammatory cytokine IL-18 (64-66).  Intriguingly, Henao-Mejia et al. 
showed that mice deficient in IL-18 develop hepatic steatosis and inflammation. In order to 
investigate whether this phenotype is caused by an altered gut microbial composition, IL-18 
knockout mice where cohoused with wild-type mice. Cohousing of these mice unexpectedly 
exacerbated hepatic steatosis and inflammation in the wild-type mice, indicating that the gut 
microbiota may promote NAFLD development (63). A causal role of the gut microbiota in 
NAFLD was supported by the finding that antibiotic treatment reduced hepatic triglyceride 
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accumulation in mice fed a high fat diet (67) or a diet rich in fructose (68), but also reduced 
hepatic T-cell infiltration in mice with concanavalin A-induced hepatitis (69). 
A causal role for the gut microbiota in systemic inflammation and insulin resistance 
was found in studies with gnotobiotic and antibiotic-treated animals. Whereas ileal TNFα 
expression did not differ between germfree mice fed a low- or high-fat diet, TNFα expression 
was elevated in conventionally-raised mice fed a high-fat diet as compared with mice fed 
a low-fat diet. Since TNFα is a biomarker of pro-inflammatory changes in the intestine, 
these data suggest that the gut microbiota, in combination with a high-fat diet, promotes 
intestinal inflammation. High TNFα levels were shown to correlate significantly with the 
progression of obesity and the development of insulin resistance (50). A causal role of the 
gut microbiota in insulin resistance is supported by the finding that vancomycin treatment 
decreased plasma TNFα levels and improved fasting blood glucose levels in mice fed a high-
fat diet (53). Compared to conventionalized mice, germfree mice were also found to have 
improved insulin sensitivity, which was accompanied by lower plasma TNFα and Serum 
Amyloid A (SAA) levels (70). High SAA levels lower insulin sensitivity in adipocytes  (71) 
and might therefore explain the insulin resistance observed in conventionalization studies 
(70, 72, 73). In addition, fasting plasma free fatty acid levels were found to be higher in 
conventionally-raised mice (70), also potentially contributing to insulin resistance (74). 
Membrez et al. (75) reported that, in two different mouse models of insulin resistance, 
treatment with norfloxin and ampicillin lowered fasting and post-GTT glucose and insulin 
plasma levels. Since norfloxin and ampicillin suppress Enterobacteriaceae and bacteria from 
the genus Bacteroides, Lactobacillus and Bifidobacterium, it can be hypothesized that these 
bacteria have detrimental effects on glucose tolerance.
A recent high profile study indicated that the gut microbiota may have anti-diabetic 
effects in humans. Infusion of gut microbiota from lean subjects into individuals with the 
metabolic syndrome increased fecal microbial diversity, including an increase in butyrate-
producing bacteria. Along with these changes in their microbial community, recipients of 
‘lean’ microbiota also showed increased insulin sensitivity (73). Although this study needs 
confirmation, it provides the first evidence for a causal link between gut microbiota and 
insulin resistance in humans.
How microbiota may affect metabolic health
The studies presented above hint at the notion that instead of merely being a consequence 
of metabolic disorders, changes in intestinal microbial composition may in fact causally 
contribute to these disorders, although more evidence is needed. The uncertainty regarding 
the causal link between gut microbiota and metabolic health has not prevented exploration 
of the potential underlying mechanisms that may connect the two, which include increased 
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energy harvest, endotoxemia, altered SCFA signaling, and choline and bile acid metabolism. 
Energy harvest and Angptl4
The gut microbiota provides the host with energy by extracting calories from otherwise 
indigestible carbohydrates via bacterial fermentation. In the intestine, complex 
carbohydrates are degraded by the gut microbiota into monosaccharides, which are 
subsequently fermented. Fermentation products include the gases H2, CO2, CH4, as well as 
SCFAs, which can be absorbed by the host and used as an energy source (28). The notion 
that the gut microbiota provides energy to the host is supported by the finding that germfree 
mice, which are not naturally colonized with microorganisms, gain less weight when fed a 
high fat diet than do conventionally-raised mice (48-50). 
In support of a role of fermentation in excess fat storage during obesity, ob/ob mice exhibit 
increased fermentation in their cecum, as revealed by an increase in the SCFAs acetate and 
propionate (76). Metagenomic analysis revealed that the ob/ob gut microbiome is enriched 
in genes involved in extracting energy from food, which may suggest that the gut microbiota 
from obese mice more efficiently extract energy from the diet. This notion was supported 
by two findings. Firstly, ob/ob mice had significantly less energy in their feces as compared 
with their wild-type littermates. Second, transplantation of the gut microbiota from ob/
ob mice to germfree mice caused a significant increase in total body fat as compared to 
transplantation from lean wild-type mice (76). Therefore, ob/ob mice may not only become 
obese because of increased food intake but possibly also due to increased energy harvest by 
altered gut microbiota. 
The main products of bacterial degradation and fermentation are monosaccharides and 
SCFAs. As a result of increased energy harvest, it was shown that conventionally-raised 
mice have increased monosaccharide uptake from their gut compared to their germfree 
counterparts. It was postulated that the increase in monosaccharide uptake promotes hepatic 
triglyceride synthesis, the accumulation of triglycerides in adipocytes, and subsequently an 
increase in body fat. Conventionally-raised mice had higher liver triglyceride levels and 
increased expression of the lipogenic transcription factors sterol regulatory element-binding 
protein (SREBP)-1 and carbohydrate-responsive element binding protein (ChREBP), as well 
as their targets acetyl-CoA carboxylase and fatty acid synthase (72). These results are in 
accordance with those of another study that showed that conventionally-raised mice on a 
high-fat diet gained more body weight compared to germfree mice, because of the more 
efficient conversion of ingested food to body weight (70). Additionally, it has been suggested 
that germfree mice and mice treated with antibiotics are better able to oxidize fatty acids in 
the liver, muscle and adipose tissue due to increased AMP-activated protein kinase (AMPK) 
activity and consequently a reduction in acetyl-CoA carboxylase activity, which might 
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protect them from DIO (48, 77).
It is noteworthy that germfree mice lacking the angiopoietin-like protein 4 (Angptl4) 
gene were not protected against body weight gain (48, 72). Intestinal Angptl4 expression was 
shown to be significantly lower in conventionally-raised mice compared to germfree mice 
(48, 72). ANGPTL4 is an inhibitor of the enzyme lipoprotein lipase, which is responsible 
for clearing triglycerides from the blood into tissues. Accordingly, suppression of Angptl4 
by the gut microbiota may enhance extraction of triglycerides from the blood and promote 
their storage in adipose tissue (72, 78). Recently it was shown that ANGPTL4 may regulate 
intestinal lipid uptake by inhibiting intestinal lipase activity. Microbial suppression of 
Angptl4 may therefore promote weight gain via the loss of the inhibitory effect of Angptl4 
on intestinal lipase activity, leading to increased intestinal triglyceride hydrolysis and lipid 
uptake (79). 
An overview of how microbiota might affect obesity via energy harvest and Angptl4 is 
displayed in Figure 1. 
Gut permeability
It has also been postulated that the microbiota may affect metabolic health by modifying 
gut permeability. Membrez et al. (75) observed that the improved glucose tolerance in mice 
treated with norfloxin and ampicillin was not due to differences in body weight but may be 
related to reduced inflammation and protection against endotoxemia, based on decreased 
plasma levels lipopolysaccharides (LPS) and jejunal TNFα expression in antibiotic-treated 
mice.
It has been suggested that endotoxemia can be triggered by diet. Fat-enriched diets alter 
gut microbial composition, as described earlier, but have also been shown to increase plasma 
Figure 1. How microbiota may affect obesity via energy harvest and Angptl4 
Gut microbiota may increase energy harvest from the diet by fermenting complex carbohydrates yielding 
energy in the form of monosaccharides and SCFAs. Increased monosaccharide absorption may lead to 
increased hepatic lipogenesis and may favor weight gain. The gut microbiota may also contribute to obesity 
by reducing free fatty oxidation and/or increasing intestinal lipid absorption. 
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LPS levels in mice (80) and humans (81). LPS is a major constituent of the gram-negative 
bacterial cell wall. Small amounts of endotoxin in the bloodstream may elicit a low-grade 
systemic immune response similar to what is observed during obesity (82). A role for the gut 
microbiota in this process was suggested because mice fed a high-fat diet had increased levels 
of cecal LPS-containing gram-negative bacteria (80) and also exhibited increased intestinal 
permeability with reduced expression of the tight junctions zonula occludens (ZO)-1 and 
occludin (62, 83). Besides reducing the expression of intestinal tight junctions, there is also 
evidence that the gut microbiota may regulate gut permeability via the endocannabinoid 
system. In a study by Muccioli et al. (84), modulation of gut microbial composition, either 
by colonizing germfree mice or treating mice with antibiotics, reduced colonic and adipose 
tissue cannabinoid receptor (Cb)-1 expression, whereas feeding the mice a high fat diet 
increased Cb1 expression. Blocking this receptor in mice through the infusion of a Cb1 
receptor antagonist resulted in an improved intestinal integrity, reduced plasma LPS levels, 
and reduced adiposity and body weight gain compared to the effects observed in saline-
infused mice. 
Lam et al. (62) found that the decrease in relative abundance of Lactobacillus and increase 
in Oscillibacter upon high fat feeding significantly correlated with a decreased transepithelial 
resistance. In turn, Cani et al. (83) showed that changing gut microbial composition with 
antibiotic treatment in mice fed a high fat diet significantly reduced gut permeability and 
increased tight junction expression, in association with reduced levels of circulating LPS 
and cecal LPS. Furthermore, it was shown that reduced plasma LPS levels upon antibiotic 
treatment also improved metabolic health in mice fed a high fat diet. Serum IL-6 and TNFα 
levels were lowered indicating reduced systemic inflammation. Antibiotic treatment also 
resulted in less infiltration of macrophages in adipose tissue, less body weight gain and 
improved insulin and glucose tolerance, all conditions related to systemic inflammation 
(77). Similar findings have been made in antibiotic treated ob/ob mice. The metabolic and 
inflammatory effects of antibiotic treatment were mostly mimicked by deletion of the LPS 
receptor CD14 (83). In addition, LPS also seems to have detrimental effects on the progression 
of NAFLD (85). Antibiotic treatment in mice with hepatic steatosis reduced hepatic lipid 
accumulation, which was associated with lower portal vein endotoxin levels(68).
Based on these and other findings, the gut microbiota may thus be involved in modifying 
intestinal permeability and trigger low grade (metabolic) endotoxemia and related 
disturbances (49, 75). However, it should be mentioned that several studies have not been 
able to replicate the elevated plasma LPS levels upon high fat feeding, despite causing obesity 
(86-88). It has also been suggested that a high fat diet increases the sensitivity of mice to LPS 
without affecting its plasma level (88). 
In addition to LPS, other bacterial cell wall components may be involved in mediating 
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the effects of gut microbiota on metabolic health. Monocolonization of germfree mice 
with Escherichia coli or a mutant E. coli variant has shown that only the wild-type E. 
coli strain raised plasma LPS levels. However, both E. coli strains impaired insulin and 
glucose tolerance and increased adiposity (49). A possible role for the bacterial cell wall 
component peptidoglycans may be hypothesized based on the finding that activation of the 
peptidoglycan receptor nucleotide-binding oligomerization domain-containing protein 
(NOD)-1 induces hepatic and peripheral insulin resistance in mice, whereas loss of NOD1 
and NOD2 in mice fed a high-fat diet resulted in higher insulin sensitive and lower adipose 
tissue inflammation (89). 
The possible effects of the gut microbiota on gut permeability, glucose metabolism and 
inflammation are depicted in Figure 2.
Microbial regulation of metabolic processes
SCFAs
SCFAs are the main end products of bacterial fermentation in the intestine. The number 
of microbiota in the gut, the microbial composition, the gut transit time and the available 
substrates for microbial fermentation are all factors that influence the production of 
SCFAs (25, 90), which serve not only as substrates for energy production, lipogenesis, and 
gluconeogenesis but can also regulate biological processes by serving as signaling molecules.
An important set of molecular target for SCFAs are the G protein-coupled receptors 
(GPCRs) 41 and 43. These proteins are expressed in numerous tissues, including adipose 
tissue and enteroendocrine cells, leading to activation of distinct downstream effects (91, 
92). GPCR41 and 43 are activated by a similar set of ligands but differ somewhat in their 
specificity. Whereas GPCR41 is activated more potently by propionate as compared with 
Figure 2. Possible effects of gut microbiota on gut permeability, glucose metabolism and inflammation
High-fat diet-induced changes microbial composition might increase gut permeability via cannabinoid 
receptor 1 and/or the expression of tight junctions. The increase in gut permeability induces endotoxemia 
and thereby possibly systemic inflammation, obesity, impaired insulin and glucose tolerance and adipose 
tissue inflammation.
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acetate, GPCR43 displays a preference for acetate over propionate (93). 
Samuel et al. (94) showed that the gut microbiota promotes adiposity and body weight 
via GPCR41-mediated signaling. They demonstrated that conventionally-raised wild-
type mice and germfree wild-type mice co-colonized with Bacteroides thetaiotaomicron 
and Methanobrevibacter smithii - two prominent bacteria in the distal human gut - had 
significantly more adiposity and gained more body weight than their conventionally-raised 
GPCR41 knockout littermates. The increased adiposity and body weight gain may be related 
to increased serum levels of peptide YY (PYY), leading to a reduced gut transit rate. As 
a consequence, conventionally-raised wild-type mice may extract calories from their diet 
more efficiently and absorb more SCFAs, resulting in enhanced hepatic de novo lipogenesis, 
as indicated by increased hepatic triglyceride levels. These features were blunted in germfree 
wild-type and GPCR41 knockout mice as well as in germfree GPCR41 knockout mice 
that were co-colonized. In contrast, Lin et al (95). found that bodyweight gain was similar 
between wild-type and GPCR41 knockout mice, suggesting a lack of effect of GPCR41 on 
adiposity. However, food intake was higher in GPCR41 knockout mice as compared to wild-
type mice, suggesting less efficient energy harvest and thus a decrease in feed efficiency ratio 
in the GPCR41 knockout mice. Adding to the controversy, oral administration of butyrate 
and propionate was found to inhibit diet-induced obesity independently of GPCR41. With 
respect to GPCR43, Kimura et al. (96) showed that acetate-mediated signaling via GPCR43 
may prevent obesity. GPCR43 knockout mice fed a high fat diet and treated with antibiotics 
and acetate had increased body and white adipose tissue weights, which were reduced in 
wild-type mice treated with the same regimen. Consistent with an anti-obesity effect of 
GPCR43, mice with adipose tissue-specific overexpression of GPCR43 had significantly 
lower body and adipose tissue weight than did their wild-type littermates. These mice also 
exhibited impaired insulin signaling in white adipose tissue, but not  in muscle and liver, 
and had increased energy expenditure, which seemed to be attributable to a muscle-specific 
increase in the expression of glycolysis- and β-oxidation genes and reduced expression 
of gluconeogenesis genes. Taken together, SCFAs, mainly acetate, might activate adipose 
tissue GPCR43 to reduce uptake of fatty acids and glucose by adipocytes and improve 
systemic insulin sensitivity, leading to consumption of lipids and glucose by other tissues. 
It has been speculated that through this mechanism, adipose tissue GPCR43 activation 
may reduce adiposity and improve systemic insulin sensitivity. Whether circulating SCFA 
concentrations are sufficiently high to cause substantial activation of GPCR43 in adipose 
tissue requires further study.
In addition, GPCR43 activation in the intestine may also have an antidiabetic effect. It 
has been shown that GPCR43 activation by SCFAs promotes the release of glucagon-like 
peptide-1 by intestinal enteroendocrine L cells, thereby stimulating the release of insulin 
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and leading to improved glucose tolerance (97). 
The above described actions of SCFAs via GPCR43 may provide a molecular explanation 
for the beneficial effects of dietary fiber on metabolic health (98). Diets rich in fiber increase 
the number of SCFA-producing bacteria and fecal SCFAs, as observed when comparing 
fecal microbiota from healthy European and African individuals (31). However, SCFA-
mediated GPCR41 signaling seems to provoke opposite effects. Therefore, additional studies 
are necessary to sort out to what extent GPCR43 and -41 mediate the metabolic effects of 
SCFA in the intestine and other organs. In a recent study, it was shown that, in addition to 
GPCRs, SCFAs may elicit their effects via the peroxisome proliferator-activator receptor γ 
(PPARγ). Specifically, it was observed that feeding mice a diet rich in inulin, which leads 
to enhanced SCFA production, induced PPAR target genes and pathways in the colon. In 
vitro studies indicated that butyrate and propionate are able to directly activate PPARγ (99). 
In another study, SCFA supplementation in mice fed a high fat diet protected against body 
weight gain, which was accompanied by improved insulin sensitivity and decreased hepatic 
triglycerides. The reduction in hepatic steatosis by SCFAs was not observed in liver-specific 
PPARγ knockout mice, whereas the reduction in bodyweight gain and the improved insulin 
sensitivity after SCFA supplementation were abolished in adipose tissue-specific PPARγ 
knockout mice, indicating that the SCFA-induced effects are mediated via a tissue-specific 
PPARγ-dependent mechanism (100). 
An overview of the possible GPCR and PPARγ-mediated effects of SCFA on obesity and 
diabetes is displayed in Figure 3. 
Choline metabolism
As described in this review, changes in gut microbial composition may be linked to the 
development of obesity and diabetes. Emerging evidence also links the gut microbiota to 
cardiovascular diseases (101-103). 
Wang et al. (101) were the first to report a relationship between microbial choline 
metabolism and development of atherosclerosis. Choline is an essential nutrient which is 
present in foods such as eggs and red meat. It is a component of cell membranes and is also 
involved in lipid metabolism (28). Feeding mice with labeled phosphatidylcholine resulted in 
increased levels of plasma trimethylamine (TMA) and subsequently trimethylamine N-oxide 
(TMAO), both metabolites of choline. TMA is formed in the intestine, absorbed and rapidly 
metabolized in the liver to TMAO by hepatic flavin-containing monooxygenases. It is of 
interest that plasma TMAO levels were not increased in phosphatidylcholine-fed germfree 
mice or mice treated with antibiotics, suggesting that the gut microbiota is involved in 
metabolic processing of dietary choline (101). 
Feeding atherosclerosis-prone ApoE knockout mice a diet supplemented with 1% choline 
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resulted in increased plasma TMAO levels and a large increase in the number of foam 
cells, probably due to the increased expression of the cholesterol influx receptors CD36 and 
SRA. In addition, an increase in atherosclerotic lesion size was observed following addition 
of choline to the diet. When the gut microbiota was suppressed by antibiotics, foam cell 
formation and atherosclerotic development were inhibited (101). Similar results were seen 
in humans. When humans were challenged with phosphatidylcholine, plasma TMAO levels 
increased. Plasma TMAO levels were almost completely blunted after antibiotic treatment 
and reappeared when the use of antibiotics was discontinued. In addition, high plasma 
TMAO levels in humans were found to be associated with a high risk for major adverse 
cardiovascular events, even when the hazard ratios were adjusted for the traditional risk 
factors (104).
Figure 3. Possible GPCR- and PPARγ-mediated effects of SCFA on obesity and diabetes
(A) Microbial fermentation induces in the production of SCFAs and subsequent signaling via GPCRs. 
SCFA-mediated GPCR41 signaling may reduce the gut transit rate, allowing more time to extract energy 
from the diet and thereby promoting energy uptake and obesity. In contrast, SCFA-mediated GPCR43 
signaling in white adipose tissue (WAT) may prevent obesity by reducing insulin-mediated lipid and 
glucose uptake in WAT and improving muscle and liver insulin sensitivity, thereby promoting fatty acid and 
glucose consumption. GPCR43 signaling may also have antidiabetic effects by increasing muscle insulin 
sensitivity and insulin secretion. (B) SCFAs may also act  in a PPARγ-dependent fashion, as observed by 
SCFA supplementation in mice fed a high fat diet. Whereas SCFA-mediated reduction in adipose PPARγ 
may prevent obesity and improve insulin sensitivity, the SCFA-attenuated hepatic PPARγ may reduce 
hepatic steatosis. 
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Expanding on the above findings, Koeth et al. (102) found that supplementation with 
either choline, L-carnitine - a nutrient in red meat that also contains a TMA - or TMAO 
reduced reverse cholesterol transport, which describes the movement of cholesterol from 
peripheral tissues back to the liver via the plasma. The reduced reverse cholesterol transport 
was abolished when the gut microbiota was suppressed with antibiotics. Taken together, 
diets rich in choline or L-carnitine raise plasma TMAO levels, possibly via their microbial 
conversion, which might thereby lead to enhanced development of atherosclerosis. An 
overview of how the gut microbiota may affect atherosclerotic development via the 
conversion of choline or L-carnitine is displayed in Figure 4. 
Bile acid metabolism
Bile acids are formed in the liver from cholesterol. The primary bile acids cholic acid and 
chenodeoxycholic acid are secreted into the small intestine to assist with the emulsification 
and absorption of dietary lipids and fat-soluble vitamins. The diversity of the primary bile 
acids is increased through bacterial activity in the gut to form the secondary bile acids 
deoxycholic acid and lithocholic acid (105). Consequently, the absence of microbiota results 
in an increased abundance of primary bile acids and a decreased abundance of secondary 
bile acids, as seen in germfree rats (106) and in humans after oral intake of Vancomycin 
for 7 days (107). About 95% of the primary and secondary bile acids are reabsorbed in the 
intestine and returned to the liver via a process referred to as the enterohepatic cycle (105). 
Bile acids also act as signaling molecules. An important molecular target of bile acids 
is the farnesoid X receptor (FXR). As the gut microbiota profoundly impacts bile acid 
metabolism, it can be hypothesized that the microbiota may also have a role in FXR 
signaling. In fact, it was found that the presence of microbiota downregulates genes involved 
in bile acid synthesis, such as the rate-limiting enzyme Cyp7a1, while upregulating genes 
encoding bile acid efflux transporters (106, 108). The effects on bile acid synthesis seems to 
Figure 4. Proposed mechanism by which the gut microbiota may affect atherosclerosis via the conversion 
of choline and/or L-carnitine
The microbiota converts choline and/or L-carnitine to TMA, which is subsequently metabolized to TMAO. 
TMAO may increase foam cell formation and reduce reverse cholesterol transport, thereby increasing the 
risk of development of atherosclerosis.
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depend on microbial FXR signaling, because the reduced liver Cyp7a1 expression, as seen in 
conventionally-raised mice as compared to germfree mice, was abolished in FXR knockout 
mice (108). Besides affecting bile acid metabolism, the gut microbiota has also been shown 
to alter the expression of genes involved in glucose and lipid metabolism related to the FXR 
pathway. Indeed, hepatic expression of phosphoenolpyruvate carboxykinase (PEPCK), 
glucose-6-phosphatase (G6PC), and SREPB-1 was upregulated in germfree and antibiotic-
treated rats as compared to conventionally-raised rats (106). In contrast, treatment of 
mice with antibiotics that had been fed a high fat diet showed downregulation of hepatic 
SREBP-1c expression, resulting in decreased hepatic de novo lipogenesis. The absence of gut 
microbiota led to a significant increase in intestinal primary tauro-β-muricholic acid, which 
cannot be converted to secondary bile acids. Tauro-β-muricholic acid in turn inhibited 
intestinal FXR signaling, leading to inhibition of ceramide synthesis and reduced  hepatic 
SREBP-1 expression and de novo lipogenesis (67). In addition to FXR, bile acids also signal 
via the membrane-bound receptor TGR5 to modulate glucose metabolism (28, 106). A 
recent study found a positive correlation between the abundance of fecal secondary bile 
acids and peripheral insulin sensitivity after modulation of the gut microbial composition 
by vancomycin treatment (107). However, a potential role for the FXR or TGR5 pathway was 
not investigated.
Several studies have shown that dietary fat content influences the gut microbiota, which 
may be mediated by changes in bile acids. (109-112). High-fat diets elevate bile secretion to 
enhance lipid emulsification and absorption and thereby also alter bile acid levels in the 
intestine. It was shown that adding cholic acid to the diet modifies gut microbial composition 
in favor of the Firmicutes and leads to increased fecal deoxycholic acid concentrations. 
Consistent with the bactericidal properties of deoxycholic acid, addition of cholic acid to the 
diet reduced total microbial counts by 51% compared to the control group (110). Accordingly, 
it can be suggested that the changes in gut microbial composition triggered by a high-
fat diet might be the consequence of increased bile acid secretion. Next to its bactericidal 
property, deoxycholic acid can also induce DNA damage. Deoxycholic acid was found to be 
significantly increased upon high-fat feeding, promoting hepatocellular carcinoma in mice 
exposed to a chemical carcinogen. When the gut microbiota was suppressed with antibiotics, 
serum deoxycholic acid levels were lowered and a significant reduction in hepatocellular 
carcinomas development was observed, indicating that changes in microbial composition 
and its metabolites can have detrimental effects in the host (113). 
Future perspectives 
In this review we carefully analyzed the literature causally linking the gut microbiota 
to metabolic health with a special interest in potential underlying mechanisms. 
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Conventionalization studies, studies in germfree mice, and studies using antibiotics have 
provided evidence that changes in gut microbiota may be causally involved in metabolic 
disease, rather than merely being a consequence of it. Several different mechanisms have 
been proposed and explored that may mediate the possible effects of the gut microbiota 
on metabolic disorders, including increased energy harvest from the diet, increased gut 
permeability, changes in SCFA-mediated signaling, and altered bile acid metabolism.
Although several studies have provided evidence that the gut microbiota is causally 
involved in the development of obesity, conflicting reports exist. Indeed, whereas Ceasar et 
al. (49) and Backhed et al. (48) found that germfree mice are protected against diet-induced 
obesity, Fleissner et al. (114) were unable to reproduce these findings. That the reduced 
diet-induced weight gain in germfree mice as compared to conventionally raised mice was 
not observed in rats is intriguing (115). Reports on the metabolic effect of the microbial 
fermentation products SCFAs in obesity development are also contradictory. SCFAs were 
suggested to promote obesity via GPCR41 signaling (94), whereas they were postulated to 
be protective against obesity through GPCR43 signaling (96) (Figure 2). These apparent 
contradictions may be explained by differences in how the gut microbiota is modulated. In 
some studies the composition of gut microbiota was modulated via the use of antibiotics, 
whereas other studies have used germfree mice. Second, diet, age, and the genetic makeup 
of the host are all confounding factors that vary among studies. Furthermore,  differences in 
the composition of the gut microbiota at the start render it difficult to compare studies and 
to identify the specific microbes responsible for the observed effects. A problem with the use 
of antibiotics is that certain bacteria are resistant to antibiotics to them, and other microbes 
such as yeast may take over, making it difficult to pinpoint to the organisms responsible for 
the observed effects. Another concern is that nearly all studies characterize the microbiota 
composition in the feces, which may differ substantially from the microbial composition  in 
the more proximal intestine (22). 
A key question is whether studies with germfree and conventionally-raised animals 
appropriately reflect the role of microbiota in metabolic health in humans. The similarity 
in gut microbial composition between mice and humans is quite low. Ley et al. (8) found 
that although most of the phyla are present in both humans and mice, 85% of the bacteria 
genera found in mice are not found in humans. In addition, although studies with germfree 
animals provide valuable information, these animals are quite ill, perhaps as a result of 
defects in immune system development, morphological intestinal defects, or poor provision 
of vitamins to the host (23, 24). As a result, studies of germfree mice may not properly 
reflect the human physiological situation. Colonization of these mice with microbiota 
promotes obesity and reduces metabolic health, but it is questionable whether the observed 
findings are very informative towards the role of microbiota in human metabolic health. 
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An appropriate alternative approach to germfree mice would be to use mice colonized with 
human intestinal communities and a proper functioning immune system and intestinal 
physiology. In this model, the effect of human microbial composition on metabolic health 
can be studied via modulation of the gut microbiota with antibiotics. Furthermore, more 
emphasis should be placed on assessing changes in microbial gene expression as opposed to 
only measuring the genomic composition.
Another approach to explore the effects of the gut microbial composition on metabolic 
health is by performing intervention studies using pre- and probiotics. The term prebiotic 
describes ‘a selectively fermented ingredient that allows specific changes both in the 
composition and/or activity in the gastrointestinal microbiota that confers benefits upon 
host well-being and health’ (116). In principle, all dietary fibers that are fermented are 
assumed to have prebiotic properties. A large body of evidence suggests that various types 
of dietary fibers beneficially affect metabolic health. For instance, inulin-type fructans have 
been shown to counteract high fat diet-induced obesity and insulin resistance (117). Studies 
using various pre-biotics are an effective way to investigate the direct influence of changes 
in gut microbial activity on metabolic parameters.
Whereas prebiotics stimulate the growth and activities of gut microbiota, probiotics are 
orally delivered live bacteria that are assumed to affect health positively. Two reports have 
suggested that probiotics reduce body weight gain and have antidiabetic effects (118, 119). 
At the same time, two other studies have not shown any benefits of probiotics for metabolic 
health (53, 120). A meta-analysis by Million et al. (120) demonstrated that the same 
Lactobacillus strain might promote weight gain in undernourished individuals, whereas it 
may reduce weight gain in obese individuals. Accordingly, the effects of probiotics are not 
only strain dependent but likely also depend on the characteristics of the host. So far, the 
European Food Safety Authority has denied any health claims for probiotics. In contrast, 
numerous claims on prebiotics, including arabinoxylan, beta-glucan, and guar gum, have 
been approved. Overall, more evidence supporting a positive influence of pre- and probiotics 
on metabolic health is needed, including data from randomized human intervention trials. 
Also, additional insight should be gained into their  mechanism of action. 
In conclusion, there is growing understanding of how changes in intestinal microbial 
composition may affect the metabolic status of the host. More human trials are needed to 
substantiate the role of the gut microbiota in metabolic health in humans. Also, targeted 
studies should be conducted to better identify which bacterial strains positively influence 
metabolic health. Once the causality between the gut microbiota and metabolic health of 
the host can be further demonstrated, dietary interventions with, for example, prebiotics, 
probiotics or a combination of both can be used to modify an individual’s gut microbial 
composition and activity toward the prevention and possibly even treatment of metabolic 
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diseases.
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Abstract
Growing evidence suggests that the bacteria present in our gut may play a role in mediating 
the effect of genetics and lifestyle on obesity and metabolic diseases. Most of the current 
literature on gut bacteria consists of cross-sectional and correlative studies, rendering it 
difficult to make any causal inferences as to the influence of gut bacteria on obesity and 
related metabolic disorders. Interventions with germ-free animals, treatment with antibiotic 
agents, and microbial transfer experiments have provided some evidence that disturbances 
in gut bacteria may causally contribute to obesity-related insulin resistance and adipose 
tissue inflammation. Several potential mediators have been hypothesized to link the activity 
and composition of gut bacteria to insulin resistance and adipose tissue function, including 
lipopolysaccharide, Angiopoietin-like protein 4, bile acids, and short-chain fatty acids. 
In this review we critically evaluate the current evidence related to the direct role of gut 
bacteria in obesity-related metabolic perturbations, with a focus on insulin resistance and 
adipose tissue inflammation. It is concluded that the knowledge base in support of a role for 
the gut microbiota in metabolic regulation and in particular insulin resistance and adipose 
tissue inflammation needs to be strengthened.
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Abstract figure. Hypothetical model of gut microbial participation in adipose tissue inflammation and 
insulin resistance
Several mediators are hypothesized to link changes in gut bacteria composition to adipose tissue 
inflammation and insulin resistance. (1) Disturbances in gut microbial composition may disrupt gut 
barrier thereby causing leakage of lipopolysaccharides (LPS) into the bloodstream. Low levels of LPS in the 
bloodstream can cause adipose tissue inflammation and insulin resistance. (2) Alterations in gut microbiota 
and subsequent changes in the conversion of primary to secondary bile acids may alter FXR signalling and 
impact adipose tissue inflammation and insulin resistance. Whether alterations in gut microbiota influence 
adipose tissue inflammation and insulin resistance via bile acid-mediated TGR5 signalling is completely 
unknown. (3) Microbial fermentation of dietary fibers generates short-chain fatty acids (SCFAs). By 
activating G protein-coupled receptors (GPCR) 41 and 43, SCFAs induce secretion of GLP-1 and PYY, 
which may inhibit adipose tissue inflammation and insulin resistance. (4) Inhibition of Angiopoietin-like 
protein 4 (ANGPTL4) by the gut microbiota may promote adiposity, but whether regulation of (intestinal) 
ANGPTL4 by the gut microbiota affects adipose tissue inflammation and insulin resistance is completely 
unknown. Dashed arrows indicate putative pathways for which more research is needed to investigate the 
direct impact of microbiota on adipose tissue inflammation and insulin resistance.
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Introduction
Obesity is associated with a variety of metabolic complications including dyslipidemia and 
insulin resistance. Evidence is accumulating that development of insulin resistance and 
other complications of obesity may be driven by a heightened inflammatory state of the 
adipose tissue. Elevated adipose tissue inflammation is characterized by the influx of various 
immune cells, including macrophages, and the upregulation of numerous inflammatory 
cytokines (Boutens & Stienstra, 2016). 
Obesity and related metabolic diseases are believed to be the result of an interaction 
between genetics and lifestyle factors, such as diet and physical activity. In the last decade, 
there has been growing realization that part of the effect of genetics and lifestyle on obesity and 
metabolic diseases may be mediated by the microorganisms residing in our gastrointestinal 
tract, which are referred to as the gut microbiota (Janssen & Kersten, 2015; Wu et al., 2015). 
Indeed, changes in gut microbiota composition have been observed in people with obesity 
(Ley RE, Turnbaugh PJ, Klein S, 2006; Schwiertz et al., 2010), and obesity-related diseases 
such as type 2 diabetes (Qin et al., 2012), non-alcoholic fatty liver disease (Mouzaki et al., 
2013; Jiang et al., 2015), and cardiovascular disease (Karlsson et al., 2012). 
The gut microbiota predominantly consists of bacteria but also includes viruses, fungi, 
protozoa, and archea. The composition of the gut microbiota varies greatly between 
individuals, reflecting the impact of the host genome and environmental factors, such 
as lifestyle, hygiene, the use of antibiotics, and especially diet. In addition, the intestinal 
microbiota composition may be affected by specific disease states (Benson et al., 2010; 
Sommer & Bäckhed, 2013). Conversely, the intestinal microbiota may impact the host and 
contribute to certain diseases (Rabot et al., 2010; Ridaura et al., 2013; Gregory et al., 2015; 
Schaubeck et al., 2016). Most of the contemporary literature on the relation between the 
composition of the gut microbiota and obesity and related parameters consists of cross-
sectional and correlative studies. Because of the complicated interaction between the host, 
environmental factors, and the gut microbiota, no causal inferences can be drawn from 
these studies about the influence of gut bacteria on obesity and obesity-related disturbances, 
which represent a major limitation. In this review we discuss the current evidence related 
to the direct role of gut bacteria in obesity-related metabolic perturbations, with a focus 
on insulin resistance and adipose tissue inflammation. In the first part, we describe the 
results of various interventions that addressed the causal role of gut bacteria in metabolic 
diseases. In the second part, we describe mechanistic studies on potential mediators that 
may link changes in gut bacteria to obesity-related insulin resistance and adipose tissue 
inflammation. 
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Possible interventions to study the role of gut bacteria in 
metabolic diseases
To investigate whether the gut bacteria contribute to insulin resistance and adipose tissue 
inflammation, interventions with germ-free animals, treatment with antibiotic agents, 
and bacterial transfer experiments are employed. Germ-free animals are maintained free 
from any microorganisms throughout life and are therefore useful to elucidate the role 
of the gut microbiota in metabolic disorders. Compared to conventionalized mice, germ-
free mice fed a high-fat diet were found to have an improved glucose tolerance, improved 
insulin sensitivity, and reduced adipose tissue inflammation (Bäckhed et al., 2004; Rabot et 
al., 2010; Caesar et al., 2012). However, it is unclear whether the elevated insulin resistance 
and adipose tissue inflammation in conventionalized mice as compared to germ-free mice 
are directly mediated by the gut microbiota, or indirectly via a higher bodyweight gain. 
To circumvent the effects of body weight and adiposity on adipose tissue inflammation, 
Caesar et al. compared germ-free and bodyweight-matched conventionally raised mice. 
Interestingly, adipose tissue inflammation was improved in germ-free mice as compared 
with conventionally raised mice. While this study thus suggests that the gut microbiota 
promote adipose tissue inflammation (Caesar et al., 2015), it is important to realize that 
interventions with germ-free mice have certain limitations. Indeed, germ-free mice have 
large defects in the development of the immune system and antibody production, show 
morphological defects in the intestine, and may suffer from a vitamin deficiency, which may 
significantly affect the experimental outcome (Smith et al., 2007; Yi & Li, 2012). 
To overcome these limitations, administration of antibiotics and microbial transfer are 
a popular alternative to modulate gut bacterial composition. Antibiotics suppress the gut 
bacteria (Cani et al., 2008; Carvalho et al., 2012). Similar to the observations in germ-free 
mice, treatment with antibiotics improved the glucose tolerance and reduced the infiltration 
of macrophages in adipose tissue in mice (Cani et al., 2008; Membrez et al., 2008; Carvalho 
et al., 2012). In contrast, in humans, administration of a cocktail of antibiotics for 4 days had 
no effect on glucose tolerance (Mikkelsen et al., 2015), while treatment with vancomycin for 
1 week decreased the peripheral insulin sensitivity (Vrieze et al., 2014). One disadvantage of 
antibiotics is that they do not suppress all gut bacteria, which might result in the overgrowth 
of non-targeted bacteria (Walsh et al., 2014; Morgun et al., 2015), or outgrowth of intestinal 
fungi (Mulligan et al., 1982; Dollive et al., 2013). Furthermore, it is important to note that 
antibiotics possess direct anti-inflammatory properties and may cause mitochondrial 
dysfunction, independent of their bactericidal or bacteriostatic effects (Tauber & Nau, 2008; 
Steel et al., 2012; Wang et al., 2015). 
Microbial transfer can be achieved by oral gavage or intrarectal administration of bacteria, 
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or by cohousing animals. Transfer of microbiota from obese-prone—but not from obese-
resistant— mice to germ-free mice increased weight gain, increased HOMA-IR (homeostasis 
model assessment of insulin resistance), and stimulated the infiltration of macrophages in 
adipose tissue (Duca et al., 2014). Another study showed that mice receiving microbiota 
from obese mice at weaning had an improved glucose tolerance as compared with mice 
receiving microbiota from lean mice, but not when the microbial transfer was performed at 
8 weeks of age (Ellekilde et al., 2014). The role of the gut microbiota in human obesity and 
insulin resistance has been investigated by transplanting fecal microbiota from female adult 
twins discordant in obesity to germ-free mice. While an increase in obesity and adiposity 
was observed in mice receiving the gut microbiota from the obese twin as compared with 
mice receiving the gut microbiota from the lean twin, only a trend towards impaired glucose 
tolerance (p=0.06) was observed (Ridaura et al., 2013). Interestingly, the transplantation of 
gut microbiota from lean individuals to patients with metabolic syndrome improved insulin 
sensitivity (Vrieze et al., 2012). Of importance, the effectiveness of bacterial transfer depends 
on whether bacteria are able to colonize in the recipients’ intestinal microbial niche. 
Microbial transfer can also be achieved by co-housing, which is exclusively applied in 
animals. Importantly, cohousing of mice with different genotypes will equalize intestinal 
bacterial composition in the cohoused animals. Therefore, only if the gut microbiota have 
profound effects on the phenotype, differences between the two co-housed groups might 
yield significant results (Laukens et al., 2016). 
The interventions mentioned above are commonly used to investigate the role of the gut 
bacteria in metabolic health. However, these interventions cannot discriminate between 
pathogenic and beneficial bacteria. Bacteria also confer health benefits related to—for 
example—vitamin supplementation, tissue homeostasis, and immune function (Smith et 
al., 2007; Sommer & Bäckhed, 2013). As a result, the loss of beneficial bacteria can have 
detrimental effects on the host. A more targeted approach to modulate the intestinal 
bacteria, for example by administrating specific bacterial species, is expected to give 
more specific insight into which and how bacteria can affect the health of the host. For 
instance, administration of Escherichia coli to germ-free mice has been shown to impair 
glucose tolerance (Caesar et al., 2012), whereas administration of Akkermansia muciniphila 
to conventional mice was shown to improve glucose tolerance (Everard et al., 2013). To 
successfully administer bacterial species, bacteria need to remain viable during storage, 
survive the passage through the gastrointestinal tract, and be able to colonize the intestine. 
Although the number of bacteria that can be cultured has gone up significantly, still many 
gastrointestinal bacteria cannot not be cultured (Li et al., 2014; Rajilić-Stojanović & de 
Vos, 2014). Hence, due to this limitation, the more targeted approach is only applicable to a 
selection of bacterial strains.
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Overall, current evidence lends some credence to the notion that changes in the gut 
bacterial composition contribute to insulin resistance and adipose tissue inflammation. 
However, additional human and animal studies are needed to bolster the causal link between 
the gut bacteria and obesity-related metabolic parameters.
Potential mediators 
Several potential mediators have been hypothesized to link the activity and composition 
of the gut microbiota to insulin resistance and adipose tissue function, including 
lipopolysaccharide (LPS), Angiopoietin-like protein 4 (ANGPTL4), bile acids, and short-
chain fatty acids (SCFAs). 
Lipopolysaccharides
LPS or so-called endotoxin is a major component of the gram-negative bacterial cell wall. 
The first indications that LPS may be involved in obesity and related metabolic disorders 
were reported by Cani et al (Cani et al., 2007). Continuous subcutaneous infusion of LPS 
for 4 weeks induced weight gain, insulin resistance, and adipose tissue inflammation to 
a similar extent as high-fat feeding. Importantly, high-fat feeding was found to elevate 
plasma LPS levels, which was associated with an increased gut permeability and a decreased 
expression of the tight junction proteins zona occludens-1 and occludin. Treatment of 
mice fed a high-fat diet with antibiotics did not increase the gut permeability and plasma 
LPS levels, suggesting a role for the gut bacteria in this process. In addition to reduced 
LPS levels, antibiotic-treated mice also displayed less macrophage infiltration in adipose 
tissue and improved glucose and insulin tolerance (Cani et al., 2008). The finding that the 
suppression of the gut bacteria improves insulin resistance and adipose tissue inflammation 
concurrent with a reduction in plasma LPS levels has also been found in other studies that 
used either mice fed a high-fat diet (Membrez et al., 2008; Carvalho et al., 2012), ob/ob mice 
(Cani et al., 2008), or germ-free mice (Caesar et al., 2012). Interestingly, supplementing A. 
muciniphila during high-fat feeding reduced fat mass gain and improved glucose tolerance 
in association with reduced serum LPS levels. These findings were not observed with heat-
killed A. muciniphila, suggesting that live A. muciniphila has a profound role in gut barrier 
function (Everard et al., 2013). 
It is important to note that not all mouse studies have provided supportive evidence for a 
role of LPS in insulin resistance (Lichtenstein et al., 2010; Laugerette et al., 2012; Caesar 
et al., 2012, 2015). Whereas administration of the gram-negative bacteria E. coli W3110 to 
germ-free mice increased plasma LPS, administration of the isogenic mutant MLK1067 did 
not. However, both strains increased adipose tissue weight and impaired glucose tolerance, 
suggesting that gut-derived LPS is not essential for adiposity and glucose and insulin 
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tolerance in mice (Caesar et al., 2012). In another study by the same authors, obesity, adipose 
tissue inflammation, and insulin resistance in mice fed a lard-based high-fat diet were not 
accompanied by a significant elevation in plasma LPS levels as compared with mice fed a fish 
oil-based high-fat diet (Caesar et al., 2015). However, lard-feeding significantly increased toll-
like receptor 4 activation (Caesar et al., 2015), which might reflect an increased sensitivity of 
the mice to LPS, a notion that was also raised in another study (Huang et al., 2007). 
Whereas the original publication by Cani and colleagues in mice reported a stimulatory 
effect of LPS on insulin resistance (Cani et al., 2008), subsequent studies in rats have failed 
to find an effect of LPS administration on insulin resistance (Liu et al., 2010; Dudele et al., 
2015). In humans, LPS injection in healthy subjects was shown to induce insulin resistance 
and adipose tissue inflammation (Dandona et al., 2010; Mehta et al., 2010). To investigate 
whether the changes in gut bacteria composition associated with overfeeding and obesity can 
elevate plasma LPS levels in humans, healthy humans were placed on high-fat/hypercaloric 
diets in two independent studies. Laugerette et al. reported that although overfeeding 
for 8 weeks caused marked weight gain, it did not influence the fasting plasma LPS levels 
(Laugerette et al., 2014). By contrast, Pendyala et al. observed that 4 weeks of Western diet 
raised the plasma LPS levels. Interestingly, the increased LPS levels were not accompanied 
by higher serum pro-inflammatory cytokine levels (Pendyala et al., 2012). 
Taken together, the current literature on LPS as a potential causal link between 
disturbances in the gut microbiota and obesity-related insulin resistance and adipose 
tissue inflammation is inconsistent. One possible explanation for the inconsistent results 
might be the difficulty of accurately measuring LPS in blood. Most studies have used the 
FDA-approved Limulus Amoebocyte Lysate (LAL) assay, which measures LPS activity via 
an enzymatic reaction. One drawback of the LAL assay is that several factors in plasma—
such as bile salts and lipoproteins—can interact and thereby inactivate LPS, rendering LPS 
undetectable. In addition, anticoagulants, including EDTA and heparin, might interfere 
with the LAL assay (Hurley, 1995; Boutagy et al., 2015). Another drawback is the risk of 
contaminations, which may give rise to false-positive results.
Angiopoietin-like protein 4 
Angiopoietin-like protein 4 (ANGPTL4) is a ubiquitously expressed glycoprotein that plays 
an important role in lipid metabolism by inhibiting the activity of the enzyme lipoprotein 
lipase (Dijk & Kersten, 2014). Lipoprotein lipase catalyzes the hydrolysis of circulating 
triglycerides along the capillary lumen of muscle and fat tissue. Bäckhed et al. first identified 
ANGPTL4 as a potential link between the gut microbiota and fat storage (Bäckhed et al., 
2004, 2007). Whereas germ-free mice were protected against diet-induced obesity, germ-
free mice lacking the Angptl4 gene were not. Conventionalization of germ-free mice 
Potential mediators linking gut bacteria to metabolic health
65
3
resulted in the suppression of Angptl4 expression in the intestines but not in adipose tissue. 
Consequently, it was suggested that downregulation of intestinal Angptl4 expression by gut 
microbiota may promote adipose tissue lipoprotein lipase activity and thereby peripheral fat 
storage (Bäckhed et al., 2004, 2007; El Aidy et al., 2013). In contrast, although Fleissner et al. 
similarly observed increased intestinal Angptl4 expression in germ-free mice, conventional 
mice were leaner than their germ-free counterparts (Fleissner et al., 2010). 
Currently, it is still unclear to what extent ANGPTL4 produced in the intestine has 
an endocrine function and is able to lower LPL activity in adipose tissue. Indeed, there 
is growing evidence suggesting that ANGPTL4 acts more locally instead of systemically 
(Dijk & Kersten, 2014). In the intestine, ANGPTL4 may primarily target pancreatic lipase 
and thereby reduce fat absorption (Mattijssen et al., 2014). Consequently, the inhibition 
of intestinal Angptl4 upon conventionalization may promotes fat storage via elevated 
pancreatic lipase activity. In terms of glucose metabolism, while some studies have found 
an effect of ANGPTL4 overexpression on glucose metabolism (Xu et al., 2005; Lichtenstein 
et al., 2007), it remains to be determined whether ANGPTL4 plays an important regulatory 
role in insulin sensitivity and glucose homeostasis.
In apparent contrast to the finding of reduced intestinal Angptl4 expression upon 
conventionalization, specific bacterial species and short-chain fatty acids potently induce 
ANGPTL4 in colonic cell lines (Are et al., 2008; Aronsson et al., 2010; Alex et al., 2013; 
Korecka et al., 2013). To further investigate the role of intestinal ANGPTL4 as a potential 
link between the gut microbiota and metabolic health, future studies using intestinal-
specific Angptl4 knockout mice should be performed. 
Bile acids
Alterations in the gut bacterial composition have profound consequences for bile acid 
metabolism. For instance, it is known that the conversion of primary bile acids to secondary 
bile acids is carried out by the gut bacteria. Besides having an important role in the 
emulsification and absorption of dietary lipids, bile acids also serve as important signalling 
molecules that act through the farnesoid X receptor (FXR) and G-protein coupled bile 
acid receptor 1 (TGR5). By activating FXR and TGR5, bile acids can influence a variety 
of biological processes including bile acid metabolism, intestinal hormone secretion, 
inflammation, and lipid, glucose and energy metabolism. Accordingly, disturbances in the 
gut bacteria are suggested to affect metabolic parameters and pathways via changes in bile 
acid metabolism (Fiorucci & Distrutti, 2015). 
Experiments in germ-free and antibiotic-treated mice (Swann et al., 2011; Sayin et al., 
2013), as well as in humans treated with antibiotics (Vrieze et al., 2014), have indicated that 
the gut bacteria play an important role in the conversion of primary into secondary bile 
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acids. In addition, germ-free and antibiotic-treated mice have an increased bile acid pool, 
increased biliary bile acid secretion and intestinal reabsorption, and decreased fecal bile acid 
excretion, indicating that the gut microbiota have a major impact on bile acid homeostasis 
(Sayin et al., 2013; Out et al., 2015). In turn, bile acids may impact the gut bacteria via their 
bactericidal properties, illustrating the complex relationship between the gut bacteria and 
bile acids (Mikkelsen et al., 2016). 
The nuclear bile acid receptor FXR is expressed at high levels in the liver and small 
intestine, which are both tissues characterized by high concentrations of bile acids. Intestinal 
FXR signalling has been shown to protect against the development of obesity and to improve 
insulin resistance (Li et al., 2013). The impact of the microbiota on FXR signalling has 
been studied using germ-free and conventional-raised wild-type and FXR knockout mice. 
While the effect of the gut microbiota on insulin tolerance was found to be dependent 
on FXR, the influence of the gut microbiota on glucose tolerance was not (Parséus et al., 
2016). Adipose tissue inflammation was significantly increased upon conventionalization 
in wild-type mice, but not in FXR-deficient mice, suggesting that the microbiota promote 
adipose tissue inflammation in a FXR-dependent manner (Parséus et al., 2016). Expression 
of FXR is relatively low in adipose tissue suggesting that effects of bile acids on adipose tissue 
inflammation are likely mediated via intestinal FXR. 
The membrane bile acid receptor TGR5 is also mainly expressed in the intestine and 
has been implicated in glucose metabolism. Specifically, activation of TGR5 by bile acids 
was shown to improve insulin sensitivity and glucose tolerance via enhanced glucagon-like 
peptide-1 (GLP-1) secretion, which was blunted in mice lacking TGR5 (Harach et al., 2012; 
Potthoff et al., 2013). 
Different bile acids are known to have a different potency towards FXR and TGR5 (de 
Aguiar Vallim et al., 2013). Accordingly, it is difficult to predict how changes in the gut 
bacterial composition and hence fecal bile acid composition affect bile acid signalling 
and subsequently impact metabolic processes. Moreover, the bile acid composition is 
substantially different between mice and humans, including differences in the production of 
the various primary bile acids and their conjugation with glycine in humans versus taurine 
in mice (Chiang, 2013). For this reason, the results obtained in mice studies cannot easily be 
extrapolated to humans.  
Short-chain fatty acids
SCFAs are the main intestinal bacterial fermentation end products of indigestible dietary 
components, such as dietary fibers. It has been hypothesized that part of the beneficial 
health effects of dietary fibers is mediated by SCFAs (Jakobsdottir et al., 2013; den Besten 
et al., 2014; Chassaing et al., 2015). In line with this notion, supplementation of SCFAs to 
Potential mediators linking gut bacteria to metabolic health
67
3
a high-fat diet protected against diet-induced obesity and improved insulin sensitivity 
(Gao et al., 2009; Lin et al., 2012; den Besten et al., 2015a). Although these data support 
a direct impact of SCFA on metabolic health, absorption of orally ingested SCFAs takes 
place already in the small intestine and not in the cecum or colon. Different hormones with 
various physiological functions are produced along the gastrointestinal tract (Murphy & 
Bloom, 2006) and as a result, SCFAs absorbed in the small intestine may give rise to different 
metabolic effects as compared to SCFA produced by bacterial fermentation and absorbed in 
the large intestine (den Besten et al., 2015b). 
The effects of SCFAs on glucose homeostasis are thought to be mediated via the secretion 
of GLP-1 and peptide YY (PYY) from enteroendocrine L-cells by activation of the G protein-
coupled receptors (GPCR) 41 and 43. In vitro primary colonic cells lacking either GPCR41 or 
-43 were shown to secrete less GLP-1 and PYY after SCFA stimulation (Tolhurst et al., 2012; 
Psichas et al., 2015). Targeted delivery of the SCFA propionate to the colon increased GLP-1 
and PYY in the portal vein in wild-type mice but not in mice lacking GPCR43 (Psichas et al., 
2015). Additionally, mice lacking GPCR41 and -43 had impaired glucose tolerance (Tolhurst 
et al., 2012; Kimura et al., 2013). In humans, rectal propionate infusions have been shown to 
increase serum glucose levels, consistent with the hypothesis of propionate being a substrate 
for gluconeogenesis (Wolever et al., 1991). By contrast, while targeted delivery of propionate 
via an inulin-propionate ester effectively increased propionate in the colon and increased 
the postprandial plasma PYY and GLP-1 concentrations, no acute effects on plasma glucose 
levels were found (Chambers et al., 2015). Interestingly, inulin-propionate supplementation 
for 24 weeks prevented a deterioration in the glycaemic response in overweight adults 
(Chambers et al., 2015). However, it is unclear whether these effects are directly mediated by 
propionate impacting gut hormones, or indirectly via the reduction in bodyweight gain and 
adiposity in the inulin-propionate group as compared to the control group. 
The direct effects of SCFAs on adipose tissue inflammation have been investigated in 
only a few studies. Since the effects of SCFAs on metabolic health frequently involve changes 
in obesity development (Canfora et al., 2015), which can be predicted to lead to changes in 
adipose tissue inflammation, the direct effects of SCFAs on adipose tissue inflammation are 
difficult to assess in vivo. 
In vitro, SCFAs have been shown to exert anti-inflammatory effects by affecting cytokine 
production and chemotaxis (Cox, 2009; Maa et al., 2010; Liu et al., 2012). The effect of SCFAs 
on inflammation seems to be dependent on the concentration and the type of SCFA as well 
as on the type of immune cell (Vinolo et al., 2009; Bailón et al., 2010; Meijer et al., 2010). For 
example, Al-Lahham et al. showed that propionate reduced several inflammatory cytokines 
and chemokines in human omental adipose tissue explants (Al-Lahham et al., 2012), which 
could only be achieved using supraphysiological concentrations (3 mmol/L). 
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Taken together, there is some evidence that SCFAs affect insulin resistance and adipose 
tissue inflammation but further research in necessary to better study the impact of 
intestinally-derived SCFAs on insulin resistance and adipose tissue inflammation  in vivo. 
Conclusion
In conclusion, several potential mediators, including LPS, ANGPTL4, bile acids, and 
SCFAs, have been proposed to link disturbances in the gut bacteria to obesity-related 
insulin resistance and adipose tissue inflammation. Currently, the literature on LPS as 
a potential causal link between the gut microbiota and obesity-related insulin resistance 
and adipose tissue inflammation is inconsistent, which may be related to the difficulty of 
accurately measuring LPS in blood. Bile acids are also suggested as a possible mediators, but 
evidence from in vivo studies is limited. Since the gut bacteria impact bile acid composition 
and vice versa, it is difficult to investigate the role of bile acids as causal mediators of the 
gut microbiota. ANGPTL4 has been proposed as a link between the gut microbiota and 
obesity, but whether regulation of (intestinal) Angptl4 by the gut microbiota also affects 
insulin resistance and adipose tissue inflammation is completely unknown. In contrast to 
LPS, ANGPTL4, and bile acids, SCFAs have been suggested to improve glucose tolerance 
and reduce adipose tissue inflammation, although further research is necessary to better 
study the impact of intestinally-derived SCFAs on insulin resistance and adipose tissue 
inflammation  in vivo. 
It should be noted that the observed effects of the gut microbiota and its potential 
mediators on insulin resistance and adipose inflammation are often confounded by changes 
in obesity development, which automatically impact insulin resistance and adipose tissue 
inflammation. Therefore, studies should be designed to better tease out the direct effect of 
the gut microbiota on insulin resistance and adipose tissue inflammation independent of 
obesity.
Studies on potential mediators linking disturbances in gut bacteria to insulin resistance 
and adipose tissue inflammation are mostly performed in mice. Although murine models 
provide a powerful tool to study host-gut microbe interactions, they do not always very 
well recapitulate the human situation, partly because the composition of the gut bacteria is 
quite dissimilar between humans and mice (Ley et al., 2005). Pre-clinical studies exploring 
the role of gut bacteria in obesity and metabolic regulation should therefore ideally be 
undertaken in a variety of mouse models on different diets. Moreover, as the gut bacteria 
composition can vary substantially in the same mouse strain depending on the animal 
facility and background diet, it is worthwhile to try to repeat existing studies in different 
animal facilities and using different diets. Finally, a more targeted approach involving 
modification of only one bacterial strain may provide more useful insight into the role of 
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the gut bacteria in obesity and metabolic regulation, as compared to interventions in which 
nearly the entire bacterial population is modulated. 
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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, yet 
the pathogenesis of NAFLD is only partially understood. Here, we investigated the role of 
the gut bacteria in NAFLD by stimulating the gut bacteria via feeding mice the fermentable 
dietary fiber guar gum and suppressing the gut bacteria via chronic oral administration of 
antibiotics. 
Guar gum feeding profoundly altered the gut microbiota composition, in parallel with 
reduced diet-induced obesity and improved glucose tolerance. Strikingly, despite reducing 
adipose tissue mass and inflammation, guar gum enhanced hepatic inflammation and 
fibrosis, concurrent with markedly elevated plasma and hepatic bile acid levels. Consistent 
with a role of elevated bile acids in the liver phenotype, treatment of mice with taurocholic 
acid stimulated hepatic inflammation and fibrosis. In contrast to guar gum, chronic oral 
administration of antibiotics effectively suppressed the gut bacteria, decreased portal 
secondary bile acid levels, and attenuated hepatic inflammation and fibrosis. Neither guar 
gum or antibiotics influenced plasma lipopolysaccharide levels. 
In conclusion, our data indicate a causal link between changes in gut microbiota and 
hepatic inflammation and fibrosis in a mouse model of NAFLD, possibly via alterations in 
bile acids. 
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Introduction
The worldwide epidemic of obesity is the primary driver for the global increase in the 
prevalence of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) (1). While 
caloric overconsumption and the associated positive energy balance are the sine qua non 
of obesity development, emerging evidence implicates gut microbes in the promotion of 
obesity and related metabolic disturbances (2–5).
The human intestine contains a variety of microbiota, mainly consisting of bacteria 
and complemented by other microorganisms such as fungi, protozoa and viruses. The gut 
microbiota form a mutualistic relationship with the host and have an important role in host 
health. Besides protecting the host against invading pathogenic microorganisms, intestinal 
bacteria facilitate the digestion of otherwise indigestible carbohydrates, produce essential 
vitamins, stimulate the development of the immune system and maintain tissue homeostasis 
(6, 7). In recent years, the gut microbiota have increasingly been connected with a number 
of diseases, including irritable bowel syndrome, Crohn’s disease, obesity, type 2 diabetes, 
atherosclerosis and NAFLD (5, 8–10).
NAFLD describes a spectrum of related liver diseases ranging from simple steatosis to 
non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis (11). Although the exact 
pathogenesis of NAFLD is unknown, multiple factors likely contribute to the progression of 
NAFLD, including genetic predisposition, lipid overload, and inflammatory insults. Indeed, 
it is believed that inflammatory mediators released locally or derived from tissues such as 
the intestine and adipose tissue play an important role in the progression of steatosis to 
NASH (12, 13). 
Recent studies have raised the possibility that NAFLD may be related to disturbances in 
the gut microbial composition. In particular, it was found that the gut microbial composition 
was different between healthy individuals and patients with NAFLD (14, 15). Furthermore, 
mouse studies suggest that changes in the gut microbial community may impact the 
development of hepatic steatosis (16), inflammation (17, 18) and fibrosis (18).
To further elaborate the concept that the gut microbiota may affect the development of 
NAFLD, we studied the influence of modulation of the gut microbiota on NAFLD. To that 
end, in a mouse model of NAFLD, we stimulated the gut bacteria by feeding mice the highly 
fermentable dietary fiber guar gum, using the poorly fermentable dietary fiber resistant 
starch as control. Inasmuch as guar gum escapes digestion in the small intestine and is 
thought to act exclusively via bacterial fermentation and concomitant alterations in gut 
microbiota, feeding guar gum is an attractive strategy to study the role of the gut microbes 
in NAFLD. Additionally, in the same mouse model of NAFLD, we studied the effect on 
NAFLD of suppressing the gut bacteria using a mixture of antibiotics.
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Overall, our data indicate that the gut microbiota have a marked impact on NAFLD. 
Specifically, specific modulation of the gut microbiota by feeding guar gum worsened 
features of NAFLD, whereas suppression of the gut bacteria using oral antibiotics protected 
against NAFLD, possibly via changes in the portal delivery of bile acids. 
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Materials and methods
Animals and diet
Animal studies were performed using pure-bred male C57Bl/6 mice. Mice were individually 
housed in temperature- and humidity-controlled specific pathogen-free conditions. Mice 
had ad libitum access to food and water. In study 1, 11-week-old mice received a low fat 
diet or a high fat/high cholesterol/high fructose diet (HFCFD) for 18 weeks, providing 10% 
or 45% energy as triglycerides (formula D12450B or D12451 from Research Diets, Inc., 
manufactured by Research Diet Services, Wijk bij Duurstede, Netherlands). The fat source of 
this HFCFD was replaced by safflower oil and supplemented with 1% cholesterol (Dishman, 
Veenendaal, Netherlands). Mice receiving the HFCFD were provided with 20% fructose water 
(wt/vol) to promote development of NAFLD (19). The fiber-enriched diets were identical to 
the HFCFD (CTRL) except that corn starch and part of the maltodextrin 10 were replaced by 
10% (wt/wt) resistant starch (RS) or guar gum (GG). The composition of the diets is shown 
in Supplemental Table 1. Resistant starch, a retrograded tapioca starch classified as RS type 
3 (brand name C* Actistar 11700) and guar gum (brand name Viscogum) were obtained 
from Cargill R&D Centre Europe (Vilvoorde, Belgium). Bodyweight and food intake were 
assessed weekly. One mouse fed the GG-enriched diet died during the study for reasons 
unrelated to the intervention. 
In study 2, 10-week-old mice received a high fat/high cholesterol/high fructose diet 
(CTRL) for 18 weeks, providing 45% energy as triglycerides (formula 58V8 manufactured 
by TestDiet, St. Louis, USA). This diet was supplemented with 1% cholesterol (Dishman, 
Veenendaal, Netherlands). The mice received 20% fructose (wt/vol) in the drinking water. 
The TMAO-enriched diet was identical to the CTRL diet except that 0.296 % of sucrose 
(wt/wt) was replaced by 0.296% TMAO-dihydrate (wt/wt) (Sigma, Zwijndrecht, The 
Netherlands) to obtain a final concentration of 0.2% TMAO (wt/wt). Bodyweight and food 
intake were assessed weekly. One mouse fed the TMAO-enriched diet died during the study 
for reasons unrelated to the intervention. One mouse in the CTRL group and one mouse fed 
the TMAO-enriched diet failed to thrive and were excluded from further analysis. 
In study 3, 4 month-old male mice received either chow (CTRL) or chow supplemented 
with 0.5% (wt/wt) taurocholic acid (TCA) (Calbiochem) for 7 days (20). Bodyweight and 
food intake were assessed daily. 
In study 4, 10-week old mice received a high fat/high cholesterol/high fructose diet 
(CTRL) for 18 weeks, providing 45% energy as triglycerides (formula 58V8 manufactured 
by TestDiet, St. Louis, USA). The diet was supplemented with 1% cholesterol (Dishman, 
Veenendaal, Netherlands). The mice received 20% fructose (wt/vol) in the drinking water. 
Mice that were given antibiotics received the same CTRL diet with the addition of 1g/l 
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Ampicillin, 1g/l Neomycin sulphate, 1g/l Metronidazole and 0.5g/l Vancomycin in the 
drinking water for 22 weeks. This antibiotic cocktail has previously been shown to deplete 
all detectable commensal bacteria (21). Bodyweight and food intake were assessed weekly. 
One mouse in the CTRL group and one mouse in the antibiotics group failed to thrive and 
were excluded from further analysis.
At the end of each study, mice were anesthetized using isoflurane and blood was collected 
by orbital puncture. Mice were euthanized via cervical dislocation after which tissues were 
excised and weighed and intestinal content was sampled. The mice were not fasted prior to 
euthanasia (e.g. ad libitum fed state). The animal experiments were approved by the local 
animal ethics committee of Wageningen University. 
Intraperitoneal glucose tolerance test
In study 1, mice were fasted for 5 hours prior to the intraperitoneal glucose tolerance 
test. During this period fructose water was replaced by tap water. Blood samples were 
collected from the tail vein immediately before (t=0 min) and at selected time points after 
intraperitoneal injection with glucose (0.8 g/kg bodyweight). Glucose was measured using 
Accu-chek Compact. Plasma concentrations of insulin were quantified after 5 hour fasting 
according to manufacturer’s instructions (Crystal Chem, Downers Grove, USA).
RNA isolation and qPCR
Total RNA was extracted from epididymal white adipose tissue, liver and scrapings of the 
distal small intestine using TRIzol reagent (Life technologies, Bleiswijk, Netherlands). 
Subsequently, 500ng RNA was used to synthesize cDNA using iScript cDNA synthesis 
kit (Bio-Rad Laboratories, Veenendaal, Netherlands). Changes in gene expression were 
determined by real-time PCR on a CFX384 Real-Time PCR detection system (Bio-Rad 
Laboratories, Veenendaal, Netherlands) by using SensiMix (Bioline, GC biotech, Alphen aan 
den Rijn, Netherlands). The housekeeping gene 36b4 or β-actin was used for normalization. 
Sequences of the used primers are listed in Supplemental Table 2. 
Histology/Immunohistochemistry
Hematoxylin and Eosin (H&E) staining of sections was performed using standard protocols. 
Paraffin-embedded liver sections (5 μm) were stained for collagen using fast green FCF/
Sirius Red F3B. Staining of neutral lipids was performed on frozen liver sections using Oil 
Red O according to standard protocols. 
Visualization of hepatic stellate cells was performed on paraffin-embedded liver sections 
with an antibody against alpha smooth muscle actin (αSMA)(M0851, Dako, Heverlee, 
Belgium). To detect macrophages, 5 μm frozen liver sections were stained for Cd68 Kupffer 
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cells (Cd68 marker, FA11) as described previously (22). 
Plasma/serum measurements
In study 1 and 3, blood was collected in EDTA-coated tubes and centrifuged for 15 minutes 
at 3000 rpm to obtain plasma. In study 2 and 4, blood was collected, allowed to clot for 45 
minutes and centrifuged for 15 minutes at 3000 rpm to obtain serum. The mice were not 
fasted prior to blood collection. Plasma and serum alanine aminotransferase activity was 
measured with a kit from Abcam (Cambridge, UK). The commercially available Limulus 
Amebocyte Lysate assay (Lonza, Walkerville, USA) was used to quantify plasma and portal 
serum endotoxin levels. Plasma concentration of total bile acids were determined using a 
colorimetric assay kit (Diazyme Laboratories, Poway, USA). Free and conjugated bile acid 
subspecies were quantified by liquid chromatography tandem MS (LC-MS/MS) using a 
SHIMADZU liquid chromatography system (SHIMADZU, Kyoto, Japan) and tandem AB 
SCIEX API-3200 triple quadrupole mass spectrometry (AB SCIEX, Framingham, USA) as 
previously described (23). TMA and TMAO plasma levels and TMAO serum levels were 
quantified by stable isotope dilution liquid chromatography tandem mass spectrometry as 
previously described (24, 25).
Fecal measurements
In study 1, during the 6th week of dietary intervention feces were collected over a period of 
48 hours. Total lipids and free fatty acids were measured in the fecal samples as mentioned 
by Govers et al. (26). Briefly, 100mg of fecal samples were weighed, dried and acidified using 
HCl. Lipids were then extracted using petroleum and diethyl ether. Ether fraction was 
collected, evaporated and the total lipids were weighed. 
Free and conjugated bile acid subspecies in the feces, collected at the end of the dietary 
intervention in study 1 and 4, were determined by capillary gas chromatography (Agilent 
6890, Amstelveen, the Netherlands) as described previously (27). 
Microarray analysis
Microarray analysis was performed on liver samples from 8 mice of the CTRL group and 
8 mice of the GG group. RNA was isolated as described above and subsequently purified 
using the RNeasy Microkit from Qiagen (Venlo, The Netherlands). RNA integrity was 
verified with RNA 6000 Nanochips on a Agilent 2100 bioanalyzer (Agilent Technologies, 
Amsterdam, the Netherlands). Purified RNA (100 ng) was labeled with the Ambion WT 
expression kit (Invitrogen, Carlsbad, USA) and hybridized to an Affymetrix Mouse Gene 
1.1 ST array plate (Affymetrix, Santa Clara, USA). Hybridization, washing, and scanning 
were carried out on an Affymetrix GeneTitan platform according to the instruction by 
Chapter 4
82
the manufacturer. Arrays were normalized using the Robust Multiarray Average method 
(28, 29). Probe sets were defined according to Dai et al. (30). In this method, probes are 
assigned to Entrez IDs as an unique gene identifier. The p-values were calculated using an 
Intensity-Based Moderated T-statistic (IBMT) (31). The q-value was calculated as measure of 
significance for false discovery rate (32). To identify the pathways most significantly altered 
in the livers of the GG group compared to the CTRL group, Ingenuity Pathway Analysis 
(Ingenuity Systems, Redwood City, USA) was performed. Input criteria were a relative fold 
change equal to or above 1.3 and a q-value equal to or below 0.01. Array data have been 
submitted to the Gene Expression Omnibus under accession number GSE76087.
A publicly available dataset (GSE34730) was downloaded from Gene Expression 
Omnibus and further processed as described above to obtain individual gene expression 
data. Ingenuity Pathway Analysis was performed on genes induced by deoxycholic acid by 
at least two-fold.
Western blot
Liver homogenates were prepared by lysing liver tissue in ice-cold Pierce IP lysis buffer 
(ThermoScientific, Rockford, USA ) containing complete protease inhibitor and PhosSTOP 
phosphatase inhibitor (both from Roche, Mannheim, Germany). Equal amounts of protein 
were loaded on a Mini Protean TGX gel, 4-15% and subsequently transferred to a PVDF 
membrane (both from Bio-Rad Laboratories, Veenendaal, The Netherlands). The primary 
antibodies for TIMP1 (Abcam, Cambridge, UK) and HSP90 (Cell Signalling) were incubated 
at 4°C overnight followed by incubation with the appropriate secondary peroxidase-
conjugated antibody (Sigma, Zwijndrecht, The Netherlands). Protein bands were visualized 
using an Enhanced Chemiluminescent substrate (Bio-Rad Laboratories, Veenendaal, The 
Netherlands). 
Liver measurements
For liver triglyceride measurement, livers were homogenized in a buffer containing 10mM 
Tris, 2mM EDTA and 250mM sucrose at pH 7.5 in a Tissue Lyser II (Qiagen, Hilden, Germany) 
to obtain 2% homogenates. Triglycerides were subsequently quantified using a Triglycerides 
liquicolormono from HUMAN Diagnostics (Wiesbaden, Germany). 4-hydroxyproline content 
was determined spectrophotometrically in liver hydrolysates as described previously (33).
For hepatic myeloperoxidase activity, liver homogenates were prepared and 
myeloperoxidase peroxidase activity was measured according to manufacturer’s instructions 
(Abcam, Cambridge, UK). 
For the quantification of liver total bile acid content, livers were homogenized in 75% 
ethanol, incubated at 50°C and centrifuged. After the collection of the supernatant, the 
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concentration of total bile acids were determined using a colorimetric assay kit (Diazyme 
Laboratories, Poway, USA).
FACS analysis
Epididymal white adipose tissue was isolated, minced and digested with 1.5 mg/ml 
collagenase type 2 (Sigma, Zwijndrecht, The Netherlands) in DMEM containing 0.5% fatty 
acid free BSA for 45 minutes at 37°C by shaking. Cell suspensions were filtered through 
a 100μM filter and centrifuged at 200g for 10 minutes. Floating mature adipocytes were 
discarded and the stromal vascular cell pellet was resuspended in erythrocyte lysis buffer for 
5 minutes. Cells were washed twice with FACS buffer (PBS + 1% BSA) and incubated with 
fluorescently labeled antibodies including CD45-ECD (Beckman Coulter, Fullerton, USA) 
, F4/80-FITC and Cd11b-PE (Biolegend, San Diego, USA). Samples were analyzed using a 
FC500 Flow Cytometer (Beckman Coulter, Fullerton, USA).
DNA extraction
In study 1, fecal samples derived from the second part of the colon were suspended in 10 
mM Tris, 1mM EDTA, 0.5% SDS and 0.2mg/ml Proteinase K (ThermoScientific, Rockford, 
USA). After addition of 0.1-0.25mm and 4mm glass beads, buffered phenol (Invitrogen, 
Carlsbad, USA) was added and cells were lysed by mechanical disruption using a bead beater 
(MP biomedicals, Santa Ana, USA) for 3 minutes. DNA was subsequently extracted using 
phenol:chloroform:isoamylalcohol [25:24:1] (Invitrogen, Carlsbad, USA), precipitated with 
isopropanol and washed with 70% ethanol. 
In study 4, fecal samples (~15-60mg) derived from the second part of the colon were 
suspended in 500μL S.T.A.R. buffer (Roche). After addition of 0.1mm zirconia and 2.5mm 
glass beads (BioSpec, Bartlesville, USA), cells were lysed by mechanical disruption using 
a bead beater (MP biomedicals, Santa Ana, USA) for 3x1 minute. DNA was subsequently 
extracted and purified using Maxwell 16 System (Promega). In brief, homogenates (250 
μL) were transferred to a prefilled reagent cartridge (Maxwell® 16 Tissue LEV Total RNA 
Purification Kit, Custom-made, Promega). Sixteen samples were processed at the same time. 
After 30 minutes the purification process was completed and DNA was eluted in 50 μL of 
water (Nuclease free)(Promega).
16S rRNA gene sequencing 
For 16S rRNA gene sequencing DNA samples were send to the Broad Institute of MIT and 
Harvard (Cambridge, USA). Microbial 16S rRNA gene was amplified targeting the hyper-
variable region V4 using forward primer 515F (5’-GTGCCAGCMGCCGCGGTAA-3’) and 
the reverse primer 806R (5’- GGACTACHVGGGTWTCTAAT-3’). The cycling conditions 
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consisted of an initial denaturation of 94°C for 3 min, followed by 25 cycles of denaturation 
at 94°C for 45 sec, annealing at 50 °C for 60 sec, extension at 72°C for 5 min, and a final 
extension at 72°C for 10 min. Sequencing was performed using the Illumina MiSeq platform 
generating paired-end reads of 175 bp in length in each direction. Overlapping paired-end 
reads were subsequently aligned. Detailed of this protocol are as previously described (34).
Raw sequence data quality was assessed using FastQC, version: 0.11.2 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Reads quality was checked with Sickle, 
version: 1.33 (https://github.com/najoshi/sickle) and low quality reads were removed. For 
visualising the taxonomic composition of the fecal microbiota and further beta diversity 
analysis, QIIME, version: 1.9.0 was used (35). In brief, closed reference OTU picking with 
97% sequence similarity against GreenGenes 13.8 reference database was done. Jackknifed 
beta-diversity of unweighted UniFrac distances with 10 jackknife replicates was measured 
at rarefaction depth of 22000 reads/sample. For statistical significance, biological relevance 
and visualisation we used linear discriminant analysis (LDA) effect size (LEfSe) method 
(https://bitbucket.org/biobakery/biobakery/wiki/lefse) (36).
Bacterial 16S rRNA gene and fungal ITS1-5.8S-ITS2 region quantification 
In study 4, real-time PCR was used to quantify 16S rRNA gene and ITS1-5.8S-ITS2 region 
in equal amounts of extracted DNA on a CFX384 Real-Time PCR detection system (Bio-
Rad Laboratories, Veenendaal, Netherlands) by using SensiMix (Bioline, GC biotech, 
Alphen aan den Rijn, Netherlands). 16S rRNA gene was amplified using the forward 
primer 1369F (5’-CGGTGAATACGTTCYCGG-3’) (37) and the reverse primer 1492R 
(5’-GGWTACCTTGTTACGACTT-3’) (38). The cycling conditions consisted of an initial 
denaturation of 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 15 sec, 
annealing at 60 °C for 30 sec and extension at 72°C for 30 sec. The ITS1-5.8S-ITS2 region was 
amplified using universal fungal primers V9D (5’-TTAAGTCCCTGCCCTTTGTA-3’) and 
LS266 (5’-GCATTCCCAAACAACTCGACTC-3’) encompassing highly conserved regions 
encoding fungal rDNA (39). The cycling conditions consisted of an initial denaturation of 
94°C for 10 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 58 °C 
for 30 sec, extension at 72°C for 30 sec and a final extension at 72°C for 10 min.
1H NMR spectroscopy
Contents of the cecum and first part of the colon were collected, mixed with phosphate 
buffer (pH 8) containing 10% deuterium oxide (D2O) and stored at -20°C. For short chain 
fatty acid (SCFA), ethanol and choline quantification samples were thawed, mixed and 
centrifuged at 14000 rpm for 5 minutes. Supernatant was collected and diluted in phosphate 
buffer containing 2mM maleic acid as standard. Subsequently, 200μl sample was transferred 
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to 3mm NMR tubes (Bruker Match System) and measured at 300K in an Avance III NMR 
spectrometer operated at 600.13 MHs as described previously (40).
Statistical analysis 
Data are presented as mean ± SEM. Statistical significant differences were determined 
with one way analysis of variance followed by Tukey’s post hoc multiple comparison test. 
Comparisons between two groups were made using two-tailed Student’s t-test. P<0.05 was 
considered as statistically significant. SPSS software (Version 21, SPSS Inc., Chicago, USA) 
was used for statistical analysis. 
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Results
High fat/high cholesterol/high fructose diet as model for NAFLD
Feeding mice a diet rich in fat, cholesterol and/or fructose are commonly used strategies 
to induce NAFLD (41–43). To verify the suitability of the high fat/high cholesterol/high 
fructose diet (HFCFD) as model for NAFLD, we tested the effect of HFCFD on various 
relevant parameters in comparison with a commonly used low fat diet. Weight gain, adipose 
tissue weight and liver weight were significantly higher in the mice fed HFCFD as compared 
to mice fed the low fat diet (Figure 1A-C). Hepatic lipid storage was markedly higher in 
mice fed HFCFD, as shown by a five-fold increase in liver triglycerides (Figure 1D) and 
by Oil Red O staining (Figure 1E). H&E confirmed the presence of microvesicular and 
macrovasicular steatosis, and showed mild infiltration of immune cells (Figure 1F). Hepatic 
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Figure 1. Effect of HFCFD on obesity and features of NAFLD 
(A) Bodyweight gain in C57Bl/6 mice fed a low fat diet or a high fat/high cholesterol/high fructose diet 
(HFCFD). Weight of (B) epididymal white adipose tissue (eWAT) and (C) liver after 18 weeks of dietary 
intervention. (D) Quantitative analysis of liver triglyceride levels. (E) Oil Red O staining and (F) H&E 
staining of representative liver sections. Arrow denotes inflammatory infiltrate. (G) Relative expression 
of inflammation and fibrosis-related genes in the liver. Gene expression levels of mice fed low fat diet were 
set at 1. (H) Activity of alanine aminotransferase (ALT) in plasma. Data are presented as mean ± SEM. 
Asterisks indicate significantly different compared with low fat diet. *p<0.05, **p≤0.001.
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expression of macrophage markers Cd68, F4/80 and Cd11c and pro-inflammatory cytokines 
Mcp-1 and Tnfα were significantly elevated in mice fed HFCFD, as was the expression of 
fibrosis markers collagen type I alpha 1 and Timp1 (Figure 1G). Finally, plasma ALT levels 
were doubled in mice fed HFCFD (Figure 1H). Taken together, these data show that feeding 
HFCFD represents a suitable model to study NAFLD in mice. 
Dietary guar gum alters colonic microbial composition
To evaluate the potential impact of alterations in the gut microbial community on the 
development of NAFLD, we fed mice the highly fermentable dietary fiber guar gum (GG) on 
a background of HFCFD for 18 weeks. Mice fed the poorly fermentable dietary fiber resistant 
starch (RS) and mice that were not fed any dietary fiber (CTRL) served as negative controls. 
To assess the effect of GG on colonic microbial composition and the relative abundance of 
specific gut microbiota taxa, 16S rRNA gene sequencing was performed on faecal samples 
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Figure 2. Guar gum alters the colonic microbial composition
(A) Principle coordinates analysis plot of unweighted UniFrac distances indicating clustering 16S 
rRNA gene sequences. Each circle represents an individual mouse. (B) Mean relative abundance of the 
predominant phyla (>0.5% in at least one of the three diet groups). (C) Mean relative abundance of bacteria 
reported to the lowest identifiable level. Taxonomic level is indicated by letter preceding the underscore: o, 
order; f, family; g, genus; s, species. (D) Cladogram representing significant enrichment of taxa in CTRL 
(red) or RS (green) colonic microbiota. (E) Cladogram representing significant enrichment of taxa in CTRL 
(red) or GG (green) colonic microbiota. The central point in the cladogram represents the domain bacteria 
and each ring represents the next lower taxonomic level (phylum to genus). 
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collected at the end of the dietary intervention. Clustering of 16S rRNA gene sequences by 
unweighted UniFrac distances per mouse revealed a sharp clustering of microbiome sequence 
data of the GG mice, indicating that the colonic microbial community was distinct between 
CTRL and GG mice. In contrast, the microbiota of the RS mice more closely resembled 
that of the CTRL mice (Figure 2A). Analysis of the microbiota at various taxonomic levels 
indicated differences in microbial composition depending on fiber type. In comparison 
with CTRL, both types of dietary fibers significantly reduced the relative abundance of 
Deferribacteres and Firmicutes, and increased the relative abundance of Bacteroidetes. The 
abundance of Actinobacteria was particularly increased in the GG mice. With a relative 
proportion of 8.23% of all phyla, the phylum Verrucomicrobia was overrepresented in the 
GG mice, whereas it was almost completely absent in CTRL and RS mice (Figure 2B and 
Supplemental Table 3). 
The differences in microbial community between the RS and GG groups became more 
apparent at lower taxonomic levels. Wheras GG increased the abundance of the genera 
Bifidobacterium and Prevotella, RS had relatively small effects on these genera. The decreased 
abundance of the phylum Firmicutes for both dietary fibers can be mainly explained by 
a decrease within the genus Lactobacillus. GG also markedly suppressed SMB53 and 
Oscillospira and increased the abundance of the species Desulfovibrio C21_c20 (Figure 2C-E 
and Supplemental Table 3). Overall, these data indicate that GG feeding markedly altered 
the bacterial composition in the colon.
Modulation of the gut microbiota by guar gum is associated with protection 
against diet-induced obesity and improved glucose tolerance
Whereas RS did not influence bodyweight gain, GG markedly attenuated bodyweight gain 
as compared to control (CTRL) (Figure 3A). The lower bodyweight could not be attributed 
to a reduced food intake (Figure 3B) or an increased fecal output (Figure 3C). Fecal lipid 
excretion was significantly higher in the GG mice as compared to the CTRL mice (Figure 
3C), suggesting that the lower bodyweight in the GG mice may be explained by decreased 
lipid absorption. Along with the lower bodyweight, weights of epididymal and mesenteric 
fat pads and liver were significantly lower in the GG group as compared with the CTRL 
group, while weight of the caecum was higher in both RS and GG groups (Figure 3D). 
In line with the suppression of bodyweight gain, GG improved whole body glucose 
tolerance (Figure 3E), reduced fasting plasma insulin levels (Figure 3F), and attenuated 
immune cells infiltration in adipose tissue. Specifically, flow cytometry analysis demonstrated 
that the abundance of leukocytes (CD45+) and macrophages (CD45+F4/80+CD11B+) was 
significantly lower in the epididymal fat depot of the GG mice as compared to the CTRL 
mice, while it was not different in the RS mice (Figure 3G-I). The decreased macrophage 
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Figure 3. Stimulation of the gut microbiota by guar gum is associated with protection against the 
development of diet-induced obesity, improved glucose tolerance and decreased adipose tissue 
inflammation
(A) Changes in bodyweight in C57Bl/6 mice fed a HFCFD (CTRL) or a HFCFD supplemented with RS or GG. 
(B) Mean food intake per day during the dietary intervention. (C) Mean fecal and lipid excretion per mouse 
per day in the sixth week of dietary intervention. (D) Weight of epididymal white adipose tissue (eWAT), 
mesenteric white adipose tissue (mWAT), liver and cecum after 18 weeks of dietary intervention. (E) Plasma 
glucose levels of CTRL, RS and GG mice following an intraperitoneal glucose tolerance test (GTT) and 
areas under the curve (AUC) after 17 weeks of dietary intervention. (F) Plasma insulin concentration after 
5 hours of fasting. (G) Representative flow cytometry plots and (H) corresponding quantitative analysis 
of infiltrated leukocytes (CD45+) in epididymal white adipose tissue (eWAT). (I) Quantitative analysis of 
macrophages (F4/80+CD11B+). (J) Relative expression of inflammatory genes in eWAT. Gene expression 
levels in CTRL mice were set at 1. Data are presented as mean ± SEM. Asterisks indicate significantly 
different compared with CTRL. *p<0.05 **p<0.001.
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abundance was corroborated by decreased expression of chemoattractant protein Mcp-1 and 
macrophages markers F4/80 and Cd68. Cd11c and Cd206 mRNA were also decreased in 
the GG group, suggesting lower presence of pro-inflammatory M1 macrophages and anti-
inflammatory M2 macrophages, respectively (Figure 3J). Taken together, GG suppressed 
bodyweight gain, which was accompanied by decreased adipose tissue inflammation and 
improved glucose tolerance. 
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Figure 4. Stimulation of the gut microbiota by guar gum is associated with reduced hepatic steatosis but 
enhanced hepatic inflammation 
(A) H&E staining of representative liver sections. Arrows denote inflammatory infiltrate and inset a higher 
magnification of the inflammatory infiltrate as observed in the livers of the GG mice. (B) Representative 
pictures of Oil Red O staining of liver sections. (C) Quantitative analysis of liver triglyceride levels. 
(D) Activity of alanine aminotransferase (ALT) in plasma. (E) Liver myeloperoxidase (MPO) activity 
representing hepatic neutrophil content. (F) Representative pictures of liver sections stained for the 
macrophage marker Cd68. (G) Relative expression of inflammatory genes in the liver. Gene expression 
levels in CTRL mice were set at 1. Data are presented as mean ± SEM. Asterisks indicate significantly 
different compared with CTRL. *p<0.05, **p<0.001. 
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Modulation of the gut microbiota by guar gum is associated with reduced hepatic 
steatosis but enhanced hepatic inflammation
In accordance with a lower fat mass in the GG mice, hepatic lipid accumulation was 
significantly lower in mice fed GG, as revealed by H&E and Oil Red O stainings and 
quantitation of liver triglycerides (Figure 4A-C). Plasma alanine aminotransferase activity, 
however, was not different between the 3 groups (Figure 4D). Interestingly, despite the 
reduction in liver triglycerides, H&E staining showed more pronounced inflammation 
in livers of GG mice, as revealed by the presence of inflammatory infiltrates (Figure 4A). 
Consistent with these data, elevated myeloperoxidase activity (Figure 4E) indicated a 
higher number of neutrophils in the livers of the GG mice. In contrast, the total macrophage 
abundance assessed by Cd68 staining and Cd68 and F4/80 expression was not different 
between the GG and CTRL mice (Figure 4F-G). Intriguingly, the higher expression of Cd11c 
and the lower expression of Cd206 and the anti-inflammatory cytokine Il-10, suggested 
that the macrophages present in the liver of the mice fed GG had a more pro-inflammatory 
phenotype (Figure 4G). To further elucidate the inflammatory status of the liver of the GG 
mice, whole genome expression profiling was performed. It was found that expression of 
3,722 genes was significantly different between the GG mice compared with the CTRL mice 
(p<0.01) (Supplemental Figure 1A). Numerous immune-related pathways, including IL-8 
signaling (p=1.05x10-6) and complement system activation (p=7.76x10-7), were altered in the 
livers of the GG mice, as determined by Ingenuity pathway analysis (Supplemental Figure 
1B). Together, these data demonstrate that although feeding GG suppressed diet-induced 
obesity, it stimulated specific inflammatory cells and pathways in the liver, whereas RS had 
no effect. 
Modulation of the gut microbiota by guar gum is associated with enhanced 
hepatic fibrosis
Strikingly, further study revealed that livers of the mice fed GG exhibited pronounced features 
of hepatic fibrosis. Sirius Red staining showed enhanced collagen deposition in the GG mice 
as compared with CTRL and RS mice (Figure 5A). Likewise, hepatic stellate cell activation 
as visualized by αSMA immunostaining and 4-hydroxyproline content were also increased 
in the GG mice (Figure 5B-C). Expression profiling followed by Ingenuity pathway analysis 
pointed to hepatic fibrosis/hepatic stellate cell activation as the most significantly regulated 
pathway (p=7.94x10-11), which was illustrated by the differential expression of numerous 
genes involved hepatic fibrosis and hepatic stellate cell activation (Figure 5D). Genes highly 
induced in livers of GG mice included various collagens and genes involved in regulation of 
extracellular matrix turnover (Timp2) and TGFβ signaling (Tgfbr1). Elevated expression of 
fibrosis-related genes was corroborated by qPCR (Figure 5E). Finally, TIMP1 protein levels 
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Figure 5. Stimulation of the gut microbiota by guar gum is associated with enhanced hepatic fibrogenesis
Representative pictures of liver sections stained for (A) collagen using fast green FCF/Sirius Red F3B 
and (B) hepatic stellate cell activation using an antibody against alpha smooth muscle actin (αSMA). (C) 
4-hydroxyproline content in the liver. (D) Heat map showing significant changes in expression of genes 
involved in hepatic fibrosis / hepatic stellate cell activation in the livers of CTRL and GG mice. The Log2 
expression signals of the CTRL group were arbitrarily set at 0. (E) Relative expression of fibrosis-related 
genes in the liver. Gene expression levels in CTRL mice were set at 1. Data are presented as mean ± SEM. 
Asterisks indicate significantly different compared with CTRL. *p<0.05. (F) TIMP1 protein expression 
measured by western blotting. HSP90 was used as loading control. 
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were elevated in livers of the GG mice (Figure 5F). These data indicate that feeding GG not 
only increased hepatic inflammation but also promoted more advanced features of NASH 
i.e. liver fibrosis.
Modulation of the gut microbiota by guar gum is associated with altered levels of 
gut-derived metabolites
To explore the possible mechanisms linking changes in gut microbiota composition to the 
observed liver pathology, we focused our attention on several microbial compounds that 
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Figure 6. Guar gum-induced elevation of TMAO does not contribute to enhanced NALFD development
(A) Plasma LPS levels. (B) Cecal and (C) colonic SCFA concentration and ethanol abundance. (D) Plasma 
TMA and TMAO levels. Mice were fed the HFCFD for 18 weeks with or without supplementation with 
TMAO. (E) Final bodyweight of mice fed CTRL or TMAO-enriched diet for 18 weeks. (F) Serum and 
urinary TMAO levels. Urinary TMAO levels are corrected for creatinine levels to adjust for urinary dilution 
(G) Quantitative analysis of liver triglyceride levels. (H) Activity of alanine aminotransferase (ALT) in 
serum. Relative expression of (I) inflammation and (J) fibrosis-related genes in the liver. Gene expression 
levels in CTRL mice were set at 1. Data are presented as mean ± SEM. Asterisks indicate significantly 
different compared with CTRL. *p<0.05, **p<0.001. (K) H&E staining of representative liver sections. (L) 
Representative pictures of liver sections stained for collagen using fast green FCF/Sirius Red F3B.
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have been proposed to mediate the effects of the gut bacteria on host metabolism, including 
the pro-inflammatory LPS and ethanol, and the anti-inflammatory short-chain fatty acids 
(SCFA) (44). Plasma levels of LPS were comparable between the GG mice and CTRL mice 
(Figure 6A), while ethanol levels in cecum and colon were decreased in the GG group 
(Figure 6B-C). With respect to the SCFA, in the cecum, the concentration of propionate 
was increased in both dietary fiber groups, whereas the butyrate concentration was only 
elevated in the GG group (Figure 6B). In the colon, GG but not RS significantly elevated 
acetate, propionate and butyrate concentrations as compared to CTRL (Figure 6C). In short, 
the observed changes in NAFLD phenotype in the GG mice are unlikely to be mediated by 
LPS, ethanol, or SCFAs.
Interestingly, plasma levels of the gut-derived metabolites trimethylamine (TMA)—a 
product of microbial conversion of choline—and trimethylamine N-oxide (TMAO), which 
is synthesized from TMA in the liver, were both significantly increased by GG, while RS 
had no effect (Figure 6D). Previously, TMAO was causally implicated in atherosclerosis and 
kidney fibrosis (9, 45, 46). 
Accordingly, to investigate if the elevated plasma TMAO levels may contribute to the 
NAFLD phenotype, mice were fed the HFCFD diet with or without 0.2% TMAO (w/w) for 
18 weeks. 18 weeks of TMAO feeding did not affect final bodyweight (Figure 6E). Although 
serum and urinary TMAO levels were about 15-fold higher in the mice fed the TMAO-
enriched diet (Figure 6F), provision of TMAO did not affect hepatic steatosis, inflammation, 
or fibrosis, as indicated by measurement of liver triglycerides (Figure 6G), serum alanine 
aminotransferase activity (Figure 6H), the expression of inflammation and fibrosis-related 
genes (Figure 6I-J), H&E staining (Figure 6K), and Sirius Red stainings (Figure 6L). 
Bile acids are also potential candidates for linking changes in gut bacteria to NAFLD. 
Strikingly, total plasma bile acid levels were nearly 4-fold higher in the GG than the CTRL 
mice, whereas they were not different in the RS mice (Figure 7A). Specifically, plasma levels 
of various primary bile acids including cholic acid, taurocholic acid, muricholic acids and 
tauromuricholic acids, as well as the secondary bile acids deoxycholic acid, taurodeoxycholic 
acid, ursodeoxycholic acid, hyodeoxycholic acid and taurohyodeoxycholic acid were 
significantly higher in the GG mice as compared with CTRL mice (Figure 7A). Moreover, 
total bile acid levels in the liver were also increased in the GG mice as compared with the 
CTRL mice (Figure 7B). The higher plasma and hepatic bile acid levels were accompanied 
by elevated hepatic expression of the FXR target Slc51b and a compensatory downregulation 
of Cyp7a1 and Cyp8b1, enzymes involved in bile acid synthesis, and Ntcp (Slc10a1), a bile salt 
importer (Figure 7C). No change was observed in the expression of the bile acid exporter 
Bsep (Abcb11) (Figure 7C). Interestingly, levels of bile acids in the feces were significantly 
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lower in the GG mice (Figure 7D), concomitant with reduced ileal expression of Fgf15 and 
elevated expression of the ileal bile acid transporter Asbt (Slc10a2) and Slc51b (Figure 7E). 
Together, these data suggest that GG enhanced bile acid absorption, leading to higher bile 
acid levels in the plasma and elevated bile acid content in the liver, which in turn triggered 
compensatory changes in the expression of genes involved in hepatic bile acid synthesis and 
uptake.
To examine if the elevated plasma levels of bile acids may contribute to hepatic 
inflammation and fibrosis, we gave mice the bile acid taurocholic acid for 7 days by mixing it 
in their feed (0.5% (wt/wt)). Provision of taurocholic acid raised plasma taurocholic acid levels 
by 40-fold as compared to CTRL (Figure 8A). In addition, taurocholic acid also significantly 
increased the primary bile acids cholic acid, glycocholic acid, chenodeoxycholic acid, 
taurochenodeoxycholic acid and unconjugated muricholic acids, as well as the secondary 
bile acids deoxycholic acid, taurodeoxycholic acid, glycodeoxycholic acid, ursodeoxycholic 
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Figure 7. Guar gum elevates plasma bile acid levels likely by promoting bile acid reabsorption 
 (A) Total bile acid concentration in plasma of CTRL, RS and GG mice and concentration of free and 
conjugated primary and secondary bile acid subspecies in the plasma of CTRL and GG mice. (B) 
Total bile acid content in the liver of CTRL and GG mice. (C) Relative expression of genes encoding 
enzymes of bile acid synthesis and bile acid transporters. Gene expression levels in CTRL mice were 
set at 1. (D) Mean excretion of free and conjugated bile acid subspecies per mouse per day in the 
CTRL and GG group at the end of the dietary intervention. (E) Relative expression of Fgf15 and bile 
acid transporters in the ileum. Gene expression levels in CTRL mice were set at 1. Data are presented 
as mean ± SEM. Asterisks indicate significantly different compared with CTRL. *p<0.05, **p<0.001.
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acid and ω-muricholic acid (Figure 8A). The higher plasma bile acid levels were associated 
with compensatory downregulation of Cyp7a1, Cyp27a1, Cyp8b1 and Ntcp and upregulation 
of Slc51b in liver (Figure 8B). Importantly, provision of taurocholic acid markedly increased 
plasma alanine aminotransferase activity (Figure 8C), upregulated the expression of 
inflammatory genes (Figure 8D), and stimulated leukocyte infiltration (Figure 8E). 
Moreover, taurocholic acid promoted hepatic fibrosis as revealed by elevated expression of 
the fibrosis markers collagen type I alpha 1 and Timp1 (Figure 8F), and enhanced collagen 
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Figure 8. Bile acids promote hepatic injury 
(A) Concentration of free and conjugated bile acid subspecies in the plasma of CTRL and taurocholic acid-
fed mice. Tr indicates that only trace levels of this bile acid could be measured. (B) Relative expression of 
genes encoding enzymes of bile acid synthesis and bile acid transporters. Gene expression levels in CTRL 
mice were set at 1. (C) Activity of alanine aminotransferase (ALT) in plasma. (D) Relative expression of 
inflammation-related genes in the liver. Gene expression levels in CTRL mice were set at 1. (E) H&E staining 
of representative liver sections. (F) Relative expression of fibrosis-related genes in the liver. Gene expression 
levels in CTRL mice were set at 1. (G) Representative pictures of liver sections stained for collagen using 
fast green FCF/Sirius Red F3B. Inset is a higher magnification of the collagen deposition as observed in the 
livers of the taurocholic acid-fed mice. Data are presented as mean ± SEM. Asterisks indicate significantly 
different compared with CTRL. *p<0.05, **p≤0.001.
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deposition (Figure 8G). Analysis of a publicly available transcriptomics dataset (GSE34730) 
of livers of mice treated with cholic acid or deoxycholic acid for 2 weeks confirmed the 
marked stimulatory effect of oral administration of bile acids on genes implicated in hepatic 
inflammation and fibrosis. Specifically, Ingenuity pathway analysis showed the significant 
induction of numerous pathways related to immune cells and cytokines signaling, including 
IL-8 signaling and acute phase response signaling, as well as hepatic fibrosis/hepatic stellate 
activation. These effects were similarly observed in conventionalized and germ-free mice, 
indicating that the effects of oral cholic and deoxycholic acid on liver inflammation and 
fibrosis are not dependent on bacterial conversion (Supplemental Figure 2). Together, these 
data suggest that elevated plasma levels of bile acids can lead to hepatic inflammation and 
fibrosis in mice fed GG.
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Figure 9. Suppression of the gut bacteria using antibiotics does not affect hepatic steatosis
(A) Weight of the cecum. (B) Quantitative analysis of fecal DNA levels. (C) qPCR amplification plot for 16S 
rRNA gene and fungal ITS1-5.8S-ITS2 region in equal amounts of fecal DNA. Solid lines indicate CTRL 
mice and dashed lines indicate ABX mice. (D) Cecal SCFA concentration. (E) Final bodyweight of mice fed 
CTRL diet with or without antibiotics supplementation. (F) Quantitative analysis of liver triglyceride levels. 
(G) H&E staining of representative liver sections. Data are presented as mean ± SEM. Asterisks indicate 
significantly different compared with CTRL. **p≤0.001.
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Suppression of the gut bacteria by oral antibiotics attenuates NAFLD development 
In order to study the direct impact of the gut microbiota on features of NAFLD, mice fed 
the HFCFD diet were given antibiotics via the drinking water for the entire duration of the 
dietary intervention. Oral administration of antibiotics led to a large increase in the weight 
of the cecum (Figure 9A), and caused a massive decrease in fecal DNA levels (Figure 9B) and 
levels of the 16S rRNA gene (Figure 9C). In addition, antibiotics dramatically reduced SCFA 
levels in the cecum (Figure 9D), demonstrating the effective suppression of the bacteria 
in the colon. Interestingly, antibiotics triggered an outgrowth of fungi (Figure 9C). At the 
end of the dietary intervention, final bodyweights were similar between the antibiotic-
treated and control mice (Figure 9E). Antibiotics treatment did not affect hepatic steatosis 
development, as indicated by quantitative measurement of liver triglycerides (Figure 9F) 
and H&E staining (Figure 9G). 
Strikingly, oral antibiotic caused a marked decrease in serum ALT activity (Figure 
10A), as well as a decrease in the expression of inflammatory markers in the liver (Figure 
10B). In addition, antibiotics treatment reduced hepatic fibrosis as indicated by markedly 
lower expression of the fibrosis markers collagen type I alpha 1, αSMA and Timp1 (Figure 
10C), and less collagen deposition (Figure 10D). While LPS levels in portal blood were not 
different between control and antibiotic-treated mice (Figure 10E), antibiotics treatment led 
to a non-significant reduction in the portal concentration of primary bile acids and a highly 
significant 10-fold reduction in the concentration of secondary bile acids (Figure 10F), 
hinting at a potential role of bile acids in the attenuation of features of NAFLD in the livers 
of the antibiotic-treated mice. Specifically, in the portal blood the primary bile acids cholic 
acid, chenodeoxycholic acid and muricholic acids and almost all secondary bile acids were 
reduced upon antibiotics treatment (Figure 10G). The reduction in portal delivery of bile 
acids was accompanied by a significant reduction in hepatic expression of the FXR target 
Slc51b and a compensatory induction of genes involved in bile acids synthesis, including 
Cyp7a1, Cyp27a1, and Cyp8b1, as well as the bile acid importer Ntcp and exporter Bsep (Figure 
10H). Surprisingly, total hepatic bile acid levels were increased in the antibiotic-treated mice 
(Figure 10I). As expected, treatment with antibiotics caused a marked reduction in fecal 
excretion of secondary bile acid levels, whereas excretion of primary bile acids remained 
unchanged (Figure 10J). Together, these data indicate that suppression of the gut bacteria 
attenuates features of NAFLD, possibly via reduced portal delivery of bile acids. 
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Figure 10. Antibiotics attenuate hepatic inflammation and fibrosis 
(A) Activity of alanine aminotransferase (ALT) in serum. Relative expression of (B) inflammatory and (C) 
fibrosis-related genes in the liver. Gene expression levels in CTRL mice were set at 1. (D) Representative 
pictures of liver sections stained for collagen using fast green FCF/Sirius Red F3B. (E) Portal serum 
lipopolysaccharide levels. (F) Concentration of primary and secondary bile acids in portal serum. (G) 
Concentration of free and conjugated primary and secondary bile acid subspecies in the portal serum of 
CTRL and GG mice. Tr indicates that only trace levels of this bile acid could be measured. Nd indicates 
that levels of this bile acid were below detectable limit. (H) Relative expression of genes encoding enzymes 
of bile acid synthesis, the FXR target gene Slc51b and hepatic bile acid transporters. Gene expression levels 
in CTRL mice were set at 1. (I) Total bile acid content in the liver. (J) Mean excretion of primary and 
secondary bile acids per mouse per day in the CTRL and ABX group at the end of the dietary intervention. 
Data are presented as mean ± SEM. Asterisks indicate significantly different compared with CTRL. *p<0.05, 
**p≤0.001.
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Discussion 
Emerging evidence points to an association between the gut microbiota and NAFLD (47). 
However, data on an actual causal role of the gut microbiota in NAFLD are very scarce. Here 
we found that stimulation of the gut microbiota using guar gum promoted liver inflammation 
and fibrosis. Inasmuch as guar gum is a pre-biotic non-digestible carbohydrate and is thus 
expected to act exclusively via its fermentation by the gut bacteria, our results suggest a direct 
impact of the gut microbiota on the pathogenesis of NAFLD. By contrast, suppression of the 
gut bacteria using oral antibiotics attenuated liver inflammation and fibrosis. The effects of 
microbial modulation by guar gum could be linked to altered circulating and hepatic levels 
of bile acids, which were shown to induce features of hepatic inflammation and fibrosis. Our 
data thus suggest that the gut bacteria may be able to influence NAFLD via bile acids.
It should be noted that the stimulation of hepatic inflammation and fibrosis by guar 
gum was unrelated to obesity—an important causal factor of NAFLD—as guar gum 
suppressed diet-induced weight gain and concomitant glucose intolerance and adipose 
tissue inflammation. In contrast to guar gum, resistant starch did not have any impact on 
NAFLD, probably due to the minor effect of resistant starch on gut microbial composition 
and levels of fermentation products (48). 
Ideally, feeding guar gum should be combined with the use of antibiotics, thereby 
allowing direct investigation of the role of the gut microbiota in the effects of guar gum. 
However, in our experience it is impossible to combine the use of antibiotics with feeding 
a diet enriched in dietary fiber. Specifically, we found that giving mice antibiotics while on 
a high fiber diet quickly led to an intestinal blockage and massive weight loss, forcing us to 
end the experiment prematurely. This observation underscores that dietary fiber cannot be 
properly processed in the absence of a well-functioning gut microbiota. 
Several mechanisms have been proposed to explain the link between the gut microbiota 
and host metabolism. These mechanisms mainly revolve around specific microbial 
metabolites or compounds, including lipopolysaccharide, SCFA, TMA, ethanol and bile 
acids, the latter of which are extensively metabolized by the gut microbiota. TMA has been 
linked to NAFLD by reflecting the microbial conversion and depletion of choline (49). We 
found significantly higher plasma TMA levels in mice fed GG. Upon absorption, TMA is 
rapidly oxidized in the liver to TMAO by flavin monooxygenases. Gao et al. showed that 
dietary TMAO increases adipose tissue mRNA levels and serum levels of MCP-1 in mice 
(50). In addition, TMAO has also been shown to exacerbate atherosclerosis development 
in mice and is positively linked to cardiovascular disease risk in humans. Importantly, 
suppression of the gut microbiota using antibiotics lowered plasma TMAO levels and reduced 
atherosclerosis (9, 45). Furthermore, TMAO was also recently implicated in kidney fibrosis 
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(46). In our study, however, elevated plasma TMAO levels did not seem to be responsible for 
the aggravation of NALFD in mice fed guar gum, as feeding mice TMAO for 18 weeks had 
no effect on any indicators of NALFD or fibrosis, despite markedly elevating circulating and 
urinary TMAO levels. 
In addition to TMA and TMAO, plasma total bile acids were elevated in the GG but not 
RS mice. The parallel reduction in fecal bile acids suggests that bile acids are more efficiently 
absorbed in the mice fed guar gum. The increase in plasma bile acid levels was accompanied 
by elevated hepatic bile acid content and worsening of NAFLD and fibrosis. To investigate if 
bile acids could be causally involved in the progression of NAFLD upon guar gum feeding, 
mice were fed chow supplemented with taurocholic acid. Taurocholic acid feeding increased 
plasma levels of a range of different bile acids, which was associated with activation of 
specific features of NAFLD. These data suggest that elevated plasma and hepatic bile acids 
are a plausible mechanistic link between changes in gut microbial composition in mice fed 
guar gum and worsening of NAFLD. Consistent with this hypothesis, hepatic bile acid levels 
were found to be elevated in humans with steatohepatitis (51). Furthermore, NAFLD was 
found to be associated with intestinal dysbiosis and altered fecal bile acid levels in human 
subjects (52).
One type of bile acid that may be particularly involved in promoting liver injury and 
NAFLD is deoxycholic acid, levels of which were increased by 4.2-fold in the plasma of 
mice fed guar gum. Recently, Yoshimoto et al. (53) linked increased deoxycholic acid levels 
upon high-fat feeding to the development of NAFLD-related hepatocellular carcinomas. 
Suppression of the microbiota by antibiotics lowered serum deoxycholic acid levels and 
mitigated hepatocellular carcinoma development, suggesting that microbial production 
of deoxycholic acid may have detrimental effects on the liver. The mechanism by which 
bile acids may promote liver injury and hepatic inflammation and fibrosis may involve 
enhanced leakage of tight junctions of bile duct epithelial cells causing cholangitis, as well 
as the activation and proliferation of periductal myofibroblasts leading to periductal fibrosis 
(54). Furthermore, it is well established that elevated intrahepatic bile acid levels trigger 
hepatocyte apoptosis, possibly leading to NASH (55–57). Future studies should address the 
cellular mechanism(s) by which microbiota-dependent changes in portal and hepatic bile 
acids may influence NAFLD.
The increase in liver bile acid content in the mice treated with antibiotics may be taken 
as evidence that bile acids cannot be responsible for the reduced liver injury, inflammation 
and fibrosis in these mice. However, it is likely that the increase in liver bile acid content 
reflects increased bile acid synthesis, as opposed to increased portal delivery of bile acids, 
which in fact was substantially decreased. It is conceivable that the newly synthesized bile 
acids are immediately secreted and are primarily located in the bile ducts, where they may 
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not inflict liver injury. By contrast, the reduction in portal delivery of bile acids may lead to 
lower uptake of bile acids by hepatocytes, and thereby attenuate liver injury, inflammation 
and fibrosis. 
Our results are consistent with previous studies showing that modulation of the gut 
microbiota influences bile acid levels and metabolism (58–60). These studies have pointed 
to intestinal FXR signaling and resultant changes in FGF15 and ceramides as potential 
intermediate between microbiota-induced changes in bile acids on the one hand, and liver 
triglycerides and bile acid synthesis on the other hand. Although our data are not inconsistent 
with a role of intestinal FXR signaling, FGF15, and ceramides, our study highlights the 
potential role of bile acids as causal factor in linking changes in the gut bacteria to altered 
liver inflammation and fibrosis.
It should be noted that in contrast to previous data (61–63), we did not find any evidence 
that the protective effect of antibiotics on the development of NAFLD might be mediated by 
LPS, as portal LPS levels were not altered upon antibiotic-treatment.
In our study, specific gut microbial taxa could be linked to the transition from simple 
steatosis to NASH and fibrosis. The higher relative abundance of the genera Bifidobacterium 
and Prevotella, and of the species Desulfovibrio C21_c20 and Akkermansia muciniphila as 
observed in the colonic luminal content of the GG mice, have not been observed in other 
mouse studies linking specific gut microbial taxa to the progression of NAFLD. However, 
these studies used either bile duct ligation (18, 64), a methionine choline-deficient diet (65) 
or carbon-tetrachloride injections (64) to induce liver injury. Bacteria within the genera 
Lactobacillus, Bifidobacterium and Streptococcus have been demonstrated to suppress 
hepatic inflammation in mice and humans (66, 67). In addition to dampening hepatic 
inflammation, Lactobacillus and Bifidobacterium have also been shown to reduce hepatic 
fibrosis (68). Furthermore, Bifidobacteria are known to be able to ferment guar gum (69, 
70) and possess active bile salt hydrolases (71). Since unconjugated bile acids are less 
efficient in the solubilization and absorption of intestinal lipids (71), one possible scenario 
is that by increasing bile salt hydrolase activity and unconjugated bile acids, the increase in 
Bifidobacterium may be responsible for the elevated fecal lipid excretion. 
Guar gum is composed of galactose and mannose residues and is extracted from the seeds 
of guar beans. It is mainly used as a thickening agent in several food products including ice 
creams, sauces and cheese spreads (72). Although we show that dietary guar gum promotes 
the progression of NAFLD, caution should be exercised in extrapolating these data to the 
human situation because, 1) the dose of guar gum used substantially exceeds the amounts 
ingested by humans, 2) the microbiota composition is vastly different between mice and 
humans. In our study, we used guar gum as a model compound to study the effect of 
modulating the gut microbiota composition on NAFLD.
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In conclusion, we find that stimulation of the gut bacteria by guar gum leads to deleterious 
effects on hepatic inflammation and fibrosis in a mouse model of NAFLD, whereas suppression 
of the gut bacteria by antibiotics attenuates NAFLD. Overall, we provide evidence of a causal 
link between disturbances in gut bacteria, bile acids, and NAFLD.
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Map4k4 9.61E-07
Rhob 9.61E-07
Rock2 8.33E-06
Rhoc 8.47E-06
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Mapk3 5.77E-05
Itgax 9.27E-05
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Pik3r5 4.45E-04
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Cxcr2 6.95E-04
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Prkcb 1.29E-03
Src 1.51E-03
Pld3 1.57E-03
Ncf2 1.75E-03
Cybb 2.46E-03
Rhoj 3.20E-03
Pld1 3.41E-03
Itgb2 3.88E-03
Fos 9.13E-03
Egf 9.62E-03
CTRL GG
Complement system
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Supplemental figure 1. Guar gum alters IL-8 signaling and complement system activation
(A) Volcano plot displaying relative changes in expression of 21115 genes (x axis) plotted against statistical 
significance (y axis) upon GG feeding. Dotted line represents cut-off for p<0.01. (B) Heat map showing 
significant changes in expression of genes involved in IL-8 signaling and complement system activation in 
the livers of CTRL and GG mice. The Log2 expression signals of the CTRL group was arbitrarily set at 0. 
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Hepatic fibrosis / Hepatic stellate cell activation
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Acute phase response signaling
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IL-8 signaling
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Supplemental figure 2. Effect of cholic acid and deoxycholic acid on hepatic genome-wide expression
Heat maps showing changes in expression of genes involved in hepatic fibrosis/hepatic stellate 
cell activation, IL-8 signaling and acute phase response signalling in the livers of germ-free and 
conventionalized mice fed either a CTRL diet or supplemented with 0.5% CA or 0.5% DCA for two 
weeks. The Log2 expression signals of CTRL was arbitrarily set at 0.
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 Control Resistant starch Guar Gum 
 g% kcal% g% kcal% g% kcal% 
Protein 24 20 24 21 24 20 
Carbohydrate 41 35 41 32 41 35 
Fat 24 45 24 47 24 45 
Total  100  100  100 
kcal/g 4.7  4.7  4.7  
       
Ingredient g kcal g kcal g kcal 
Casein, 30 Mesh 200 800 200 800 200 800 
L-Cystine 3 12 3 12 3 12 
Corn Starch 72.8 291 0 0 0 0 
Resistant Starch 0 0 86.7 173.4 0 0 
Guar Gum 0 0 0 0 86.7 346.8 
Maltodextin 10 100 400 86.1 344.4 86.1 344.4 
Sucrose 172.8 691 172.8 691 172.8 691 
Cellulose, BW200 50 0 50 0 50 0 
Soybean Oil 25 225 25 225 25 225 
Safflower Oil 177.5 1598 177.5 1598 177.5 1598 
Cholesterol 8.66 0 8.66 0 8.66 0 
Mineral Mix S10026 10 0 10 0 10 0 
DiCalcium Phosphate 13 0 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 5.5 0 
Patassium Citrate 16.5 0 16.5 0 16.5 0 
Vitamin Mix V10001 10 40 10 40 10 40 
Choline Bitartrate 2 0 2 0 2 0 
Total  866.8 4057 866.8 3884 866.8 4057 
 
Supplemental table 1. Macronutrient and ingredient composition of various diets based on 
formula D12451 study 1
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Supplemental table 2. Primer sequences used for qPCR
 Primer Sequence  
Name Forward Reverse 
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mβ-actin GATCTGGCACCACACCTTCT GGGGTGTTGAAGGTCTCAAA 
mCd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
mF4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
mCd11c CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA 
mCd206 GCTTCCGTCACCCTGTATGC GTGTGTCATTCTTACACTCCC 
mMcp-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
mTnfα CAACCTCCTCTCTGCCGTCAA TGACTCCAAAGTAGACCTGCCC 
mIl-10 CTGGACAACATACTGCTAACCG GGGCATCACTTCTACCAGGTAA 
mCol1α1 TGTGTGCGATGACGTGCAAT GGGTCCCTCGACTCCTACA 
mαSma GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA 
mTimp1 GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT 
mCyp7a1 CAGGGAGATGCTCTGTGTTCA AGGCATACATCCCTTCCGTGA 
mCyp27a1 GCCTTGCACAAGGAAGTGACT CGCAGGGTCTCCTTAATCACA 
mCyp8b1 CCTCTGGACAAGGGTTTTGTG GCACCGTGAAGACATCCCC 
mSlc51b AGATGCGGCTCCTTGGAATTA TGGCTGCTTCTTTCGATTTCTG 
mNtcp ATGACCACCTGCTCCAGCTT GCCTTTGTAGGGCACCTTGT 
mBsep CTGCCAAGGATGCTAATGCA CGATGGCTACCCTTTGCTTCT 
mFgf15 GCTCTGAAGACGATTGCCATC TTCCTCCCTGAAGGTACAGTC 
mAsbt ATGGCGACATGGACCTCAGT CCCGAGTCAACCCACATCTTG 
mIbabp CTTCCAGGAGACGTGATTGAAA CCTCCGAAGTCTGGTGATAGTTG 
mSlc51a GTTCCAGGTGCTTGTCATCC CCACTGTTAGCCAAGATGGAGAA 
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Supplemental table 3. Relative abundance of microbiota in colonic luminal content study 1
 
Phylum Class Order Family Genus Species CTRL (%) RS (%) GG (%) FC RS* P-value RS** FC GG* P-value GG**
Actinobacteria 0.26 1.54 15.63 5.9 0.012 59.2 p<0,001
Actinobacteria 0.26 1.54 15.63 5.9 0.012 59.2 p<0,001
Bifidobacteriales 0.26 1.54 15.63 5.9 0.012 59.2 p<0,001
Bifidobacteriaceae 0.26 1.54 15.63 5.9 0.012 59.2 p<0,001
Bifidobacterium 0.26 1.54 15.63 5.9 0.012 59.2 p<0,001
Bacteroidetes 4.51 17.16 14.49 3.8 0.002 3.2 p<0,001
Bacteroidia 4.51 17.16 14.49 3.8 0.002 3.2 p<0,001
Bacteroidales 4.51 17.16 14.49 3.8 0.002 3.2 p<0,001
Unidentified 2.18 5.70 0.52 2.6 0.038 -4.2 0.002
Paraprevotellaceae 0.12 0.09 3.24 -1.3 0.046 27.2 p<0,001
Prevotella 0.12 0.09 3.24 -1.3 0.046 27.2 p<0,001
Bacteroidaceae 1.21 3.94 5.26 3.2 0.01 4.3 0.002
Bacteroides 1.21 3.94 5.26 3.2 0.01 4.3 0.002
S24-7 0.99 7.43 5.47 7.5 0.001 5.5 p<0,001
Unidentified 0.99 7.43 5.47 7.5 0.001 5.5 p<0,001
Deferribacteres 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Deferribacteres 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Deferribacterales 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Deferribacteraceae 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Mucispirillum 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Mucispirillum schaedleri 4.95 1.71 1.12 -2.9 0.038 -4.4 0.006
Firmicutes 84.63 74.76 55.43 -1.1 0.016 -1.5 p<0,001
Bacilli 9.99 1.88 0.62 -5.3 0.012 -16.1 p<0,001
Lactobacillales 9.99 1.88 0.62 -5.3 0.012 -16.1 p<0,001
Lactobacillaceae 9.99 1.88 0.62 -5.3 0.012 -16.1 p<0,001
Lactobacillus 9.99 1.88 0.62 -5.3 0.012 -16.1 p<0,001
Clostridia 26.58 9.61 9.94 -2.8 0.002 -2.7 0.001
Clostridiales 26.58 9.61 9.94 -2.8 0.002 -2.7 0.001
Unidentified 17.87 3.99 6.34 -4.5 0.001 -2.8 0.006
Clostridiaceae 4.09 3.03 0.00 -1.3 ns -2275.9 0.001
SMB53 4.09 3.03 0.00 -1.3 ns -2275.9 0.001
Lachnospiraceae 1.70 1.56 3.19 -1.1 ns 1.9 ns
Unidentified 1.40 1.28 2.16 -1.1 ns 1.5 ns
Ruminococcus 0.30 0.27 1.03 -1.1 ns 3.4 ns
Ruminococcus gnavus 0.30 0.27 1.03 -1.1 ns 3.4 ns
Ruminococcaceae 2.92 1.04 0.41 -2.8 ns -7.2 p<0,001
Oscillospira 2.92 1.04 0.41 -2.8 ns -7.2 p<0,001
Erysipelotrichi 48.06 63.27 44.87 1.3 ns -1.1 ns
Erysipelotrichales 48.06 63.27 44.87 1.3 ns -1.1 ns
Erysipelotrichaceae 48.06 63.27 44.87 1.3 ns -1.1 ns
Allobaculum 48.06 63.27 44.87 1.3 ns -1.1 ns
Proteobacteria 5.51 4.81 5.10 -1.1 ns -1.1 ns
Deltaproteobacteria 5.51 4.81 5.10 -1.1 ns -1.1 ns
Desulfovibrionales 5.51 4.81 5.10 -1.1 ns -1.1 ns
Desulfovibrionaceae 5.51 4.81 5.10 -1.1 ns -1.1 ns
Bilophila 3.08 2.22 1.53 -1.4 ns -2.0 ns
Desulfovibrio 2.43 2.59 3.56 1.1 ns 1.5 ns
Unidentified 2.42 2.47 1.60 1.0 ns -1.5 ns
Desulfovibrio C21_c20 0.00 0.12 1.97 83.2 ns 1308.8 0.002
Verrucomicrobia 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Verrucomicrobiae 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Verrucomicrobiales 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Verrucomicrobiaceae 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Akkermansia 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Akkermansia muciniphila 0.14 0.01 8.23 -17.3 ns 60.8 p<0,001
Abundance treshold for presentation in the table >0.5% in at least one of the three diet groups
* fold change (FC) compared with CTRL
** significance according to Kruskal-Wallis test followed by unpaired Wilcoxon rank-sum test to test significance compared with CTRL
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Abstract
Recently, the administration of the mucin-degrading bacteria Akkermansia muciniphila was 
shown to protect against diet-induced obesity and glucose intolerance in mice. However, 
whether A. muciniphila or other mucin-degrading bacteria influence non-alcoholic fatty 
liver disease (NAFLD) in obese mice is currently unknown. To resolve this question, mice 
were fed a high fat/high cholesterol/high fructose diet for 13 weeks to induce NAFLD, 
followed by daily oral gavage of either live A. muciniphila, heat-killed A. muciniphila, live 
Bacteroides thetaiotaomicron, heat-killed B. thetaiotaomicron, or control gavage, for a total 
of 5 weeks.
Daily administration of viable A. muciniphila effectively increased the abundance of 
A. muciniphila in the colon, whereas administration of viable B. thetaiotaomicron had no 
effect on B. thetaiotaomicron abundance. All treatments caused a substantial decrease in 
bodyweight during the first week of oral gavages, which stabilized the remaining 4 weeks. 
No significant differences in bodyweight gain could be observed among the different 
treatments. Treatment of obese mice with A. muciniphila or B. thetaiotaomicron did not 
affect hepatic steatosis, inflammation or fibrosis. Finally, gut permeability and portal serum 
LPS levels were also not altered by treatment with A. muciniphila or B. thetaiotaomicron.
Taken together, treatment of obese mice with live or heat-killed A. muciniphila or B. 
thetaiotaomicron for 5 weeks did not significantly affect obesity, gut barrier function or 
features of NAFLD.  Whether a higher dose or longer duration of A. muciniphila treatment 
may affect hepatic fibrosis remains to be investigated. 
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Introduction
In the past two decades, it has become increasingly apparent that the intestinal microbiota 
are involved in mediating the effects of host genetics and environment on the health status 
of the host. Numerous studies have shown that by modulating the intestinal microbiota, 
changes in gut microbial composition may have a causal role in various diseases (1–4). For 
example, mice harbouring no microbiota in the gut —so-called germ-free mice— do not 
develop diet-induced obesity and related metabolic disturbances, whereas conventionally-
raised mice do (5, 6). Similarly, the administration of specific bacterial communities has 
been shown to confer beneficial health effects, such as attenuating non-alcoholic fatty 
liver disease (NAFLD) and reducing atherosclerosis (7–9). We recently demonstrated that 
modulation of the gut microbiota can be protective against diet-induced obesity, while at the 
same time promote NAFLD (10). Understanding how and which microbial species impact 
host health may provide useful insights into the role of the gut bacteria in metabolic diseases 
and may pave the way for new therapeutic targets in metabolic diseases. 
One bacterium that gained a lot of interest in the last decade is the gram-negative 
anaerobic Akkermansia muciniphila. A. muciniphila is the only cultivable member of the 
Verrucomicrobia phylum and resides in the mucus layer of the intestinal tract (11, 12). With 
a relative abundance of 1-4%, A. muciniphila constitutes one of the most abundant species in 
the colon of human subjects (13, 14). Multiple studies have shown that the relative abundance 
of A. muciniphila inversely correlates with bodyweight and blood glucose levels in mice 
(15–17), as well as in humans (18–21). Moreover, weight loss has been shown to be associated 
with an increase in A. muciniphila (22, 23). By supplementing A. muciniphila to mice, it was 
demonstrated that A. muciniphila may be causally linked to obesity and glucose tolerance. 
Daily oral gavage of A. muciniphila to mice fed a chow diet or a high fat diet (15, 24–26) 
reduced bodyweight gain and improved glucose homeostasis, and was shown to reduce 
atherosclerosis (27). The improvement in metabolic status upon A. muciniphila treatment is 
suggested to be related to an improved integrity of the gut barrier. A. muciniphila degrades 
mucins in the mucus layer to obtain energy and as the sole source of carbon and nitrogen 
required for their growth (28). As a result, the mucus layer is constantly refreshed, which 
prevents thinning of the mucus layer and leakage of LPS into the circulation (15). Since 
entry of LPS into the circulating has been linked to weight gain and glucose intolerance 
(29), the counteracting effect of A. muciniphila on obesity and associated disorders might be 
explained by decreased plasma LPS levels (15, 24, 25, 27). 
Another gram-negative anaerobic bacterium that is also able to degrade mucins is 
Bacteroides thetaiotaomicron. B. thetaiotaomicron is a dominant member of the intestinal 
microbiota of human and mice, and belongs to the phylum Bacteroidetes (30). B. 
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thetaiotaomicron obtains energy by the degradation of complex dietary polysaccharides, 
but is able to switch its gene expression to metabolize host mucus polysaccharides when 
dietary polysaccharides are scarce (31). Recently, it was shown that the relative abundance 
of B. thetaiotaomicron is significantly lower in patients with the metabolic syndrome (32). 
Although the effect of B. thetaiotaomicron on host metabolism is less well studied than A. 
muciniphila, two studies have reported that B. thetaiotaomicron promotes fat storage in 
germ-free mice (1, 33). In addition, it is also suggested that B. thetaiotaomicron can modulate 
host immune responses (34, 35). As B. thetaiotaomicron has been suggested to promote 
goblet cell differentiation and thereby induce mucin synthesis (36), it can be hypothesized 
that B. thetaiotaomicron may affect host metabolism via changes in the gut barrier. 
NAFLD is a liver disease commonly seen in overweight and obese individuals. 
NAFLD is characterized by excessive fat accumulation in the liver, and varies 
from simple steatosis to non-alcoholic steatohepatitis and cirrhosis. Key features 
of  non-alcoholic steatohepatitis are lobular inflammation and ballooning of 
hepatocytes, which may progress towards fibrosis (37). Changes in the gut microbiota 
and subsequent alterations in gut barrier function have been suggested to be 
involved in the pathogenesis of NAFLD (38, 39). Taking into account the reported protective 
effect of A. muciniphila and B. thetaiotaomicron on gut barrier function, we hypothesized 
that treatment of obese mice with A. muciniphila and B. thetaiotaomicron may attenuate 
NAFLD development. To investigate this hypothesis, obesity and NAFLD were elicited in 
mice by feeding a diet rich in fat, cholesterol and fructose, followed by administration of live 
or heat-killed A. muciniphila and B. thetaiotaomicron for 5 weeks. 
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Materials and methods
Animals and diet
10-week-old C57Bl/6 male mice were maintained on a 12 hr light-dark cycle under specific 
pathogen-free conditions. The mice had ad libitum access to a high fat/high cholesterol/high 
fructose diet (HFCFD), providing 45% energy as triglycerides (formula 58V8 manufactured 
by TestDiet, St. Louis, USA) for 18 weeks. To promote the development of NAFLD, the diet 
was supplemented with 1% cholesterol (Dishman, Veenendaal, Netherlands) and the mice 
received 20% fructose in their drinking water (wt/vol) (10). After 13 weeks HFCFD we 
started with daily oral gavage of 2x108 cfu/0.2ml of either live or pasteurized A. muciniphila 
or B. thetaiotaomicron for a period of 5 weeks. Control mice received an equivalent volume 
of sterile anaerobic PBS containing 5% glycerol. 
Bodyweight and food intake were assessed weekly. 6 mice died during the bacterial 
administration period for unknown reasons. These mice were inspected and no abnormalities 
were found. At the end of the study, mice were anesthetized with isoflurane and portal 
blood was collected. After euthanization, tissues and intestinal content was collected for 
further analysis. This animal study was approved by the local animal ethics committee of 
Wageningen University. 
 
Culture and pasteurization of A. muciniphila and B. thetaiotaomicron
Akkermansia muciniphila cells were prepared as described before (25). B. thetaiotaomicron 
cells were grown on BHIS (40) till mid exponential phase. The cells were harvested and 
washed with PBS and then concentrated in PBS with 10% glycerol to 2x109 CFU/ml and 
stored at -80C. Additionally, a separate batch of  A. muciniphila and B. thetaiotaomicron 
at a concentration of 2x109 CFU/ml was inactivated by pasteurization for 30 min at 70°C. 
Shortly before gavage the cells were diluted in anaerobic PBS to an end concentration of 
2x108 CFU/0.2 ml. 
DNA extraction
DNA was extracted from fecal samples, as previously described (10). Briefly, 15-40 mg of 
fecal samples were lysed using a bead beater (BioSpec, Bartlesville, USA) and DNA was 
subsequently extracted and purified using a Maxwell 16 System (Promega).
Bacteria quantification
Standard curves were prepared by amplifying 16S rRNA gene using fecal DNA of the control 
group or genomic DNA of A. muciniphila or B. thetaiotaomicron using the universal 16S primers 
27F (5’-GTTTGATCCTGGCTCAG-3’) and 1492R (5’-CGGCTACCTTGTTACGAC-3’). The 
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cycling conditions consisted of an initial denaturation of 95°C for 5 min, followed by 35 
cycles of denaturation at 95°C for 30 sec, annealing at 52°C for 40 sec and extension at 
72°C for 90 sec, and a final extension at 72°C for 7 min. After verifying the amplicon size 
by agarose electrophoresis, the amplicon was purified using a commercial available PCR 
purification kit (ThermoScientific) and diluted in series ranging from 108 to 101 16S rRNA 
gene copies/μl was generated.
Real-time PCR was performed using SensiMix (Bioline, GC biotech, Alphen aan 
den Rijn, Netherlands) on a CFX384 Real-Time PCR detection system (Bio-Rad 
Laboratories, Veenendaal, Netherlands). Amplification conditions were 95°C for 5 
min, followed by 40 cycles of 95°C (15 sec), 60°C (30 sec) and 72°C (30 sec). For 16S 
rRNA gene the primers 1369F (5’-CGGTGAATACGTTCYCGG-3’) (41) and 1492R 
(5’-GGWTACCTTGTTACGACTT-3’) (42) were used, for A. muciniphila AM1 
(5’-CAGCACGTGAAGGTGGGGAC-3’) and AM2  (5’-CCTTGCGGTTGGCTTCAGAT-3’) 
(13) and for B. thetaiotaomicron Bt.1F (5’-ATAGCCTTTCGAAAGRAAGAT-3’) and Bt.1R 
(5’-CCAGTATCAACTGCAATTTTA-3’) (33). 
Plasma parameters
Plasma concentrations of triglycerides (HUMAN Diagnostics, Wiesbaden, Germany), 
glucose and cholesterol (DiaSys Diagnostic Systems, Holzheim, Germany) were deteremined 
according to manufacturers’ instructions. Plasma alanine aminotransferase activity was 
measured with a kit from Abcam (Cambridge, UK).
Portal serum LPS levels
Portal vein plasma LPS concentration was measured using an Endosafe-Multi-Cartridge 
System (Charles River Laboratories, MA, USA), as previously described (15).
Liver triglyceride quantification
Liver samples were homogenized in a buffer containing 10mM Tris, 2mM EDTA and 250mM 
sucrose at pH 7.5 with a Tissue Lyser II (Qiagen, Hilden, Germany).  Triglycerides were 
subsequently quantified using Triglycerides liquicolormono kit from HUMAN Diagnostics 
(Wiesbaden, Germany). Protein concentration was determined using a BCA protein assay 
kit (Pierce, Rockford, USA). 
Intestinal permeability assay
After 4 weeks bacterial administration an intestinal permeability assay was performed using 
4 kilodalton fluorescein isothiocyanate (FITC)-dextran (600 mg/kg bodyweight, 40mg/ml). 
Blood was drawn from the tail vein prior to administration to correct for autofluorescence 
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and 1 hour after oral gavage. Blood was stored on ice in the dark and centrifuged for 15 
minutes at 3000 rpm to obtain plasma. Plasma was diluted in PBS and fluorescent intensity 
was measured using a Fluorescence Spectrophotometer (excitation at 485nm and emission 
at 538nm). FITC-dextran concentrations were determined from a standard curve generated 
by diluting FITC-dextran in PBS.
RNA isolation and qPCR
TRIzol reagent (Life technologies, Bleiswijk, Netherlands) was used to extract RNA from 
liver and scrapings of the colon. 500ng RNA was reverse transcribed to cDNA using a iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Veenendaal, Netherlands). Real-time PCR 
was performed using SensiMix (Bioline, GC biotech, Alphen aan den Rijn, Netherlands) 
on a CFX384 Real-Time PCR detection system (Bio-Rad Laboratories, Veenendaal, 
Netherlands). 36B4 was used as a housekeeping gene. Sequences of the used primers are 
listed in Supplemental Table 1.
1H NMR spectroscopy
Short-chain fatty acids levels in the content of the cecum were measured in an Avance III 
NMR spectrometer, as previously described (10).
Histology
The liver and colon, rolled as a ‘Swiss roll’, were fixed in 4% formaldehyde and embedded 
in paraffin. Paraffin-embedded liver sections (5μm) were stained with hematoxylin and 
eosin (H&E) using standard protocols and for collagen using fast green FCF/Sirius Red F3B. 
Cross-sections of the colon (5μm) were stained with H&E and Alcian Blue according to 
standard protocols. 
 
Statistics
Results are presented as mean ± SEM. Analysis of variance followed by a Tukey’s post hoc 
multiple comparison test was performed to evaluate differences (GraphPad Software, Inc., 
La Jolla, USA). P<0.05 was considered as statistically significant. 
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Results 
Administration of A. muciniphila and B. thetaiotaomicron had no effect on 
obesity
Supplementing mice fed a high fat diet with A. muciniphila has been shown to lead to 
beneficial metabolic health effects (15, 25–27). However, the effect of A. muciniphila 
supplementation or other mucin-degrading bacteria in obese mice is currently unknown. 
Accordingly, mice were fed a high fat/high cholesterol/high fructose diet for 13 weeks to 
induce NAFLD, followed by daily oral gavage of either live A. muciniphila, heat-killed A. 
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Figure 1. Administration of A. muciniphila and B. thetaiotaomicron has no effect on obesity
(A) Study design. Mice were fed a high fat/high cholesterol/high fructose diet (HFCFD) for 13 weeks 
followed by daily oral gavage (OG) of live or heat-killed (HK) Akkermansia muciniphila (Akk) or Bacteroides 
thetaiotaomicron (Bact) for 5 weeks. The control group received an oral gavage of sterile anaerobic PBS. (B) 
16S rRNA and (C) A. muciniphila and B. thetaiotaomicron gene copies per gram feces. (D) Course of the 
bodyweight gain during entire study and (E) changes in bodyweight gain during oral administration of the 
different bacteria. (F) Weight of epididymal white adipose tissue depot. (G) Mean food intake per mouse 
per day. Data are presented as mean ± SEM. Differences were evaluated for statistical significance by one-
way ANOVA followed by Tukey’s post hoc multiple comparison test. *p<0.05.
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muciniphila, live Bacteroides thetaiotaomicron, heat-killed Bacteroides thetaiotaomicron, 
or control gavage, for a total of 5 weeks (Figure 1A). Treatment of obese mice with live 
A. muciniphila significantly increased the abundance of A. muciniphila as compared with 
treatment of mice with PBS or heat-killed A. muciniphila, whereas total bacterial numbers 
in the feces were comparable between the groups (Figure 1B-C). Daily supplementation 
of B. thetaiotaomicron resulted in a trend, though not-significant, towards increased fecal 
amounts of B. thetaiotaomicron (Figure 1C). 
Bodyweight went up steadily in the first 13 weeks of high fat/high cholesterol/high 
fructose. By contrast, bodyweight declined during the first week of  daily oral gavage, which 
stabilized during the remaining 4 weeks (Figure 1D). Administration of A. muciniphila or 
B. thetaiotaomicron, viable or heat-killed, had no effect on bodyweight gain or epididymal 
fat mass (Figure 1E-F). Levels of food intake were also similar between the groups (Figure 
1G). At the end of the dietary intervention, all mice were hyperglycemic, with plasma glucose 
levels being slightly but not significantly lower in the mice supplemented with heat-killed 
A. muciniphila. Plasma triglyceride and cholesterol levels were not different between the 5 
groups (Figure 2). Together, these findings indicate that supplementation of obese mice with 
A. muciniphila or B. thetaiotaomicron does not affect bodyweight, plasma glucose, plasma 
cholesterol, and plasma triglyceride levels. 
Administration of A. muciniphila and B. thetaiotaomicron had no effect on 
features of NAFLD
We previously demonstrated that feeding mice a HFCFD induces many features of NAFLD 
and is therefore a suitable mouse model to study obesity-related NAFLD (10). Treatment of 
obese mice with A. muciniphila or B. thetaiotaomicron had no effect on liver weight (Figure 
3A). In addition, treatment with A. muciniphila or B. thetaiotaomicron did not influence 
P
la
sm
a 
G
lu
co
se
 (m
M
)
Ctr
l
Akk
Akk
 HK Bac
t
Bac
t H
K
0
3
6
9
12
P
la
sm
a 
T
rig
ly
ce
rid
es
 (m
M
)
Ctr
l
Akk
Akk
 HK Bac
t
Bac
t H
K
0.0
0.2
0.4
0.6
0.8
1.0
P
la
sm
a 
C
ho
le
st
er
ol
 (m
M
)
Ctr
l
Akk
Akk
 HK Bac
t
Bac
t H
K
0
2
4
6
8
Figure 2. Administration of A. muciniphila and B. thetaiotaomicron has no effect on plasma parameters
Plasma glucose, triglyceride and cholesterol levels upon the administration of viable or heat-killed A. 
muciniphila or B. thetaiotaomicron to high fat diet-fed mice. Data are presented as mean ± SEM. Differences 
were evaluated for statistical significance by one-way ANOVA followed by Tukey’s post hoc multiple 
comparison test.
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hepatic steatosis, as indicated by liver triglyceride concentration and H&E staining (Figure 
3B-C), nor plasma alanine transferase activity, indicating that bacterial administration did 
not protect against liver damage (Figure 4A). Further analysis of the liver revealed that 
the expression of several macrophage markers and cytokines, including Mcp-1, Tnfα, Il-1β 
and Il-1ra, was not different between the 5 groups (Figure 4B-C). Treatment with viable A. 
muciniphila or B. thetaiotaomicron also did not affect hepatic fibrosis, as the expression of 
fibrosis markers and collagen deposition were similar to that of the control mice (Figure 
4D-E). These data show that treatment of obese mice with either A. muciniphila or B. 
thetaiotaomicron had no effect on features of NAFLD.
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Figure 3. Administration of A. muciniphila and B. thetaiotaomicron has no effect on hepatic steatosis
(A) Weight of the liver. (B) Quantification of liver triglyceride levels. Data are presented as mean ± SEM. 
Differences were evaluated for statistical significance by one-way ANOVA followed by Tukey’s post hoc 
multiple comparison test. (C) Representative pictures of the liver stained with H&E. 
A. muciniphila and B. thetaiotaomicron have no effect on NAFLD
125
5
Figure 4
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Figure 4. Administration of A. muciniphila and B. thetaiotaomicron has no effect on hepatic 
inflammation and fibrosis (A) Activity of alanine aminotransferase (ALT) in plasma. Relative expression 
of (B) macrophage markers, (C) cytokines and (D) fibrosis-related genes in the liver. Gene expression levels 
in CTRL mice were set at 1. Data are presented as mean ± SEM. Differences were evaluated for statistical 
significance by one-way ANOVA followed by Tukey’s post hoc multiple comparison test. (E) Representative 
pictures of the liver stained for collagen using fast green FCF/Sirius Red F3B.
Administration of A. muciniphila and B. thetaiotaomicron did not alter gut 
permeability and LPS levels in portal serum
Considering that the beneficial effects of A. muciniphila treatment on bodyweight and glucose 
homeostasis in mice fed a high fat diet were associated with improved gut barrier integrity 
(15, 27) and since A. muciniphila and B. thetaiotaomicron are mucin-degrading bacteria, we 
investigated whether A. muciniphila or B. thetaiotaomicron altered gut permeability in obese 
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mice. Gut permeability was determined by measuring levels of plasma FITC-dextran in the 
circulation after oral administration. Plasma FITC-dextran levels were similar between the 
groups, indicating that gut permeability was not affected by the different bacteria (Figure 
5A). The lack of an effect on gut permeability was accompanied by similar expression levels 
of the tight junction proteins Occludin and ZO-1. (Figure 5B). Despite the absence of an 
effect on gut permeability, expression of the main secreted mucin, Muc2, was significantly 
lower in the colon of mice treated with live B. thetaiotaomicron. Colonic expression of Muc3, 
a membrane-bound mucin, was similar in all groups (Figure 5C). Based on H&E and Alcian 
Blue stainings of the colon, no difference in the goblet cell number could be observed (Figure 
5D-E). As A. muciniphila supplementation has been associated with a reduction in plasma 
LPS levels, we also quantified LPS levels in portal blood. No difference in portal LPS levels 
was found between the groups (Figure 5F). In conclusion, treatment of obese mice with A. 
A B
FI
T
C
-d
ex
tra
n 
(μ
g/
m
l)
Ctr
l
Akk
Akk
 HK Bac
t
Bac
t H
K
0.0
0.5
1.0
1.5
P
or
ta
l s
er
um
 L
P
S
 (E
U
/m
l)
Ctr
l
Akk
Akk
 HK Bac
t
Bac
t H
K
0.0
0.3
0.6
0.9
1.2
R
el
at
iv
e 
ex
pr
es
si
on
Occludin ZO-1
0.0
0.5
1.0
1.5 Ctrl
Akk
Akk HK
Bact
Bact HK
R
el
at
iv
e 
ex
pr
es
si
on
Muc2 Muc3
0.0
0.5
1.0
1.5 Ctrl
Akk
Akk HK
Bact
Bact HK
C
F
*
D
Ctrl Akk HKAkk Bact HKBact
20x 20x20x20x20x
20x 20x20x20x20x
E
Figure 5. Administration of A. muciniphila and B. thetaiotaomicron does not alter gut permeability 
and LPS levels in portal serum
(A) Intestinal permeability as assessed by plasma FITC-dextran concentration 1 hour after oral 
administration. Relative expression of  (B) tight junction and (C) mucin genes. Gene expression levels in 
CTRL mice were set at 1. Representative pictures of the colon stained with (D) H&E and (E) Alcian blue. 
(F) LPS concentration in portal serum. Data are presented as mean ± SEM. Differences were evaluated for 
statistical significance by one-way ANOVA followed by Tukey’s post hoc multiple comparison test. *p<0.05.
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muciniphila or B. theteiotaomicron did not significantly affect obesity, features of NAFLD, 
gut permeability, and portal LPS levels.
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Discussion
Previously, the effect of A. muciniphila supplementation was studied in lean mice that 
were fed a high-fat diet in a parallel with supplementation with A. muciniphila (15, 25–27). 
To our knowledge, this is the first time that the metabolic effects of A. muciniphila or B. 
thetaiotaomicron are investigated in obese mice. In our study, mice were first fed a high fat/
high cholesterol/high fructose diet for 13 weeks to induce obesity-related NAFLD, followed 
by daily administration of live or heat-killed A. muciniphila or B. thetaiotaomicron. It was 
observed that  treatment of mice with A. muciniphila or B. thetaiotaomicron did not affect 
bodyweight, gut barrier function, or features of NAFLD. 
In several studies, obesity was shown to be associated with a decrease in the relative 
abundance of A. muciniphila (17, 22, 43). Treatment of mice on a high-fat diet with live 
A. muciniphila was shown to suppress diet-induced obesity (15, 26). Recently, Plovier et al. 
(25) demonstrated that pasteurized, but not autoclaved A. muciniphila, has a stronger effect 
on bodyweight and glucose homeostasis than live A. muciniphila (25). The reduction in 
bodyweight was associated with an increase in fecal energy excretion and was suggested to 
be mediated by Amuc_1100, a protein located on the outer membrane of A. muciniphila that 
resists denaturation at temperatures of pasteurization (25). In our study, we also made use 
of pasteurized A. muciniphila as control for the treatment of live A. muciniphila. However, 
neither live or pasteurized A. muciniphila significantly affected bodyweight. Several factors 
may explain the difference in effect of A. muciniphila on bodyweight in obese mice as 
compared to lean mice, despite live A. muciniphila administration effectively increasing the 
number of A. muciniphila in the colon. First, obese mice have a much thinner mucus layer 
than lean mice (15). As A. muciniphila usually resides in the mucus layer and obtains energy 
from the mucus layer, it is very likely that colonization in a gut with a thin mucus layer is 
more difficult and takes more time than in a gut with a thicker mucus layer. Secondly, the 
gut microbial composition is profoundly different between obese and lean mice (44, 45). 
Therefore, A. muciniphila has to compete with other microbes than in lean mice. Since the 
exact mechanism by which A. muciniphila exerts beneficial effects on host metabolism in 
lean mice is currently unknown, it cannot be excluded that the effects of A. muciniphila may 
be (partly) mediated by other microbial communities that either directly or indirectly affect 
host metabolism. The absence of an effect of A. muciniphila administration on bodyweight 
gain and glucose tolerance in Apoe-/- mice (27) could therefore possibly also be explained by 
differences in the gut microbial composition between different mice strains (26, 46). 
In comparison to A. muciniphila, B. thetaiotaomicron was not able to colonize the colon 
in 5 weeks of B. thetaiotaomicron administration. Whereas two studies reported that B. 
thetaiotaomicron administration promotes adiposity (1, 33), B. thetaiotaomicron had no 
effect on bodyweight in our study. Since the promotion of adiposity upon B. thetaiotaomicron 
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treatment was observed in germ-free mice, it can be speculated that in our study, other 
microbes may have hampered the effect of B. thetaiotaomicron. Future studies should 
address whether B. thetaiotaomicron may affect bodyweight in conventionally-raised lean 
mice, which have a different gut microbiota as compared to obese mice. 
In our study, we did not find a significant effect of either A. muciniphila or B. thetaiotaomicron 
administration on features of NAFLD, using a protocol of daily administration of 2x108 cells 
for 7 days a week during 5 weeks. Interestingly, in a recent study, three times administration 
of 1.5x109 cells A. muciniphila to mice with alcoholic fatty liver disease led to improved liver 
injury markers and hepatic inflammation (47). Accordingly, it is possible that higher doses 
of A. muciniphila are needed to show an effect on hepatic fibrosis or possibly for a longer 
treatment duration. 
A. muciniphila and B. thetaiotaomicron are mucin-degrading bacteria. Accordingly, the 
effects of A. muciniphila on the host are suggested to be mediated by improvements in the 
gut barrier. The gut barrier physically separates the gut lumen from the underlying tissues of 
the body and is composed of a mucus layer, epithelial cells and the lamina propria. The gut 
barrier integrity is mainly maintained by tight junction protein complexes that seal adjacent 
epithelial cells, which is complemented by the overlying mucus layer to add further protection. 
The expression of tight junctions proteins and the quantitation of mucus layer thickness are 
indirect measures for gut barrier function. To directly assess the functionality of the gut 
barrier, gut permeability tests have been developed (48, 49). A commonly used strategy to 
asses gut permeability is by administrating a non-digestible marker, such as FITC-dextran, 
which will only end up in the circulation when the gut barrier function is diminished. 
In our study, plasma FITC-dextran levels were not altered upon administration of live A. 
muciniphila or B. thetaiotaomicron. Although we did find a significant reduction in the 
expression of the main secretory mucin Muc2 upon live B. thetaiotaomicron administration, 
this result did not translate in a different gut barrier function. The lack of an effect of A. 
muciniphila on gut permeability is in accordance with a recently published study in which 
mice were first fed a high fat diet for 4 weeks and then treated with live A. muciniphila for 6 
weeks (16). In contrast, Li et al. showed that 8 weeks of A. muciniphila treatment significantly 
improved gut permeability in mice fed a high fat diet (27). Considering the high dose and the 
long treatment duration used by Li et al., it is possible that higher doses and longer treatment 
durations are needed for an effect of A. muciniphila on gut barrier function in obese mice. 
Disruption of the gut barrier may lead to increased translocation of harmful substances, 
such as LPS, to the circulation. Previously, it has been shown that elevated plasma LPS levels 
may be involved in mediating the harmful effect of high-fat induced obesity on insulin 
resistance (29). In addition, LPS has also been suggested to mediate the effects of the gut 
microbiota on NAFLD (50, 51). While administration of A. muciniphila to lean mice caused 
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a reduction in portal LPS levels (15, 25, 27), in obese mice we did not find a difference in 
portal LPS levels, possible due to the lack of an effect on gut barrier function. 
In our study, all treatments caused a substantial decrease in bodyweight during the first 
week of oral gavage. Oral gavage is considered as a potentially stressful procedure to mice 
and may therefore explain the bodyweight loss. Though, since this reduction in bodyweight 
occurred in all groups, we do not believe that this may have influenced the outcome of the 
study. 
In conclusion, treatment of obese mice with 2x108 CFU of A. muciniphila or B. 
thetaiotaomicron for 5 weeks did not affect obesity, gut barrier function, or features of 
NAFLD. Whether a higher dose or longer duration of A. muciniphila treatment may affect 
hepatic fibrosis remains to be investigated.
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Supplemental table
Supplemental table 1. Primer sequences used for qPCR
 Primer Sequence  
Name Forward Reverse 
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mCd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
mF4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
mCd11c CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA 
mCd206 GCTTCCGTCACCCTGTATGC GTGTGTCATTCTTACACTCCC 
mMcp-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
mTnfα CAACCTCCTCTCTGCCGTCAA TGACTCCAAAGTAGACCTGCCC 
mIl-1β CAGGCAGGCAGTATCACTCA AGGTGCTCATGTCCTCATCC 
mIl-1ra AAATCTGCTGGGGACCCTAC TGAGCTGGTTGTTTCTCAGG 
mCol1α1 TGTGTGCGATGACGTGCAAT GGGTCCCTCGACTCCTACA 
mαSma GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA 
mTimp1 GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT 
mTgf-β1 CCGCAACAACGCCATCTATG CTCTGCACGGGACAGCAAT 
mOccludin CTGGATCTATGTACGGCTCACA TCCACGTAGAGACCAGTACCT 
mZO-1 GAGCGGGCTACCTTACTGAAC GTCATCTCTTTCCGAGGCATTAG 
mMuc2 AGGGCTCGGAACTCCAGAAA CCAGGGAATCGGTAGACATCG 
mMuc3 AGCGTAGAGATAGAGCCGACA TCTTCAGACTTTCGGTCCTGTAG 
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Abstract
Background
Studies in mice have shown that PPARα is an important regulator of lipid metabolism in 
liver and key transcription factor involved in the adaptive response to fasting. However, 
much less is known about the role of PPARα in human liver.
Methods
Here we set out to study the function of PPARα in human liver via analysis of whole genome 
gene regulation in human liver slices treated with the PPARα agonist Wy14643. 
Results
Quantitative PCR indicated that PPARα is well expressed in human liver and human 
liver slices and that the classical PPARα targets PLIN2, VLDLR, ANGPTL4, CPT1A and 
PDK4 are robustly induced by PPARα activation. Transcriptomics analysis indicated that 
617 genes were upregulated and 665 genes were downregulated by PPARα activation (q 
value<0.05). Many genes induced by PPARα activation were involved in lipid metabolism 
(ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or 
the unfolded protein response, whereas most of the downregulated genes were involved in 
immune-related pathways. Among the most highly repressed genes upon PPARα activation 
were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon γ-induced 
genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. 
TLR3, NOS2, and LCN2). Comparative analysis of gene regulation by Wy14643 between 
human liver slices and primary human hepatocytes showed that down-regulation of gene 
expression by PPARα is much better captured by liver slices as compared to primary 
hepatocytes. In particular, PPARα activation markedly suppressed immunity/inflammation-
related genes in human liver slices but not in primary hepatocytes. Finally, several putative 
new target genes of PPARα were identified that were commonly induced by PPARα activation 
in the two human liver model systems, including TSKU, RHOF, CA12 and VSIG10L.
Conclusion
Our manuscript demonstrates the suitability and superiority of human liver slices over 
primary hepatocytes for studying the functional role of PPARα in human liver. Our data 
underscore the major role of PPARα in regulation of hepatic lipid and xenobiotic metabolism 
in human liver and reveal a marked immuno-suppressive/anti-inflammatory effect of 
PPARα in human liver slices that may be therapeutically relevant for non-alcoholic fatty 
liver disease.
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Introduction
The Peroxisome Proliferator Activated Receptors (PPARs) represent an important group 
of receptors involved in mediating the pleiotropic effects of various environmental 
contaminants, food components, and drugs [1]. PPARs are members of the nuclear receptor 
superfamily and induce the expression of numerous genes by functioning as ligand-
activated transcription factors. The ligands for PPARs encompass a range of synthetic 
compounds and endogenous lipids, including various fatty acids and eicosanoids. Three 
different PPARs can be distinguished: PPARα, PPARδ, and PPARγ, each characterized 
by a distinct tissue expression profile and set of functions [2, 3]. Multiple functions have 
been assigned to PPARδ, including roles in inflammation, lipid metabolism and cancer [4]. 
Due to the ubiquitous expression pattern and diverse cellular actions of PPARδ, there is 
no single descriptor that appropriately captures its biological function. PPARγ is known as 
the key transcriptional regulator that drives adipogenesis [5], the process by which fat cells 
differentiate from pre-adipocytes into mature adipose cells. Apart from adipocytes, PPARγ 
is also expressed in a limited number of other cell types where it exerts anti-inflammatory 
actions and promotes lipid storage [6]. By serving as the molecular target of the insulin-
sensitizing drugs pioglitazone and rosiglitazone, PPARγ is one of the key receptors in the 
pharmacological treatment of type 2 diabetes  [7]. 
PPARα is best known for its role in the liver, where it acts as the master regulator of 
lipid metabolism, especially during fasting [8-10]. Fasting is associated with dramatic 
changes in lipid handling in liver, which is coordinated by PPARα. Specifically, low and high 
throughput gene expression analyses have demonstrated that PPARα governs expression 
of numerous genes involved in nearly every single aspect of lipid metabolism, including 
fatty acid  uptake, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis, and 
formation and breakdown of triglycerides and lipid droplets [11]. 
Similar to other members of the PPAR family, PPARα is activated by a range of different 
fatty acids and eicosanoids [12-16]. In addition, PPARα serves as receptor for a diverse array 
of synthetic compounds collectively referred to as peroxisome proliferators [17]. These 
include phthalates, insecticides, herbicides, surfactants, organic solvents, and hypolipidemic 
fibrate drugs. Fibrates have been used for several decades mainly for their ability to lower 
circulating triglycerides [18]. More recently, pharmacological targeting of PPARα has shown 
promise for the treatment of non-alcoholic fatty liver disease. Specifically, the dual PPARα/δ 
agonist GFT505 was shown to improve liver dysfunction markers, decrease hepatic lipid 
accumulation, and reduce inflammatory gene expression in liver in several animal models 
of non-alcoholic fatty liver disease (NAFLD) [19]. Furthermore, GFT505 treatment lowered 
liver dysfunction markers and improved hepatic and peripheral insulin sensitivity in human 
Chapter 6
140
subjects [19, 20]. 
Most of our insights into the physiological, toxicological and pharmacological role 
of PPARα has been derived from experiments in animals and in particular from rodent 
studies. These studies have revealed that PPARα is not only involved in the adaptive response 
to fasting but also mediates the hepatocarcinogenic effects of peroxisome proliferators [21]. 
Whether PPARα exerts similar functions in human liver has been the subject of controversy 
[22], which has been fueled by the perceived lack of effect of PPARα agonists on peroxisomal 
fatty acid oxidation in humans [23], as well as due to the presumed low expression of PPARα 
in human liver [24]. However, more recent studies have partly refuted those notions, showing 
that a) PPARα expression is similar in mouse and human liver, b) in human hepatocytes 
PPARα governs the expression of numerous genes in various lipid metabolic pathways, 
including peroxisomal fatty acid oxidation [25, 26].
Nevertheless, the absence of more complex human model systems has hampered our 
ability to gain insight into the molecular function of PPARα in human liver, in particular 
with respect to target gene regulation. To overcome this limitation, we collected precision cut 
liver slices (PCLS) from human subjects and studied the effect of PPARα activation on gene 
expression using whole genome expression profiling. In contrast to primary hepatocytes, 
PCLS mimic the multi-cellularity and structural organization of whole liver and thus 
represent a superior ex-vivo model system for human liver [27]. So far the use of PCLS for the 
study of nuclear receptors and specifically PPARα function has been limited [28-30]. Here 
we report the use of PCLS in combination with whole genome gene expression profiling to 
gain insight into PPARα-mediated gene regulation in human liver.
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Materials and methods
Collection of liver biopsies
In all patients a laparoscopic Roux-en-Y Gastric Bypass was performed under general 
anesthesia as treatment for their morbid obesity. Patients were instructed to fasten for solid 
foods and liquids starting at the night before surgery. During surgery a biopsy of the liver 
was obtained with the help of ultrasound dissection (UltraCision®). The biopsy was collected 
from the liver edge. The majority of the liver biopsies collected (n=15) were immediately 
frozen in liquid nitrogen and stored at -80°C. The liver biopsies targeted for slicing (n=4) 
were immediately placed in ice-cold oxygenated Belzer UW Cold Storage Solution (Bridge 
to Life Ltd, Columbia, SC, USA) and quickly transferred to our laboratory for further 
processing of PCLS. Only healthy livers were used for slicing. Biopsies were provided by 
the biobank of the Rijnstate hospital. Collection of biopsies for research purposes into the 
biobank was approved by the local institutional review board on behalf of the medical ethics 
review committee of the Radboud University Medical Centre. All patients signed informed 
consent for collection of the biopsy prior to surgery. Donor characteristics of livers used for 
slicing are shown in Table 1.
Table 1. Donor characteristics of livers used for slicing
Patient Gender Age (years) Body Mass Index (g/m2) 
1 Female 34 41 
2 Female 46 43 
3 Female 39 35 
4 Female 41 38 
 
Preparation and treatment of precision cut liver slices
PCLS were prepared and cultured as described previously [31]. 5 mm cylindrical liver 
cores were prepared with a surgical biopsy punch and sectioned to 200 μm slices using 
a Krumdieck tissue slicer (Alabama Research and Development, Munford, AL, USA) 
filled with carbonated KHB (pH 7.4, supplemented with 25mM glucose). Liver slices were 
incubated in William’s E Medium (Gibco, Paisley, Scotland) supplemented with penicillin/
streptomycin in 6-well plates at 37°C/5% CO2/80% O2 under continuous shaking (70 rpm). 
Duplicate wells were used per donor with 3 liver slices per well. After 1 hour the media was 
replaced with fresh William’s E Medium in the presence or absence of Wy14643 (100 μM) 
dissolved in dimethyl sulfoxide (DMSO, final concentration 0.1%). This concentration was 
chosen based on the affinity of human PPARα for Wy14643. [32]. After 24 h incubation, liver 
slices were snap-frozen in liquid nitrogen and stored in −80°C for RNA isolation. 
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Primary human hepatocytes
The treatment of primary human hepatocytes with Wy14643 has been previously described 
[26]. Briefly, human hepatocytes from six different donors were purchased from Lonza 
(Verviers, Belgium). Hepatocytes were isolated with two-step collagenase perfusion method. 
Cell viability was over 80%. The cells were incubated for 24h in the presence or absence of 
Wy14643 (50 µM) dissolved in DMSO, followed by RNA isolation.
RNA isolation and qPCR 
Total RNA was isolated using TRIzol reagent (Invitrogen). RNA integrity number was 
found to be above 7.1 for all samples suggesting that the human liver slices were of good 
quality. The RNA integrity number is based on a digital electropherogram generated using a 
Agilent bioanalyzer. It describes the degree of degradation of RNA with level 10 representing 
completely intact RNA. RNA was reverse transcribed using a iScript cDNA Synthesis Kit 
(Bio-Rad Laboratories BV, Veenendaal, The Netherlands). Real-time PCR was carried out 
using SensiMiX (Bioline) on a CFX 384 Bio-Rad thermal cycler (Bio-Rad). 36B4 was used as 
housekeeping gene. Primers sequences used are shown in Table 2.
Table 2. Primer sequences used for qPCR
 Primer Sequence  
Name Forward Reverse 
36B4 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC 
ANGPTL4 CACAGCCTGCAGACACAACTC GGAGGCCAAACTGGCTTTGC 
PLIN2 ATGGCATCCGTTGCAGTTGAT GATGGTCTTCACACCGTTCTC 
PDK4 TGGAGCATTTCTCGCGCTAC ACAGGCAATTCTTGTCGCAAA 
CPT1A TCCAGTTGGCTTATCGTGGTG CTAACGAGGGGTCGATCTTGG 
VLDLR GGTGAAAATGATTGTGACAGTGG GTGAACTCGTCGGGACTACA 
 
Microarray analysis
Total RNA was purified with RNeasy Minikit columns (Qiagen) and RNA quality was 
assessed using RNA 6000 Nano chips on the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Amsterdam, The Netherlands). Purified RNA (100 ng) was labeled with the Ambion WT 
expression kit (Invitrogen) and hybridized to an Affymetrix Human Gene 1.1 ST array 
plate (Affymetrix, Santa Clara, CA). Hybridization, washing, and scanning were carried 
out on an Affymetrix GeneTitan platform according to the instruction by the manufacturer. 
Arrays were normalized using the Robust Multiarray Average method [33, 34]. Probe sets 
were defined according to Dai et al.[35]. In this method probes are assigned to Entrez IDs as 
an unique gene identifier. The P values for the effect of Wy14643 treatment were calculated 
using an Intensity-Based Moderated T-statistic (IBMT) [36]. The q value was calculated as 
measure of significance for false discovery rate [37]. The microarray data for the human liver 
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slices were submitted to the Gene Expression Omnibus (GSE71731). The microarray data 
for the human primary hepatocytes have been previously submitted to Gene Expression 
Omnibus (GSE17251). 
Gene set enrichment analysis (GSEA) was used to find enriched gene sets in the induced 
or suppressed genes [38]. Genes were ranked based on the paired IBMT-statistic and 
subsequently analyzed for over- or underrepresentation in predefined gene sets derived 
from Gene Ontology, KEGG, National Cancer Institute, PFAM, Biocarta, Reactome and 
WikiPathways pathway databases. Only gene sets consisting of more than 15 and fewer than 
500 genes were taken into account. Statistical significance of GSEA results was determined 
using 1,000 permutations.
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Results
First, we determined the relative expression level of PPARα in PCLS in comparison with 
human liver. After correcting for the housekeeping gene 36B4, mRNA levels of PPARα in 
human PCLS after 24h incubation were about ten-fold lower as compared to snap-frozen 
human liver biopsies (Figure 1A). To verify that the human liver slices maintain their ability 
to respond to PPARα activation, we exposed the PCLS to 100 μM Wy14643, isolated total 
RNA and performed qPCR to determine the expression of a number of well-established 
PPARα target genes, including PLIN2, VLDLR, ANGPTL4, CPT1A and PDK4 (Figure 
1B). All PPARα target genes analyzed showed significant induction following Wy14643 
treatment, indicating the validity of our model to study PPARα-mediated gene regulation.
To study the effect of PPARα activation on whole genome gene expression we performed 
microarray analysis. Wy14643-induced changes in expression of the selected PPARα target 
genes were very similar between the microarray and qPCR analysis (Figure 1C). Using 
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Figure 1. Classical PPARα targets genes are robustly induced by PPARα activation in human PCLS
(A) Expression level of PPARα in human liver biopsies (n=15) and human PCLS (n=5). (B) Gene expression 
changes of selected PPARα target genes in human PCLS in response to 24h Wy14643 treatment as 
determined by quantitative real-time PCR. (C) Gene expression changes of the same genes according to 
microarray. Error bars represent SEM. Asterisk indicates statistically significant (P<0.05, Students t-test).
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a FDR q-value of 0.05 as cut-off (IBMT regularised paired t-test),  the expression of 1282 
genes (out of 19654 genes on the array) was found to be significantly altered by Wy14643 
treatment, of which 617 genes were upregulated and 665 genes were downregulated. The 
top 25 of most significantly induced genes, ranked according to statistical significance, are 
shown in Figure 2A. The full list is available as Supplemental Table 1. The list includes 
many well-known PPARα target genes involved in lipid metabolism (e.g. VLDLR, ACADVL, 
PLIN2, ANGPTL4, CPT1A), as well as many other genes covering a wide variety of biological 
A
B
-2  -1.5  -1  -0.5   0   0.5   1   1.5   2signal log ratio
gene name description P1 P2 P3 P4 gene function q-value 
POR P450 (cytochrome) oxidoreductase supports cytochrome P450 enzymes 1.22E-07
ANGPTL4 angiopoietin-like 4 regulation plasma triglyceride hydrolysis 1.22E-07
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 drug transport 2.41E-07
EID3 EP300 interacting inhibitor of differentiation 3 co-repression of nuclear receptors 2.73E-07
CPT1A carnitine palmitoyltransferase 1A (liver) uptake fatty acids into mitochondria 3.97E-07
VLDLR very low density lipoprotein receptor binding of very low density lipoproteins 4.38E-07
ACSL5 acyl-CoA synthetase long-chain family member 5 activation of fatty acids 4.38E-07
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 drug metabolism 5.23E-07
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 drug metabolism 5.97E-07
TXNRD1 thioredoxin reductase 1 support anti-oxidant enzymes 6.36E-07
ENTPD7 ectonucleoside triphosphate diphosphohydrolase 7 lowering of ATP levels 6.46E-07
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 triglyceride synthesis 6.46E-07
CD14 CD14 molecule cellular binding of lipopolysaccharide 8.61E-07
SLC22A3 solute carrier family 22 (organic cation transporter), member 3 transport of neurotransmitters 8.61E-07
TMED5 transmembrane emp24 protein transport domain containing 5 unknown 1.02E-06
FADS1 fatty acid desaturase 1 desaturation (d5) of fatty acids 1.02E-06
ACADVL acyl-CoA dehydrogenase, very long chain mitochondrial oxidation of fatty acids 1.06E-06
TSKU tsukushi, small leucine rich proteoglycan inhibition Wnt and BMP signaling 1.98E-06
PLIN2 perilipin 2 lipid droplet associated protein 2.46E-06
FAH fumarylacetoacetate hydrolase (fumarylacetoacetase) catabolism of tyrosine 2.46E-06
VSIG10L V-set and immunoglobulin domain containing 10 like unknown 2.84E-06
SRXN1 sulfiredoxin 1 protection against oxidative stress 3.46E-06
RHOF ras homolog family member F (in filopodia) remodels actin cytoskeleton 4.50E-06
SLC27A4 solute carrier family 27 (fatty acid transporter), member 4 transport of fatty acids 4.50E-06
TALDO1 transaldolase 1 pentose phosphate pathway 4.50E-06
gene name description P1 P2 P3 P4 gene function q-value 
ELOVL2 ELOVL fatty acid elongase 2 elongation of fatty acids 4.38E-07
UBD ubiquitin D proteasome binding and proteolysis 1.02E-06
CLDN1 claudin 1 component of tight junction strands 1.06E-06
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 promotes cell differentiation 1.34E-06
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 induction of apoptosis, "death receptor" 1.99E-06
TGFB2 transforming growth factor, beta 2 cell differentiation and proliferation 2.30E-06
SPON2 spondin 2, extracellular matrix protein unknown 2.46E-06
DUOXA2 dual oxidase maturation factor 2 ROS production 3.05E-06
XAF1 XIAP associated factor 1 tumor suppressor, promotes apoptosis 3.46E-06
TRIM22 tripartite motif containing 22 anti-viral activity 4.50E-06
IL18BP interleukin 18 binding protein innate immunity 4.50E-06
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 production lysophosphatidic acid 4.50E-06
DUOX2 dual oxidase 2 ROS production 5.01E-06
FAXDC2 fatty acid hydroxylase domain containing 2 unknown 5.01E-06
ZNF608 zinc finger protein 608 unknown 5.01E-06
IDO1 indoleamine 2,3-dioxygenase 1 tryptophan degradation 5.65E-06
IFITM1 interferon induced transmembrane protein 1 anti-viral activity 5.65E-06
TLR3 toll-like receptor 3 pattern recognition receptor for dsRNA 5.76E-06
ALDH8A1 aldehyde dehydrogenase 8 family, member A1 retinoid metabolism 6.05E-06
AHNAK2 AHNAK nucleoprotein 2 unknown 6.05E-06
IFI6 interferon, alpha-inducible protein 6 possible role in apoptosis 1.29E-05
TP63 tumor protein p63 tissue/organ development 2.02E-05
FGL1 fibrinogen-like 1 hepatocyte proliferation/energy metabolism2.06E-05
SERPINA10 serpin peptidase inhibitor, clade A (antitrypsin), member 10 blood coagulation 2.15E-05
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) cholesterol synthesis 2.35E-05
B
Figure 2. Top 25 genes induced or repressed by Wy14643 in human PCLS
Heatmap showing gene expression changes of the top 25 most significantly induced (A) and repressed (B) 
genes in human PCLS treated with Wy14643 for 24h, as determined by microarray analysis. Genes were 
ranked based on statistical significance in the form of q-value (IBMT regularised paired t-test). P1 to P4 
represent the four human subjects that donated a liver specimen for preparation of PCLS. 
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functions. In addition, the list includes a number of genes with unknown function. Figure 
2B shows the top 25 of most significantly repressed genes, many of which are related to 
immune function and inflammation. The full list of significantly downregulated genes is 
available as Supplemental Table 2.
To gain better insight into the biological function of genes regulated by PPARα activation 
in human liver slices, we performed gene set enrichment analysis (GSEA). Pathways related 
to lipid metabolism or directly involving PPARα featured prominently among the gene sets 
induced by Wy14643 (Figure 3). Also, several gene sets induced by Wy14643 were related to 
the unfolded protein response and UPR signaling by IRE1α and XBP1. Finally, we observed 
significant enrichment of genes related to oxidative stress and xenobiotic/drug metabolism. 
Gene sets downregulated by PPARα activation were all related to immune function and 
inflammation, illustrating a potent anti-inflammatory/immuno-suppressive action of 
PPARα in human liver. 
An important goal of the present work was to test the suitability of liver slices as a model 
to study PPARα dependent gene regulation and compare it with other available model 
systems for human liver. To that end, we compared the whole genome expression profiles 
of human liver slices treated with Wy14643 with the expression profiles of primary human 
hepatocytes treated with Wy14643. The expression profiles of primary human hepatocytes 
have been previously published but were re-analyzed [26]. The primary human hepatocytes 
were treated for the same duration and microarray analysis was performed in the same 
laboratory on the same microarray platform. 
The comparative analysis between primary human hepatocytes and human liver 
slices was performed on a common gene set of 17351 genes. Using a statistical cut-off of 
P<0.001 (IBMT regularised paired t-test) combined with a fold-change cut-off of 1.2, we 
found 347 genes to be upregulated in human liver slices, as compared to 121 genes in the 
hepatocytes (Figure 4A), with an overlap of 47 genes. Remarkably, whereas 401 genes were 
downregulated by Wy14643 in the liver slices, only 25 genes were downregulated by Wy14643 
in the human hepatocytes, with an overlap of only 4 genes. The data indicate that the human 
liver slices are much more sensitive towards especially downregulation of gene expression 
by Wy14643 as compared to human hepatocytes. This notion was further supported 
by correlation analysis in the form of a scatter plot (Figure 4B). The upper right portion 
of the scatter plot was well filled (Figure 4B), reflecting common induction by Wy14643 
in PCLS and primary hepatocytes, including well-known PPARα targets such as FABP1, 
PLIN2, PDK4 and ANGPTL4. In contrast, the lower left portion of the scatter plot was much 
less filled (Figure 4B), reflecting little agreement between PCLS and primary hepatocytes 
with respect to downregulation of gene expression by Wy14643. In fact, many genes were 
markedly downregulated by Wy14643 in the liver slices but showed no change in expression 
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Figure 3. Top 20 gene sets induced or repressed by Wy14643 in human PCLS
The top 20 most significantly induced or repressed pathways in human PCLS in response to 24h Wy14643 
treatment were determined by gene set enrichment analysis. Gene sets were ranked according to normalized 
enrichment score (NES). 
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Figure 4. Comparative analysis of effect Wy14643 on gene expression in human PCLS and primary 
hepatocytes
(A) The number of differentially expressed genes in human PCLS and human primary hepatocytes in 
response to 24h Wy14643 treatment in a common geneset of 17351 genes was calculated based on a statistical 
significance cut-off of P<0.001 (IBMT regularised paired t-test) and fold-change >1.20. Genes were separated 
according to up- or down-regulation. (B) Correlation plot showing changes in gene expression in response 
to Wy14643 (expressed as signal log ratio) in human PCLS (x-axis) and primary human hepatocytes (y-axis). 
Selected PPARα target genes commonly induced by Wy14643 in PCLS and hepatocytes are highlighted in 
red. Selected inflammation-related genes specifically repressed by Wy14643 in PCLS are highlighted in 
blue. Selected lipid metabolism-related genes specifically induced by Wy14643 in primary hepatocytes are 
highlighted in green. (C) Volcano plot showing relative changes in gene expression in response to Wy14643 
(expressed as signal log ratio, x-axis) plotted against statistical significance (expressed as IBMT regularised 
paired t-test P-value, y-axis) for the PCLS and primary hepatocytes. 
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in the hepatocytes. Nearly all genes conforming to this type of expression were involved in 
immune-related function, as illustrated by the chemokines CXCL9, CXCL10, and CXCL11. 
Interestingly, a number of genes was explicitly induced by PPARα activation in primary 
hepatocytes but not in liver slices, including FABP3 as well as CREB3L3, a possible mediator 
of the stimulatory effects of PPARα on hepatic gene expression [11]. Subsequent analysis 
by Volcano plot confirmed the overall more pronounced effect of PPARα activation on 
gene expression in liver slices as compared to primary hepatocytes and also corroborated 
the relatively minor down-regulation of gene expression by PPARα activation in primary 
hepatocytes (Figure 4C).
Figure 5. Comparative heatmap analysis of effect Wy14643 on gene expression in human PCLS and 
primary hepatocytes
Genes that were statistically significantly regulated by Wy14643 in human PCLS (P<0.001, IBMT 
regularised paired t-test) were ranked according to fold-change in expression. The top 40 genes with highest 
fold-induction (A) or fold-repression (B) are shown. Expression changes of the same gene set in primary 
hepatocytes is shown in the right panel. P1 to P4 represent the four human subjects that donated a liver 
specimen for preparation of PCLS. P5 to P10 represent the six human subjects that donated a liver specimen 
for preparation of human hepatocytes.
gene P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
VLDLR
AKR1B10
CYP3A4
FADS1
PLIN2
TSKU
POR
ANGPTL4
CYP2B7P
RHOF
OXT
VSIG10L
FADS2
SLC22A3
GPR64
ABCC2
CA12
CPT1A
EID3
CYP3A5
AGPAT9
CYP2B6
PDK4
RALGPS2
CD14
SRXN1
LOC344887
CYP1B1
FABP1
ENTPD7
SFN
SLC27A4
MBL2
ALAS1
GDF15
ELOVL6
MEGF9
TRIM55
ACSL5
GCLC
gene P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
CXCL9
CXCL10
CXCL11
DUOXA2
NOS2
DUOX2
CCL8
IFI44L
GBP5
IDO1
IFITM1
IFIT2
ELOVL2
GRIA3
CX3CL1
TLR3
STEAP4
IFIT1
MMP12
FAXDC2
TP63
ALDH8A1
TNFSF14
SPON2
IFIT3
XAF1
EPSTI1
TRIM22
FCAMR
LCN2
HAMP
GBP2
GBP4
CXCL6
UBD
SERPINA10
TDO2
WDR72
RARRES3
PIGR
PCLS Primary hepatocytes PCLS Primary hepatocytes
A B
-2  -1.5  -1  -0.5   0   0.5   1   1.5   2
signal log
        ratio
Chapter 6
150
To further investigate this observation, we took the 40 genes most highly induced or 
repressed by Wy14643 in the liver slices (P<0.001 and ranked according to fold-change) and 
studied the response to Wy14643 of the same genes in the primary hepatocytes. Whereas 
the majority of genes induced by Wy14643 in liver slices were also induced by Wy14643 
in the hepatocytes (Figure 5A) – as illustrated by the common induction of well-known 
targets such as FABP1, PLIN2, FADS1 and ANGPTL4 – few genes that were downregulated 
by Wy14643 in liver slices were also consistently downregulated by Wy14643 in primary 
hepatocytes (Figure 5B). Also, the magnitude of gene suppression by Wy14643 was generally 
much less pronounced in primary hepatocytes. Confirming the GSEA results, the majority 
of the most highly repressed genes were related to immunity and inflammation, including 
the aforementioned chemokines (CXCL9-11, CCL8, CX3CL1, CXCL6), interferon γ-induced 
genes (IFITM1, IFIT1, IFIT2, IFIT3) and other immune-related genes (TLR3,  NOS2, and 
LCN2).
To further explore the similarity in gene regulation by Wy14643 between PCLS and 
primary hepatocytes, we took the enriched genes within the positively or negatively 
enriched gene sets “IRE1α activated chaperones”, “metabolism of xenobiotics by 
cytochrome P450”, and “Interferon alpha beta signaling” (Figure 3), and compared gene 
expression changes between PCLS and primary hepatocytes. Induction of most genes part 
of “metabolism of xenobiotics by cytochrome P450” was more pronounced in PCLS than 
in primary hepatocytes but reasonably well conserved between the two model systems 
(Figure 6A). A limited number of genes (i.e. CYP2J2) showed higher fold-inductions in the 
primary hepatocytes as compared to PCLS. Induction of genes part of “IRE1α activated 
chaperones” was generally less pronounced in comparison with genes part of “metabolism 
of xenobiotics by cytochrome P450”, and was relatively weakly conserved between PCLS 
and primary hepatocytes (Figure 6B). An exception is ACADVL. However, the inclusion of 
ACADVL (very long chain acyl-CoA dehydrogenase = fatty acid oxidation) within “IRE1α 
activated chaperones” may be questioned.  Consistent with the other data showing potent 
downregulation of immune- and inflammation-related genes by PPARα activation in PCLS 
but not primary hepatocytes, suppression of genes part of  “Interferon alpha beta signaling” 
was exclusively observed in PCLS (Figure 6C).
Finally, we used the microarray data of the human primary hepatocytes and human PCLS 
treated with Wy14643 to generate a detailed gene map of known and putative PPARα target 
genes involved in lipid metabolic pathways (Figure 7). The map illustrates that regulation 
of bile acid synthesis and secretion, which is a well-established PPARα target pathway in 
mouse, was only evident in primary hepatocytes and not in liver slices. Conversely, genes 
involved in fatty acid elongation and desaturation were clearly induced by PPARα activation 
in human liver slices but not in primary hepatocytes. 
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Figure 6. Regulation of selected gene sets by Wy14643 in human PCLS and primary hepatocytes
Heatmap showing gene expression changes of enriched genes that are part of the gene sets “metabolism 
of xenobiotics by cytochrome P450” (A), “IRE1a activated chaperones” (B), and “Interferon alpha beta 
signaling” (C) in human PCLS and primary hepatocytes. P1 to P4 represent the four human subjects that 
donated a liver specimen for preparation of PCLS. P5 to P10 represent the six human subjects that donated 
a liver specimen for preparation of human hepatocytes.
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Figure 7. Overview of regulation of lipid metabolism by PPARα in human liver
A detailed overview map was created of metabolic genes upregulated by PPARα in human liver based on 
transcriptomics analysis of human PCLS and primary hepatocytes treated with Wy14643. Genes indicated 
in red are significantly induced by Wy14643 in human PCLS and primary hepatocytes. Genes indicated in 
green are significantly induced by Wy14643 in human PCLS but not primary hepatocytes. Genes indicated 
in blue are significantly induced by Wy14643 in human primary hepatocytes but not PCLS. Statistical 
significance was determined by IBMT regularised paired t-test (P<0.01).
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Discussion
The main conclusion of our study is that induction of gene expression by PPARα activation 
is generally well captured and shows significant overlap between human liver slices and 
primary human hepatocytes, showing consistent upregulation of genes involved in lipid 
and xenobiotic metabolism in the two model systems. In contrast, downregulation of gene 
expression by PPARα activation is almost exclusively observed in human liver slices. A 
previous study comparing mouse primary hepatocytes, mouse liver slices and mouse liver 
reached a similar conclusion [30]. Overall, our data indicate that human PCLS are a superior 
model to study PPARα-dependent gene regulation and PPARα functions in human liver. 
As indicated above, PPARα activation caused major downregulation of gene expression 
in human liver slices but not in primary hepatocytes. A key difference between primary 
hepatocytes and liver slices is that the primary hepatocyte culture consists of only 
hepatocytes, whereas the liver slices include other cell types, including stellate cells and 
Kupffer cells. A large portion of the downregulated genes and pathways in the liver slices 
was found to be connected to the immune system. Genes that were highly repressed upon 
PPARα activation included several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), 
interferon γ-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-
related genes (e.g. TLR3, NOS2, and LCN2). Downregulation of gene expression is unlikely to 
be mediated by PPARα present in non-parenchymal cells, as PPARα expression in these cells 
is very low [30, 39]. Instead we prefer a scenario in which the immuno-suppressive action 
of PPARα activation in hepatocytes is dependent on (inflammatory) signals emanating 
from non-parenchymal cells. Indeed, downregulation of inflammatory gene expression in 
primary hepatocytes and mouse liver by PPARα activation is sensitive to the presence of pro-
inflammatory stimuli [40, 41]. Previously, we and others already demonstrated that Kupffer 
cells promote fat storage in hepatocytes by releasing inflammatory signals such as IL-1β, 
causing downregulation of PPARα gene expression [42, 43]. Overall, these data suggest that 
the full scope of functions of PPARα in hepatocytes is critically dependent on the interaction 
with other liver cell types. It is of interest to note that recently the anti-inflammatory action 
of PPARα in mouse liver was unequivocally attributed to the ability of PPARα to interact with 
other transcription factor pathways – a property referred to as transrepression – independent 
of the DNA-binding ability of PPARα, as shown in the context of steatohepatitis [44].
Despite the clear clinical efficacy of fibrates towards lowering of circulating triglycerides, 
the lack of peroxisome proliferation in human primary hepatocytes following PPARα 
activation has fed the idea that humans are largely insensitive to peroxisome-proliferator-
induced hepatic effects and that the functional role of PPARα in human liver may be 
limited [45-47]. Subsequent whole genome expression profiling studies in primary human 
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hepatocytes have mostly discounted these notions [25, 26]. We found that PPARα is highly 
expressed in human liver with Ct values ranging from 22 to 26, which is similar to the 
values observed in mouse liver (data not shown). Importantly, despite the markedly lower 
expression of PPARα in human PCLS as compared to human liver, activation of PPARα in 
PCLS caused pronounced upregulation or downregulation of numerous genes, including 
many known PPARα targets, strongly supporting the functionality of PPARα in human 
PCLS and giving even more credibility to an important in vivo role of PPARα in human 
liver. Recently, it was found that human liver PPARα gene expression correlates negatively 
with the severity of steatohepatitis and with measures of insulin resistance. Furthermore, 
histological improvement in a follow-up biopsy was associated with increased expression of 
PPARα and its target genes, suggesting that PPARα is involved in and may be therapeutically 
targeted for human steatohepatitis [48].
The majority of gene sets enriched among the upregulated genes were related to lipid and 
xenobiotic metabolism, which are well-established target pathways of PPARα. Intriguingly, 
several highly enriched gene sets were part of the unfolded protein response and IRE1α-
XBP1 signaling, two key factors involved in governing UPR. Currently, there are no 
published data linking PPARα to IRE1α-XBP1 signaling and regulation of UPR, though it 
has been observed that PPARα is involved in regulating proteome maintenance by inducing 
numerous heat shock proteins [49]. Surprisingly, recently it was demonstrated that IRE1α-
XBP1 signaling leads to activation of PPARα via direct binding of XBP1s to the promoter 
of PPARα, thereby stimulating mitochondrial β-oxidation and ketogenesis [50]. Thus, 
there appear to be reciprocal interactions between PPARα and UPR. The wider biological 
framework for regulation of UPR requires further clarification. 
Our analysis reveals differential regulation of a number of PPARα targets between liver 
slices and primary hepatocytes. For instance, VNN1 was significantly upregulated by 
PPARα activation in primary hepatocytes but showed no change in expression in liver slices. 
Conversely, expression of FADS2 was significantly increased in human liver slices but showed 
no change in primary hepatocytes. The differential regulation of specific PPARα target genes 
by Wy14643 between primary hepatocytes and liver slices may be a reflection of the different 
cellular context in the two models systems, with non-hepatocytes potentially exerting a 
stimulatory or inhibitory influence on PPARα-dependent gene induction. However, it should 
be realized that for a number of genes the seemingly differential regulation may reflect a 
quantitative difference rather than a true qualitative difference. For example, SLC25A20 was 
induced significantly by 1.58-fold in primary hepatocytes as compared to a non-significant 
1.34-fold induction in liver slices, barely missing the statistical significance cut-off. 
Our analysis yielded a number of relatively poorly characterized genes that showed a 
pronounced and consistent upregulation upon PPARα activation in the two human liver 
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model systems. These include TSKU, RHOF, CA12 and VSIG10L. Interestingly, many genes 
that were found to be induced by PPARα in early microarray analyses and which did not 
have an assigned function at the time were later shown to be involved in some aspect of lipid 
metabolism. Accordingly, it can be hypothesized that the above mentioned genes as well as 
other poorly characterized genes that are commonly induced by Wy14643 in various liver 
model systems may be directly or indirectly connected to lipid metabolism. 
The comparative microarray analysis of the effect of PPARα activation in primary human 
hepatocytes and human liver slices is somewhat hampered by a number of different factors, 
including the use of different types of Affymetrix gene chips, different human donors, and 
an unequal number of biological replicates per group. However, treatments of liver slices 
and hepatocytes were carried out for the same duration and with the same PPARα agonist. 
Furthermore, RNA was isolated and labeled via the same technique, hybridizations were 
performed on the same platform by the same technician, and the microarray data were 
processed in parallel using the same analysis methods.  
On a final note, the data collected in this paper were added to a publicly available overview 
map of known (lipid) metabolic genes upregulated by PPARα in human liver (accessible via: 
http://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_alpha), which 
was generated largely by using published transcriptome datasets.
In conclusion, our manuscript demonstrates the suitability and superiority of PCLS over 
primary human hepatocytes for studying the functional role of PPARα in human liver. 
Our data underscore the major role of PPARα in regulation of hepatic lipid and xenobiotic 
metabolism and reveal a marked immuno-suppressive/anti-inflammatory effect of PPARα 
in human liver that may be therapeutically relevant for NAFLD. The data add to our growing 
understanding of the critical role of PPARα in gene regulation in human liver.
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Supplemental tables
Supplemental table 1.  Full list of genes induced by Wy14643 in human PCLS
     
     
     
Entrez ID Gene name Fold change q-value Description 
7436 VLDLR 4.11 4.38E-07 very low density lipoprotein receptor 
57016 AKR1B10 3.09 6.09E-05 aldo-keto reductase family 1, member B10 (aldose reductase) 
1576 CYP3A4 3.07 5.23E-07 cytochrome P450, family 3, subfamily A, polypeptide 4 
3992 FADS1 3.06 1.02E-06 fatty acid desaturase 1 
123 PLIN2 2.91 2.46E-06 perilipin 2 
25987 TSKU 2.90 1.98E-06 tsukushi, small leucine rich proteoglycan 
5447 POR 2.90 1.22E-07 P450 (cytochrome) oxidoreductase 
1551 CYP3A7 2.85 2.50E-02 cytochrome P450, family 3, subfamily A, polypeptide 7 
51129 ANGPTL4 2.82 1.22E-07 angiopoietin-like 4 
1556 CYP2B7P 2.64 6.79E-04 cytochrome P450, family 2, subfamily B, polypeptide 7, pseudogene 
54509 RHOF 2.52 4.50E-06 ras homolog family member F (in filopodia) 
5020 OXT 2.52 9.73E-06 oxytocin/neurophysin I prepropeptide 
147645 VSIG10L 2.40 2.84E-06 V-set and immunoglobulin domain containing 10 like 
9415 FADS2 2.37 2.15E-05 fatty acid desaturase 2 
6581 SLC22A3 2.26 8.61E-07 solute carrier family 22 (organic cation transporter), member 3 
10149 GPR64 2.23 4.02E-05 G protein-coupled receptor 64 
1244 ABCC2 2.23 2.41E-07 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 
771 CA12 2.18 3.21E-05 carbonic anhydrase XII 
1374 CPT1A 2.12 3.97E-07 carnitine palmitoyltransferase 1A (liver) 
493861 EID3 2.10 2.73E-07 EP300 interacting inhibitor of differentiation 3 
1577 CYP3A5 2.09 5.97E-07 cytochrome P450, family 3, subfamily A, polypeptide 5 
84803 AGPAT9 2.05 6.46E-07 1-acylglycerol-3-phosphate O-acyltransferase 9 
1555 CYP2B6 2.04 4.78E-05 cytochrome P450, family 2, subfamily B, polypeptide 6 
5166 PDK4 2.01 1.28E-04 pyruvate dehydrogenase kinase, isozyme 4 
55103 RALGPS2 1.99 6.09E-05 Ral GEF with PH domain and SH3 binding motif 2 
929 CD14 1.95 8.61E-07 CD14 molecule 
140809 SRXN1 1.95 3.46E-06 sulfiredoxin 1 
344887 LOC344887 1.90 4.01E-03 NmrA-like family domain containing 1 pseudogene 
1545 CYP1B1 1.87 7.74E-05 cytochrome P450, family 1, subfamily B, polypeptide 1 
2168 FABP1 1.87 7.58E-06 fatty acid binding protein 1, liver 
57089 ENTPD7 1.87 6.46E-07 ectonucleoside triphosphate diphosphohydrolase 7 
2810 SFN 1.86 4.82E-05 stratifin 
10999 SLC27A4 1.82 4.50E-06 solute carrier family 27 (fatty acid transporter), member 4 
4153 MBL2 1.80 3.76E-03 mannose-binding lectin (protein C) 2, soluble 
211 ALAS1 1.78 6.88E-06 aminolevulinate, delta-, synthase 1 
135656 DPCR1 1.77 4.24E-02 diffuse panbronchiolitis critical region 1 
9518 GDF15 1.77 7.30E-05 growth differentiation factor 15 
79071 ELOVL6 1.77 1.94E-03 ELOVL fatty acid elongase 6 
1955 MEGF9 1.76 6.13E-05 multiple EGF-like-domains 9 
84675 TRIM55 1.75 1.78E-03 tripartite motif containing 55 
51703 ACSL5 1.75 4.38E-07 acyl-CoA synthetase long-chain family member 5 
2729 GCLC 1.75 7.08E-06 glutamate-cysteine ligase, catalytic subunit 
28449 IGHV3-13 1.75 2.94E-02 immunoglobulin heavy variable 3-13 
54210 TREM1 1.73 3.69E-04 triggering receptor expressed on myeloid cells 1 
2151 F2RL2 1.73 3.11E-02 coagulation factor II (thrombin) receptor-like 2 
10786 SLC17A3 1.73 9.39E-03 solute carrier family 17 (organic anion transporter), member 3 
6974 TRGV2 1.72 4.52E-02 T cell receptor gamma variable 2 
7296 TXNRD1 1.72 6.36E-07 thioredoxin reductase 1 
4835 NQO2 1.72 5.65E-06 NAD(P)H dehydrogenase, quinone 2 
37 ACADVL 1.72 1.06E-06 acyl-CoA dehydrogenase, very long chain 
23657 SLC7A11 1.71 1.25E-03 solute carrier family 7 (anionic amino acid transporter light chain, xc- system),  
    member 11 
552 AVPR1A 1.71 1.56E-03 arginine vasopressin receptor 1A 
3131 HLF 1.70 6.58E-03 hepatic leukemia factor 
11069 RAPGEF4 1.70 1.78E-03 Rap guanine nucleotide exchange factor (GEF) 4 
10058 ABCB6 1.70 6.09E-05 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
1591 CYP24A1 1.66 3.37E-02 cytochrome P450, family 24, subfamily A, polypeptide 1 
2184 FAH 1.66 2.46E-06 fumarylacetoacetate hydrolase (fumarylacetoacetase) 
13 AADAC 1.65 1.04E-04 arylacetamide deacetylase 
8431 NR0B2 1.65 1.18E-02 nuclear receptor subfamily 0, group B, member 2 
3148 HMGB2 1.65 1.24E-03 high mobility group box 2 
89866 SEC16B 1.64 2.22E-03 SEC16 homolog B (S. cerevisiae) 
7363 UGT2B4 1.64 7.62E-06 UDP glucuronosyltransferase 2 family, polypeptide B4 
23189 KANK1 1.64 1.40E-05 KN motif and ankyrin repeat domains 1 
990 CDC6 1.64 2.47E-02 cell division cycle 6 
2730 GCLM 1.63 1.44E-05 glutamate-cysteine ligase, modifier subunit 
54346 UNC93A 1.63 1.38E-03 unc-93 homolog A (C. elegans) 
57761 TRIB3 1.62 5.48E-04 tribbles pseudokinase 3 
7378 UPP1 1.62 1.47E-03 uridine phosphorylase 1 
168620 BHLHA15 1.61 1.30E-03 basic helix-loop-helix family, member a15 
1528 CYB5A 1.61 3.69E-04 cytochrome b5 type A (microsomal) 
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2167 FABP4 1.61 4.10E-02 fatty acid binding protein 4, adipocyte 
1559 CYP2C9 1.61 1.76E-04 cytochrome P450, family 2, subfamily C, polypeptide 9 
4862 NPAS2 1.60 5.28E-03 neuronal PAS domain protein 2 
6584 SLC22A5 1.60 3.82E-03 solute carrier family 22 (organic cation/carnitine transporter), member 5 
54518 APBB1IP 1.60 6.47E-04 amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 
1891 ECH1 1.59 5.33E-05 enoyl CoA hydratase 1, peroxisomal 
65084 TMEM135 1.59 9.41E-04 transmembrane protein 135 
1645 AKR1C1 1.58 6.09E-05 aldo-keto reductase family 1, member C1 
11153 FICD 1.58 2.38E-04 FIC domain containing 
11200 CHEK2 1.58 4.83E-02 checkpoint kinase 2 
54551 MAGEL2 1.58 3.94E-02 MAGE-like 2 
2852 GPER1 1.57 4.80E-03 G protein-coupled estrogen receptor 1 
79729 SH3D21 1.57 7.73E-04 SH3 domain containing 21 
164832 LONRF2 1.57 1.39E-02 LON peptidase N-terminal domain and ring finger 2 
8644 AKR1C3 1.57 3.76E-03 aldo-keto reductase family 1, member C3 
8462 KLF11 1.57 1.86E-04 Kruppel-like factor 11 
4882 NPR2 1.56 3.72E-03 natriuretic peptide receptor 2 
84263 HSDL2 1.55 2.41E-05 hydroxysteroid dehydrogenase like 2 
50999 TMED5 1.55 1.02E-06 transmembrane emp24 protein transport domain containing 5 
6319 SCD 1.54 1.17E-03 stearoyl-CoA desaturase (delta-9-desaturase) 
55532 SLC30A10 1.54 8.22E-05 solute carrier family 30, member 10 
1271 CNTFR 1.53 5.22E-03 ciliary neurotrophic factor receptor 
51076 CUTC 1.53 4.39E-04 cutC copper transporter 
133746 JMY 1.53 9.05E-03 junction mediating and regulatory protein, p53 cofactor 
3024 HIST1H1A 1.53 5.74E-03 histone cluster 1, H1a 
193629 LINC00189 1.52 9.60E-03 long intergenic non-protein coding RNA 189 
84883 AIFM2 1.52 1.30E-04 apoptosis-inducing factor, mitochondrion-associated, 2 
64061 TSPYL2 1.52 1.55E-03 TSPY-like 2 
5226 PGD 1.51 9.62E-06 phosphogluconate dehydrogenase 
7466 WFS1 1.51 1.59E-03 Wolfram syndrome 1 (wolframin) 
3613 IMPA2 1.51 1.47E-02 inositol(myo)-1(or 4)-monophosphatase 2 
91614 DEPDC7 1.50 3.03E-03 DEP domain containing 7 
275 AMT 1.50 1.20E-03 aminomethyltransferase 
5652 PRSS8 1.50 9.97E-03 protease, serine, 8 
1647 GADD45A 1.50 1.00E-02 growth arrest and DNA-damage-inducible, alpha 
4189 DNAJB9 1.50 4.13E-04 DnaJ (Hsp40) homolog, subfamily B, member 9 
79631 EFTUD1 1.49 1.39E-02 elongation factor Tu GTP binding domain containing 1 
65124 SOWAHC 1.49 1.28E-03 sosondowah ankyrin repeat domain family member C 
161436 EML5 1.49 1.55E-02 echinoderm microtubule associated protein like 5 
3309 HSPA5 1.49 2.20E-05 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
51083 GAL 1.49 2.56E-02 galanin/GMAP prepropeptide 
1376 CPT2 1.49 7.56E-03 carnitine palmitoyltransferase 2 
10110 SGK2 1.48 3.63E-02 serum/glucocorticoid regulated kinase 2 
26291 FGF21 1.48 3.54E-02 fibroblast growth factor 21 
1558 CYP2C8 1.48 6.39E-05 cytochrome P450, family 2, subfamily C, polypeptide 8 
2936 GSR 1.47 5.65E-06 glutathione reductase 
10166 SLC25A15 1.47 5.23E-03 solute carrier family 25 (mitochondrial carrier ///  ornithine transporter) member 15 
83667 SESN2 1.47 4.17E-03 sestrin 2 
83699 SH3BGRL2 1.47 3.83E-03 SH3 domain binding glutamate-rich protein like 2 
734 OSGIN2 1.47 8.41E-04 oxidative stress induced growth inhibitor family member 2 
132299 OCIAD2 1.47 1.48E-04 OCIA domain containing 2 
114038 LINC00313 1.46 6.80E-03 long intergenic non-protein coding RNA 313 
54825 CDHR2 1.45 1.27E-03 cadherin-related family member 2 
444 ASPH 1.45 1.04E-04 aspartate beta-hydroxylase 
3242 HPD 1.45 7.99E-06 4-hydroxyphenylpyruvate dioxygenase 
51117 COQ4 1.45 6.58E-03 coenzyme Q4 
144423 GLT1D1 1.45 1.31E-03 glycosyltransferase 1 domain containing 1 
6505 SLC1A1 1.45 3.87E-03 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system 
    Xag), member 1 
84243 ZDHHC18 1.45 7.30E-05 zinc finger, DHHC-type containing 18 
9540 TP53I3 1.44 9.80E-03 tumor protein p53 inducible protein 3 
8517 IKBKG 1.44 3.37E-03 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma 
8800 PEX11A 1.44 8.67E-03 peroxisomal biogenesis factor 11 alpha 
201161 CENPV 1.44 1.23E-02 centromere protein V 
389432 SAMD5 1.44 2.20E-03 sterile alpha motif domain containing 5 
54884 RETSAT 1.43 3.62E-03 retinol saturase (all-trans-retinol 13,14-reductase) 
730102 LOC730102 1.43 2.76E-02 quinone oxidoreductase-like protein 2 pseudogene 
1548 CYP2A6 1.43 3.35E-04 cytochrome P450, family 2, subfamily A, polypeptide 6 
2632 GBE1 1.43 9.92E-05 glucan (1,4-alpha-), branching enzyme 1 
127845 GOLT1A 1.43 7.42E-03 golgi transport 1A 
22949 PTGR1 1.43 1.36E-04 prostaglandin reductase 1 
9709 HERPUD1 1.42 9.37E-03 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain  
    member 1 
5238 PGM3 1.42 7.30E-05 phosphoglucomutase 3 
114883 OSBPL9 1.42 5.01E-06 oxysterol binding protein-like 9 
7498 XDH 1.42 1.13E-02 xanthine dehydrogenase 
The impact of PPARα activation in human PCLS
161
6
Entrez ID Gene name Fold change q-value Description 
8501 SLC43A1 1.42 1.98E-03 solute carrier family 43 (amino acid system L transporter), member 1 
54978 SLC35F6 1.42 2.47E-03 solute carrier family 35, member F6 
51302 CYP39A1 1.42 1.21E-02 cytochrome P450, family 39, subfamily A, polypeptide 1 
133686 NADK2 1.42 4.50E-04 NAD kinase 2, mitochondrial 
25998 IBTK 1.41 2.35E-05 inhibitor of Bruton agammaglobulinemia tyrosine kinase 
4337 MOCS1 1.41 6.77E-03 molybdenum cofactor synthesis 1 
3690 ITGB3 1.41 5.11E-04 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
55323 LARP6 1.41 2.16E-03 La ribonucleoprotein domain family, member 6 
79605 PGBD5 1.41 2.11E-02 piggyBac transposable element derived 5 
65009 NDRG4 1.41 3.79E-02 NDRG family member 4 
152189 CMTM8 1.40 1.97E-03 CKLF-like MARVEL transmembrane domain containing 8 
30061 SLC40A1 1.40 3.68E-02 solute carrier family 40 (iron-regulated transporter), member 1 
79922 MRM1 1.40 4.56E-02 mitochondrial rRNA methyltransferase 1 homolog (S. cerevisiae) 
51559 NT5DC3 1.40 2.51E-02 5'-nucleotidase domain containing 3 
54893 MTMR10 1.40 6.83E-04 myotubularin related protein 10 
343099 CCDC18 1.40 6.00E-03 coiled-coil domain containing 18 
51533 PHF7 1.40 6.39E-03 PHD finger protein 7 
10162 LPCAT3 1.40 1.45E-02 lysophosphatidylcholine acyltransferase 3 
6888 TALDO1 1.39 4.50E-06 transaldolase 1 
2110 ETFDH 1.39 8.52E-04 electron-transferring-flavoprotein dehydrogenase 
997 CDC34 1.39 3.37E-03 cell division cycle 34 
10486 CAP2 1.39 3.43E-03 CAP, adenylate cyclase-associated protein, 2 (yeast) 
23327 NEDD4L 1.39 1.30E-03 neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin  
    protein ligase 
847 CAT 1.39 1.91E-04 catalase 
89894 TMEM116 1.39 1.75E-02 transmembrane protein 116 
345757 FAM174A 1.39 1.00E-02 family with sequence similarity 174, member A 
220108 FAM124A 1.39 3.84E-02 family with sequence similarity 124A 
124512 METTL23 1.39 1.38E-02 methyltransferase like 23 
4925 NUCB2 1.39 8.11E-03 nucleobindin 2 
10113 PREB 1.38 1.25E-02 prolactin regulatory element binding 
57406 ABHD6 1.38 1.32E-02 abhydrolase domain containing 6 
51567 TDP2 1.38 2.79E-04 tyrosyl-DNA phosphodiesterase 2 
84719 LINC00260 1.38 2.72E-02 long intergenic non-protein coding RNA 260 
56605 ERO1LB 1.38 1.76E-03 ERO1-like beta (S. cerevisiae) 
64093 SMOC1 1.38 1.04E-02 SPARC related modular calcium binding 1 
63874 ABHD4 1.38 4.43E-04 abhydrolase domain containing 4 
1646 AKR1C2 1.38 2.78E-04 aldo-keto reductase family 1, member C2 
100272147 CMC4 1.38 1.15E-02 C-x(9)-C motif containing 4 
2108 ETFA 1.38 1.38E-04 electron-transfer-flavoprotein, alpha polypeptide 
3708 ITPR1 1.38 8.27E-04 inositol 1,4,5-trisphosphate receptor, type 1 
11001 SLC27A2 1.38 1.29E-03 solute carrier family 27 (fatty acid transporter), member 2 
57149 LYRM1 1.38 2.82E-03 LYR motif containing 1 
2673 GFPT1 1.38 2.35E-03 glutamine--fructose-6-phosphate transaminase 1 
112849 L3HYPDH 1.38 2.11E-02 L-3-hydroxyproline dehydratase (trans-) 
9601 PDIA4 1.38 1.20E-03 protein disulfide isomerase family A, member 4 
100033432 SNORD116-21 1.37 3.54E-02 small nucleolar RNA, C/D box 116-21 
10449 ACAA2 1.37 7.03E-04 acetyl-CoA acyltransferase 2 
8856 NR1I2 1.37 1.17E-02 nuclear receptor subfamily 1, group I, member 2 
10891 PPARGC1A 1.37 3.61E-03 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
257364 SNX33 1.37 1.03E-02 sorting nexin 33 
29948 OSGIN1 1.37 7.07E-04 oxidative stress induced growth inhibitor 1 
101928229 NA 1.37 1.96E-02 NA 
11080 DNAJB4 1.37 3.84E-02 DnaJ (Hsp40) homolog, subfamily B, member 4 
55062 WIPI1 1.37 4.74E-04 WD repeat domain, phosphoinositide interacting 1 
5603 MAPK13 1.37 3.20E-02 mitogen-activated protein kinase 13 
9871 SEC24D 1.37 9.59E-04 SEC24 family member D 
22885 ABLIM3 1.37 1.30E-03 actin binding LIM protein family, member 3 
84561 SLC12A8 1.37 4.05E-03 solute carrier family 12, member 8 
79746 ECHDC3 1.37 4.97E-03 enoyl CoA hydratase domain containing 3 
2948 GSTM4 1.37 1.21E-02 glutathione S-transferase mu 4 
2651 GCNT2 1.37 1.55E-02 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 
81539 SLC38A1 1.37 1.83E-03 solute carrier family 38, member 1 
5256 PHKA2 1.36 1.59E-03 phosphorylase kinase, alpha 2 (liver) 
22853 LMTK2 1.36 4.74E-04 lemur tyrosine kinase 2 
2052 EPHX1 1.36 2.78E-04 epoxide hydrolase 1, microsomal (xenobiotic) 
79935 CNTD2 1.36 3.61E-02 cyclin N-terminal domain containing 2 
27242 TNFRSF21 1.36 1.29E-02 tumor necrosis factor receptor superfamily, member 21 
3625 INHBB 1.36 4.83E-02 inhibin, beta B 
375757 SWI5 1.36 4.25E-03 SWI5 recombination repair homolog (yeast) 
203228 C9orf72 1.36 3.67E-03 chromosome 9 open reading frame 72 
3251 HPRT1 1.36 4.70E-04 hypoxanthine phosphoribosyltransferase 1 
7873 MANF 1.36 1.02E-03 mesencephalic astrocyte-derived neurotrophic factor 
100130742 LRRC69 1.36 2.85E-02 leucine rich repeat containing 69 
493 ATP2B4 1.36 6.31E-03 ATPase, Ca++ transporting, plasma membrane 4 
168451 THAP5 1.36 3.53E-02 THAP domain containing 5 
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9942 XYLB 1.36 5.23E-03 xylulokinase homolog (H. influenzae) 
8878 SQSTM1 1.36 4.02E-05 sequestosome 1 
3159 HMGA1 1.35 8.87E-03 high mobility group AT-hook 1 
128853 DUSP15 1.35 1.74E-02 dual specificity phosphatase 15 
27090 ST6GALNAC4 1.35 8.74E-04 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
    alpha-2,6-sialyltransferase 4 
5009 OTC 1.35 3.01E-02 ornithine carbamoyltransferase 
6520 SLC3A2 1.35 2.79E-04 solute carrier family 3 (amino acid transporter heavy chain), member 2 
26064 RAI14 1.35 9.97E-04 retinoic acid induced 14 
400798 C1orf220 1.35 1.05E-02 chromosome 1 open reading frame 220 
54700 RRN3 1.35 2.47E-02 RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) 
122970 ACOT4 1.35 3.11E-02 acyl-CoA thioesterase 4 
84681 HINT2 1.35 1.56E-02 histidine triad nucleotide binding protein 2 
6482 ST3GAL1 1.35 1.10E-03 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
901 CCNG2 1.35 2.46E-02 cyclin G2 
55728 N4BP2 1.35 1.81E-02 NEDD4 binding protein 2 
8209 C21orf33 1.34 1.10E-03 chromosome 21 open reading frame 33 
548645 DNAJC25 1.34 2.31E-03 DnaJ (Hsp40) homolog, subfamily C , member 25 
6675 UAP1 1.34 3.83E-03 UDP-N-acteylglucosamine pyrophosphorylase 1 
2274 FHL2 1.34 8.81E-03 four and a half LIM domains 2 
91050 CCDC149 1.34 2.69E-02 coiled-coil domain containing 149 
8309 ACOX2 1.34 3.84E-02 acyl-CoA oxidase 2, branched chain 
645 BLVRB 1.34 1.52E-03 biliverdin reductase B (flavin reductase (NADPH)) 
55219 TMEM57 1.34 5.79E-03 transmembrane protein 57 
7754 ZNF204P 1.34 3.85E-02 zinc finger protein 204, pseudogene 
692099 FAM86DP 1.34 8.01E-04 family with sequence similarity 86, member D, pseudogene 
10126 DNAL4 1.34 3.22E-02 dynein, axonemal, light chain 4 
5243 ABCB1 1.34 9.46E-03 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
1119 CHKA 1.34 2.72E-02 choline kinase alpha 
58510 PRODH2 1.34 1.24E-02 proline dehydrogenase (oxidase) 2 
643246 MAP1LC3B2 1.34 4.21E-02 microtubule-associated protein 1 light chain 3 beta 2 
9532 BAG2 1.34 1.94E-03 BCL2-associated athanogene 2 
27440 CECR5 1.34 3.17E-02 cat eye syndrome chromosome region, candidate 5 
4359 MPZ 1.34 2.74E-02 myelin protein zero 
79739 TTLL7 1.33 2.93E-02 tubulin tyrosine ligase-like family, member 7 
64816 CYP3A43 1.33 4.90E-02 cytochrome P450, family 3, subfamily A, polypeptide 43 
271 AMPD2 1.33 7.37E-03 adenosine monophosphate deaminase 2 
8027 STAM 1.33 1.78E-03 signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 
9955 HS3ST3A1 1.33 3.49E-02 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 
23753 SDF2L1 1.33 6.72E-03 stromal cell-derived factor 2-like 1 
6786 STIM1 1.33 1.21E-03 stromal interaction molecule 1 
135398 C6orf141 1.33 5.22E-03 chromosome 6 open reading frame 141 
1373 CPS1 1.33 5.09E-03 carbamoyl-phosphate synthase 1, mitochondrial 
26995 TRUB2 1.32 5.56E-04 TruB pseudouridine (psi) synthase family member 2 
27230 SERP1 1.32 1.22E-03 stress-associated endoplasmic reticulum protein 1 
8165 AKAP1 1.32 1.75E-03 A kinase (PRKA) anchor protein 1 
256987 SERINC5 1.32 2.67E-03 serine incorporator 5 
3290 HSD11B1 1.32 2.87E-03 hydroxysteroid (11-beta) dehydrogenase 1 
189 AGXT 1.32 1.48E-03 alanine-glyoxylate aminotransferase 
23743 BHMT2 1.32 4.30E-04 betaine--homocysteine S-methyltransferase 2 
27347 STK39 1.32 3.73E-02 serine threonine kinase 39 
171586 ABHD3 1.32 6.31E-03 abhydrolase domain containing 3 
3081 HGD 1.32 2.11E-02 homogentisate 1,2-dioxygenase 
8412 BCAR3 1.32 1.69E-02 breast cancer anti-estrogen resistance 3 
79003 MIS12 1.32 1.07E-02 MIS12 kinetochore complex component 
493856 CISD2 1.31 1.83E-02 CDGSH iron sulfur domain 2 
10726 NUDC 1.31 1.28E-03 nudC nuclear distribution protein 
84288 EFCAB2 1.31 3.61E-02 EF-hand calcium binding domain 2 
55974 SLC50A1 1.31 7.27E-03 solute carrier family 50 (sugar efflux transporter), member 1 
79701 OGFOD3 1.31 1.23E-02 2-oxoglutarate and iron-dependent oxygenase domain containing 3 
114907 FBXO32 1.30 3.00E-02 F-box protein 32 
399665 FAM102A 1.30 1.71E-02 family with sequence similarity 102, member A 
1050 CEBPA 1.30 2.46E-02 CCAAT/enhancer binding protein (C/EBP), alpha 
6836 SURF4 1.30 4.36E-04 surfeit 4 
2878 GPX3 1.30 2.47E-03 glutathione peroxidase 3 (plasma) 
51651 PTRH2 1.30 1.83E-02 peptidyl-tRNA hydrolase 2 
84513 PPAPDC1B 1.30 6.39E-03 phosphatidic acid phosphatase type 2 domain containing 1B 
7068 THRB 1.30 4.82E-02 thyroid hormone receptor, beta 
202915 TMEM184A 1.30 1.54E-02 transmembrane protein 184A 
84447 SYVN1 1.30 5.23E-03 synovial apoptosis inhibitor 1, synoviolin 
8565 YARS 1.30 1.34E-03 tyrosyl-tRNA synthetase 
2770 GNAI1 1.30 4.79E-02 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 
83752 LONP2 1.30 1.30E-03 lon peptidase 2, peroxisomal 
56261 GPCPD1 1.30 4.59E-02 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 
157922 CAMSAP1 1.30 5.74E-03 calmodulin regulated spectrin-associated protein 1 
25791 NGEF 1.30 3.85E-02 neuronal guanine nucleotide exchange factor 
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219743 TYSND1 1.30 1.00E-02 trypsin domain containing 1 
29968 PSAT1 1.30 3.16E-02 phosphoserine aminotransferase 1 
286343 LURAP1L 1.29 2.66E-02 leucine rich adaptor protein 1-like 
3775 KCNK1 1.29 2.11E-02 potassium channel, subfamily K, member 1 
2035 EPB41 1.29 1.00E-02 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 
3655 ITGA6 1.29 2.42E-03 integrin, alpha 6 
11162 NUDT6 1.29 3.01E-02 nudix (nucleoside diphosphate linked moiety X)-type motif 6 
10165 SLC25A13 1.29 3.83E-03 solute carrier family 25 (aspartate/glutamate carrier), member 13 
2717 GLA 1.29 1.78E-03 galactosidase, alpha 
55343 SLC35C1 1.29 4.90E-02 solute carrier family 35 (GDP-fucose transporter), member C1 
79161 TMEM243 1.29 3.00E-02 transmembrane protein 243, mitochondrial 
2109 ETFB 1.29 5.58E-03 electron-transfer-flavoprotein, beta polypeptide 
27304 MOCS3 1.29 4.82E-02 molybdenum cofactor synthesis 3 
51136 RNFT1 1.29 1.17E-02 ring finger protein, transmembrane 1 
114818 KLHL29 1.29 1.24E-02 kelch-like family member 29 
3693 ITGB5 1.29 2.71E-03 integrin, beta 5 
283464 GXYLT1 1.29 2.17E-03 glucoside xylosyltransferase 1 
23576 DDAH1 1.29 2.09E-03 dimethylarginine dimethylaminohydrolase 1 
79594 MUL1 1.29 1.48E-02 mitochondrial E3 ubiquitin protein ligase 1 
1491 CTH 1.29 3.96E-02 cystathionase (cystathionine gamma-lyase) 
11260 XPOT 1.28 9.69E-03 exportin, tRNA 
7371 UCK2 1.28 6.56E-03 uridine-cytidine kinase 2 
9821 RB1CC1 1.28 2.28E-03 RB1-inducible coiled-coil 1 
196410 METTL7B 1.28 1.53E-02 methyltransferase like 7B 
9697 TRAM2 1.28 2.19E-03 translocation associated membrane protein 2 
200933 FBXO45 1.28 2.35E-02 F-box protein 45 
3032 HADHB 1.28 1.95E-03 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional  
    protein), beta subunit 
152641 WWC2-AS2 1.28 2.03E-02 WWC2 antisense RNA 2 
9975 NR1D2 1.28 4.04E-03 nuclear receptor subfamily 1, group D, member 2 
29958 DMGDH 1.28 3.89E-02 dimethylglycine dehydrogenase 
57161 PELI2 1.28 1.03E-02 pellino E3 ubiquitin protein ligase family member 2 
51099 ABHD5 1.28 3.68E-02 abhydrolase domain containing 5 
8366 HIST1H4B 1.28 4.05E-02 histone cluster 1, H4b 
10397 NDRG1 1.28 1.32E-02 N-myc downstream regulated 1 
29925 GMPPB 1.28 1.33E-02 GDP-mannose pyrophosphorylase B 
5795 PTPRJ 1.28 7.07E-03 protein tyrosine phosphatase, receptor type, J 
85377 MICALL1 1.28 4.87E-02 MICAL-like 1 
6249 CLIP1 1.28 9.72E-04 CAP-GLY domain containing linker protein 1 
7922 SLC39A7 1.28 3.02E-03 solute carrier family 39 (zinc transporter), member 7 
9093 DNAJA3 1.28 2.42E-03 DnaJ (Hsp40) homolog, subfamily A, member 3 
80218 NAA50 1.28 3.30E-04 N(alpha)-acetyltransferase 50, NatE catalytic subunit 
55605 KIF21A 1.28 4.19E-03 kinesin family member 21A 
25850 ZNF345 1.28 4.54E-02 zinc finger protein 345 
84725 PLEKHA8 1.28 3.54E-02 pleckstrin homology domain containing, family A (phosphoinositide binding specific)  
    member 8 
55435 AP1AR 1.28 4.96E-03 adaptor-related protein complex 1 associated regulatory protein 
10560 SLC19A2 1.27 3.17E-02 solute carrier family 19 (thiamine transporter), member 2 
84818 IL17RC 1.27 2.95E-02 interleukin 17 receptor C 
23277 CLUH 1.27 1.55E-03 clustered mitochondria (cluA/CLU1) homolog 
216 ALDH1A1 1.27 8.23E-03 aldehyde dehydrogenase 1 family, member A1 
5053 PAH 1.27 4.16E-02 phenylalanine hydroxylase 
133 ADM 1.27 2.75E-02 adrenomedullin 
28955 DEXI 1.27 3.71E-02 Dexi homolog (mouse) 
91526 ANKRD44 1.27 8.26E-03 ankyrin repeat domain 44 
9980 DOPEY2 1.27 2.80E-02 dopey family member 2 
2247 FGF2 1.27 1.70E-02 fibroblast growth factor 2 (basic) 
83606 GUCD1 1.27 8.74E-04 guanylyl cyclase domain containing 1 
64755 C16orf58 1.27 8.02E-03 chromosome 16 open reading frame 58 
2646 GCKR 1.27 2.82E-02 glucokinase (hexokinase 4) regulator 
5062 PAK2 1.27 8.74E-04 p21 protein (Cdc42/Rac)-activated kinase 2 
1843 DUSP1 1.27 4.50E-04 dual specificity phosphatase 1 
5217 PFN2 1.27 4.91E-03 profilin 2 
51114 ZDHHC9 1.27 2.55E-03 zinc finger, DHHC-type containing 9 
64216 TFB2M 1.27 7.34E-03 transcription factor B2, mitochondrial 
201232 SLC16A13 1.27 1.42E-02 solute carrier family 16, member 13 
57414 RHBDD2 1.27 7.75E-03 rhomboid domain containing 2 
56288 PARD3 1.27 7.37E-04 par-3 family cell polarity regulator 
3741 KCNA5 1.27 4.52E-02 potassium voltage-gated channel, shaker-related subfamily, member 5 
2872 MKNK2 1.27 3.98E-02 MAP kinase interacting serine/threonine kinase 2 
10483 SEC23B 1.26 3.44E-03 Sec23 homolog B (S. cerevisiae) 
56997 ADCK3 1.26 4.95E-02 aarF domain containing kinase 3 
22928 SEPHS2 1.26 3.48E-03 selenophosphate synthetase 2 
5387 PMS2P3 1.26 1.24E-02 postmeiotic segregation increased 2 pseudogene 3 
4953 ODC1 1.26 1.79E-03 ornithine decarboxylase 1 
57834 CYP4F11 1.26 2.04E-02 cytochrome P450, family 4, subfamily F, polypeptide 11 
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5621 PRNP 1.26 3.26E-03 prion protein 
29088 MRPL15 1.26 4.38E-02 mitochondrial ribosomal protein L15 
79144 PPDPF 1.26 1.78E-02 pancreatic progenitor cell differentiation and proliferation factor 
29926 GMPPA 1.26 8.97E-03 GDP-mannose pyrophosphorylase A 
23223 RRP12 1.26 4.19E-03 ribosomal RNA processing 12 homolog (S. cerevisiae) 
55330 BLOC1S4 1.26 4.91E-02 biogenesis of lysosomal organelles complex-1, subunit 4, cappuccino 
10525 HYOU1 1.26 1.19E-02 hypoxia up-regulated 1 
1978 EIF4EBP1 1.26 2.50E-02 eukaryotic translation initiation factor 4E binding protein 1 
1579 CYP4A11 1.26 3.27E-02 cytochrome P450, family 4, subfamily A, polypeptide 11 
51058 ZNF691 1.26 4.33E-02 zinc finger protein 691 
54929 TMEM161A 1.26 4.43E-02 transmembrane protein 161A 
63893 UBE2O 1.26 1.42E-02 ubiquitin-conjugating enzyme E2O 
10400 PEMT 1.26 1.11E-02 phosphatidylethanolamine N-methyltransferase 
6782 HSPA13 1.26 2.76E-03 heat shock protein 70kDa family, member 13 
22809 ATF5 1.26 1.18E-02 activating transcription factor 5 
254887 ZDHHC23 1.26 1.05E-02 zinc finger, DHHC-type containing 23 
9570 GOSR2 1.26 6.56E-03 golgi SNAP receptor complex member 2 
84649 DGAT2 1.25 3.46E-02 diacylglycerol O-acyltransferase 2 
79875 THSD4 1.25 3.73E-02 thrombospondin, type I, domain containing 4 
55884 WSB2 1.25 4.75E-03 WD repeat and SOCS box containing 2 
7923 HSD17B8 1.25 9.05E-03 hydroxysteroid (17-beta) dehydrogenase 8 
134147 CMBL 1.25 1.03E-02 carboxymethylenebutenolidase homolog (Pseudomonas) 
8608 RDH16 1.25 3.60E-02 retinol dehydrogenase 16 (all-trans) 
2669 GEM 1.25 1.83E-02 GTP binding protein overexpressed in skeletal muscle 
144811 LACC1 1.25 1.29E-02 laccase (multicopper oxidoreductase) domain containing 1 
221756 SERPINB9P1 1.25 4.95E-02 serpin peptidase inhibitor, clade B (ovalbumin), member 9, pseudogene 1 
7132 TNFRSF1A 1.25 2.76E-03 tumor necrosis factor receptor superfamily, member 1A 
8439 NSMAF 1.25 1.97E-02 neutral sphingomyelinase (N-SMase) activation associated factor 
55132 LARP1B 1.25 3.17E-02 La ribonucleoprotein domain family, member 1B 
9429 ABCG2 1.25 3.67E-02 ATP-binding cassette, sub-family G (WHITE), member 2 
200844 C3orf67 1.25 2.98E-02 chromosome 3 open reading frame 67 
29914 UBIAD1 1.25 1.47E-02 UbiA prenyltransferase domain containing 1 
56947 MFF 1.24 9.39E-03 mitochondrial fission factor 
9689 BZW1 1.24 1.29E-02 basic leucine zipper and W2 domains 1 
10099 TSPAN3 1.24 3.96E-03 tetraspanin 3 
10933 MORF4L1 1.24 1.62E-02 mortality factor 4 like 1 
8187 ZNF239 1.24 4.52E-02 zinc finger protein 239 
30836 DNTTIP2 1.24 7.07E-03 deoxynucleotidyltransferase, terminal, interacting protein 2 
5565 PRKAB2 1.24 2.10E-02 protein kinase, AMP-activated, beta 2 non-catalytic subunit 
84085 FBXO30 1.24 1.77E-03 F-box protein 30 
5830 PEX5 1.24 7.83E-03 peroxisomal biogenesis factor 5 
54867 TMEM214 1.24 1.66E-02 transmembrane protein 214 
347735 SERINC2 1.24 1.54E-02 serine incorporator 2 
5164 PDK2 1.24 3.99E-02 pyruvate dehydrogenase kinase, isozyme 2 
26777 SNORA71A 1.24 2.47E-02 small nucleolar RNA, H/ACA box 71A 
23483 TGDS 1.24 8.81E-03 TDP-glucose 4,6-dehydratase 
7184 HSP90B1 1.24 1.56E-03 heat shock protein 90kDa beta (Grp94), member 1 
60314 C12orf10 1.24 1.55E-02 chromosome 12 open reading frame 10 
51582 AZIN1 1.23 7.57E-04 antizyme inhibitor 1 
221656 KDM1B 1.23 1.34E-02 lysine (K)-specific demethylase 1B 
84336 TMEM101 1.23 4.08E-02 transmembrane protein 101 
10613 ERLIN1 1.23 2.22E-02 ER lipid raft associated 1 
3998 LMAN1 1.23 1.55E-02 lectin, mannose-binding, 1 
162989 DEDD2 1.23 4.10E-02 death effector domain containing 2 
23139 MAST2 1.23 8.15E-03 microtubule associated serine/threonine kinase 2 
10598 AHSA1 1.23 1.84E-03 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) 
64795 RMND5A 1.23 4.95E-02 required for meiotic nuclear division 5 homolog A (S. cerevisiae) 
64425 POLR1E 1.23 2.08E-02 polymerase (RNA) I polypeptide E, 53kDa 
54676 GTPBP2 1.23 2.92E-02 GTP binding protein 2 
153241 CEP120 1.23 4.82E-02 centrosomal protein 120kDa 
360023 ZBTB41 1.23 3.01E-02 zinc finger and BTB domain containing 41 
63971 KIF13A 1.23 1.16E-02 kinesin family member 13A 
79018 GID4 1.23 4.71E-02 GID complex subunit 4 
55313 CPPED1 1.23 2.45E-03 calcineurin-like phosphoesterase domain containing 1 
58477 SRPRB 1.23 2.54E-03 signal recognition particle receptor, B subunit 
51649 MRPS23 1.23 3.70E-02 mitochondrial ribosomal protein S23 
7514 XPO1 1.23 7.72E-03 exportin 1 
64175 LEPRE1 1.23 3.41E-02 leucine proline-enriched proteoglycan (leprecan) 1 
978 CDA 1.22 1.86E-02 cytidine deaminase 
11108 PRDM4 1.22 1.28E-02 PR domain containing 4 
7071 KLF10 1.22 5.44E-03 Kruppel-like factor 10 
96610 BMS1P20 1.22 2.96E-02 BMS1 pseudogene 20 
90411 MCFD2 1.22 6.31E-03 multiple coagulation factor deficiency 2 
7165 TPD52L2 1.22 4.91E-03 tumor protein D52-like 2 
3030 HADHA 1.22 1.70E-02 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase  
    (trifunctional protein), alpha subunit 
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5167 ENPP1 1.22 1.11E-02 ectonucleotide pyrophosphatase/phosphodiesterase 1 
50640 PNPLA8 1.22 2.19E-02 patatin-like phospholipase domain containing 8 
64771 C6orf106 1.22 8.02E-03 chromosome 6 open reading frame 106 
375035 SFT2D2 1.22 1.94E-02 SFT2 domain containing 2 
26207 PITPNC1 1.22 9.59E-03 phosphatidylinositol transfer protein, cytoplasmic 1 
26151 NAT9 1.22 2.75E-02 N-acetyltransferase 9 (GCN5-related, putative) 
5412 UBL3 1.22 9.85E-03 ubiquitin-like 3 
27248 ERLEC1 1.22 2.49E-02 endoplasmic reticulum lectin 1 
91252 SLC39A13 1.22 2.42E-02 solute carrier family 39 (zinc transporter), member 13 
9557 CHD1L 1.22 3.63E-02 chromodomain helicase DNA binding protein 1-like 
54469 ZFAND6 1.22 3.09E-02 zinc finger, AN1-type domain 6 
10196 PRMT3 1.22 2.69E-02 protein arginine methyltransferase 3 
80273 GRPEL1 1.22 7.67E-03 GrpE-like 1, mitochondrial (E. coli) 
10838 ZNF275 1.22 2.47E-02 zinc finger protein 275 
51566 ARMCX3 1.22 3.95E-02 armadillo repeat containing, X-linked 3 
26608 TBL2 1.22 4.81E-02 transducin (beta)-like 2 
9917 FAM20B 1.21 1.10E-02 family with sequence similarity 20, member B 
7419 VDAC3 1.21 5.82E-04 voltage-dependent anion channel 3 
54517 PUS7 1.21 1.76E-02 pseudouridylate synthase 7 (putative) 
3295 HSD17B4 1.21 1.41E-02 hydroxysteroid (17-beta) dehydrogenase 4 
400 ARL1 1.21 2.02E-02 ADP-ribosylation factor-like 1 
8907 AP1M1 1.21 3.82E-02 adaptor-related protein complex 1, mu 1 subunit 
5054 SERPINE1 1.21 2.61E-02 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1),  
    member 1 
8100 IFT88 1.21 2.46E-02 intraflagellar transport 88 homolog (Chlamydomonas) 
85379 KIAA1671 1.21 1.10E-02 KIAA1671 
2801 GOLGA2 1.21 1.67E-02 golgin A2 
10322 SMYD5 1.21 2.74E-02 SMYD family member 5 
4780 NFE2L2 1.21 1.39E-02 nuclear factor, erythroid 2-like 2 
84919 PPP1R15B 1.21 2.14E-02 protein phosphatase 1, regulatory subunit 15B 
57222 ERGIC1 1.21 4.17E-03 endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 
27075 TSPAN13 1.20 3.73E-02 tetraspanin 13 
4199 ME1 1.20 1.04E-02 malic enzyme 1, NADP(+)-dependent, cytosolic 
91272 BOD1 1.20 1.49E-02 biorientation of chromosomes in cell division 1 
5467 PPARD 1.20 3.13E-02 peroxisome proliferator-activated receptor delta 
9146 HGS 1.20 1.70E-02 hepatocyte growth factor-regulated tyrosine kinase substrate 
56647 BCCIP 1.20 3.36E-02 BRCA2 and CDKN1A interacting protein 
1979 EIF4EBP2 1.20 2.57E-03 eukaryotic translation initiation factor 4E binding protein 2 
56683 C21orf59 1.20 1.20E-02 chromosome 21 open reading frame 59 
6746 SSR2 1.20 1.11E-02 signal sequence receptor, beta (translocon-associated protein beta) 
4233 MET 1.20 3.45E-02 met proto-oncogene 
7965 AIMP2 1.20 1.70E-02 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 
6683 SPAST 1.20 1.56E-02 spastin 
1317 SLC31A1 1.20 2.19E-02 solute carrier family 31 (copper transporter), member 1 
7295 TXN 1.20 1.00E-02 thioredoxin 
6780 STAU1 1.20 3.62E-03 staufen double-stranded RNA binding protein 1 
134553 C5orf24 1.20 3.17E-02 chromosome 5 open reading frame 24 
81671 VMP1 1.20 1.94E-03 vacuole membrane protein 1 
56910 STARD7 1.20 3.38E-03 StAR-related lipid transfer (START) domain containing 7 
1497 CTNS 1.20 2.93E-02 cystinosin, lysosomal cystine transporter 
5686 PSMA5 1.20 3.64E-02 proteasome (prosome, macropain) subunit, alpha type, 5 
55829 VIMP 1.20 3.25E-02 VCP-interacting membrane protein 
11046 SLC35D2 1.20 2.81E-02 solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2 
10455 ECI2 1.19 9.14E-03 enoyl-CoA delta isomerase 2 
6732 SRPK1 1.19 2.45E-02 SRSF protein kinase 1 
7764 ZNF217 1.19 3.37E-02 zinc finger protein 217 
51061 TXNDC11 1.19 3.67E-02 thioredoxin domain containing 11 
8772 FADD 1.19 3.69E-02 Fas (TNFRSF6)-associated via death domain 
10953 TOMM34 1.19 1.34E-02 translocase of outer mitochondrial membrane 34 
63929 XPNPEP3 1.19 4.99E-02 X-prolyl aminopeptidase (aminopeptidase P) 3, putative 
10130 PDIA6 1.19 2.18E-02 protein disulfide isomerase family A, member 6 
29855 UBN1 1.19 4.92E-02 ubinuclein 1 
7813 EVI5 1.19 3.70E-02 ecotropic viral integration site 5 
10728 PTGES3 1.19 1.75E-02 prostaglandin E synthase 3 (cytosolic) 
9184 BUB3 1.19 3.57E-02 BUB3 mitotic checkpoint protein 
10120 ACTR1B 1.19 3.47E-02 ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
4257 MGST1 1.19 5.78E-03 microsomal glutathione S-transferase 1 
613 BCR 1.19 4.16E-02 breakpoint cluster region 
8630 HSD17B6 1.19 2.10E-02 hydroxysteroid (17-beta) dehydrogenase 6 
23230 VPS13A 1.19 2.88E-02 vacuolar protein sorting 13 homolog A (S. cerevisiae) 
26354 GNL3 1.19 1.40E-02 guanine nucleotide binding protein-like 3 (nucleolar) 
10885 WDR3 1.19 2.75E-02 WD repeat domain 3 
25923 ATL3 1.19 6.77E-03 atlastin GTPase 3 
84522 JAGN1 1.19 3.31E-02 jagunal homolog 1 (Drosophila) 
25888 ZNF473 1.19 3.55E-02 zinc finger protein 473 
55907 CMAS 1.19 4.84E-02 cytidine monophosphate N-acetylneuraminic acid synthetase 
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127262 TPRG1L 1.19 4.14E-02 tumor protein p63 regulated 1-like 
22931 RAB18 1.18 8.02E-03 RAB18, member RAS oncogene family 
85021 REPS1 1.18 5.26E-03 RALBP1 associated Eps domain containing 1 
9950 GOLGA5 1.18 4.72E-02 golgin A5 
142891 SAMD8 1.18 1.56E-02 sterile alpha motif domain containing 8 
8886 DDX18 1.18 1.29E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 
58513 EPS15L1 1.18 3.86E-02 epidermal growth factor receptor pathway substrate 15-like 1 
7342 UBP1 1.18 2.89E-02 upstream binding protein 1 (LBP-1a) 
7267 TTC3 1.18 3.24E-02 tetratricopeptide repeat domain 3 
50865 HEBP1 1.18 4.12E-02 heme binding protein 1 
51430 SUCO 1.18 2.47E-02 SUN domain containing ossification factor 
6868 ADAM17 1.18 3.15E-02 ADAM metallopeptidase domain 17 
116064 LRRC58 1.18 3.71E-02 leucine rich repeat containing 58 
9921 RNF10 1.18 1.38E-02 ring finger protein 10 
9043 SPAG9 1.18 4.48E-02 sperm associated antigen 9 
22937 SCAP 1.18 2.98E-02 SREBF chaperone 
92140 MTDH 1.18 6.72E-03 metadherin 
30 ACAA1 1.18 1.15E-02 acetyl-CoA acyltransferase 1 
8882 ZPR1 1.18 2.36E-02 ZPR1 zinc finger 
57587 KIAA1430 1.18 1.97E-02 KIAA1430 
200734 SPRED2 1.18 3.34E-02 sprouty-related, EVH1 domain containing 2 
8476 CDC42BPA 1.18 3.17E-02 CDC42 binding protein kinase alpha (DMPK-like) 
55760 DHX32 1.17 1.49E-02 DEAH (Asp-Glu-Ala-His) box polypeptide 32 
55003 PAK1IP1 1.17 1.97E-02 PAK1 interacting protein 1 
2288 FKBP4 1.17 2.65E-02 FK506 binding protein 4, 59kDa 
262 AMD1 1.17 2.30E-02 adenosylmethionine decarboxylase 1 
80854 SETD7 1.17 7.61E-03 SET domain containing (lysine methyltransferase) 7 
7110 TMF1 1.17 1.86E-02 TATA element modulatory factor 1 
51012 SLMO2 1.17 2.96E-02 slowmo homolog 2 (Drosophila) 
10105 PPIF 1.17 2.82E-02 peptidylprolyl isomerase F 
84246 MED10 1.17 2.83E-02 mediator complex subunit 10 
3633 INPP5B 1.17 4.68E-02 inositol polyphosphate-5-phosphatase, 75kDa 
169200 TMEM64 1.17 2.18E-02 transmembrane protein 64 
85403 EAF1 1.17 1.70E-02 ELL associated factor 1 
9731 CEP104 1.17 3.01E-02 centrosomal protein 104kDa 
7106 TSPAN4 1.17 2.74E-02 tetraspanin 4 
9475 ROCK2 1.17 1.93E-02 Rho-associated, coiled-coil containing protein kinase 2 
55127 HEATR1 1.17 4.95E-02 HEAT repeat containing 1 
55667 DENND4C 1.17 2.81E-02 DENN/MADD domain containing 4C 
58472 SQRDL 1.17 4.00E-02 sulfide quinone reductase-like (yeast) 
5929 RBBP5 1.17 4.78E-02 retinoblastoma binding protein 5 
22870 PPP6R1 1.17 3.57E-02 protein phosphatase 6, regulatory subunit 1 
3459 IFNGR1 1.17 2.76E-03 interferon gamma receptor 1 
9654 TTLL4 1.17 3.20E-02 tubulin tyrosine ligase-like family, member 4 
1604 CD55 1.17 3.17E-02 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
3692 EIF6 1.17 5.00E-02 eukaryotic translation initiation factor 6 
5352 PLOD2 1.16 4.45E-02 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
4170 MCL1 1.16 1.08E-02 myeloid cell leukemia 1 
26003 GORASP2 1.16 1.54E-02 golgi reassembly stacking protein 2, 55kDa 
2317 FLNB 1.16 2.14E-02 filamin B, beta 
4927 NUP88 1.16 3.98E-02 nucleoporin 88kDa 
2803 GOLGA4 1.16 8.74E-03 golgin A4 
155061 ZNF746 1.16 3.54E-02 zinc finger protein 746 
55054 ATG16L1 1.16 4.94E-02 autophagy related 16-like 1 (S. cerevisiae) 
1983 EIF5 1.16 2.47E-02 eukaryotic translation initiation factor 5 
26100 WIPI2 1.16 4.90E-02 WD repeat domain, phosphoinositide interacting 2 
5092 PCBD1 1.16 2.95E-02 pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear 
    factor 1 alpha 
5203 PFDN4 1.16 4.65E-02 prefoldin subunit 4 
51181 DCXR 1.16 4.12E-02 dicarbonyl/L-xylulose reductase 
571 BACH1 1.16 4.56E-02 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
3312 HSPA8 1.16 9.45E-03 heat shock 70kDa protein 8 
4799 NFX1 1.16 3.95E-02 nuclear transcription factor, X-box binding 1 
79691 QTRTD1 1.16 4.75E-02 queuine tRNA-ribosyltransferase domain containing 1 
3376 IARS 1.16 2.42E-02 isoleucyl-tRNA synthetase 
3313 HSPA9 1.16 1.31E-02 heat shock 70kDa protein 9 (mortalin) 
6856 SYPL1 1.16 3.57E-02 synaptophysin-like 1 
27339 PRPF19 1.15 4.77E-02 pre-mRNA processing factor 19 
8615 USO1 1.15 2.81E-02 USO1 vesicle transport factor 
221749 PXDC1 1.15 3.71E-02 PX domain containing 1 
5264 PHYH 1.15 3.01E-02 phytanoyl-CoA 2-hydroxylase 
1650 DDOST 1.15 4.85E-02 dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit (non-catalytic) 
1212 CLTB 1.15 3.72E-02 clathrin, light chain B 
10969 EBNA1BP2 1.15 2.73E-02 EBNA1 binding protein 2 
10857 PGRMC1 1.15 6.31E-03 progesterone receptor membrane component 1 
8833 GMPS 1.15 4.25E-02 guanine monphosphate synthase 
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8454 CUL1 1.15 1.03E-02 cullin 1 
60481 ELOVL5 1.15 1.40E-02 ELOVL fatty acid elongase 5 
201627 DENND6A 1.14 3.19E-02 DENN/MADD domain containing 6A 
7415 VCP 1.14 4.53E-03 valosin containing protein 
23214 XPO6 1.14 2.63E-02 exportin 6 
7763 ZFAND5 1.14 1.48E-02 zinc finger, AN1-type domain 5 
7358 UGDH 1.14 8.38E-03 UDP-glucose 6-dehydrogenase 
5007 OSBP 1.14 4.78E-02 oxysterol binding protein 
3069 HDLBP 1.14 4.45E-02 high density lipoprotein binding protein 
23074 UHRF1BP1L 1.14 3.84E-02 UHRF1 binding protein 1-like 
3326 HSP90AB1 1.14 1.56E-02 heat shock protein 90kDa alpha (cytosolic), class B member 1 
92856 IMP4 1.14 1.33E-02 IMP4, U3 small nucleolar ribonucleoprotein 
55970 GNG12 1.13 2.98E-02 guanine nucleotide binding protein (G protein), gamma 12 
9275 BCL7B 1.13 3.34E-02 B-cell CLL/lymphoma 7B 
4259 MGST3 1.13 4.79E-02 microsomal glutathione S-transferase 3 
1635 DCTD 1.13 3.73E-02 dCMP deaminase 
3416 IDE 1.13 3.17E-02 insulin-degrading enzyme 
94056 SYAP1 1.13 2.35E-02 synapse associated protein 1 
821 CANX 1.12 2.87E-02 calnexin 
3267 AGFG1 1.12 3.58E-02 ArfGAP with FG repeats 1 
5052 PRDX1 1.11 4.10E-02 peroxiredoxin 1 
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4283 CXCL9 -7.25 5.28E-05 chemokine (C-X-C motif) ligand 9 
3627 CXCL10 -6.88 6.58E-05 chemokine (C-X-C motif) ligand 10 
6373 CXCL11 -5.65 3.69E-04 chemokine (C-X-C motif) ligand 11 
405753 DUOXA2 -3.97 3.05E-06 dual oxidase maturation factor 2 
4843 NOS2 -3.62 5.43E-03 nitric oxide synthase 2, inducible 
50506 DUOX2 -3.24 5.01E-06 dual oxidase 2 
6355 CCL8 -3.07 3.67E-03 chemokine (C-C motif) ligand 8 
10964 IFI44L -3.06 4.43E-04 interferon-induced protein 44-like 
115362 GBP5 -2.94 6.83E-04 guanylate binding protein 5 
3620 IDO1 -2.91 5.65E-06 indoleamine 2,3-dioxygenase 1 
8519 IFITM1 -2.67 5.65E-06 interferon induced transmembrane protein 1 
3433 IFIT2 -2.61 2.28E-03 interferon-induced protein with tetratricopeptide repeats 2 
54898 ELOVL2 -2.61 4.38E-07 ELOVL fatty acid elongase 2 
2892 GRIA3 -2.60 3.06E-05 glutamate receptor, ionotropic, AMPA 3 
6376 CX3CL1 -2.57 4.43E-04 chemokine (C-X3-C motif) ligand 1 
7098 TLR3 -2.55 5.76E-06 toll-like receptor 3 
79689 STEAP4 -2.50 8.35E-05 STEAP family member 4 
3434 IFIT1 -2.48 2.64E-03 interferon-induced protein with tetratricopeptide repeats 1 
4321 MMP12 -2.45 2.30E-04 matrix metallopeptidase 12 (macrophage elastase) 
10826 FAXDC2 -2.42 5.01E-06 fatty acid hydroxylase domain containing 2 
8626 TP63 -2.41 2.02E-05 tumor protein p63 
64577 ALDH8A1 -2.41 6.05E-06 aldehyde dehydrogenase 8 family, member A1 
8740 TNFSF14 -2.40 6.35E-05 tumor necrosis factor (ligand) superfamily, member 14 
10417 SPON2 -2.39 2.46E-06 spondin 2, extracellular matrix protein 
3437 IFIT3 -2.38 2.74E-04 interferon-induced protein with tetratricopeptide repeats 3 
54739 XAF1 -2.35 3.46E-06 XIAP associated factor 1 
94240 EPSTI1 -2.29 2.79E-04 epithelial stromal interaction 1 (breast) 
10346 TRIM22 -2.28 4.50E-06 tripartite motif containing 22 
83953 FCAMR -2.28 1.16E-02 Fc receptor, IgA, IgM, high affinity 
3934 LCN2 -2.26 1.95E-04 lipocalin 2 
388646 GBP7 -2.25 1.82E-04 guanylate binding protein 7 
57817 HAMP -2.24 5.28E-05 hepcidin antimicrobial peptide 
2634 GBP2 -2.22 6.65E-05 guanylate binding protein 2, interferon-inducible 
9288 TAAR3 -2.22 2.65E-02 trace amine associated receptor 3 (gene/pseudogene) 
115361 GBP4 -2.21 2.38E-04 guanylate binding protein 4 
6372 CXCL6 -2.20 8.74E-04 chemokine (C-X-C motif) ligand 6 
10537 UBD -2.19 1.02E-06 ubiquitin D 
11274 USP18 -2.18 3.82E-04 ubiquitin specific peptidase 18 
51156 SERPINA10 -2.18 2.15E-05 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10 
6999 TDO2 -2.16 9.97E-03 tryptophan 2,3-dioxygenase 
256764 WDR72 -2.15 1.02E-03 WD repeat domain 72 
5920 RARRES3 -2.12 1.34E-06 retinoic acid receptor responder (tazarotene induced) 3 
5284 PIGR -2.11 1.97E-03 polymeric immunoglobulin receptor 
4939 OAS2 -2.10 5.36E-04 2'-5'-oligoadenylate synthetase 2, 69/71kDa 
113146 AHNAK2 -2.09 6.05E-06 AHNAK nucleoprotein 2 
4599 MX1 -2.07 5.70E-04 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) 
4940 OAS3 -2.06 4.49E-04 2'-5'-oligoadenylate synthetase 3, 100kDa 
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57507 ZNF608 -2.06 5.01E-06 zinc finger protein 608 
2633 GBP1 -2.04 1.05E-04 guanylate binding protein 1, interferon-inducible 
3626 INHBC -2.03 9.40E-05 inhibin, beta C 
117153 MIA2 -2.02 2.07E-04 melanoma inhibitory activity 2 
80833 APOL3 -2.01 1.86E-04 apolipoprotein L, 3 
10068 IL18BP -1.97 4.50E-06 interleukin 18 binding protein 
54809 SAMD9 -1.97 2.61E-05 sterile alpha motif domain containing 9 
84873 GPR128 -1.97 4.02E-05 G protein-coupled receptor 128 
5168 ENPP2 -1.97 4.50E-06 ectonucleotide pyrophosphatase/phosphodiesterase 2 
5207 PFKFB1 -1.96 3.69E-04 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 
10272 FSTL3 -1.96 6.80E-03 follistatin-like 3 (secreted glycoprotein) 
6289 SAA2 -1.96 1.46E-03 serum amyloid A2 
10561 IFI44 -1.95 2.40E-04 interferon-induced protein 44 
420 ART4 -1.94 1.30E-04 ADP-ribosyltransferase 4 (Dombrock blood group) 
219285 SAMD9L -1.94 7.48E-04 sterile alpha motif domain containing 9-like 
4938 OAS1 -1.94 1.86E-04 2'-5'-oligoadenylate synthetase 1, 40/46kDa 
80380 PDCD1LG2 -1.93 1.30E-03 programmed cell death 1 ligand 2 
23586 DDX58 -1.93 8.22E-05 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
9636 ISG15 -1.92 8.26E-04 ISG15 ubiquitin-like modifier 
4547 MTTP -1.91 1.65E-04 microsomal triglyceride transfer protein 
343450 KCNT2 -1.90 6.93E-05 potassium channel, subfamily T, member 2 
5288 PIK3C2G -1.90 2.58E-04 phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma 
2537 IFI6 -1.89 1.29E-05 interferon, alpha-inducible protein 6 
1592 CYP26A1 -1.89 7.57E-04 cytochrome P450, family 26, subfamily A, polypeptide 1 
342372 PKD1L3 -1.89 2.15E-03 polycystic kidney disease 1-like 3 
353514 LILRA5 -1.87 1.46E-03 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 
7042 TGFB2 -1.87 2.30E-06 transforming growth factor, beta 2 
23767 FLRT3 -1.86 2.25E-04 fibronectin leucine rich transmembrane protein 3 
83666 PARP9 -1.86 3.18E-05 poly (ADP-ribose) polymerase family, member 9 
412 STS -1.85 4.62E-04 steroid sulfatase (microsomal), isozyme S 
10677 AVIL -1.84 4.43E-04 advillin 
83729 INHBE -1.84 6.47E-04 inhibin, beta E 
163351 GBP6 -1.82 1.65E-02 guanylate binding protein family, member 6 
2635 GBP3 -1.82 3.43E-04 guanylate binding protein 3 
55008 HERC6 -1.81 3.76E-03 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 
6274 S100A3 -1.81 4.79E-02 S100 calcium binding protein A3 
55601 DDX60 -1.81 3.68E-04 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 
114899 C1QTNF3 -1.80 2.75E-02 C1q and tumor necrosis factor related protein 3 
27289 RND1 -1.79 1.56E-04 Rho family GTPase 1 
952 CD38 -1.78 6.84E-04 CD38 molecule 
9510 ADAMTS1 -1.78 2.41E-02 ADAM metallopeptidase with thrombospondin type 1 motif, 1 
5737 PTGFR -1.78 7.03E-04 prostaglandin F receptor (FP) 
51056 LAP3 -1.78 1.46E-03 leucine aminopeptidase 3 
64108 RTP4 -1.77 1.33E-03 receptor (chemosensory) transporter protein 4 
6363 CCL19 -1.77 5.33E-05 chemokine (C-C motif) ligand 19 
4068 SH2D1A -1.77 1.20E-02 SH2 domain containing 1A 
7127 TNFAIP2 -1.76 5.43E-03 tumor necrosis factor, alpha-induced protein 2 
28951 TRIB2 -1.75 1.94E-03 tribbles pseudokinase 2 
222643 UNC5CL -1.75 1.02E-03 unc-5 homolog C (C. elegans)-like 
9076 CLDN1 -1.75 1.06E-06 claudin 1 
6690 SPINK1 -1.74 3.81E-03 serine peptidase inhibitor, Kazal type 1 
200373 PCDP1 -1.74 1.56E-03 primary ciliary dyskinesia protein 1 
6352 CCL5 -1.74 6.93E-04 chemokine (C-C motif) ligand 5 
8875 VNN2 -1.73 7.42E-04 vanin 2 
11074 TRIM31 -1.73 6.09E-05 tripartite motif containing 31 
8743 TNFSF10 -1.73 1.99E-06 tumor necrosis factor (ligand) superfamily, member 10 
118932 ANKRD22 -1.73 8.29E-03 ankyrin repeat domain 22 
3430 IFI35 -1.72 5.43E-03 interferon-induced protein 35 
3560 IL2RB -1.72 2.29E-03 interleukin 2 receptor, beta 
8470 SORBS2 -1.72 9.72E-04 sorbin and SH3 domain containing 2 
60489 APOBEC3G -1.72 2.10E-02 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
5698 PSMB9 -1.72 1.20E-03 proteasome (prosome, macropain) subunit, beta type, 9 
7045 TGFBI -1.71 1.04E-04 transforming growth factor, beta-induced, 68kDa 
2877 GPX2 -1.71 8.74E-03 glutathione peroxidase 2 (gastrointestinal) 
51513 ETV7 -1.71 1.86E-02 ets variant 7 
284111 SLC13A5 -1.71 4.83E-04 solute carrier family 13 (sodium-dependent citrate transporter), member 5 
6288 SAA1 -1.71 3.91E-04 serum amyloid A1 
5320 PLA2G2A -1.70 1.06E-03 phospholipase A2, group IIA (platelets, synovial fluid) 
4212 MEIS2 -1.70 2.58E-04 Meis homeobox 2 
64127 NOD2 -1.70 2.34E-02 nucleotide-binding oligomerization domain containing 2 
6906 SERPINA7 -1.69 1.77E-03 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 
64902 AGXT2 -1.69 1.93E-02 alanine--glyoxylate aminotransferase 2 
6362 CCL18 -1.69 7.01E-04 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 
56521 DNAJC12 -1.69 2.28E-03 DnaJ (Hsp40) homolog, subfamily C, member 12 
100423062 IGLL5 -1.69 4.02E-02 immunoglobulin lambda-like polypeptide 5 
7274 TTPA -1.68 1.32E-02 tocopherol (alpha) transfer protein 
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29760 BLNK -1.68 2.88E-03 B-cell linker 
6335 SCN9A -1.68 2.84E-03 sodium channel, voltage-gated, type IX, alpha subunit 
126410 CYP4F22 -1.68 2.94E-03 cytochrome P450, family 4, subfamily F, polypeptide 22 
126 ADH1C -1.67 3.50E-02 alcohol dehydrogenase 1C (class I), gamma polypeptide 
10351 ABCA8 -1.67 1.30E-02 ATP-binding cassette, sub-family A (ABC1), member 8 
3003 GZMK -1.66 6.15E-03 granzyme K (granzyme 3 ///  tryptase II) 
9971 NR1H4 -1.66 8.69E-05 nuclear receptor subfamily 1, group H, member 4 
5629 PROX1 -1.66 3.84E-05 prospero homeobox 1 
388403 YPEL2 -1.65 2.42E-04 yippee-like 2 (Drosophila) 
84072 HORMAD1 -1.65 4.16E-02 HORMA domain containing 1 
347051 SLC10A5 -1.65 8.97E-03 solute carrier family 10, member 5 
6318 SERPINB4 -1.63 2.98E-02 serpin peptidase inhibitor, clade B (ovalbumin), member 4 
5858 PZP -1.63 2.91E-03 pregnancy-zone protein 
4982 TNFRSF11B -1.63 1.41E-03 tumor necrosis factor receptor superfamily, member 11b 
3429 IFI27 -1.62 1.42E-03 interferon, alpha-inducible protein 27 
2621 GAS6 -1.62 1.94E-03 growth arrest-specific 6 
7447 VSNL1 -1.61 1.36E-03 visinin-like 1 
834 CASP1 -1.61 2.46E-02 caspase 1, apoptosis-related cysteine peptidase 
6366 CCL21 -1.60 1.76E-02 chemokine (C-C motif) ligand 21 
6775 STAT4 -1.60 2.49E-03 signal transducer and activator of transcription 4 
84171 LOXL4 -1.60 3.32E-02 lysyl oxidase-like 4 
2212 FCGR2A -1.60 3.96E-03 Fc fragment of IgG, low affinity IIa, receptor (CD32) 
10158 PDZK1IP1 -1.60 2.84E-02 PDZK1 interacting protein 1 
4316 MMP7 -1.60 2.24E-02 matrix metallopeptidase 7 (matrilysin, uterine) 
7097 TLR2 -1.59 2.26E-03 toll-like receptor 2 
8736 MYOM1 -1.59 1.24E-02 myomesin 1 
401474 SAMD12 -1.59 2.02E-02 sterile alpha motif domain containing 12 
64135 IFIH1 -1.59 2.98E-03 interferon induced with helicase C domain 1 
958 CD40 -1.59 1.20E-02 CD40 molecule, TNF receptor superfamily member 5 
27074 LAMP3 -1.58 1.86E-04 lysosomal-associated membrane protein 3 
10261 IGSF6 -1.58 2.81E-03 immunoglobulin superfamily, member 6 
6890 TAP1 -1.58 3.37E-03 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
1080 CFTR -1.58 7.70E-04 cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family  
    C, member 7) 
117247 SLC16A10 -1.57 1.05E-04 solute carrier family 16 (aromatic amino acid transporter), member 10 
10906 TRAFD1 -1.57 8.33E-03 TRAF-type zinc finger domain containing 1 
6716 SRD5A2 -1.57 2.74E-04 steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4- 
    dehydrogenase alpha 2) 
400986 ANKRD36C -1.57 4.91E-04 ankyrin repeat domain 36C 
6696 SPP1 -1.57 1.41E-03 secreted phosphoprotein 1 
719 C3AR1 -1.57 4.19E-03 complement component 3a receptor 1 
10903 MTMR11 -1.56 2.31E-03 myotubularin related protein 11 
4739 NEDD9 -1.56 1.28E-03 neural precursor cell expressed, developmentally down-regulated 9 
30835 CD209 -1.56 5.51E-03 CD209 molecule 
2267 FGL1 -1.56 2.06E-05 fibrinogen-like 1 
3157 HMGCS1 -1.56 2.35E-05 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 
389197 C4orf50 -1.56 6.25E-03 chromosome 4 open reading frame 50 
114836 SLAMF6 -1.56 3.72E-02 SLAM family member 6 
3175 ONECUT1 -1.55 1.98E-03 one cut homeobox 1 
2690 GHR -1.55 3.72E-03 growth hormone receptor 
3659 IRF1 -1.55 6.31E-03 interferon regulatory factor 1 
7078 TIMP3 -1.55 9.19E-04 TIMP metallopeptidase inhibitor 3 
80310 PDGFD -1.55 9.79E-03 platelet derived growth factor D 
5359 PLSCR1 -1.55 1.73E-04 phospholipid scramblase 1 
4837 NNMT -1.55 2.35E-03 nicotinamide N-methyltransferase 
55013 CCDC109B -1.55 1.04E-04 coiled-coil domain containing 109B 
55076 TMEM45A -1.55 1.12E-02 transmembrane protein 45A 
3383 ICAM1 -1.55 2.24E-03 intercellular adhesion molecule 1 
28755 TRAC -1.55 1.75E-03 T cell receptor alpha constant 
9627 SNCAIP -1.54 8.39E-03 synuclein, alpha interacting protein 
6772 STAT1 -1.54 1.28E-03 signal transducer and activator of transcription 1, 91kDa 
994 CDC25B -1.54 7.05E-04 cell division cycle 25B 
3001 GZMA -1.54 1.99E-02 granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 
221468 TMEM217 -1.54 6.07E-03 transmembrane protein 217 
117283 IP6K3 -1.54 1.18E-02 inositol hexakisphosphate kinase 3 
597 BCL2A1 -1.53 8.77E-03 BCL2-related protein A1 
10568 SLC34A2 -1.53 4.17E-03 solute carrier family 34 (type II sodium/phosphate contransporter), member 2 
57393 TMEM27 -1.53 1.51E-02 transmembrane protein 27 
10866 HCP5 -1.53 3.84E-03 HLA complex P5 (non-protein coding) 
5721 PSME2 -1.53 1.29E-02 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 
8564 KMO -1.53 2.47E-03 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
7453 WARS -1.52 6.26E-03 tryptophanyl-tRNA synthetase 
5341 PLEK -1.52 3.76E-03 pleckstrin 
55304 SPTLC3 -1.52 1.76E-03 serine palmitoyltransferase, long chain base subunit 3 
2 A2M -1.52 2.84E-02 alpha-2-macroglobulin 
54625 PARP14 -1.52 6.41E-03 poly (ADP-ribose) polymerase family, member 14 
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338809 C12orf74 -1.51 1.54E-02 chromosome 12 open reading frame 74 
9563 H6PD -1.50 1.86E-02 hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 
727 C5 -1.50 1.29E-02 complement component 5 
9332 CD163 -1.50 1.63E-02 CD163 molecule 
5696 PSMB8 -1.50 1.10E-03 proteasome (prosome, macropain) subunit, beta type, 8 
80323 CCDC68 -1.50 2.66E-02 coiled-coil domain containing 68 
6351 CCL4 -1.50 3.85E-02 chemokine (C-C motif) ligand 4 
145864 HAPLN3 -1.49 4.00E-02 hyaluronan and proteoglycan link protein 3 
54757 FAM20A -1.49 1.00E-02 family with sequence similarity 20, member A 
3075 CFH -1.49 1.61E-04 complement factor H 
59269 HIVEP3 -1.49 2.14E-03 human immunodeficiency virus type I enhancer binding protein 3 
9830 TRIM14 -1.49 1.04E-04 tripartite motif containing 14 
84174 SLA2 -1.49 6.31E-03 Src-like-adaptor 2 
338821 SLCO1B7 -1.49 3.54E-02 solute carrier organic anion transporter family, member 1B7 (non-functional) 
39 ACAT2 -1.49 9.40E-05 acetyl-CoA acetyltransferase 2 
150864 FAM117B -1.48 1.47E-03 family with sequence similarity 117, member B 
1824 DSC2 -1.48 1.79E-04 desmocollin 2 
64116 SLC39A8 -1.48 2.14E-03 solute carrier family 39 (zinc transporter), member 8 
81788 NUAK2 -1.48 1.72E-02 NUAK family, SNF1-like kinase, 2 
4261 CIITA -1.47 2.11E-02 class II, major histocompatibility complex, transactivator 
3128 HLA-DRB6 -1.47 3.96E-02 major histocompatibility complex, class II, DR beta 6 (pseudogene) 
54463 FAM134B -1.47 1.94E-03 family with sequence similarity 134, member B 
50604 IL20 -1.47 4.13E-02 interleukin 20 
116071 BATF2 -1.47 4.24E-02 basic leucine zipper transcription factor, ATF-like 2 
8854 ALDH1A2 -1.47 2.03E-02 aldehyde dehydrogenase 1 family, member A2 
6446 SGK1 -1.47 2.21E-03 serum/glucocorticoid regulated kinase 1 
10384 BTN3A3 -1.47 6.77E-03 butyrophilin, subfamily 3, member A3 
127733 UBXN10 -1.47 1.09E-02 UBX domain protein 10 
94241 TP53INP1 -1.47 1.10E-03 tumor protein p53 inducible nuclear protein 1 
5699 PSMB10 -1.46 2.00E-03 proteasome (prosome, macropain) subunit, beta type, 10 
25939 SAMHD1 -1.46 1.19E-02 SAM domain and HD domain 1 
843 CASP10 -1.46 1.96E-02 caspase 10, apoptosis-related cysteine peptidase 
129607 CMPK2 -1.46 2.91E-02 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 
10993 SDS -1.46 2.10E-03 serine dehydratase 
158584 FAAH2 -1.46 8.28E-03 fatty acid amide hydrolase 2 
113263 GLCCI1 -1.46 1.47E-03 glucocorticoid induced transcript 1 
1723 DHODH -1.46 4.59E-02 dihydroorotate dehydrogenase (quinone) 
1806 DPYD -1.46 2.10E-03 dihydropyrimidine dehydrogenase 
4494 MT1F -1.46 1.86E-04 metallothionein 1F 
158219 TTC39B -1.46 6.77E-03 tetratricopeptide repeat domain 39B 
55603 FAM46A -1.46 8.97E-03 family with sequence similarity 46, member A 
81794 ADAMTS10 -1.46 7.03E-04 ADAM metallopeptidase with thrombospondin type 1 motif, 10 
28638 TRBC2 -1.46 2.60E-02 T cell receptor beta constant 2 
128439 SNHG11 -1.46 1.72E-02 small nucleolar RNA host gene 11 (non-protein coding) 
51313 FAM198B -1.46 4.69E-03 family with sequence similarity 198, member B 
8600 TNFSF11 -1.46 2.18E-03 tumor necrosis factor (ligand) superfamily, member 11 
10154 PLXNC1 -1.45 1.31E-02 plexin C1 
168537 GIMAP7 -1.45 4.60E-03 GTPase, IMAP family member 7 
57674 RNF213 -1.45 2.89E-03 ring finger protein 213 
10225 CD96 -1.45 5.43E-03 CD96 molecule 
55075 UACA -1.45 3.09E-03 uveal autoantigen with coiled-coil domains and ankyrin repeats 
2272 FHIT -1.45 4.50E-02 fragile histidine triad 
84419 C15orf48 -1.45 2.99E-02 chromosome 15 open reading frame 48 
10379 IRF9 -1.45 7.70E-04 interferon regulatory factor 9 
3431 SP110 -1.45 2.58E-03 SP110 nuclear body protein 
100133315 LOC100133315 -1.44 2.60E-02 transient receptor potential cation channel, subfamily C, member 2-like 
406 ARNTL -1.44 5.20E-03 aryl hydrocarbon receptor nuclear translocator-like 
3005 H1F0 -1.44 7.10E-04 H1 histone family, member 0 
337972 KRTAP19-5 -1.44 4.67E-02 keratin associated protein 19-5 
3728 JUP -1.44 2.78E-04 junction plakoglobin 
2160 F11 -1.44 6.75E-04 coagulation factor XI 
23213 SULF1 -1.44 1.39E-02 sulfatase 1 
953 ENTPD1 -1.44 4.64E-03 ectonucleoside triphosphate diphosphohydrolase 1 
6385 SDC4 -1.44 1.78E-03 syndecan 4 
1520 CTSS -1.44 2.65E-03 cathepsin S 
259307 IL4I1 -1.44 8.20E-03 interleukin 4 induced 1 
3929 LBP -1.44 1.77E-03 lipopolysaccharide binding protein 
440836 ODF3B -1.44 3.11E-02 outer dense fiber of sperm tails 3B 
6590 SLPI -1.43 2.71E-03 secretory leukocyte peptidase inhibitor 
6499 SKIV2L -1.43 1.12E-02 superkiller viralicidic activity 2-like (S. cerevisiae) 
199 AIF1 -1.43 1.64E-02 allograft inflammatory factor 1 
4008 LMO7 -1.42 1.97E-03 LIM domain 7 
23460 ABCA6 -1.42 1.08E-02 ATP-binding cassette, sub-family A (ABC1), member 6 
4318 MMP9 -1.42 6.31E-03 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 
8832 CD84 -1.42 5.45E-03 CD84 molecule 
5031 P2RY6 -1.42 3.42E-02 pyrimidinergic receptor P2Y, G-protein coupled, 6 
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79132 DHX58 -1.42 3.43E-02 DEXH (Asp-Glu-X-His) box polypeptide 58 
8013 NR4A3 -1.42 4.19E-03 nuclear receptor subfamily 4, group A, member 3 
23012 STK38L -1.42 4.42E-05 serine/threonine kinase 38 like 
2766 GMPR -1.42 4.93E-02 guanosine monophosphate reductase 
6892 TAPBP -1.42 1.59E-04 TAP binding protein (tapasin) 
25816 TNFAIP8 -1.42 8.39E-03 tumor necrosis factor, alpha-induced protein 8 
91351 DDX60L -1.42 2.46E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 
1643 DDB2 -1.42 2.30E-03 damage-specific DNA binding protein 2, 48kDa 
23780 APOL2 -1.42 4.60E-03 apolipoprotein L, 2 
7412 VCAM1 -1.41 4.45E-02 vascular cell adhesion molecule 1 
3113 HLA-DPA1 -1.41 5.99E-03 major histocompatibility complex, class II, DP alpha 1 
132321 C4orf33 -1.41 2.50E-02 chromosome 4 open reading frame 33 
51348 KLRF1 -1.41 1.38E-02 killer cell lectin-like receptor subfamily F, member 1 
58476 TP53INP2 -1.41 6.07E-03 tumor protein p53 inducible nuclear protein 2 
976 CD97 -1.41 4.10E-02 CD97 molecule 
3176 HNMT -1.41 6.89E-04 histamine N-methyltransferase 
83875 BCO2 -1.41 2.47E-02 beta-carotene oxygenase 2 
3140 MR1 -1.41 4.81E-03 major histocompatibility complex, class I-related 
1236 CCR7 -1.41 4.59E-02 chemokine (C-C motif) receptor 7 
166336 PRICKLE2 -1.40 3.02E-02 prickle homolog 2 (Drosophila) 
56892 C8orf4 -1.40 1.14E-03 chromosome 8 open reading frame 4 
83593 RASSF5 -1.40 2.72E-02 Ras association (RalGDS/AF-6) domain family member 5 
79668 PARP8 -1.40 4.01E-03 poly (ADP-ribose) polymerase family, member 8 
10410 IFITM3 -1.39 4.62E-04 interferon induced transmembrane protein 3 
9235 IL32 -1.39 1.01E-03 interleukin 32 
55064 SPATA6L -1.39 1.86E-02 spermatogenesis associated 6-like 
6480 ST6GAL1 -1.39 6.72E-03 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
9746 CLSTN3 -1.39 1.04E-04 calsyntenin 3 
4343 MOV10 -1.39 1.30E-03 Mov10, Moloney leukemia virus 10, homolog (mouse) 
255231 MCOLN2 -1.39 3.34E-02 mucolipin 2 
6695 SPOCK1 -1.39 8.47E-03 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 
6718 AKR1D1 -1.39 2.41E-03 aldo-keto reductase family 1, member D1 
10100 TSPAN2 -1.38 3.56E-02 tetraspanin 2 
30817 EMR2 -1.38 9.46E-03 egf-like module containing, mucin-like, hormone receptor-like 2 
3717 JAK2 -1.38 2.08E-02 Janus kinase 2 
79776 ZFHX4 -1.38 6.71E-03 zinc finger homeobox 4 
348645 C22orf34 -1.38 4.61E-02 chromosome 22 open reading frame 34 
91937 TIMD4 -1.38 1.30E-02 T-cell immunoglobulin and mucin domain containing 4 
1033 CDKN3 -1.38 4.83E-02 cyclin-dependent kinase inhibitor 3 
10863 ADAM28 -1.38 2.08E-02 ADAM metallopeptidase domain 28 
93663 ARHGAP18 -1.38 4.55E-03 Rho GTPase activating protein 18 
1073 CFL2 -1.38 7.21E-04 cofilin 2 (muscle) 
64218 SEMA4A -1.38 1.89E-03 sema domain, immunoglobulin domain(Ig), transmembrane domain(TM) and short   
    cytoplasmic domain, (semaphorin) 4A 
26031 OSBPL3 -1.38 1.69E-02 oxysterol binding protein-like 3 
148213 ZNF681 -1.38 2.66E-02 zinc finger protein 681 
26191 PTPN22 -1.38 4.51E-02 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
140564 APOBEC3D -1.38 3.00E-02 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 
401494 PTPLAD2 -1.37 3.49E-02 protein tyrosine phosphatase-like A domain containing 2 
6653 SORL1 -1.37 1.38E-02 sortilin-related receptor, L(DLR class) A repeats containing 
7903 ST8SIA4 -1.37 1.62E-02 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 
55824 PAG1 -1.37 1.82E-02 phosphoprotein associated with glycosphingolipid microdomains 1 
9246 UBE2L6 -1.37 1.62E-02 ubiquitin-conjugating enzyme E2L 6 
6347 CCL2 -1.37 1.39E-02 chemokine (C-C motif) ligand 2 
145957 NRG4 -1.37 2.78E-02 neuregulin 4 
6891 TAP2 -1.37 4.26E-02 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
3026 HABP2 -1.37 1.59E-03 hyaluronan binding protein 2 
81704 DOCK8 -1.37 8.38E-03 dedicator of cytokinesis 8 
9175 MAP3K13 -1.37 4.25E-02 mitogen-activated protein kinase kinase kinase 13 
10457 GPNMB -1.37 3.71E-02 glycoprotein (transmembrane) nmb 
79370 BCL2L14 -1.37 2.73E-02 BCL2-like 14 (apoptosis facilitator) 
4084 MXD1 -1.37 9.72E-04 MAX dimerization protein 1 
3070 HELLS -1.37 4.87E-02 helicase, lymphoid-specific 
5880 RAC2 -1.37 9.40E-03 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 
5027 P2RX7 -1.37 8.81E-03 purinergic receptor P2X, ligand-gated ion channel, 7 
857 CAV1 -1.36 1.64E-02 caveolin 1, caveolae protein, 22kDa 
10203 CALCRL -1.36 1.77E-02 calcitonin receptor-like 
2207 FCER1G -1.36 9.73E-03 Fc fragment of IgE, high affinity I, receptor for ///  gamma polypeptide 
8502 PKP4 -1.36 5.46E-04 plakophilin 4 
8836 GGH -1.36 2.47E-02 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
90527 DUOXA1 -1.36 7.43E-03 dual oxidase maturation factor 1 
8673 VAMP8 -1.36 7.98E-05 vesicle-associated membrane protein 8 
3122 HLA-DRA -1.36 3.73E-03 major histocompatibility complex, class II, DR alpha 
123803 NTAN1 -1.36 4.53E-03 N-terminal asparagine amidase 
94015 TTYH2 -1.36 2.56E-03 tweety family member 2 
3604 TNFRSF9 -1.36 1.83E-02 tumor necrosis factor receptor superfamily, member 9 
Chapter 6
172
Entrez ID Gene name Fold change q-value Description 
10288 LILRB2 -1.36 4.75E-02 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), 
    member 2 
481 ATP1B1 -1.36 2.68E-03 ATPase, Na+/K+ transporting, beta 1 polypeptide 
10581 IFITM2 -1.36 1.13E-02 interferon induced transmembrane protein 2 
23648 SSBP3 -1.36 1.11E-02 single stranded DNA binding protein 3 
64092 SAMSN1 -1.35 5.45E-03 SAM domain, SH3 domain and nuclear localization signals 1 
342132 ZNF774 -1.35 4.35E-02 zinc finger protein 774 
57169 ZNFX1 -1.35 8.82E-03 zinc finger, NFX1-type containing 1 
4588 MUC6 -1.35 4.84E-02 mucin 6, oligomeric mucus/gel-forming 
10133 OPTN -1.35 1.06E-03 optineurin 
55509 BATF3 -1.35 7.56E-03 basic leucine zipper transcription factor, ATF-like 3 
23768 FLRT2 -1.35 5.43E-03 fibronectin leucine rich transmembrane protein 2 
961 CD47 -1.35 5.96E-03 CD47 molecule 
1767 DNAH5 -1.35 3.89E-02 dynein, axonemal, heavy chain 5 
84166 NLRC5 -1.35 3.43E-02 NLR family, CARD domain containing 5 
241 ALOX5AP -1.35 8.51E-03 arachidonate 5-lipoxygenase-activating protein 
2627 GATA6 -1.35 1.44E-02 GATA binding protein 6 
50515 CHST11 -1.34 7.48E-04 carbohydrate (chondroitin 4) sulfotransferase 11 
1519 CTSO -1.34 1.64E-02 cathepsin O 
669 BPGM -1.34 1.06E-03 2,3-bisphosphoglycerate mutase 
7111 TMOD1 -1.34 2.87E-02 tropomodulin 1 
6367 CCL22 -1.34 1.96E-02 chemokine (C-C motif) ligand 22 
51704 GPRC5B -1.34 1.34E-03 G protein-coupled receptor, class C, group 5, member B 
38 ACAT1 -1.34 1.27E-03 acetyl-CoA acetyltransferase 1 
725 C4BPB -1.34 3.36E-02 complement component 4 binding protein, beta 
972 CD74 -1.34 7.61E-03 CD74 molecule, major histocompatibility complex, class II invariant chain 
89870 TRIM15 -1.34 3.61E-02 tripartite motif containing 15 
1004 CDH6 -1.34 9.60E-03 cadherin 6, type 2, K-cadherin (fetal kidney) 
25903 OLFML2B -1.34 4.67E-02 olfactomedin-like 2B 
9223 MAGI1 -1.34 4.24E-03 membrane associated guanylate kinase, WW and PDZ domain containing 1 
164656 TMPRSS6 -1.33 1.44E-03 transmembrane protease, serine 6 
85441 HELZ2 -1.33 2.85E-02 helicase with zinc finger 2, transcriptional coactivator 
7456 WIPF1 -1.33 2.23E-02 WAS/WASL interacting protein family, member 1 
55619 DOCK10 -1.33 1.64E-02 dedicator of cytokinesis 10 
57530 CGN -1.33 6.26E-03 cingulin 
3108 HLA-DMA -1.33 1.63E-02 major histocompatibility complex, class II, DM alpha 
57619 SHROOM3 -1.33 2.47E-02 shroom family member 3 
1880 GPR183 -1.33 1.17E-02 G protein-coupled receptor 183 
1890 TYMP -1.33 6.65E-03 thymidine phosphorylase 
7743 ZNF189 -1.33 4.89E-03 zinc finger protein 189 
4300 MLLT3 -1.33 3.98E-02 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) ///   
    translocated to, 3 
728411 GUSBP1 -1.33 6.77E-03 glucuronidase, beta pseudogene 1 
57655 GRAMD1A -1.32 2.19E-02 GRAM domain containing 1A 
151636 DTX3L -1.32 6.37E-03 deltex 3 like, E3 ubiquitin ligase 
3937 LCP2 -1.32 1.93E-02 lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa) 
11199 ANXA10 -1.32 2.97E-02 annexin A10 
5734 PTGER4 -1.32 1.75E-02 prostaglandin E receptor 4 (subtype EP4) 
920 CD4 -1.32 2.47E-02 CD4 molecule 
64393 ZMAT3 -1.32 1.59E-03 zinc finger, matrin-type 3 
80765 STARD5 -1.32 4.37E-02 StAR-related lipid transfer (START) domain containing 5 
23338 JADE2 -1.32 3.53E-02 jade family PHD finger 2 
717 C2 -1.32 5.70E-04 complement component 2 
694 BTG1 -1.32 1.52E-04 B-cell translocation gene 1, anti-proliferative 
5552 SRGN -1.32 1.46E-03 serglycin 
64167 ERAP2 -1.32 3.83E-02 endoplasmic reticulum aminopeptidase 2 
7104 TM4SF4 -1.32 3.42E-02 transmembrane 4 L six family member 4 
8869 ST3GAL5 -1.32 4.11E-02 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
18 ABAT -1.32 1.29E-02 4-aminobutyrate aminotransferase 
11067 C10orf10 -1.31 1.35E-03 chromosome 10 open reading frame 10 
359845 FAM101B -1.31 6.38E-03 family with sequence similarity 101, member B 
1030 CDKN2B -1.31 8.76E-03 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 
5294 PIK3CG -1.31 3.94E-02 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 
133308 SLC9B2 -1.31 2.05E-03 solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 
51312 SLC25A37 -1.31 9.47E-03 solute carrier family 25 (mitochondrial iron transporter), member 37 
5918 RARRES1 -1.31 2.04E-02 retinoic acid receptor responder (tazarotene induced) 1 
126917 IFFO2 -1.31 2.58E-02 intermediate filament family orphan 2 
135112 NCOA7 -1.31 7.35E-03 nuclear receptor coactivator 7 
9873 FCHSD2 -1.31 5.67E-03 FCH and double SH3 domains 2 
64856 VWA1 -1.31 3.68E-02 von Willebrand factor A domain containing 1 
5788 PTPRC -1.31 4.67E-02 protein tyrosine phosphatase, receptor type, C 
1356 CP -1.31 5.03E-03 ceruloplasmin (ferroxidase) 
4524 MTHFR -1.31 1.86E-02 methylenetetrahydrofolate reductase (NAD(P)H) 
6609 SMPD1 -1.30 1.40E-02 sphingomyelin phosphodiesterase 1, acid lysosomal 
79895 ATP8B4 -1.30 5.00E-02 ATPase, class I, type 8B, member 4 
2595 GANC -1.30 2.92E-02 glucosidase, alpha ///  neutral C 
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51279 C1RL -1.30 5.89E-03 complement component 1, r subcomponent-like 
732 C8B -1.30 4.99E-03 complement component 8, beta polypeptide 
1500 CTNND1 -1.30 5.77E-03 catenin (cadherin-associated protein), delta 1 
6567 SLC16A2 -1.30 1.86E-02 solute carrier family 16, member 2 (thyroid hormone transporter) 
57185 NIPAL3 -1.30 2.98E-02 NIPA-like domain containing 3 
2040 STOM -1.30 3.61E-03 stomatin 
6387 CXCL12 -1.30 1.30E-03 chemokine (C-X-C motif) ligand 12 
200316 APOBEC3F -1.30 1.49E-02 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F 
3115 HLA-DPB1 -1.30 3.01E-02 major histocompatibility complex, class II, DP beta 1 
118788 PIK3AP1 -1.29 2.62E-02 phosphoinositide-3-kinase adaptor protein 1 
23094 SIPA1L3 -1.29 3.83E-03 signal-induced proliferation-associated 1 like 3 
118429 ANTXR2 -1.29 6.39E-04 anthrax toxin receptor 2 
4430 MYO1B -1.29 1.60E-03 myosin IB 
63901 FAM111A -1.29 2.75E-02 family with sequence similarity 111, member A 
5796 PTPRK -1.29 1.30E-03 protein tyrosine phosphatase, receptor type, K 
5519 PPP2R1B -1.29 1.27E-03 protein phosphatase 2, regulatory subunit A, beta 
55902 ACSS2 -1.29 1.23E-02 acyl-CoA synthetase short-chain family member 2 
53 ACP2 -1.29 5.23E-03 acid phosphatase 2, lysosomal 
9881 TRANK1 -1.29 2.08E-02 tetratricopeptide repeat and ankyrin repeat containing 1 
27106 ARRDC2 -1.29 1.00E-02 arrestin domain containing 2 
2266 FGG -1.28 6.80E-03 fibrinogen gamma chain 
10039 PARP3 -1.28 1.30E-02 poly (ADP-ribose) polymerase family, member 3 
23424 TDRD7 -1.28 3.10E-02 tudor domain containing 7 
9674 KIAA0040 -1.28 1.07E-02 KIAA0040 
10026 PIGK -1.28 3.82E-02 phosphatidylinositol glycan anchor biosynthesis, class K 
11221 DUSP10 -1.28 8.93E-03 dual specificity phosphatase 10 
822 CAPG -1.28 2.50E-02 capping protein (actin filament), gelsolin-like 
54557 SGTB -1.28 4.05E-02 small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta 
285830 HLA-F-AS1 -1.28 4.86E-02 HLA-F antisense RNA 1 
2028 ENPEP -1.28 3.11E-02 glutamyl aminopeptidase (aminopeptidase A) 
23235 SIK2 -1.28 3.77E-02 salt-inducible kinase 2 
1959 EGR2 -1.28 1.61E-02 early growth response 2 
11151 CORO1A -1.28 1.86E-02 coronin, actin binding protein, 1A 
55620 STAP2 -1.28 2.36E-02 signal transducing adaptor family member 2 
5045 FURIN -1.28 6.20E-03 furin (paired basic amino acid cleaving enzyme) 
10437 IFI30 -1.28 4.21E-02 interferon, gamma-inducible protein 30 
726 CAPN5 -1.28 2.02E-02 calpain 5 
3134 HLA-F -1.28 3.22E-02 major histocompatibility complex, class I, F 
9032 TM4SF5 -1.28 2.96E-02 transmembrane 4 L six family member 5 
23705 CADM1 -1.28 4.25E-03 cell adhesion molecule 1 
54464 XRN1 -1.28 1.55E-02 5'-3' exoribonuclease 1 
5720 PSME1 -1.27 6.25E-03 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) 
3096 HIVEP1 -1.27 1.18E-03 human immunodeficiency virus type I enhancer binding protein 1 
5345 SERPINF2 -1.27 2.14E-02 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived  
    factor), member 2 
1512 CTSH -1.27 2.57E-03 cathepsin H 
1803 DPP4 -1.27 2.41E-02 dipeptidyl-peptidase 4 
90139 TSPAN18 -1.27 3.62E-02 tetraspanin 18 
6615 SNAI1 -1.27 4.10E-02 snail family zinc finger 1 
51542 VPS54 -1.27 3.68E-02 vacuolar protein sorting 54 homolog (S. cerevisiae) 
5058 PAK1 -1.27 1.28E-02 p21 protein (Cdc42/Rac)-activated kinase 1 
11161 C14orf1 -1.27 1.39E-02 chromosome 14 open reading frame 1 
5610 EIF2AK2 -1.27 1.93E-02 eukaryotic translation initiation factor 2-alpha kinase 2 
115825 WDFY2 -1.27 3.42E-03 WD repeat and FYVE domain containing 2 
5337 PLD1 -1.27 4.48E-02 phospholipase D1, phosphatidylcholine-specific 
8542 APOL1 -1.27 3.17E-02 apolipoprotein L, 1 
9926 LPGAT1 -1.27 2.96E-02 lysophosphatidylglycerol acyltransferase 1 
11278 KLF12 -1.27 3.84E-02 Kruppel-like factor 12 
374378 GALNT18 -1.27 3.42E-02 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 18 
23654 PLXNB2 -1.27 1.86E-04 plexin B2 
56829 ZC3HAV1 -1.27 1.77E-03 zinc finger CCCH-type, antiviral 1 
6240 RRM1 -1.27 4.26E-02 ribonucleotide reductase M1 
5641 LGMN -1.26 7.37E-03 legumain 
8148 TAF15 -1.26 7.03E-04 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa 
84159 ARID5B -1.26 2.67E-03 AT rich interactive domain 5B (MRF1-like) 
3587 IL10RA -1.26 2.51E-02 interleukin 10 receptor, alpha 
221895 JAZF1 -1.26 4.96E-02 JAZF zinc finger 1 
124540 MSI2 -1.26 1.18E-02 musashi RNA-binding protein 2 
3683 ITGAL -1.26 4.54E-02 integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1 ///   
    alpha polypeptide) 
2934 GSN -1.26 1.71E-02 gelsolin 
8530 CST7 -1.26 3.33E-02 cystatin F (leukocystatin) 
6768 ST14 -1.26 2.41E-02 suppression of tumorigenicity 14 (colon carcinoma) 
285440 CYP4V2 -1.26 1.17E-03 cytochrome P450, family 4, subfamily V, polypeptide 2 
64780 MICAL1 -1.26 4.29E-02 microtubule associated monooxygenase, calponin and LIM domain containing 1 
629 CFB -1.26 6.18E-04 complement factor B 
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3732 CD82 -1.26 1.53E-02 CD82 molecule 
9945 GFPT2 -1.26 4.62E-02 glutamine-fructose-6-phosphate transaminase 2 
64761 PARP12 -1.26 6.07E-03 poly (ADP-ribose) polymerase family, member 12 
6307 MSMO1 -1.26 3.17E-02 methylsterol monooxygenase 1 
85461 TANC1 -1.26 8.85E-03 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 
81553 FAM49A -1.26 4.31E-02 family with sequence similarity 49, member A 
407018 MIR27A -1.26 3.53E-02 microRNA 27a 
9414 TJP2 -1.26 1.15E-02 tight junction protein 2 
3684 ITGAM -1.26 1.83E-02 integrin, alpha M (complement component 3 receptor 3 subunit) 
10018 BCL2L11 -1.26 1.86E-02 BCL2-like 11 (apoptosis facilitator) 
5654 HTRA1 -1.26 1.83E-02 HtrA serine peptidase 1 
2995 GYPC -1.26 4.35E-03 glycophorin C (Gerbich blood group) 
718 C3 -1.26 1.59E-03 complement component 3 
51474 LIMA1 -1.26 1.00E-02 LIM domain and actin binding 1 
51667 NUB1 -1.25 8.02E-03 negative regulator of ubiquitin-like proteins 1 
2037 EPB41L2 -1.25 4.73E-02 erythrocyte membrane protein band 4.1-like 2 
3507 IGHM -1.25 3.73E-02 immunoglobulin heavy constant mu 
10982 MAPRE2 -1.25 2.70E-02 microtubule-associated protein, RP/EB family, member 2 
716 C1S -1.25 3.37E-03 complement component 1, s subcomponent 
84885 ZDHHC12 -1.25 2.65E-02 zinc finger, DHHC-type containing 12 
10157 AASS -1.25 3.95E-02 aminoadipate-semialdehyde synthase 
10420 TESK2 -1.25 3.36E-02 testis-specific kinase 2 
23136 EPB41L3 -1.25 2.40E-02 erythrocyte membrane protein band 4.1-like 3 
4853 NOTCH2 -1.25 1.08E-02 notch 2 
80830 APOL6 -1.25 3.44E-02 apolipoprotein L, 6 
51768 TM7SF3 -1.25 8.33E-03 transmembrane 7 superfamily member 3 
5993 RFX5 -1.25 4.03E-02 regulatory factor X, 5 (influences HLA class II expression) 
3426 CFI -1.25 2.51E-02 complement factor I 
868 CBLB -1.25 2.22E-03 Cbl proto-oncogene B, E3 ubiquitin protein ligase 
55281 TMEM140 -1.25 2.80E-02 transmembrane protein 140 
4067 LYN -1.25 4.68E-03 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
5538 PPT1 -1.25 2.81E-02 palmitoyl-protein thioesterase 1 
4818 NKG7 -1.25 4.68E-02 natural killer cell granule protein 7 
7277 TUBA4A -1.24 2.91E-02 tubulin, alpha 4a 
55337 C19orf66 -1.24 1.36E-02 chromosome 19 open reading frame 66 
93349 SP140L -1.24 4.37E-02 SP140 nuclear body protein-like 
3371 TNC -1.24 2.34E-02 tenascin C 
330 BIRC3 -1.24 3.31E-02 baculoviral IAP repeat containing 3 
123036 TC2N -1.24 3.98E-02 tandem C2 domains, nuclear 
3601 IL15RA -1.24 7.43E-03 interleukin 15 receptor, alpha 
23253 ANKRD12 -1.24 4.68E-03 ankyrin repeat domain 12 
2224 FDPS -1.24 4.91E-02 farnesyl diphosphate synthase 
134429 STARD4 -1.24 2.67E-03 StAR-related lipid transfer (START) domain containing 4 
57381 RHOJ -1.24 2.10E-02 ras homolog family member J 
4891 SLC11A2 -1.24 9.74E-03 solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 
4647 MYO7A -1.24 2.91E-02 myosin VIIA 
89796 NAV1 -1.24 1.03E-02 neuron navigator 1 
8728 ADAM19 -1.24 1.06E-02 ADAM metallopeptidase domain 19 
23157 6/sep -1.24 1.54E-02 septin 6 
12 SERPINA3 -1.24 1.80E-02 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
84230 LRRC8C -1.23 9.60E-03 leucine rich repeat containing 8 family, member C 
4124 MAN2A1 -1.23 3.37E-03 mannosidase, alpha, class 2A, member 1 
10046 MAMLD1 -1.23 8.96E-03 mastermind-like domain containing 1 
3588 IL10RB -1.23 1.10E-02 interleukin 10 receptor, beta 
3017 HIST1H2BD -1.23 2.26E-02 histone cluster 1, H2bd 
260425 MAGI3 -1.23 1.77E-02 membrane associated guanylate kinase, WW and PDZ domain containing 3 
123096 SLC25A29 -1.23 3.85E-02 solute carrier family 25 (mitochondrial carnitine/acylcarnitine carrier), member 29 
23635 SSBP2 -1.23 2.26E-02 single-stranded DNA binding protein 2 
22920 KIFAP3 -1.23 1.16E-02 kinesin-associated protein 3 
3398 ID2 -1.23 1.82E-02 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
9766 KIAA0247 -1.23 2.65E-02 KIAA0247 
214 ALCAM -1.23 2.19E-02 activated leukocyte cell adhesion molecule 
23406 COTL1 -1.23 4.73E-02 coactosin-like F-actin binding protein 1 
10957 PNRC1 -1.23 6.43E-03 proline-rich nuclear receptor coactivator 1 
8613 PPAP2B -1.23 3.98E-02 phosphatidic acid phosphatase type 2B 
140606 SELM -1.23 3.77E-03 selenoprotein M 
23033 DOPEY1 -1.23 3.17E-02 dopey family member 1 
178 AGL -1.23 3.00E-02 amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase 
4704 NDUFA9 -1.23 3.61E-02 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa 
27244 SESN1 -1.22 4.68E-02 sestrin 1 
7263 TST -1.22 3.46E-02 thiosulfate sulfurtransferase (rhodanese) 
23293 SMG6 -1.22 3.47E-02 SMG6 nonsense mediated mRNA decay factor 
8844 KSR1 -1.22 1.41E-02 kinase suppressor of ras 1 
2683 B4GALT1 -1.22 4.54E-02 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
659 BMPR2 -1.22 1.23E-02 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
9021 SOCS3 -1.22 2.80E-02 suppressor of cytokine signaling 3 
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11031 RAB31 -1.22 1.03E-02 RAB31, member RAS oncogene family 
114569 MAL2 -1.22 6.25E-03 mal, T-cell differentiation protein 2 (gene/pseudogene) 
5156 PDGFRA -1.22 3.54E-02 platelet-derived growth factor receptor, alpha polypeptide 
51170 HSD17B11 -1.22 3.96E-02 hydroxysteroid (17-beta) dehydrogenase 11 
29992 PILRA -1.22 2.80E-02 paired immunoglobin-like type 2 receptor alpha 
56927 GPR108 -1.22 4.31E-02 G protein-coupled receptor 108 
79815 NIPAL2 -1.22 4.96E-02 NIPA-like domain containing 2 
23604 DAPK2 -1.21 4.96E-02 death-associated protein kinase 2 
80344 DCAF11 -1.21 1.86E-02 DDB1 and CUL4 associated factor 11 
2647 BLOC1S1 -1.21 2.97E-02 biogenesis of lysosomal organelles complex-1, subunit 1 
3428 IFI16 -1.21 4.83E-02 interferon, gamma-inducible protein 16 
55803 ADAP2 -1.21 3.48E-02 ArfGAP with dual PH domains 2 
196527 ANO6 -1.21 6.48E-03 anoctamin 6 
307 ANXA4 -1.21 4.24E-02 annexin A4 
285513 GPRIN3 -1.21 3.34E-02 GPRIN family member 3 
9770 RASSF2 -1.21 1.06E-02 Ras association (RalGDS/AF-6) domain family member 2 
647135 SRGAP2B -1.21 9.80E-03 SLIT-ROBO Rho GTPase activating protein 2B 
355 FAS -1.21 2.11E-02 Fas cell surface death receptor 
3087 HHEX -1.21 1.57E-02 hematopoietically expressed homeobox 
91452 ACBD5 -1.21 2.80E-02 acyl-CoA binding domain containing 5 
55748 CNDP2 -1.21 3.73E-02 CNDP dipeptidase 2 (metallopeptidase M20 family) 
6672 SP100 -1.20 1.99E-02 SP100 nuclear antigen 
11329 STK38 -1.20 1.79E-02 serine/threonine kinase 38 
88455 ANKRD13A -1.20 4.01E-03 ankyrin repeat domain 13A 
4478 MSN -1.20 7.81E-03 moesin 
2581 GALC -1.20 4.37E-02 galactosylceramidase 
80021 TMEM62 -1.20 4.23E-02 transmembrane protein 62 
10769 PLK2 -1.20 1.32E-02 polo-like kinase 2 
79056 PRRG4 -1.20 2.81E-02 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 
900 CCNG1 -1.20 2.47E-03 cyclin G1 
25937 WWTR1 -1.20 3.42E-02 WW domain containing transcription regulator 1 
9124 PDLIM1 -1.19 3.67E-02 PDZ and LIM domain 1 
722 C4BPA -1.19 9.29E-03 complement component 4 binding protein, alpha 
57186 RALGAPA2 -1.19 2.91E-02 Ral GTPase activating protein, alpha subunit 2 (catalytic) 
7052 TGM2 -1.19 3.50E-02 transglutaminase 2 
23102 TBC1D2B -1.19 4.98E-02 TBC1 domain family, member 2B 
6709 SPTAN1 -1.19 1.15E-02 spectrin, alpha, non-erythrocytic 1 
1730 DIAPH2 -1.19 2.42E-02 diaphanous-related formin 2 
6282 S100A11 -1.19 3.86E-02 S100 calcium binding protein A11 
6934 TCF7L2 -1.19 1.14E-02 transcription factor 7-like 2 (T-cell specific, HMG-box) 
23516 SLC39A14 -1.18 4.82E-02 solute carrier family 39 (zinc transporter), member 14 
4646 MYO6 -1.18 1.55E-02 myosin VI 
223082 ZNRF2 -1.18 3.89E-02 zinc and ring finger 2 
59338 PLEKHA1 -1.18 2.64E-02 pleckstrin homology domain containing, family A (phosphoinositide binding specific)  
    member 1 
7538 ZFP36 -1.18 2.60E-02 ZFP36 ring finger protein 
23646 PLD3 -1.18 2.50E-02 phospholipase D family, member 3 
3065 HDAC1 -1.18 6.61E-03 histone deacetylase 1 
55014 STX17 -1.18 2.47E-02 syntaxin 17 
6774 STAT3 -1.18 1.00E-02 signal transducer and activator of transcription 3 (acute-phase response factor) 
9500 MAGED1 -1.18 3.11E-02 melanoma antigen family D, 1 
5446 PON3 -1.18 3.44E-02 paraoxonase 3 
115548 FCHO2 -1.17 2.96E-02 FCH domain only 2 
51088 KLHL5 -1.17 4.52E-02 kelch-like family member 5 
3985 LIMK2 -1.17 2.46E-02 LIM domain kinase 2 
25865 PRKD2 -1.17 2.58E-02 protein kinase D2 
27436 EML4 -1.17 2.23E-02 echinoderm microtubule associated protein like 4 
1021 CDK6 -1.17 4.10E-02 cyclin-dependent kinase 6 
808 CALM3 -1.17 4.03E-02 calmodulin 3 (phosphorylase kinase, delta) 
3699 ITIH3 -1.17 2.03E-02 inter-alpha-trypsin inhibitor heavy chain 3 
8892 EIF2B2 -1.17 1.37E-02 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 
6558 SLC12A2 -1.17 4.60E-02 solute carrier family 12 (sodium/potassium/chloride transporter), member 2 
6594 SMARCA1 -1.17 3.84E-02 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily 
    a, member 1 
3106 HLA-B -1.17 3.84E-02 major histocompatibility complex, class I, B 
800 CALD1 -1.17 2.52E-02 caldesmon 1 
51571 FAM49B -1.17 2.77E-02 family with sequence similarity 49, member B 
731 C8A -1.17 3.49E-02 complement component 8, alpha polypeptide 
5562 PRKAA1 -1.17 2.65E-02 protein kinase, AMP-activated, alpha 1 catalytic subunit 
567 B2M -1.17 4.48E-02 beta-2-microglobulin 
3611 ILK -1.16 1.32E-02 integrin-linked kinase 
23530 NNT -1.16 2.53E-02 nicotinamide nucleotide transhydrogenase 
667 DST -1.16 2.80E-02 dystonin 
30844 EHD4 -1.16 2.98E-02 EH-domain containing 4 
11059 WWP1 -1.15 3.49E-02 WW domain containing E3 ubiquitin protein ligase 1 
48 ACO1 -1.15 4.78E-02 aconitase 1, soluble 
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Entrez ID Gene name Fold change q-value Description 
7317 UBA1 -1.15 2.60E-02 ubiquitin-like modifier activating enzyme 1 
1282 COL4A1 -1.15 4.54E-02 collagen, type IV, alpha 1 
9879 DDX46 -1.15 4.03E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 
4670 HNRNPM -1.15 2.10E-02 heterogeneous nuclear ribonucleoprotein M 
23607 CD2AP -1.15 2.74E-02 CD2-associated protein 
309 ANXA6 -1.15 3.69E-02 annexin A6 
2244 FGB -1.15 3.69E-02 fibrinogen beta chain 
1431 CS -1.15 4.02E-02 citrate synthase 
715 C1R -1.14 2.63E-02 complement component 1, r subcomponent 
3263 HPX -1.14 1.62E-02 hemopexin 
1389 CREBL2 -1.14 3.42E-02 cAMP responsive element binding protein-like 2 
51585 PCF11 -1.14 4.89E-02 PCF11 cleavage and polyadenylation factor subunit 
10096 ACTR3 -1.13 3.46E-02 ARP3 actin-related protein 3 homolog (yeast) 
6314 ATXN7 -1.12 3.47E-02 ataxin 7 
805 CALM2 -1.12 3.33E-02 calmodulin 2 (phosphorylase kinase, delta) 
8553 BHLHE40 -1.12 4.29E-02 basic helix-loop-helix family, member e40 
3315 HSPB1 -1.12 4.45E-02 heat shock 27kDa protein 1 
7533 YWHAH -1.12 4.62E-02 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta 
975 CD81 -1.12 2.43E-02 CD81 molecule 
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Abstract
Background
The bile acid-activated farnesoid X receptor (FXR) is a nuclear receptor regulating bile acid, 
glucose and cholesterol homeostasis. Obeticholic acid (OCA), a promising drug for the 
treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, activates FXR. Mouse 
studies demonstrated that FXR activation by OCA alters hepatic expression of many genes. 
However, no data are available on the effects of OCA in human liver. Here we generated gene 
expression profiles in human precision cut liver slices (hPCLS) after treatment with OCA.
Methods
hPCLS were incubated with OCA for 24 h. WT or FXR-/- mice received OCA or vehicle by 
oral gavage for 7 days.
Results
Transcriptomic analysis showed that well-known FXR target genes, including NR0B2 (SHP), 
ABCB11 (BSEP), SLC51A (OSTα) and SLC51B (OSTβ), and ABCB4 (MDR3) are regulated 
by OCA in hPCLS. Ingenuity pathway analysis confirmed that ‘FXR/RXR activation’ is the 
most significantly changed pathway upon OCA treatment. Comparison of gene expression 
profiles in hPCLS and mouse livers identified 18 common potential FXR targets. ChIP-
sequencing in mouse liver confirmed FXR binding to IR1 sequences of Akap13, Cgnl1, 
Dyrk3, Pdia5, PPP1R3B and Tbx6. 
Conclusions
Our study shows that hPCLS respond to OCA treatment by upregulating well-known FXR 
target genes, demonstrating its suitability to study FXR-mediated gene regulation. We 
identified 6 novel bona-fide FXR target genes in both mouse and human liver. Finally, we 
discuss a possible explanation for changes in HDL/LDL observed in NASH and primary 
biliary cirrhosis patients treated with OCA based on the genomic expression profile in 
hPCLS. 
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Introduction
In many countries, non-alcoholic fatty liver disease (NAFLD) has become the most common 
liver disorder, surpassing viral hepatitis. NAFLD is frequently accompanied by obesity and 
is sometimes referred to as the hepatic manifestation of the metabolic syndrome. The main 
initial feature of NAFLD is hepatic steatosis. In some cases steatosis progresses to non-
alcoholic steatohepatitis (NASH), which is characterized by fatty infiltration along with liver 
inflammation. In Western countries, the prevalence of NASH is about 2-3% and is expected 
to further increase in parallel with the global expansion in the prevalence of obesity [1]. If left 
untreated, NASH will worsen with time and may eventually proceed to liver cirrhosis and 
liver cancer. Presently, the only effective treatment for NASH is weight loss combined with 
other lifestyle modifications, but the long term compliance to these changes is disappointing. 
A promising new drug-based approach to NASH consists of treatment with obeticholic acid 
(OCA, INT-747, 6α-ethyl-chenodeoxycholic acid), a semi-synthetic agonist of the nuclear 
receptor FXR [2]. FXR is a ligand-activated transcription factor that is considered as the 
master regulator of bile acid metabolism in liver and intestine. FXR is activated by bile acids 
and — once activated — stimulates transcription of genes involved in synthesis, transport 
and metabolism of bile acids [3]. A major target of FXR is NR0B2, encoding SHP, acting as a 
transcriptional repressor of bile acid synthesis via downregulation of CYP7A1 and CYP8B1 
[4]. FXR also induces transcription of BAAT, ABCB11 (BSEP), and ABCB4 (MDR3), thereby 
inducing bile acid conjugation and export of bile acids and phospholipids from hepatocytes 
into the bile canaliculus, respectively [5-7]. 
As indicated above, FXR can be activated by the clinically relevant compound OCA. In 
studies using murine disease models for hepatic inflammation and renal dysfunction, it 
has been shown that OCA can resolve disease symptoms in wild type mice, but not FXR 
knockout mice, indicating that OCA acts mainly via FXR [8-10]. In a recent proof of concept 
study in NAFLD and type 2 diabetic patients, OCA was shown to increase insulin sensitivity 
and reduce markers of liver inflammation and fibrosis [11]. In a larger clinical study in NASH 
patients, OCA improved biochemical and histological features of NASH [2]. However, OCA 
treatment also decreased hepatic insulin sensitivity and raised serum concentrations of total 
and LDL cholesterol, while lowering HDL cholesterol. Currently, most insights into the effect 
of OCA and FXR activation are derived from animal experiments or cell lines. The lack of 
a more complex human model system has hampered our ability to investigate the impact 
of FXR activation by OCA in human liver. Therefore, in this study, we tested the effect of 
FXR activation by OCA on gene regulation in human Precision Cut Liver Slices (hPCLS). 
The advantage of hPCLS over primary human hepatocytes is that their preparation does not 
require any proteolytic enzymes that might disturb cell-cell interactions and can induce 
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cell damage. Moreover, because cell-cell interactions and cell heterogeneity are maintained 
within the original tissue matrix, the hPCLS better reflect the high level of biological 
organization of the liver [12]. 
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Materials and methods
Collection of human liver biopsies 
Liver biopsies were taken from 15 patients undergoing laparoscopic Roux-en-Y Gastric 
Bypass and were immediately frozen in liquid nitrogen and stored at -80°C. Precision cut 
liver slices (PCLS) were generated from fresh liver biopsies of 3 patients as described before 
[13]. Biopsies were stained with H&E and Sirius Red to determine steatosis and fibrosis, 
respectively. Slides were blindly scored by a pathologist. All 3 livers were scored with a Brunt 
score for steatosis of 0 (<5% steatosis) and an F score of 0 (no fibrosis) [14, 15] , indicating no 
signs of liver disease (see Supplemental Figure 1A). Biopsies were provided by the biobank 
of the Rijnstate hospital. Collection of biopsies for research purposes into the biobank was 
approved by the local institutional review board on behalf of the medical ethics review 
committee of the Radboud University Medical Centre. All patients signed informed consent 
for collection of the biopsies prior to surgery.
Preparation and treatment of precision cut liver slices
Human and mouse (C57Bl6) PCLS were prepared and cultured as described previously 
[16]. Briefly, 5 mm cylindrical liver cores were prepared with a surgical biopsy punch 
and sectioned to 200 μm slices using a Krumdieck tissue slicer (Alabama Research and 
Development, Munford, AL, USA) filled with carbonated KHB (pH 7.4, supplemented 
with 25mM glucose). Liver slices were incubated in William’s E Medium (Gibco, Paisley, 
Scotland) supplemented with pen/strep in 6-well plates at 37°C/5% CO2/80% O2 under 
continuous shaking (70 rpm). Duplicate wells were used per donor with 3 liver slices per 
well. After 1 hour medium was replaced with fresh William’s E Medium in the presence or 
absence of OCA (1 μM) dissolved in dimethyl sulfoxide (DMSO, final concentration 0.1%). 
OCA was kindly provided by Luciano Adorini (Intercept Pharmaceuticals Inc., San Diego, 
California, USA). After 24 h incubation, liver slices were snap-frozen in liquid nitrogen and 
stored in −80°C for RNA isolation. 
Animal experiment
The experiment was approved by the ethics committee of the University Medical Center 
Utrecht and was in accordance with European law. 9-12 weeks old male C57BL/6 wild-
type (WT) and FXR-/- mice [17] were housed in a room with controlled temperature (20-
24°C), relative humidity (55%±15%) and a 12h light dark cycle. Mice were fed chow and 
demineralized water ad libitum. Mice received either a treatment with OCA (10 mg/kg/day) 
to pharmacologically activate FXR, or vehicle (1% methyl cellulose) daily by oral gavage for 
7 days. On the last day, mice were starved and received a final dose of OCA or vehicle. After 
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4h, mice were sacrificed, livers were collected, snap-frozen in liquid nitrogen and stored at 
-80°C. 
RNA isolation and qPCR
Total RNA of human and mouse tissue was isolated using TRIzol reagent (Invitrogen). RNA 
was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories BV, 
Veenendaal, The Netherlands). Real-time PCR was carried out using SensiMiX (Bioline) on 
a CFX 384 Bio-Rad thermal cycler (Bio-Rad). mRNA expression of genes of interest were 
normalized to Cyclophillin and 36B4. Primers sequences are shown in Supplemental Table 
1.
Microarray analysis
For microarray hybridization, the isolated human and mouse RNA was further purified 
using RNeasy Minikit columns (Qiagen). RNA concentrations were measured on a nanodrop 
ND-1000 UV-Vis spectrophotometer (Isogen, Maarssen, The Netherlands) and analyzed 
on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands) with 
6000 Nano Chips, according to the manufacturer’s protocol. RNA was judged suitable for 
array hybridization only if samples exhibited intact bands corresponding to the 18S and 
28S ribosomal RNA subunits, and displayed no chromosomal peaks or RNA degradation 
products. 
Purified RNA (100 ng) was labeled with the Ambion WT expression kit (Invitrogen) and 
hybridized to either Affymetrix Human Gene 1.1 ST arrays or to Affymetrix Mouse Gene 1.1 
ST arrays, provided in plate format (Affymetrix, Santa Clara, CA). Hybridization, washing 
and scanning of the array plates was performed on an Affymetrix GeneTitan instrument, 
according to the manufacturer’s recommendations. Normalized expression estimates were 
obtained from the raw intensity values applying the robust multi-array analysis (RMA) 
[18,19] preprocessing algorithm available in the Bioconductor library AffyPLM with default 
settings. Probe sets were defined according to Dai et al. [20]. In this method probes are 
assigned to Entrez IDs as a unique gene identifier. In this study, probes were reorganized 
based on the Entrez Gene database, build 37, version 1 (remapped CDF v19). The P values 
were calculated using an Intensity-Based Moderated T-statistic (IBMT) [21]. Probe sets that 
satisfied the criterion of a P value < 0.01 were considered significantly regulated and used 
for further bioinformatics analysis. In total 6 human arrays (3 patients, per patient 1 DMSO 
control and 1 treated with OCA) and 24 mouse arrays were performed (6/group, 4 groups; 
WT vehicle, WT OCA, FXR-/- vehicle and FXR-/- OCA). Microarray datasets have been 
submitted to Gene Expression Omnibus, accession number GSE76163.
To identify biological processes influenced by FXR activation and ablation pathway 
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analysis was performed using Ingenuity Canonical Pathway Analysis (Ingenuity® Systems, 
www.ingenuity.com). This analysis identifies the pathways from the Ingenuity Pathway 
Analysis library of canonical pathways that are most significant to a microarray dataset. 
Fisher’s exact test was used to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway is explained by 
chance alone. 
Chromatin immunoprecipitation
30 mg of snap-frozen liver tissue from vehicle or OCA treated WT mice was cross-linked 
using DSG and formaldehyde, as described by Nowak et al [22]. The nuclei were extracted and 
sonicated to yield 500-1,000 basepair (bp) DNA fragments. ChIP was performed according 
to Saccani et al [23], using an anti-FXR antibody (sc-13063, SantaCruz, CA).
ChIP-sequencing
Immunoprecipitated material and input DNA from each sample was re-sonicated to achieve 
an average fragment size of around 300bp; DNA was processed using the SOLiD ChIP-seq 
kit, and sequenced on a SOLiD 5500 WF platform. Alignment to the mm9 reference genome 
was carried out using BWA allowing for up to 2 mismatches. For display, mapped reads from 
ChIP datasets were extended to 200bp and summed in 50 bp bins using standard perl scripts. 
Regions of 15 kb around the detected peaks are shown from livers collected from 2 mice. FXR 
peaks were identified using MACS 1.4 (with parameters: pvalue=1e-4, nomodel, nolambda, 
shiftsize=150). Peaks located within 10 kb up and downstream annotated genes according 
to the mm9 refGene table of RefSeq genes (UCSC genome browser) were considered for 
further analysis. Genomic distances were calculated using BEDtools [24]. IR1 motifs [25] 
were searched in peak regions proximal to target genes using the HOMER suite [26] and 
qPCR primers were designed in proximity to these motifs. Results from representative 
FXR ChIP experiments are shown at the following coordinates (mm9): Akap13 (chr7: 
82892181-82907181), Cgnl1 (chr9: 71566626-71581626), Dyrk3 (chr1: 133015491-133030491), 
Pdia5 (chr16: 35482324-35497324), Ppp1r3b (chr8: 36431025-36446025) and Tbx6 (chr7: 
133918281-133933281). Primer sequences can be found in Supplemental Table 1. ChIP 
sequencing datasets have been submitted to Gene Expression Omnibus, accession number 
GSE73624. 
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Results
FXR expression and target gene induction in hPCLS
Apart from human liver biopsies from patients treated with OCA, which are unavailable 
for experimental studies, hPCLS are the next best model to study gene regulation in human 
liver. To characterize hPCLS with respect to FXR and FXR target genes, we determined 
the relative expression of FXR in hPCLS after 24h in culture medium in comparison with 
human liver biopsies immediately snap-frozen after collection. FXR is well expressed in 
hPCLS at Ct values ranging from 23-26, which is about 6.5-fold lower as compared to frozen 
biopsies (Supplementary Figure 1B). To verify that hPCLS maintain their ability to respond 
to FXR activation, we exposed the slices to 1 µM OCA for 24h. The expression level of the 
known FXR target genes NR0B2 (SHP), ABCB11 (BSEP), SLC51A (OSTα) was significantly 
induced upon OCA treatment, indicating the validity of our model to study FXR-mediated 
gene regulation (Figure 1A). Induction of ABCB4 (MDR3) did not reach significance.
Differentially expressed genes upon FXR activation in hPCLS
To study genome-wide effects of FXR activation on human liver slices, we performed 
microarray analysis. The OCA-induced upregulation of selected FXR target genes was 
similar between microarray and qPCR analysis. Using p<0.01 as cut-off (IBMT regularized 
paired t-test), OCA treatment altered the expression of 627 genes in hPCLS. Of these 627 
genes, 299 genes were upregulated and 328 genes were downregulated. The 25 most highly 
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Figure 1. Classical FXR target genes are robustly induced by the FXR agonist OCA in human liver slices 
(A) Gene expression of selected FXR target genes in hPCLS (n=3/group) in response to a 24h treatment with 
OCA as determined by qPCR. Expression of DMSO is set at 1 and OCA treatment is relative to DMSO. Data 
are shown as mean ± SEM, *p<0.05 by a Students t-test (one sided). (B) Release of FGF19 in the medium 
of OCA-treated hPCLS as measured by ELISA (n=3/group). Data are shown as mean ± SEM, *p<0.05 by a 
Students t-test.
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induced genes can be found in Table 1 and contained the well-known FXR target genes 
NR0B2 (SHP), ABCB11 (BSEP), SLC51A (OSTα) and SLC51B (OSTβ), and ABCB4 (MDR3), 
all of which are involved in bile acid metabolism. Remarkably, the most highly upregulated 
gene upon OCA treatment in hPCLS was FGF19. FGF19 is known as FXR target gene in the 
ileum and encodes a hormone produced in the ileum upon bile acid absorption. Release of 
FGF19 into the medium was markedly stimulated by OCA treatment (Figure 1B). 
Table 2 shows the most highly repressed genes in hPCLS upon OCA treatment. The list of 
downregulated genes does not contain any well-known FXR targets. CYP7A1 and CYP8B1, 
normally downregulated upon FXR activation, were not expressed in hPCLS, presumably 
because their expression is rapidly lost upon culturing (Supplemental Figure 1C). Loss of 
expression of P450 enzymes is also observed in other liver-derived in vitro systems, such 
as HepG2 cells [27]. Genes downregulated by OCA were mainly involved in inflammatory 
responses (CHI3L1, IL18BP), cilium morphogenesis (PCDP1, AVIL1), cholesterol and 
triglycerides homeostasis (MIA2) and signal transduction (CXCL10, RAP1GAP).
Human 
Gene name Description FC 
FGF19 fibroblast growth factor 19 20.0 
RHCG Rh family, C glycoprotein 3.6 
PALMD palmdelphin 3.2 
TRAV14DV4 T cell receptor alpha variable 14/delta variable 4 3.2 
FNDC5 fibronectin type III domain containing 5 3.1 
NR0B2 nuclear receptor subfamily 0, group B, member 2 2.8 
RHOF ras homolog family member F  2.7 
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 2.6 
OR2L8 olfactory receptor, family 2, subfamily L, member 8 2.5 
HSPA12A heat shock 70kDa protein 12A 2.5 
SLC51A solute carrier family 51, alpha subunit 2.5 
CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13 2.2 
RTP3 receptor (chemosensory) transporter protein 3 2.1 
PEG10 paternally expressed 10 2.1 
SLC51B solute carrier family 51, beta subunit 2.1 
MFSD2A major facilitator superfamily domain containing 2A 2.1 
LOXL4 lysyl oxidase-like 4 2.0 
CCL15 chemokine (C-C motif) ligand 15 1.9 
TRGV2 T cell receptor gamma variable 2 1.9 
IGHG3 immunoglobulin heavy constant gamma 3 1.9 
G6PC glucose-6-phosphatase, catalytic subunit 1.9 
PHKA1 phosphorylase kinase, alpha 1 (muscle) 1.9 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 1.9 
IGLON5 IgLON family member 5 1.8 
ACTA2-AS1 ACTA2 antisense RNA 1 1.8 
FC, fold change. 
 
Table 1. The 25 highest upregulated genes (p<0.01) in hPCLS upon treatment with OCA 
Chapter 7
188
Biological pathways in human and mouse tissue upon OCA treatment
To gain better insight into the biological function of genes regulated by FXR activation in 
hPCLS, we performed Ingenuity Pathway Analysis on all differentially expressed genes 
(p<0.01). The most significantly changed pathway in hPCLS by OCA treatment was ‘FXR/
RXR activation’ (Figure 2A). In addition, pathways involving RXR, the heterodimeric 
partner of FXR, feature prominently among the most changed pathways. 
Whereas hPCLS represents the most suitable in vitro model system to study gene 
regulation by OCA in human liver, treatment of mice with OCA followed by harvesting of 
livers represent the most feasible and suitable in vivo model system. Therefore, we studied 
the effect of orally-provided OCA on hepatic gene expression in WT and FXR-/- mice. In WT 
mice, OCA treatment significantly changed the expression of 619 genes (p<0.01, 333 up- and 
286 genes downregulated). Ingenuity Pathway Analysis showed that the most significantly 
changed pathways were related to cholesterol and fatty acid metabolism (Figure 2B). 
Differential expression of FXR target genes in hPCLS and mouse liver
To gain more insight into the commonality of gene regulation by OCA in hPCLS and 
mouse liver, we analyzed the expression of known FXR target genes [28-30] in hPCLS and 
Table 2. The 25 highest downregulated genes (p<0.01) in hPCLS upon treatment with OCA 
Human 
Gene name Description FC 
LOC728554 THO complex 3 pseudogene -2.6 
LOC100130207 uncharacterized LOC100130207 -2.4 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -2.0 
MAGEA3 melanoma antigen family A, 3 -2.0 
SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 -1.9 
CXCL10 chemokine (C-X-C motif) ligand 10 -1.9 
WDR72 WD repeat domain 72 -1.8 
MTMR11 myotubularin related protein 11 -1.7 
ESPNP espin pseudogene -1.7 
TRIB2 tribbles pseudokinase 2 -1.7 
DUOX2 dual oxidase 2 -1.7 
PCDP1 primary ciliary dyskinesia protein 1 -1.7 
RAP1GAP RAP1 GTPase activating protein -1.7 
DTWD2 DTW domain containing 2 -1.7 
ENKUR enkurin, TRPC channel interacting protein -1.6 
DUOXA2 dual oxidase maturation factor 2 -1.6 
AHNAK2 AHNAK nucleoprotein 2 -1.6 
MIA2 melanoma inhibitory activity 2 -1.6 
NIPAL3 NIPA-like domain containing 3 -1.6 
SPATA6L spermatogenesis associated 6-like -1.6 
AVIL advillin -1.6 
DHODH dihydroorotate dehydrogenase (quinone) -1.6 
GBP4 guanylate binding protein 4 -1.6 
IL18BP interleukin 18 binding protein -1.6 
FASTKD3 FAST kinase domains 3 -1.6 
  FC, fold change. 
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compared it to mouse liver. OCA treatment significantly increased the expression of the 
FXR target genes ABCB11, ABCB4, ABCG5, ABCG8, ALAS1, FETUB, FGF19, ICAM1, KNG1, 
NR0B2, SLC51A and SLC51B in hPCLS, whereas the expression of ABCC2 was significantly 
decreased (Figure 3).
In WT mice, OCA treatment significantly induced the expression of Fasn, Nr0b2, Nr1i2 
and Slc51b and reduced the expression of Csad and Cyp8b1 (Figure 3). As expected, the 
stimulatory effect of OCA treatment on FXR targets was abolished in FXR-/-  mice, except for 
a significant downregulation of Apoa5, indicating that the regulation of bile acid metabolism 
genes by OCA is mediated by FXR. Furthermore, baseline expression of most FXR target 
genes was decreased in the FXR-/-  mice as compared to the WT mice.
Identification of putative novel FXR target genes
To focus on FXR-dependent gene regulation, we excluded genes up- or downregulated by 
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Figure 2. Top 10 canonical pathways from Ingenuity Pathway Analysis changed by OCA treatment 
The 10 most significantly changed pathways (p<0.01) for hPCLS (A) and in mouse WT livers (B). 
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OCA in a similar direction in WT and FXR-/- livers (Figure 4A). Of the 11 genes that were 
significantly regulated in both WT and KO mice, 8 genes were excluded because they changed 
in the same direction. The remaining 3 genes were not excluded as they were regulated in the 
opposite direction. In total, 611 genes were regulated in an FXR dependent manner in mouse 
liver tissue, and 235 genes were regulated independently of FXR.
When comparing all genes significantly induced by OCA (p<0.01) in hPCLS (n=627) and 
Gene p1 p2 p3 p1 p2 p3 m1 m2 m3 m4 m5 m6 m7 m8 m9 m10 m11 m12 m13 m14 m15 m16 m17 m18 m19 m20 m21 m22 m23 m24
FGF19  #
ABCB11  #  §
SLC51A  # §
NR0B2  # ¶ §
ABCB4  #
ABCG8  #
SLC51B # ¶ §
ABCG5  #
ALAS1  #
ICAM1 #
UGT2B4 §
PPARA
ABCC2 #  §
KNG1  #
FASN  ¶ §
SDC1 §
SLC1A5  §
SLC22A7 §
PLTP §
DDAH1  §
NOS3
NR1I2 ¶ §
FGA
APOA5   § *
UGT2B7  §
C3
FGB
APOA1  §
FABP6
VIPR1  §
FGG  §
INSIG1  §
SLC10A2  §
APOC3
SLCO1B3
AGTR2
FETUB  #
SLC13A1
CSAD  ¶ §
SLC27A5 §
CYP8B1  ¶ §
SLC01B1
CYP3A43
BAAT
SULT2A1
CRYAB  §
no mouse homologue assigned
Signal log ratio -2 -1.5 -1 -0.5 0 0.5 1 1.5 2
KO OCA
Human Mouse
DMSO OCA WT vehicle WT OCA KO vehicle
Figure. 3. Comparative heatmap analysis of the effect of OCA on FXR target genes [28-30] in hPCLS 
and mouse liver
P1 to P3 represent the 3 human subjects that donated a liver specimen for preparation of hPCLS. hPCLS 
were incubated with DMSO (control) and OCA, and # indicates significant changed genes, p<0.01. 
Regarding the mouse data, the effect of OCA on gene expression in the WT mice (m7-m12) was compared 
to the WT vehicle-treated mice (m1-6) and significant genes (p<0.01) are indicated by ¶. The effect of 
FXR ablation was studied by comparing FXR-/- vehicle-treated mice (m13-18) to the WT vehicle-treated 
mice and significant differences (p<0.01) are indicated with §. The effect of OCA in FXR-/- mice (m19-24) 
compared to FXR-/- vehicle treated mice yield 1 significant different gene (p<0.01) indicated by *.
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mouse liver (n=611), only a small overlap of 31 overlapping genes was found (Figure 4B). We 
tested whether the small overlap was due to experimental differences (human liver slices vs 
whole mouse tissue) by validating FXR target gene expression changes in mouse precision 
cut liver slices. The FXR target genes Abcb11, Slc51a and Abcb4 were not regulated in mouse 
liver tissue and were also not regulated in the mouse liver slices (Supplemental Figure 2). 
Slc51b was upregulated in mouse liver tissue and was also upregulated in the mouse liver 
slices. We therefore conclude that experimental differences in the setup of the study are 
probably not responsible for the small overlap in human and mouse OCA- regulated genes, 
but that the limited overlap is most probably due to species differences. 
Within this overlap of 31 genes, 20 genes changed expression in the same direction 
in both models (Figure 4C). Among those 20 genes were the known FXR targets NR0B2 
and SLC51B (OSTβ) and 18 genes not yet described as FXR targets. The 11 genes that were 
regulated oppositely in mouse and human were not considered further, because we reasoned 
that target genes should be regulated similarly in human and mouse liver. 
Figure 4. Comparative analysis of the effect of OCA on gene expression in human liver slices and mouse 
liver 
(A) Venn diagram showing the number of genes regulated by OCA in WT mice, in FXR-/- mice and the 
number of overlapping genes (p<0.01). (B) Venn diagram showing the number of genes regulated in hPCLS, 
in mouse liver and the number of overlapping genes (p<0.01). (C) Comparative heatmap analysis of the 
overlapping genes, which were significantly changed (p<0.01) in the hPCLS as well as in mouse liver.
Gene p1 p2 p3 p1 p2 p3 m1 m2 m3 m4 m5 m6 m7 m8 m9 m10 m11 m12 m13 m14 m15 m16 m17 m18 m19 m20 m21 m22 m23 m24
SLC25A35
ACVR1B
TCTN3
TMEM62
GBP4
AKAP13
MYH9
TSC22D2
CEBPG
PDIA5
TBX6
CGNL1
FRMD4B
DYRK3
PPP1R3B
PFKFB3
C1orf116
INHBA
SLC51B
NR0B2
Signal log ratio -2 -1.5 -1 -0.5 0 0.5 1 1.5 2
Human Mouse
DMSO OCA WT vehicle WT OCA KO vehicle KO OCA
A
C
596 580
overlap: 31 genes
of which 20 genes change in 
the same direction
31
human liver slices mouse liver tissue
B
608 22711
overlap: 11 genes
of which 8 genes change in 
the same direction
OCA effect 
in WT mice
OCA effect in 
FXR-/-  mice
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Confirmation of novel FXR targets by ChIP-sequencing
To examine whether these 18 genes may be novel FXR targets, we generated genome-wide 
FXR binding profiles by ChIP-sequencing in mouse liver. Binding of FXR was observed for 
Akap13, Cgnl1, Dyrk3, Pdia5, Ppp1r3b and Tbx6 genes within 10kb distance to the genes. 
Binding was observed close to the transcription start site (TSS) for Akap13, in introns 1 or 
2 (Cgnl1, Pdia5, Pfkfb3, Ppp1r3b, Tbx6) regions, or intergenic (Dyrk3) (Figure 5A). Since 
Akap13
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Cgnl1
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16
Dyrk3
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52
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*
*
*
Akap13 Cgnl1 Dyrk3 Pdia5 Ppp1r3b Tbx6
WT OCA (FXR)
WT OCA (IgG)
* * *
* * *
Negative controls Positive controls Novel FXR target genes
%
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Figure 5. Identification of 6 novel FXR target genes 
(A) FXR ChIPseq tracks from 2 independent mouse livers (WT) showing 15Kb around FXR peaks proximal 
to putative target genes. The IR-1 motif was found in all cases at the peak’s summit. (B) Validation of 
candidate peaks by ChIP-qPCR. Globin and Fabp6 were used as negative controls for FXR in the liver; 
Slc51b Nr0b2 and Abcb11 were used as positive controls. Data are shown as mean ± SEM, n=2, *p<0.05 by 
a Students t-test.
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FXR is known to bind a consensus sequence comprising an inverted NR-hexamer sequence 
(IR1) [25], we looked for IR1 sites in the selected peaks and found them being present in 
the analyzed regions (Table 3). Next, primers were designed in the region surrounding the 
IR1 sites, and ChIP-qPCR was performed to validate FXR binding in these regions (Figure 
5B). Globin and Fabp6 promoters were used as negative control regions, since they have 
been described to be depleted of FXR in liver tissue [31], whereas Slc51b, Nr0b2 and Abcb11 
were used as positive controls for FXR binding. Of the putative novel FXR target genes, we 
confirmed that FXR binds to Akap13, Cgnl1, Dyrk3, Pdia5, Ppp1r3b and Tbx6 promoters 
in mouse liver. FXR binding was similar in OCA and vehicle treated mice (Supplemental 
Figure 3), which is line with the previous observation that treatment of mice with an FXR 
agonist does not result in an increase in FXR binding in liver tissue [22]. 
Table 3. IR1-like motifs found in 2 known FXR target genes and 8 putative novel FXR target 
genes 
Motifs were located in the summit of the peak. 
TSS, transcription start site; TTS; transcription termination site. 
 
Gene Annotation Distance to target  
gene 
Distance to  
transcription start site IR1 motif sequence 
Homer motif     
FXR(NR), IR1    AGGTCANTGACCTB 
     
Known targets     
Nr0b2 Promotor-TSS -272 -272 GGGTTAATGACCCT 
Slc51b Promotor-TSS -193 -193 GGGTGAATGACCCC 
     
Putative targets     
Akap13 TTS 187 -93544 GGGTCACTGACCCA 
Cgnl1 Intron 1 out of 18 0 45284 GGTGTAATGACCTC 
Dyrk3 Intergenic 2026 11821 AGGGTAATGACCCT 
Pdia5 Intron 1 out of 16 0 636 AGGTCAGTCCCCTG 
Ppp1r3b Intron 1 out of 1 0 3143 AGGGCACTGACTGC 
Tbx6 Intron 2 out of 7 0 783 GGGTCAAGGACCAG 
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Discussion
This is the first study to investigate the effect of the novel drug OCA, now in phase 3 clinical 
trials for NASH, on liver gene expression using hPCLS as a model system for human liver. 
Using whole genome profiling, we show that multiple genes are highly and consistently 
responsive to FXR activation in hPCLS, including many established FXR target genes, 
thereby providing valuable new insights into the potential mechanisms underlying the 
therapeutic efficacy of OCA in humans. Our data suggest that hPCLS are an excellent model 
to study the impact of FXR activation on gene expression in human liver. 
In our study, the number of FXR target genes commonly regulated in mouse liver and 
hPCLS was relatively small. The small overlap might be explained by several factors. First, 
the human donors were females, whereas we used male mice. Second, hPCLS were incubated 
for 24h with OCA, whereas mice received a daily oral gavage with OCA for 7 days with 
the last dose provided 4h before sacrifice. Thirdly, orally provided OCA circulates in the 
enterohepatic cycle and accumulates in the bile acid pool. Therefore, the exact amount of 
OCA reaching the liver in mice is not known. In contrast, the concentration of OCA that 
hPCLS are exposed to can be very carefully controlled. Finally, some genes altered by OCA 
in mouse livers may be regulated secondary to FXR activation in the ileum or even other 
tissues, which is not a concern in hPCLS. Along the same lines, we previously found limited 
overlap in gene regulation upon activation of the PPARα nuclear receptor between primary 
mouse hepatocytes and human hepatocytes [32]. This is in contrast to comparative ChIP-
sequencing studies for PPARγ, were approximately 50% of regulated genes between mouse 
and human match in adipose tissue [33, 34]. However, these comparative ChIP-Seq studies 
do not measure regulation of gene expression but rather genomic binding. These studies, 
although useful, provide no information on conservation of gene regulation between species 
(for instance, binding sites may be conserved but may not result in gene regulation). In 
addition, the overall number of genes regulated by FXR is substantially lower as compared 
to PPARs, making a direct comparison difficult. We therefore believe that the small overlap 
is probably mainly due to species differences and not to experimental differences, as FXR 
target gene regulation was similar between mouse livers and mouse liver slices.
OCA caused a marked increase in mRNA levels of the gene encoding fibroblast growth 
factor 19 (FGF19) in hPCLS. Expression of FGF19 is known to be induced by FXR in the 
ileum but has been reported to remain below detection in mouse liver [35]. In humans a 
liver-specific upregulation of FGF19 was described in patients with extrahepatic cholestasis 
[36] and in primary biliary cirrhosis [37], but no FGF19 mRNA was detected in healthy 
human livers [36-38]. Consistent with these data, FGF19 was not expressed in untreated 
hPCLS, as judged by the intensity of the FGF19 signal on the microarray. However, FGF19 
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mRNA expression and release of protein were dramatically induced by OCA. While it has 
been reported that FGF19 is expressed in cholangiocytes [39], it is unlikely that this cell type 
is responsible for the 20-fold induction in FGF19 gene expression, as only ~2% of liver tissue 
consists of cholangiocytes. At this moment we do not know if the upregulation of FGF19 is a 
consequence of the model—because of the absence of the enterohepatic circulation—or that 
this upregulation also occurs in humans treated with OCA. 
By comparing the effects of OCA in the two model systems, we were able to identify 
several novel target genes of FXR. These novel targets induced by FXR activation in both 
human and mouse liver include Akap13, Cgnl1, Dyrk3, Pdia5, Ppp1r3b and Tbx6. Akap13 
(also Lymphoid Blast Crisis) is a Rho guanine-nucleotide exchange factor that activates Rho 
GTPase implicated in cancer and metastasis [40]. Cgnl1 (Cingulin-like1 or paracingulin) is 
also involved in regulating the activity of GTPases Rho and Rac1, thereby mediating cell-cell 
junction assembly [41]. Interestingly, the anti-apoptotic DYRK3 (dual-specificity tyrosine-
(Y)-phosphorylation regulated kinase 3) promotes cell survival through phosphorylation 
and activation of SIRT1, a protein deacetylase essential in a variety of physiological processes 
including stress response and energy metabolism [42]. Mice overexpressing SIRT1 have 
an impaired farnesoid X receptor (FXR) activity due to persistent deacetylation and lower 
protein expression that was shown to lead to decreased expression of the FXR targets Shp 
and Bsep, and increased expression of Cyp7A1 [43]. In our studies, Dyrk3 was upregulated by 
FXR activation in mouse liver and hPCLS, which might be indicative of a negative feedback 
mechanism of FXR function. Not much is known about Tbx6 and Pdia5, other than that 
Tbx6 is a T-box gene encoding for transcription factors regulating developmental processes, 
and Pdia5 encodes for a protein with disulfide isomerase activity.
Another gene that was identified as a novel FXR target gene in our study is PPP1R3B, 
encoding a regulatory subunit of the glycogen-associated protein phosphatase-1 (PP-
1). PP-1 has been shown to play an important role in the regulation of glycogen synthase 
activity and as such promotes glycogen synthesis. A substitution in the 3’-untranslated 
region (UTR) detected in Pima Indians results in destabilization of PPP1R3B mRNA and 
concomitant decreased protein levels, and is associated with insulin resistance and type 2 
diabetes in the Pimas [44]. Another polymorphism, Asp905Tyr, was shown to be associated 
with decreased glycogen synthesis and an increased basal glucose oxidation rate when 
compared with wild type carriers [45]. Association studies suggest that genetic variants in 
or near PPP1R3B are associated with insulin resistance and type 2 diabetes [44-48], hepatic 
steatosis and altered serum lipids [49] and with increased hepatic triglyceride content [50]. 
Also, the hepatic steatosis increasing variant in PPP1R3B is associated with increased HDL- 
and LDL cholesterol levels and decreased fasting glucose [49]. In line with these findings, 
overexpression of mouse Ppp1r3b in mouse liver resulted in significantly lower plasma 
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HDL-levels as well as total cholesterol [51]. We find PPP1R3B upregulated in mouse liver and 
human PCLS which is consistent with decreased HDL levels in patients treated with OCA 
[2, 52]. The mechanism by which PPP1R3B affects HDL concentrations is currently unclear, 
and might be secondary to changes in energy metabolism. 
NASH patients treated with OCA exhibit increased total and LDL cholesterol levels [2]. 
It was suggested that these changes are mediated by decreased expression of Cyp7A1, which 
converts cholesterol to bile acids. However, in a recent study in PBC patients, LDL cholesterol 
was not significantly changed upon OCA-treatment, while total cholesterol was decreased 
[52]. The discrepancy in regulation of total cholesterol and LDL cholesterol between these 
two patient groups raises the question whether LDL levels are mediated directly by FXR, 
or may rather be a consequence of the high fat/cholesterol environment in livers of NASH 
patients. It should be noted here that although no steatosis and fibrosis were observed, the 
hPCLS used for this study were obtained from patients with a high BMI (35-43 kg/m2), 
A decrease in HDL levels after treatment with OCA was found in both NASH and PBC 
patients [2, 52]. In a further attempt to understand the decreased HDL levels in both studies, 
we reviewed the literature for mouse knockout models associated with this feature and 
compared them to the expression data in hPCLS. It has been shown that knock out models 
of Abca1 (cholesterol efflux pump) and Tgm2 [53], Fgl1 [54], Npc1l1 (uptake free cholesterol) 
[55], Angptl4 [56], Hif1an [57] and Ghr [58], which were all downregulated in hPCLS 
(p< 0.03) upon OCA treatment, are associated with decreased HDL levels. Furthermore, 
knockout mice for Ldlr (low density lipoprotein receptor) [59], Gpr12 [60], and Scp2 [61] 
have increased plasma HDL levels. In line with this observation, hPCLS treated with OCA 
showed a significant upregulation of LDLR, SCP2 (p<0.01) and a trend for increased GPR12 
(p=0.06). Altogether, these genes may be suggested to possibly contribute to the decreased 
HDL plasma levels of patients treated with OCA. The relation of these genes to FXR activity, 
via direct or indirect regulation, should be investigated further.
In conclusion, our study shows that hPCLS respond to OCA treatment by upregulating 
many well-known FXR target genes, demonstrating the suitability of hPCLS to study FXR-
mediated gene regulation. By comparing human and mouse liver gene expression profiles, 
Akap13, Cgnl1, Dyrk3, Pdia5, Ppp1r3b and Tbx6 were identified as bona-fide FXR target genes 
in mouse and human liver. Overall, our study provides novel insights into the mechanisms 
of action of OCA and a possible explanation for decreased HDL and increased LDL levels 
observed in patients treated with OCA.
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Supplemental figures and tables
Supplemental figure 1. Characteristics of liver tissue and slices. 
(A) Liver slices of p1-3 stained for HE to determine steatosis and Sirius Red to determine fibrosis. There 
were no signs of steatosis and fibrosis in these livers. (B) Expression level of FXR (%) in human liver biopsies 
(n=15) and human precision cut liver slices (n=3). (C) Relative expression levels of Cyp7a1 and Cyp8B1 in 
fresh liver tissue, in PCLS after cutting but before incubation, and after 24h of DMSO incubation (n=3).
Supplemental figure 2. Expression of FXR target genes in mouse liver tissue (n=6) and mouse PCLS 
(n=3) upon treatment with OCA shows a similar profile.
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Supplemental figure 3. Identification of 6 novel FXR target genes. 
Globin and Fabp6 were used as negative controls for FXR in the liver; Slc51b Nr0b2 and Abcb11 were used as 
positive controls. Data are shown as mean ± SEM, n=2, *p<0.05 by a Students t-test.
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Supplemental table 1. Primer sequences used for qPCR
 
 Primer Sequence  
Name Forward Reverse 
h36B4 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC 
hCYCLOPHILIN CCCACCGTGTTCTTCGACAT TCTTTGGGACCTTGTCTGCAA 
hFXR ACCAGCCTGAAAATCCTCAACAC CTCTCCATGACATCAGCATCTCAG 
hNR0B2 CCCAAGATGCTGTGACCTTTGAG TGGGGTCTGTCTGGCAGTTG 
hABCB11 GCAGAGGGAGCTACCAGGATAG ACAACAGCTAATGGAGGTTCGTG 
hSLC51A TTCCTCTAAAACCAGGTCTCAAGT GCACAGTCATTAGAAAAGTCTCCA 
hABCB4 TTTTCCTTGTCGCTGCTAAATCC AGCACCCAATCCTGAGTAGTAA 
   
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mAbcb4 TATCCGCTATGGCCGTGGGAA ATCGGTGAGCTATCACAATGG 
mAbcb11 CTGCCAAGGATGCTAATGCA CGATGGCTACCCTTTGCTTCT 
mSlc51a GTTCCAGGTGCTTGTCATCC CCACTGTTAGCCAAGATGGAGAA 
mSlc51b AGATGCGGCTCCTTGGAATTA TGGCTGCTTCTTTCGATTTCTG 
mCyp7a1 CAGGGAGATGCTCTGTGTTCA AGGCATACATCCCTTCCGTGA 
mCyp8b1 CCTCTGGACAAGGGTTTTGTG GCACCGTGAAGACATCCCC 
   
mGlob ChIP CCTGCCCTCTCTATCCTGTG GCAAATGTGTTGCCAAAAAG 
mFabp6 ChIP ACACTCTGTGGCCGTCCT GGAAAAACACCTACAATCCCACT 
mSlc51a ChIP CAGTGGAAGTGGCTTGAGTC GGGCAGGAGAGGAAGCTAAG 
mSlc51b ChIP CCGCAATGGCAGATCATAC GTGAATGACCCCACGAATG 
mNr0b2 ChIP CATGGAAATGGGCATCAATA CGTGGCCTTGCTATCACTTT 
mAbcb11 ChIP TCAATTCTCCATGAAACTTTGG GTGACATCCTGGGTTGCAG 
mAkap13 ChIP GGGAGTAGGGTGTAAGGAGGA CAGTGACCCTGGAGGTTTG 
mCgnl1 ChIP TGTCCTTGAGCCTGTGTGAC ACACCAGAGACTGCCCTCAG 
mDyrk3 ChIP TGACCCTTTCAACTGTCTGCT GGTGGTTTTGCCTGTCCTTA 
mPdia5 ChIP ACTGAAGGGAGGGAAAAAGG AGTTGGGCTGACTCCCATC 
mPpp1r3b ChIP TTAGCAGTGGGGAACTTTGC AAGGTCCGGCTGTAGAGAGA 
mTbx6 ChIP AGGGGCCGTGTGTGACTA AGCTCACACGGTAGGCAATC 
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Abstract
Angiopoietin-like 4 (ANGPTL4) raises plasma triglyceride levels by inhibiting lipoprotein 
lipase. A set of compounds that are able to reduce plasma triglyceride levels are  bile acids 
(BA). Because BA have been shown to decrease ANGPTL4 secretion by intestinal cells, 
we hypothesized that BA lower plasma triglycerides (partly) via ANGPTL4. To test that 
hypothesis, wild-type and Angptl4−/− mice were fed chow supplemented with taurocholic 
acid (TCA) for seven days. TCA supplementation effectively lowered plasma triglycerides 
in wild-type and Angptl4−/− mice, indicating that ANGPTL4 is not required for plasma 
triglyceride-lowering by BA. Intriguingly, however, plasma and hepatic BA concentrations 
were significantly lower in TCA-supplemented Angptl4−/− mice than in TCA-supplemented 
wild-type mice. These changes in the Angptl4−/− mice were accompanied by lower BA levels 
in ileal scrapings and decreased expression of FXR-target genes in the ileum, including the 
BA transporter Slc10a2. By contrast, faecal excretion of specifically primary BA was higher 
in the Angptl4−/− mice, suggesting that loss of ANGPTL4 impairs intestinal BA absorption. 
Since the gut microbiota convert primary BA into secondary BA, elevated excretion of 
primary BA in Angptl4−/− mice may reflect differences in gut microbial composition and/
or functionality. Indeed, colonic microbial composition was markedly different between 
Angptl4−/− and wild-type mice. Suppression of the gut bacteria using antibiotics abolished 
differences in plasma, hepatic, and faecal BA levels between TCA-supplemented Angptl4−/− 
and wild-type mice. In conclusion, 1) ANGPTL4 is not involved in the triglyceride-lowering 
effect of BA; 2) ANGPTL4 promotes BA absorption during TCA supplementation via a 
mechanism dependent on the gut microbiota.  
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Introduction 
Dietary triglycerides are digested in the small intestine primarily via the action of the 
enzyme pancreatic lipase. The activity of pancreatic lipase and subsequent breakdown of 
triglycerides is supported by bile acids (BA). BA are amphipathic molecules that are able 
to emulsify triglycerides and stimulate pancreatic lipase activity. The resulting fatty acids 
are taken up by enterocytes and re-esterified into triglycerides, which in turn are packed 
in chylomicrons and secreted into the lymph (1–3). Circulating triglycerides—as intestine-
derived chylomicrons or liver-derived very low-density lipoproteins—are cleared from the 
bloodstream by hydrolysis catalyzed by lipoprotein lipase (LPL), an enzyme attached to 
the capillary wall in adipose tissue and muscle (4, 5). The activity of LPL is regulated by a 
number of proteins, including the ubiquitously expressed angiopoietin-like 4 (ANGPTL4). 
Numerous studies have shown that ANGPTL4 potently inhibits the activity of LPL, likely 
by unfolding and thereby destabilizing LPL, leading to its degradation (6–9). Accordingly, 
mice lacking Angptl4 have reduced plasma triglyceride levels, whereas mice overexpressing 
Angptl4 have elevated plasma triglyceride levels as compared with wild-type mice (6, 10–12). 
Overall, it is becoming increasingly apparent that ANGPTL4 is the main factor governing 
the physiological changes in LPL activity in white adipose tissue during fasting, in brown 
adipose tissue during cold exposure, and in muscle during exercise (6, 13, 14). 
In addition to supporting the function of pancreatic lipase in lipid digestion, BA also 
have major regulatory roles in the control of lipid, glucose and energy metabolism through 
activation of the bile acid receptors FXR and TGR5 (15). Importantly, the various BA species 
that are present in rodents and humans show differential potencies towards the different BA 
signaling pathways (16). In addition, BA may influence biological processes via interactions 
with the gut microbiota. An intricate interrelationship exists between the gut microbiota, BA, 
and host metabolism. While the gut microbiota influences BA composition by deconjugating 
BA and transforming primary BA into secondary BA, alterations in BA composition may in 
turn affect the gut microbiota (17–20). By modulating BA composition, the gut microbiota 
may significantly impact BA signaling and, thereby, host metabolism (15, 21). 
An important manifestation of the regulatory role of BA in lipid metabolism is their ability 
to influence plasma triglyceride levels. The hypertriglyceridemic effect of BA-binding 
resins and the hypotriglyceridemic effects of oral BA therapies are well-documented in 
humans (22–26). Direct and dose-dependent suppression of the production of very low-
density lipoproteins by BA has been demonstrated in cultured human and rat hepatocytes 
(27)(28). Evidence has also been presented indicating that the hypotriglyceridemic effect 
of BA is mediated by hepatic FXR activation, leading to up- and down-regulation of 
Apoc2 and Apoc3 expression, respectively, collectively resulting in enhanced triglyceride 
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clearance (29)(30). In addition, hepatic FXR activation has been suggested to lead to reduced 
hepatic lipogenesis via SREBP1c (25). Nevertheless, complete insight into the mechanisms 
underlying the triglyceride-lowering actions of BA is still lacking. Previously, we observed 
that BA potently lower ANGPTL4 secretion from the human duodenal cell line Hutu-80. 
Based on this observation and given the prominent role of ANGPTL4 in the regulation of 
plasma triglyceride levels, we hypothesized that the triglyceride-lowering effect of BA may, 
at least in part, be mediated via down-regulation of ANGPTL4 in intestine and/or liver (31). 
To test this hypothesis, wild-type and Angptl4−/− mice were supplemented with the 
primary BA taurocholic acid (TCA) for seven days by adding it to the feed. TCA effectively 
lowered circulating triglycerides in both wild-type and Angptl4−/− mice, indicating that 
ANGPTL4 is not required for the plasma triglyceride-lowering action of BA. Interestingly, 
however, our studies revealed a novel and unexpected interaction between ANGPTL4 and 
BA metabolism that is dependent on the gut microbiota.
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Materials and methods
Animals and diet
Animal studies were performed using pure-bred wild-type and Angptl4−/− mice on a C57BL/6 
background that were bred and maintained in the same facility for more than 20 generations. 
Angptl4−/− mice have been obtained via homologous recombination of embryonic stem cells 
and lack part of the Angptl4 gene, resulting in a non-functional ANGPTL4 protein (11, 32). 
Mice were individually housed in temperature- and humidity-controlled specific pathogen-
free conditions. In study 1, 4 month-old male mice received either chow (control, n=8) or 
chow supplemented with 0.5% (wt/wt) taurocholic acid (TCA, n=8) (Calbiochem, La Jolla, 
CA) for 7 days. Chow was sterilized by γ-irradiation at 20-50kGy. TCA was added to the 
chow by crushing the chow pellets and mixing in the TCA. Diets were provided to the mice 
in a powdered form. In study 2, 12-week old male wild-type and Angptl4−/− mice (n=10 per 
group) received a run-in diet for 3 weeks consisting of a powdered AIN-93G purified diet 
(TestDiet, St. Louis, USA, sterilized by γ-irradiation at 18-50kGy) and an antibiotic cocktail 
in the drinking water. The antibiotic cocktail consisted of 1g/l Ampicillin, 1g/l Neomycin 
sulphate and 0.5g/l Metronidazole. After 3 weeks the mice were switched to a powdered 
AIN-93G purified diet supplemented with 0.5% (wt/wt) TCA (Calbiochem) for 7 days, while 
still receiving the antibiotic cocktail in the drinking water. The mice had ad libitum access 
to food and water. Body weight and food intake were assessed daily. At the end of the study, 
mice were anesthetized using isoflurane and blood was collected by orbital puncture. Mice 
were euthanized via cervical dislocation after which tissues were excised and weighed. The 
small intestine was divided into three equal parts along the distal-to-proximal axis and 
epithelial cells were obtained by scraping the mucosal lining. All animal experiments were 
approved by the local animal ethics committee of Wageningen University. 
 
Plasma parameters
Blood was collected in EDTA-coated tubes and centrifuged for 15 minutes at 3000 rpm 
to obtain plasma. Plasma free fatty acid and triglyceride concentrations were determined 
according to manufacturer’s instructions using commercially available kits (Wako 
chemicals, Neuss, Germany and HUMAN Diagnostics, Wiesbaden, Germany). Plasma 
cholesterol was quantified using a kit from Elitech (Sees, France). Free and conjugated 
BA species were quantified by liquid chromatography tandem MS (LC-MS/MS) using a 
SHIMADZU liquid chromatography system (SHIMADZU, Kyoto, Japan) and tandem AB 
SCIEX API-3200 triple quadrupole mass spectrometer (AB SCIEX, Framingham, USA) as 
previously described (33). 
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RNA isolation and qPCR
Total RNA was extracted from scrapings of the distal small intestine and liver using TRIzol 
reagent (Life technologies, Bleiswijk, Netherlands). Subsequently, 500 ng RNA was used to 
synthesize cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Veenendaal, 
the Netherlands). Changes in gene expression were determined by real-time PCR on a 
CFX384 Real-Time PCR detection system (Bio-Rad) by using SensiMix (Bioline, GC biotech, 
Alphen aan den Rijn, the Netherlands). The housekeeping genes 36b4 and β-actin were used 
for normalization. Sequences of the used primers are listed in Supplemental Table 1. 
Bile acid quantification in liver and ileal scrapings
Total bile acids were quantified in the liver and scrapings of the ileum. Livers and ileal 
scrapings were homogenized in 75% ethanol, incubated at 50°C and centrifuged. After the 
collection of the supernatant, the concentration of total bile acids was determined using a 
colorimetric assay kit (Diazyme Laboratories, Poway, USA).
Faecal measurements
Prior to euthanasia, faeces were collected over a period of 48 hours. Total lipids were 
measured in the faecal samples as described by Govers et al (34). Briefly, 100 mg of faecal 
samples were weighed, dried and acidified using HCl. Lipids were then extracted using 
petroleum and diethyl ether. The ether fraction was collected, evaporated and total lipids 
were weighed. Faecal bile salt composition and faecal neutral sterols were determined by 
capillary gas chromatography (Agilent 6890, Amstelveen, the Netherlands) as described 
previously (35, 36). 
Bacterial DNA extraction, 16S rRNA gene sequencing and analysis (Study 1)
In study 1, DNA was extracted from the freeze-dried luminal content of the colon 
as described previously (37). Universal primers were used for initial amplification of 
part of the 16S rRNA gene: forward primer, ‘5-TCGTCGGCAGCGTCAGATGTGTA 
TAAGAGACAGCCTACGGGAGGCAGCAG-3’ (broadly conserved bacterial primer 357F) 
and reverse primer, ‘5-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTACNV 
GGGTATCTAAKCC’ (broadly conserved bacterial primer 802R). To the purified PCR 
product, Illumina sequencing adapters were added and the 16S rRNA gene was subsequently 
sequenced on the Illumina MiSeq (PE300 cycles run) platform. 
Sequences were analyzed using a workflow based on QIIME 1.8 (38). OTU clustering, 
taxonomic assignment and reference alignment were done with the pick_open_reference_
otus.py workflow script of QIIME, using uclust as clustering method (97% identity) and 
GreenGenes v13.8 as reference database for taxonomic assignment. Reference-based 
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chimera removal was done with uchime. Redundancy analysis (RDA) was performed in 
Canoco version 5 (39).
Bacterial DNA extraction and 16S rRNA gene quantification (Study 2)
In study 2, fecal samples (~40-90mg), which were collected over a period of 48 hours, were 
suspended in 600μL S.T.A.R. buffer (Roche). After addition of 0.1mm zirconia and 2.5mm 
glass beads (BioSpec, Bartlesville, USA), cells were lysed by mechanical disruption using 
a bead beater (MP biomedicals, Santa Ana, USA) for 3x1 minute. DNA was subsequently 
extracted and purified using Maxwell 16 System (Promega). In brief, homogenates (250 
μL) were transferred to a prefilled reagent cartridge (Maxwell® 16 Tissue LEV Total RNA 
Purification Kit, Custom-made, Promega). Sixteen samples were processed at the same time. 
After 30 minutes the purification process was completed and DNA was eluted in 50 μL of 
water (Nuclease free)(Promega).
Real-time PCR was used to quantify 16S rRNA gene in equal amounts of extracted DNA on a 
CFX384 Real-Time PCR detection system (Bio-Rad Laboratories, Veenendaal, Netherlands) 
by using SensiMix (Bioline, GC biotech, Alphen aan den Rijn, Netherlands). 16S rRNA gene 
was amplified using the forward primer 1369F (5’-CGGTGAATACGTTCYCGG-3’)(40) and 
the reverse primer 1492R (5’-GGWTACCTTGTTACGACTT-3’)(41). The cycling conditions 
consisted of an initial denaturation of 95°C for 5 min, followed by 40 cycles of denaturation 
at 95°C for 15 sec, annealing at 60 °C for 30 sec and extension at 72°C for 30 sec.
Statistical analysis
Data are presented as mean ± SEM. Statistical significant differences were determined with 
two-way analysis of variance with Bonferroni post-hoc tests or by Student’s t-test where 
appropriate using GraphPad Prism (GraphPad Software, Inc., La Jolla, USA).  P<0.05 was 
considered as statistically significant. For microbiota analysis, false discovery rate (FDR)-
corrected P-values were estimated for each taxon to correct for multiple testing. Bacterial 
taxa with a FDR-corrected P-value < 0.20 were considered significant. Significance of 
RDA analysis was determined using Monte-Carlo permutation (500 randomizations) as 
implemented in Canoco 5 (39).
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Results
ANGPTL4 is not implicated in the triglyceride-lowering effects of BA
To investigate the potential role of ANGPTL4 in the lowering of plasma triglycerides by BA, 
wild-type and Angptl4−/− mice were fed either chow or chow supplemented with taurocholic 
acid (TCA) for seven days (Figure 1A). The TCA-supplemented diet slightly reduced food 
intake and body weight. However, no differences were observed between the genotypes 
(Supplemental Figure 1). In contrast to our hypothesis that BA may down-regulate Angptl4 
expression, mRNA levels of Angptl4 were either unchanged (liver; Figure 1B) or increased 
(ileum; Figure 1C) by TCA supplementation. As expected, TCA supplementation markedly 
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Figure 1. ANGPTL4 is not part of the triglyceride-lowering effects of bile acids 
(A) Schematic representation of the dietary intervention with 0.5% w/w taurocholic acid (TCA) in wild-
type and Angptl4−/− mice. Relative gene expression of (B) hepatic Angptl4, (C) ileal Angptl4 in wild-type 
and Angptl4−/− mice fed chow (CTRL) of chow supplemented with TCA for 7 days. Gene expression levels in 
wild-type mice fed the control diet were set at 1. (D) Plasma triglycerides, (E) Plasma free fatty acids (FFA), 
and (F) Plasma cholesterol concentration. (G) Relative gene expression of Angptl3 and the apolipoproteins 
Apoc1, Apoc2, Apoc3 and Apoa5 in the liver. Data are presented as mean ± SEM. Asterisks indicate 
significant differences compared with wild-type mice or between groups as indicated by bars according to 
two- way ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.001. (H) Hypothetical model of 
how TCA may lower plasma triglyceride levels. 
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Figure 2. Loss of ANGPTL4 decreases plasma BA levels and increases faecal BA levels in TCA-
supplemented mice
Total plasma BA concentration (A), total BA excretion (B), and plasma concentration of free and conjugated 
BA subspecies (C) in wild-type and Angptl4−/− mice fed chow (CTRL) or chow supplemented with TCA for 
7 days. (D) Mean excretion of free and conjugated BA subspecies. Bd indicates that levels of this BA were 
below the detection limit. Nd indicates that this BA was not determined. Mean excretion of total neutral 
sterols (E), coprostanol, cholesterol, and dihydro-cholesterol (F), and lipids (G). Data are presented as mean 
± SEM. Asterisks indicate significant differences compared with wild-type mice or between groups as 
indicated by bars according to two- way ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.001
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lowered plasma triglyceride levels in wild-type mice. Interestingly, however, TCA also 
effectively lowered plasma triglyceride levels in mice lacking ANGPTL4 (Figure 1D). Other 
plasma lipid parameters, including free fatty acids (Figure 1E) and  cholesterol (Figure 1F) 
were not different between the genotypes and were also not affected by TCA supplementation. 
These data indicate that ANGPTL4 is not involved in the plasma triglyceride-lowering effect 
of BA. Since loss of ANGPTL4 did not lead to a further reduction in plasma triglycerides 
in TCA-supplemented mice, TCA likely lowers plasma triglyceride levels via a mechanism 
similar to loss of ANGPTL4 (e.g. enhanced LPL activity). Interestingly, the expression 
of Angptl3 and Apoc3, two known inhibitors of LPL, was strongly reduced upon TCA 
supplementation in both wild-type and Angptl4−/− mice, whereas the expression of Apoc1, 
Apoc2 and Apoa5 was not altered (Figure 1G), suggesting that TCA might lower plasma 
triglycerides by downregulating Angptl3 and/or Apoc3 expression (Figure 1H).  
Loss of ANGPTL4 leads to reduced BA absorption in TCA-supplemented mice
As expected, the TCA-supplemented diet significantly increased total BA levels in plasma 
and total BA excretion in the faeces (Figure 2A & 2B). Intriguingly, the total plasma 
BA concentration was significantly lower in the TCA-supplemented Angptl4−/− mice 
as compared to the TCA-supplemented wild-type mice, while faecal BA excretion was 
significantly higher in the Angptl4−/− mice (Figure 2A & 2B). These observations suggest that 
the loss of ANGPTL4 reduces the absorption of BA. To further study the effect of Angptl4 
deletion on BA absorption, we quantified the levels of individual BA in plasma and faeces. 
In wild-type mice, TCA supplementation significantly increased plasma levels of primary 
BA, including cholic acid, taurocholic acid, glycocholic acid, chenodeoxycholic acid, 
taurochenodeoxycholic acid and unconjugated muricholic acids, as well as secondary BA, 
including deoxycholic acid, taurodeoxycholic acid, ursodeoxycholic acid and ω-muricholic 
acid. The lower levels of total plasma BA in TCA-supplemented Angptl4−/− mice as compared 
to TCA-supplemented wild-type mice were primarily accounted for by lower plasma levels 
of the primary BA cholic acid and β-muricholic acid, and the secondary BA deoxycholic acid 
and ω-muricholic acid (Figure 2C). With respect to faecal BA levels, TCA supplementation 
in wild-type mice markedly increased the excretion of the primary BA cholic acid and 
deoxycholic acid, and the secondary BA hyodeoxycholic acid. The increased excretion of 
BA in the TCA-supplemented Angptl4−/− mice as compared to TCA-supplemented wild-type 
mice was mainly accounted for by an increase in excretion of cholic acid and β-muricholic 
acid, whereas faecal excretion of the secondary BA deoxycholic acid and ω-muricholic acid, 
as well as the excretion of neutral sterols and lipids, was not different between the genotypes 
(Figure 2D – 2G). The observation that differences in plasma BA between Angptl4−/− and wild-
type mice after TCA-supplementation were caused by differences in unconjugated cholic 
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acid and deoxycholic acid, without significant differences in tauroconjugates, is indicative 
of decreased ileal BA absorption in the Angptl4−/− mice. Overall, these data indicate that the 
loss of ANGPTL4 in mice supplemented with TCA reduces BA absorption, leading to lower 
levels of BA in the circulation and higher faecal BA loss.
The lower absorption of BA in the Angptl4−/− mice is expected to significantly impact ileal 
and hepatic BA levels, as well as BA signaling via FXR. Consistent with this notion, total BA 
levels in ileal scraping were increased in TCA-supplemented wild-type but not Angptl4−/− 
mice (Figure 3A). Moreover, ileal expression of several FXR target genes, including Fgf15, 
Slc51a (Ostα), and Slc51b (Ostβ), as well as expression of Fxr itself, was significantly lower 
in TCA-supplemented Angptl4−/− mice than TCA-supplemented wild-type mice (Figure 
3B, Supplemental Figure 2). Interestingly, ileal expression of the BA transporter Slc10a2 
(Asbt) was markedly lower in the Angptl4−/− mice as compared to wild-type mice after TCA 
supplementation, potentially contributing to the lower BA absorption (Figure 3B).
In the liver, total BA levels were also significantly lower in the TCA-supplemented 
Angptl4−/−  mice as compared to TCA-supplemented wild-type mice (Figure 3C). The lower 
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Figure 3. Levels of BA in liver and ileal scrapings after TCA supplementation are lower in Angptl4−/− 
mice as compared to wild-type mice
(A) Total BA levels in ileal scraping of wild-type and Angptl4−/− mice fed chow (CTRL) or chow supplemented 
with TCA for 7 days. (B) Relative expression of ileal BA transporters and BA-responsive genes, Fgf15, Fxr, 
Slc51a, Slc51b and Slc10a2. Gene expression levels in wild-type mice fed the CTRL diet were set at 1. (C) Total 
BA levels in the liver. (D) Relative hepatic expression of genes involved in BA synthesis and metabolism. 
Data are presented as mean ± SEM. Asterisks indicate significant differences compared with wild-type mice 
or between groups as indicated by bars according to two- way ANOVA followed by a Bonferroni post-hoc 
test. *p<0.05, **p<0.001
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hepatic BA levels and the reduced expression of Fgf15 in the ileum of Angptl4−/− mice were 
associated with markedly higher hepatic expression of genes involved in BA synthesis, 
including Cyp7a1 and Cyp8b1, whereas hepatic expression of other genes involved in BA 
metabolism was not or only slightly different between the Angptl4−/− and wild-type mice 
(Figure 3D, Supplemental Figure 2). Taken together, the TCA-supplemented Angptl4−/− 
mice display reduced bile acid absorption as compared to TCA-supplemented wild-type 
mice, consequently leading to lower total bile acids levels in the plasma and liver and 
subsequently to the induction of genes involved in bile acid synthesis.
ANGPTL4 affects TCA-induced changes in gut microbial composition 
As pointed out above, the excretion of the primary BA cholic acid and β-muricholic acid was 
significantly higher in Angptl4−/− mice, whereas the excretion of secondary BA and neutral 
sterols was not different between the genotypes. Inasmuch as the conversion of primary BA 
into secondary BA is mediated by the gut microbiota, the higher excretion of specifically 
primary BA in the faeces of Angptl4−/− mice suggests that loss of ANGPTL4 may impact gut 
microbial composition. Analysis of the colonic microbial composition by 16S rRNA gene 
sequencing revealed substantial differences between Angptl4−/− and wild-type mice, both on 
the control diet and on the TCA-supplemented diet. Redundancy analysis (RDA) showed 
that the explanatory variables diet and genotype explained 34.9% of the total variation in 
the colonic microbiota composition (Figure 4). To determine which variable was the most 
important determinant of colonic microbial composition, a partial RDA was performed. 
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Figure 4.  TCA supplementation and Angptl4 genotype affect gut microbial composition  
Redundancy analysis (RDA) correlation biplot describing the relationship between colonic luminal 
microbiota composition and the differences caused by genotype and diet. The explanatory variables diet 
and genotype explained 34.9% of the total variation in the microbiota composition. 
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While genotype explained 10.9% of the total variation in microbial composition, diet was 
more important and explained 25.1% of the microbial variation (Figure 5A & 5B). 
Since the differences in BA metabolism between Angptl4−/− and wild-type mice were most 
evident after TCA supplementation, the composition of the colonic microbiota of wild-
type and Angptl4−/− mice fed the TCA-supplemented diet was compared in more detail. At 
the phylum level, the relative abundance of Actinobacteria was significantly higher in the 
Angptl4−/− mice than in the wild-type mice, whereas the relative abundance of Bacteroidetes 
and Cyanobacteria followed an opposite pattern (Figure 6, Supplemental Table 2). The 
increased abundance of the phylum Actinobacteria was largely explained by a significant 
increase within the genus Adlercreutzia. Concurrently, the decrease in the phylum 
Bacteroidetes was mainly accounted for by a significant decrease in the genus Prevotella 
(Figure 6, Supplemental Table 2). Interestingly, while the relative abundance of the phylum 
Proteobacteria was comparable between the genotypes, the family of Enterobacteriaceae 
was, with a relative abundance of 3.6%, 158-fold (FDR-corrected p-value = 0.188) more 
abundant in the colon of the Angptl4−/− mice as compared with wild-type mice (Figure 6, 
Supplemental Table 2). Conversely, the abundance of Bilophila was significantly lower in 
the colonic luminal content of Angptl4−/− mice as compared with wild-type mice. Finally, the 
species Lactobacillus reuteri was present in the colonic luminal content of wild-type mice, 
whereas it was almost absent in the Angptl4−/− mice (Figure 6, Supplemental Table 2). These 
data reveal pronounced differences in gut microbiota composition between wild-type and 
Angptl4−/− mice supplemented with TCA.
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Figure 5. Bile acid feeding has more impact on gut microbial composition than Angptl4 genotype 
(A-B) Partial RDA correlation biplot describing the relationship between colonic luminal microbiota 
composition and explanatory variables (A) genotype and (B) diet. Genotype explained 10.9% and diet 
25.1% of total variation in microbiota composition. 
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Figure 6. Differences in microbial composition between wild-type and Angptl4−/− mice after TCA 
supplementation
Nodes represent taxa and the edges link the different taxonomic levels. The fold increase is calculated as 
the 2log of the ratio of the relative abundance in Angptl4−/− and wild-type mice after TCA supplementation. 
Significance is expressed as the FDR-corrected p-value. 
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Suppression of the gut microbiota abolishes the decrease in BA absorption in 
Angptl4−/− mice after TCA supplementation 
To investigate if the reduction in BA absorption in the Angptl4−/− mice supplemented 
with TCA is dependent on the gut microbiota, wild-type and Angptl4−/− mice fed the 
TCA-supplemented diet were given antibiotics via the drinking water for 7 days. Oral 
antibiotics markedly reduced DNA levels in the faeces and decreased 16S rRNA gene 
amplification (Figure 7A), indicating an effective suppression of bacteria numbers in the 
colon. After treatment with antibiotics, plasma triglyceride levels were markedly lower in 
TCA-supplemented Angptl4−/− mice as compared to TCA-supplemented wild-type mice, 
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Figure 7. Antibiotics abolish the difference in BA (re)absorption between TCA-supplemented Angptl4−/− 
and wild-type mice
(A) Quantitative analysis of faecal DNA levels and Ct values of qPCR amplification of 16S rRNA gene in 
equal amounts of faecal DNA. Data are presented as mean ± SEM. Asterisks indicate significant differences 
according to two-way ANOVA followed by a Bonferroni post-hoc test. (B) Plasma triglycerides (TG), free 
fatty acid (FFA) and cholesterol concentration in wild-type and Angptl4−/− mice fed the TCA-supplemented 
diet for 7 days with antibiotics provided via the drinking water. (C) Total plasma BA concentration. (D) 
total BA excretion. Ns indicates not significant. (E) Plasma concentration of free and conjugated BA 
subspecies. (F) Mean excretion of free and conjugated BA subspecies. Data are presented as mean ± SEM. 
Asterisks indicate significant differences compared with wild-type mice according to a Student’s t-test. 
*p<0.05, **p<0.001.
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consistent with the function of ANGPTL4 as LPL inhibitor, whereas plasma free fatty acids 
and cholesterol were not different between the genotypes (Figure 7B). In contrast to the 
observations made in mice not given antibiotics, after antibiotics treatment, total plasma BA 
levels (Figure 7C) and faecal BA excretion (Figure 7D) were similar in TCA-supplemented 
Angptl4−/− and TCA-supplemented wild-type mice. Although several BA species fell below 
the detection limit after antibiotics treatment, levels of individual primary and secondary 
BA in plasma (Figure 7E) and in faeces (Figure 7F) were similar in the two sets of mice. 
Also, after antibiotics treatment, ileal expression of Fxr and Slc51b were higher in TCA-
supplemented Angptl4−/− mice than TCA-supplemented wild-type mice, while the expression 
of Fgf15, Slc51a or Slc10a2 was not different between the two genotypes (Figure 8A). The 
latter result contrasts with the lower ileal expression of Fgf15, Fxr, Slc51a (Ostα), Slc51b 
(Ostβ), and Slc10a2 (Asbt) in the TCA-supplemented Angptl4−/− mice as compared to TCA-
supplemented wild-type mice in the absence of antibiotics (Figure 3A). After antibiotics 
treatment, BA levels in the ileal scrapings were still significantly lower in TCA-supplemented 
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Figure 8. Antibiotics largely abolish the difference in ileal and hepatic bile acid levels and gene 
expression between TCA-supplemented Angptl4−/− and wild-type mice
(A) Relative expression of ileal BA transporters and BA-responsive genes Fgf15, Fxr, Slc51a, Slc51b and 
Slc10a2, in wild-type and Angptl4−/− mice fed the TCA-supplemented diet for 7 days with antibiotics 
provided via the drinking water. Gene expression levels in wild-type mice were set at 1. (B) Total BA levels 
in ileal scraping. (C) Relative hepatic expression of genes involved in BA synthesis and metabolism. (D) 
Total BA levels in the liver. Data are presented as mean ± SEM. Asterisks indicate significant differences 
compared with wild-type mice according to a Student’s t-test. *p<0.05, **p<0.001.
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Angptl4−/− mice as compared to TCA-supplemented wild-type mice (Figure 8B), though less 
pronounced than in the absence of antibiotics (Figure 3A). Furthermore, after antibiotics 
treatment, no differences in hepatic BA levels and hepatic expression of genes related to BA 
synthesis and metabolism could be observed between the two sets of mice (Figure 8C-D), 
which is in line with the lack of difference in plasma BA levels between the two genotypes 
after antibiotics treatment. Overall, these data suggest that loss of ANGPTL4 reduces BA 
absorption via a mechanism that is dependent on the gut microbiota.   
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Discussion 
Oral administration of BA has been shown to lower plasma triglyceride levels in mice 
and humans. In contrast, promoting BA excretion via resin treatment has the opposite 
effect (22–26). In the present paper, we found that TCA supplementation caused a marked 
reduction in plasma triglycerides in both wild-type and Angptl4−/− mice, suggesting that 
ANGPTL4 is not involved in the triglyceride-lowering effect of BA. Interestingly, however, 
we found that plasma and hepatic BA concentrations were significantly lower in TCA-
supplemented Angptl4−/− mice than in TCA-supplemented wild-type mice. Moreover, after 
TCA-supplementation, BA levels in ileal scrapings were lower in Angptl4−/− mice compared 
to wild-type mice, whereas faecal excretion of specifically primary BA was significantly 
higher in Angptl4−/− mice, suggesting that loss of ANGPTL4 leads to impaired intestinal 
BA absorption. Changes in ileal and hepatic gene expression in Angptl4−/− mice were 
consistent with this scenario. Furthermore, we found that suppression of the gut bacteria via 
oral antibiotics abolished the lower BA absorption in TCA-supplemented Angptl4−/− mice 
as compared to wild-type mice. Overall, our data indicate that ANGPTL4 promotes BA 
absorption via a mechanism dependent on the gut microbiota. 
The observation that loss of ANGPTL4 does not further reduce plasma triglyceride 
levels in mice supplemented with TCA may imply that ANGPTL4 and TCA decrease 
plasma triglycerides via  similar non-additive mechanisms. Since loss of ANGPTL4 lowers 
plasma triglycerides by stimulating LPL-dependent plasma triglyceride clearance, TCA 
supplementation likely has a similar mode of action. By contrast, if TCA would lower plasma 
triglyceride levels by reducing VLDL-TG production in the liver, loss of ANGPTL4 may 
be expected to lead to a further decrease in plasma triglycerides in TCA-supplemented 
mice. Previous studies have provided evidence that the hypotriglyceridemic effect of BA 
occurs via activation of FXR, either via enhanced triglyceride clearance via regulation of 
APOC2 and/or APOC3, and/or reduced hepatic triglyceride production via SREBP1c (25, 
29, 30). Additionally, triglyceride-lowering by BA may be mediated by downregulation of 
Angptl3, which akin to Angptl4 encodes an inhibitor of LPL (25). Consistent with these 
studies, we found that the expression of Apoc3 and Angptl3 was markedly reduced by TCA 
supplementation, lending credence to the notion that the triglyceride-lowering effect of BA 
may be mediated by downregulation of the LPL inhibitors ANGPTL3 and APOC3.
An interesting new observation is the markedly lower concentration of plasma BA in 
Angptl4−/− mice as compared to wild-type mice after TCA supplementation. This finding may 
be explained by the decreased expression of Slc10a2—the main active transporter for BA 
absorption—in the ileum of Angptl4−/− mice (42). Expression of Slc10a2 in the ileum is down-
regulated by FXR via a negative feedback mechanism that involves activation of the small 
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heterodimer partner (SHP) and subsequent repression of liver related homolog-1 (LRH-1) 
(42–44). Various BA activate intestinal FXR, but their potency to activate FXR varies greatly 
(43, 45). Indeed, a recent study demonstrated that different BA species differentially affect the 
expression of Fxr and FXR-target genes such as Fgf15 and Slc10a2 (46). More hydrophilic BA 
such as tauro-β-muricholic acid have been suggested to act as antagonists of FXR (47). Since 
Angptl4−/− mice had a significantly higher excretion of specifically primary BA, it can be 
hypothesized that the lower ileal expression of Slc10a2 in Angptl4−/− mice may be explained 
by differences in intestinal BA composition between Angptl4−/− and wild-type mice. 
Gut microbial composition potently influences intestinal BA metabolism and BA 
composition. Indeed, the gut microbiota converts primary BA to secondary BA via 
7α-dehydroxylation activity, thereby increasing the hydrophobicity of BA. In addition, the 
gut microbiota promote the deconjugation of BA, thereby preventing the active absorption 
of BA by SLC10A2 (15, 17, 20). As a result, alterations in gut microbial composition, for 
example by treatment with antibiotics, probiotics or a high-fat diet, significantly impact 
the abundance of secondary BA and overall BA homeostasis (19, 46–49). In addition to 
promoting 7α-dehydroxylation and deconjugation of BA, the gut microbiota may influence 
BA metabolism via other mechanisms. For example, a recent study has shown that bacterial 
metabolites can modulate FXR activity (50) and that conventionalization of germ-free mice 
increases the expression of FXR-target genes (47). Moreover, it was shown that suppression 
of the gut microbiota by antibiotics treatment reduced activation of GATA4, a transcription 
factor that negatively regulates the expression of the Slc10a2 transporter, resulting in higher 
expression of Slc10a2 and higher BA absorption, whereas conventionalization of germ-free 
mice lowered Slc10a2 expression (51, 52). 
Given the intricate relationship between the gut microbiota and BA metabolism, we 
hypothesized that differences in BA metabolism between wild-type and Angptl4−/− mice after 
TCA supplementation are accounted for by differences in microbial composition between 
the two sets of mice. Indeed, we detected a higher abundance of the Enterobacteriaceae, a 
family that includes several pathogenic strains such as Salmonella and E.Coli, and a lower 
abundance of bile-loving, sulphite-reducing Bilophila in the colon of TCA-supplemented 
Angptl4−/− mice as compared with TCA-supplemented wild-type mice (53). In human 
subjects, Enterobacteriaceae have been associated with the presence of primary BA in the 
faeces and have been linked to pathologies such as hepatic encephalopathy and Crohn’s 
disease (54–56). 
Importantly, suppression of the gut bacteria by antibiotics abolished the decrease in BA 
absorption in TCA-supplemented Angptl4−/−  mice compared to TCA-supplemented wild-
type mice, suggesting that the difference in bile acid metabolism between Angptl4−/− and 
wild-type mice is dependent on the gut bacteria. It remains to be investigated, however, 
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whether the microbial changes in the Angptl4−/− mice are directly responsible for the 
difference in bile acid absorption or whether the microbial changes modulate a possible 
direct effect of ANGPTL4 on bile acid absorption (Figure 9). 
Ideally, we should have used the same diet in the study without antibiotics and in the 
study with antibiotics. However, in our experience, it is impossible to give chow-fed mice 
antibiotics, as it leads to intestinal blockage and weight loss, likely due to the high fiber 
content in chow. For this reason, we switched to the semi-purified AIN-93G diet in the 
second study, which does not cause health problems when combined with antibiotics. 
The difference in gut microbial composition between Angptl4−/− and wild-type mice, 
which is already noticeable in the absence  of TCA supplementation (Supplemental 
Figure 3, Supplemental Table 3), is quite remarkable. The origin of these differences is 
presently unclear, which is partly due to the partially unresolved function(s) of intestinal 
ANGPTL4. In human intestine, immunofluorescent staining showed that ANGPTL4 is 
particularly abundant in entero-endocrine cells (31). However, it is evident that Angptl4 
expression is not restricted to entero-endocrine cells, as several enterocyte cell lines produce 
and secrete ample amounts of ANGPTL4 (57). Expression of ANGPTL4 in a number of 
intestinal cell lines is highly sensitive to various stimuli such as BA, fatty acids, bacteria, 
and bacterial metabolites (31, 57–60). One of the key issues is whether ANGPTL4 produced 
by enterocytes is secreted into the blood stream and/or into the intestinal tract (31, 61). 
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Figure 9. Hypothetical model of how ANGPTL4 may influence bile acid metabolism 
An intricate relationship exists between ANGPTL4, the intestinal microbiota, and bile acid metabolism. 
ANGPTL4 influences the gut microbiota and vice versa. The gut microbiota influence intestinal bile acids and 
vice versa. Previous studies have shown that bile acids may influence ANGPTL4 secretion. Data presented 
in this manuscript suggest that ANGPTL4 may influence bile acid metabolism. It can be hypothesized that 
the changes in gut microbial composition caused by loss of ANGPTL4 directly impact bile acid metabolism, 
implying that ANGPTL4 influences bile acid metabolism via the gut microbiota. Alternatively, it is possible 
that (loss of) ANPGTL4 directly influences bile acid metabolism via a mechanism that is dependent on the 
gut microbiota.  
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Bäckhed et al. showed that conventionalization of germ-free mice suppressed intestinal 
Angptl4 expression. In some though not all studies, conventionalization increased adiposity 
in wild-type but not Angptl4−/− mice via the purported loss of endocrine inhibition on 
adipose tissue LPL activity (62–65). In contrast, in line with observations that suggest a 
local instead of endocrine function of ANGPTL4, we found that intestinal ANGPTL4 has 
the capacity to inhibit pancreatic lipase, a family member of LPL and the main enzyme 
responsible for the hydrolysis of dietary triglycerides in the gastro-intestinal tract (8, 9, 61). 
Multiple studies indicate that elevated levels of lipids in the ileum and colon can markedly 
influence the gut microbial composition, indicating that the differences in gut microbial 
composition between wild-type and Angptl4−/− mice may be explained by differences in 
dietary fat metabolism (66, 67). It can be speculated that the origin of the differences in 
gut microbial composition between wild-type and Angptl4−/− mice may lie during suckling, 
when pups receive a high amount of lipid-containing milk. Differences in gut microbial 
composition may also be related to differences in intestinal immunity, as it was recently 
shown that Angptl4−/− mice have increased leukocyte infiltration and inflammation in the 
colon upon DSS treatment, concurrent with differences in gut microbial composition (68). 
Future studies using intestine-specific Angptl4−/− mice should investigate whether intestinal-
derived ANGPTL4 is responsible for the changes in gut microbiota composition and clarify 
how ANGPTL4 influences the gut microbiota composition. 
In conclusion, we demonstrate that loss of ANGPTL4 significantly reduces plasma, hepatic, 
and ileal BA levels and increases BA excretion in mice supplemented with TCA. Suppression 
of the gut bacteria by antibiotics largely abolished the decrease in bile acid absorption in 
Angptl4−/− mice, suggesting that ANGPTL4 promotes bile acid absorption via a mechanism 
dependent on the gut microbiota. Our studies thus reveal a novel interaction between 
ANGPTL4 and BA metabolism that is dependent on the gut microbiota. Finally, we show 
that ANGPTL4 is not required for the plasma triglyceride lowering action of BA.
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Supplemental figures and tables
Supplemental figure 1. Bodyweight and food intake in wild-type and Angptl4-/- mice fed chow or chow 
supplemented with TCA. (A) Final body weight of wild-type and Angptl4-/- mice fed chow (CTRL) or chow 
supplemented with TCA for 7 days. (B) Mean food intake per day during dietary intervention. Data are 
presented as mean ± SEM. Asterisks indicate significant differences between groups as indicated by bars 
according to two-way ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.001
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Supplemental figure 2. Ileal and hepatic gene expression in wild-type and Angptl4-/- mice fed chow or 
chow supplemented with TCA. (A) Relative gene expression of ileal Abcc2 and Fabp6 in wild-type and 
Angptl4-/- mice fed chow (CTRL) or chow supplemented with TCA for 7 days. Relative hepatic expression 
portal BA transporters (B) and genes involved in canalicular bile acid, cholesterol, and phosphatidylcholine 
export (C). Gene expression levels in wild-type mice fed CTRL diet were set at 1. Data are presented as 
mean ± SEM. Asterisks indicate significant differences compared with wild-type mice or between groups as 
indicated by bars according to two- way ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.001
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Supplemental figure 3. Differences in microbial composition between wild-type and Angptl4-/- mice fed 
the control diet. Nodes represent taxa and the edges link the different taxonomic levels. The fold increase is 
calculated as the 2log of the ratio of the relative abundance in Angptl4-/- and wild-type mice fed the control 
(CTRL) diet. Significance is expressed as the FDR-corrected p-value.
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Supplemental table 1. Primer sequences used for qPCR
 
 Primer Sequence  
Name Forward Reverse 
General    
mAngptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG 
 
Liver   
mβ-Actin GATCTGGCACCACACCTTCT GGGGTGTTGAAGGTCTCAAA 
mAngptl3 ACTGTGATACCCAATCAGGCA CCTCCCAAAGCCCTTTTCGTA 
mAngptl8 CACTGTACGGAGACTACAAGTGC GTGGCTCTGCTTATCAGCTCG 
mCyp7a1 CAGGGAGATGCTCTGTGTTCA AGGCATACATCCCTTCCGTGA 
mCyp27a1 CCAGGCACAGGAGAGTACG GGGCAAGTGCAGCACATAG 
mCyp8b1 CCTCTGGACAAGGGTTTTGTG GCACCGTGAAGACATCCCC 
mFgfr4 CGTGGTCGTCACTGGTACAAA CCTCTCCAACCCCGTACTC 
mShp CCTAGCCAAGACAGTAGCCTTC CCAACCCAAGCAGGAAGAGAG 
mNtcp ATGACCACCTGCTCCAGCTT GCCTTTGTAGGGCACCTTGT 
mOatp1a1 GTGCATACCTAGCCAAATCACT CCAGGCCCATAACCACACATC 
mBsep CTGCCAAGGATGCTAATGCA CGATGGCTACCCTTTGCTTCT 
mMrp2 GTGTGGATTCCCTTGGGCTTT CACAACGAACACCTGCTTGG 
mAbcg5 TCAGGACCCCAAGGTCATGAT AGGCTGGTGGATGGTGACAAT 
mAbcg8 GACAGCTTCACAGCCCACAA GCCTGAAGATGTCAGAGCGA 
mMdr2 TATCCGCTATGGCCGTGGGAA ATCGGTGAGCTATCACAATGG 
mApoC1 TCCTGTCCTGATTGTGGTCGT CCAAAGTGTTCCCAAACTCCTT 
mApoC2 AGCTGCCTGATATGGAAGGA GCTGTCTGGGACCTGAATGT 
mApoC3 TACAGGGCTACATGGAACAAGC CAGGGATCTGAAGTGATTGTCC 
mApoA5 TCCTCGCAGTGTTCGCAAG CGAAGCTGCCTTTCAGGTTCT 
 
Ileum    
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mAsbt  ATGGCGACATGGACCTCAGT CCCGAGTCAACCCACATCTTG 
mIbabp CTTCCAGGAGACGTGATTGAAA CCTCCGAAGTCTGGTGATAGTTG 
mMrp2  GGATGGTGACTGTGGGCTGAT GGCTGTTCTCCCTTCTCATGG 
mFgf15 GCTCTGAAGACGATTGCCATC TTCCTCCCTGAAGGTACAGTC 
mFxr  GACCTCCACAACCAAGTTTTGC TGATTTCCTGAGGCATTCTCTGTT 
mOstα GTTCCAGGTGCTTGTCATCC CCACTGTTAGCCAAGATGGAGAA 
mOstβ GATGCGGCTCCTTGGAATTA GGAGGAACATGCTTGTCATGAC 
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Supplemental table 2. Relative abundance of microbiota in colonic luminal of wild-type and 
Angptl4-/- mice fed  chow supplemented with TCA
 
Phylum Class Order Family Genus Species Wild-type (%) Angptl4 -/- (%) FC FDR-corrected P-value*
Actinobacteria 3.05 6.03 2.0 0.16
Coriobacteriia 2.57 5.99 2.3 0.12
Coriobacteriales 2.57 5.99 2.3 0.12
Coriobacteriaceae 2.57 5.99 2.3 0.19
Adlercreutzia 1.51 4.77 3.2 0.11
Firmicutes 70.13 72.28 1.0 ns
Clostridia 48.04 59.24 1.2 0.12
Clostridiales 48.04 59.24 1.2 0.12
Lachnospiraceae 16.68 24.23 1.5 0.19
[Ruminococcus] 6.32 8.28 1.3 0.11
[Ruminococcus] gnavus 6.32 8.28 1.3 0.06
Dorea 0.41 1.13 2.7 0.11
Ruminococcaceae 13.53 11.36 -1.2 ns
Ruminococcus 2.98 4.46 1.5 0.11
Mogibacteriaceae 0.14 0.46 3.4 0.19
Erysipelotrichi 7.89 3.46 -2.3 ns
Erysipelotrichales 7.89 3.46 -2.3 ns
Erysipelotrichaceae 7.89 3.46 -2.3 ns
Allobaculum 7.30 1.69 -4.3 0.11
Bacilli 14.19 9.57 -1.5 ns
Lactobacillales 14.03 9.54 -1.5 ns
Lactobacillaceae 13.96 9.37 -1.5 ns
Lactobacillus 13.96 9.37 -1.5 ns
Lactobacillus reuteri 0.12 0.00 -205.1 0.06
Bacteroidetes 8.13 3.57 -2.3 0.16
Bacteroidia 8.13 3.57 -2.3 0.12
Bacteroidales 8.13 3.57 -2.3 0.12
[Paraprevotellaceae] 1.10 0.13 -8.2 0.19
[Prevotella] 1.10 0.13 -8.2 0.11
Prevotellaceae 0.26 0.07 -3.7 0.19
Prevotella 0.25 0.07 -3.6 0.11
Proteobacteria 11.99 13.27 1.1 ns
Gammaproteobacteria 0.03 3.65 119.4 0.12
Enterobacteriales 0.02 3.63 158.7 0.12
Enterobacteriaceae 0.02 3.63 158.7 0.19
Deltaproteobacteria 8.65 7.16 -1.2 ns
Desulfovibrionales 8.65 7.15 -1.2 ns
Desulfovibrionaceae 8.65 7.15 -1.2 ns
Bilophila 1.44 0.38 -3.8 0.11
Cyanobacteria 0.31 0.07 -4.8 0.10
4C0d_2 0.31 0.05 -5.9 0.12
YS2 0.31 0.05 -6.0 0.12
Threshold for presentation: an abundance of >0.1% in one of the two genotypes, a relative foldchange of >0.25 and a p-value <0.1 in the lowest identifiable taxon
* significance according to unpaired Wilcoxon rank-sum test followed by a Benjamini-Hochberg correction. 
   A FDR-corrected P-value <0.20 was considered statistically significant
Chapter 8
234
Supplemental table 3. Relative abundance of microbiota in colonic luminal of wild-type and 
Angptl4-/- mice fed chow
 
Phylum Class Order Family Genus Species Wild-type (%) Angptl4 -/- (%) FC FDR-corrected P-value*
Actinobacteria 9.80 8.95 -1.1 ns
Actinobacteria 0.14 0.02 -7.6 ns
Bifidobacteriales 0.13 0.00 -548.7 0.09
Bifidobacteriaceae 0.13 0.00 -548.7 0.06
Bifidobacterium 0.13 0.00 -548.7 0.05
Firmicutes 72.51 60.86 -1.2 0.15
Clostridia 54.33 45.36 -1.2 ns
Clostridiales 54.33 45.36 -1.2 ns
Lachnospiraceae 17.29 18.13 1.0 ns
[Ruminococcus] 3.87 2.29 -1.7 0.05
[Ruminococcus] gnavus 3.87 2.29 -1.7 0.05
Coprococcus 0.31 0.06 -5.7 0.02
Dorea 0.58 0.37 -1.6 0.05
Ruminococcaceae 8.30 1.22 -6.8 0.03
Ruminococcus 1.28 0.31 -4.2 0.05
Oscillospira 3.63 0.17 -21.1 0.02
Clostridiaceae 1.73 2.44 1.4 ns
Clostridium 0.39 2.08 5.4 0.05
Dehalobacteriaceae 0.31 0.12 -2.7 0.06
Dehalobacterium 0.31 0.12 -2.7 0.05
Erysipelotrichi 3.28 1.06 -3.1 0.13
Erysipelotrichales 3.28 1.06 -3.1 0.09
Erysipelotrichaceae 3.28 1.06 -3.1 0.06
Allobaculum 2.90 0.56 -5.2 0.02
Bacilli 14.89 14.44 1.0 ns
Turicibacterales 0.66 0.00 -252.5 0.09
Turicibacteraceae 0.66 0.00 -252.5 0.06
Turicibacter 0.66 0.00 -252.5 0.05
Lactobacillales 14.23 14.44 1.0 ns
Streptococcaceae 0.06 0.15 2.5 0.04
Streptococcus 0.05 0.15 2.8 0.02
Enterococcaceae 0.34 0.00 -1408.6 0.06
Enterococcus 0.34 0.00 -1398.8 0.05
TM7 8.91 22.83 2.6 0.02
TM7_3 8.91 22.83 2.6 0.03
CW040 8.91 22.83 2.6 0.04
F16 8.91 22.83 2.6 0.03
Cyanobacteria 0.07 0.13 1.8 0.10
4C0d_2 0.07 0.12 1.8 0.13
YS2 0.07 0.12 1.8 0.09
Threshold for presentation: an abundance of >0.1% in one of the two genotypes, a relative foldchange of >0.25 and a p-value <0.1 in the lowest identifiable taxon
* significance according to unpaired Wilcoxon rank-sum test followed by a Benjamini-Hochberg correction. 
   A FDR-corrected P-value <0.20 was considered statistically significant
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Abstract
ANGPTL4 is an important regulator of triglyceride metabolism by inhibiting the enzymes 
lipoprotein lipase and pancreatic lipase. Although ANGPTL4 has been implicated in 
obesity, study of the direct role of ANGPTL4 in diet-induced obesity and related metabolic 
dysfunction is hampered by the massive acute phase response and lethal chylous ascites and 
peritonitis in Angptl4-/- mice fed the standard high fat diet. To overcome that obstacle and to 
investigate the influence of ANGPTL4 on diet-induced obesity and metabolic dysfunction, 
we fed wild-type and Angptl4-/- mice a high fat diet rich in unsaturated fat, combined with 
fructose and cholesterol. 
Mice lacking Angptl4 displayed increased bodyweight gain, adipose tissue LPL activity, 
adipose tissue mass, and adipose tissue inflammation, but unexpectedly had markedly 
improved glucose tolerance. The improved glucose tolerance was accompanied by elevated 
insulin levels, whereas insulin sensitivity was not affected. Inasmuch as the gut microbiota 
have been suggested to influence insulin secretion and as ANGPTL4 has been proposed to 
link the gut microbiota to host metabolism, we hypothesized a potential role for the gut 
microbiota. Gut microbiota composition was significantly different between Angptl4-/- mice 
and wild-type mice. Interestingly, suppression of the gut microbiota using antibiotics largely 
abolished the differences in glucose tolerance and insulin levels between wild-type and 
Angptl4-/- mice.
In conclusion, despite increasing fat mass, loss of ANGPTL4 improves glucose tolerance, 
at least partly via a mechanism dependent on the gut microbiota. 
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Introduction
In the last few decades, obesity has become an immense global health problem. Obesity 
is often accompanied by a state of insulin resistance, which greatly increases the risk of 
cardiometabolic complications such as type 2 diabetes, non-alcoholic fatty liver disease, and 
coronary artery disease (1, 2). Part of the effect of insulin resistance on cardiometabolic risk 
is mediated by changes in plasma lipoproteins. The concentrations of plasma lipoproteins are 
regulated at the level of production and/or degradation via a complex interplay of enzymes, 
receptors and transporters active in a variety of tissues. 
A particular class of lipoproteins are the triglyceride-rich lipoproteins consisting of 
chylomicrons produced in the intestine and very low density lipoproteins (VLDL) produced 
by the liver (3). Once in the blood, the triglyceride-rich lipoproteins are quickly captured by 
lipoprotein lipase (LPL) in the capillaries of fat and muscle tissue (4–6). Apart from binding 
the triglyceride-rich lipoproteins, LPL also catalyzes the hydrolysis of the triglyceride 
cargo into fatty acids. These fatty acids are subsequently taken up by the underlying fat 
and muscle cells and either stored or used as fuel (4, 7). To ensure that the rate of uptake of 
fatty acids matches the physiological conditions and local energy demands, the activity of 
LPL is subject to numerous regulatory mechanisms. An important group of physiological 
regulators of LPL activity are the Angiopoietin-like proteins, consisting of ANGPTL3, 
ANGPTL4, and ANGPTL8. These three secreted proteins share the ability to inhibit LPL, 
thereby raising plasma levels of triglyceride-rich lipoproteins. Whereas ANGPTL3 and 
ANGPTL8 are mainly produced in the liver, ANGPTL4 is synthesized by a variety of tissues 
including liver, intestine, skeletal muscle, heart, and adipose tissue (8). We and others have 
shown that ANGPTL4 post-translationally inhibits LPL activity under various physiological 
conditions, including fasting, exercise and cold exposure, thereby raising plasma triglyceride 
levels (9–13). Biochemical studies have shown that ANGPTL4 inhibits LPL by promoting the 
unfolding of LPL, resulting in the dissociation of the catalytically active LPL dimers into 
inactive LPL monomers. In adipocytes, these events likely serve as the trigger leading to the 
intracellular breakdown of LPL (14–16).
Besides inhibiting LPL, ANGPTL4 has also been shown to inhibit pancreatic lipase, the 
main enzyme responsible for the hydrolysis of dietary triglycerides in the gastro-intestinal 
tract and a structural homolog of LPL. Consequently, mice lacking ANGPTL4 have 
enhanced dietary lipid absorption as compared with wild-type mice, resulting in higher fat 
mass and bodyweight (17). 
In addition to a role in lipid metabolism, a number of studies have also implicated 
ANGPTL4 in the regulation of glucose metabolism. Whereas plasma glucose levels do not 
appear to be changed in Angptl4-/- mice, overexpression of Angptl4 by adenovirus was shown 
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to lower circulating glucose levels and improve glucose tolerance, which was suggested to 
be mediated by decreased hepatic glucose production (18). By contrast, glucose tolerance 
was lower in whole-body Angptl4-transgenic mice after prolonged high-fat feeding (19). 
According to clamp studies, transgenic Angptl4 overexpression leads to impaired glucose 
utilization and insulin resistance in the periphery, but higher insulin-mediated suppression 
of glucose production in the liver (15). Hence, published data do not present a uniform 
picture on the influence of ANGPTL4 on glucose metabolism and insulin sensitivity. 
Considering the involvement of ANGPTL4 in fat uptake and storage and its potential 
role in glucose metabolism, it is of interest to investigate the role of ANGPTL4 in metabolic 
dysfunction and insulin sensitivity during obesity. Unfortunately, the study of ANGPTL4 in 
diet-induced obesity and associated metabolic dysfunction is hampered by the massive acute 
phase response and lethal chylous ascites and peritonitis in Angptl4-/- mice fed a high fat 
diet. This severe inflammatory response is specifically provoked by a diet high in saturated 
fatty acids. By contrast, feeding Angptl4-/- mice a diet rich in cis- or trans-unsaturated fatty 
acids does not trigger an inflammatory response (20). Accordingly, in the present paper we 
investigated the influence of ANGPTL4 on diet-induced obesity and metabolic dysfunction 
by feeding wild-type and Angptl4-/- mice a high fat diet rich in unsaturated fatty acids, 
followed by detailed investigation of the metabolic phenotype.
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Materials and methods
Animals and diet
Animal studies were performed using pure-bred wild-type and Angptl4-/- mice on a C57Bl/6 
background that were bred and maintained in the same facility for more than 20 generations 
(21). Mice were individually housed in temperature- and humidity-controlled specific 
pathogen-free conditions. Mice had ad libitum access to food and water.
In study 1, 10-week-old wild-type (n=12) and Angptl4-/- mice (n=12) were fed a high 
fat/high cholesterol/high fructose diet, providing 45% energy as triglycerides (formula 
D12451 Research Diets, Inc., manufactured by Research Diet Services, Wijk bij Duurstede, 
Netherlands, sterilized with γ-irradiation at 9kGy) for 18 weeks. The fat source of this diet 
was replaced by safflower oil and supplemented with 1% cholesterol (Dishman, Veenendaal, 
Netherlands). Fructose was administered by adding 20% fructose (wt/vol) to the drinking 
water. In study 2, 21-week-old wild-type (n=18) and Angptl4-/- mice (n=22) received the same 
diet (formula 58V8 manufactured by TestDiet, St. Louis, USA, sterilized with γ-irradiation 
at 18-50kGy) as in study 1 for 18 weeks. The fat source of this diet was also replaced by 
safflower oil. A mixture of broad-spectrum antibiotics was provided in the drinking water 
(1g/l Ampicillin, 1g/l Neomycin sulphate and 0.5g/l Metronidazole). Bodyweight and food 
intake were assessed weekly in both studies. 
At the end of each study, mice were anesthetized using isoflurane and blood was collected 
by orbital puncture. Mice were sacrificed via cervical dislocation after which tissues were 
excised and weighed and intestinal content was sampled. Animal experiments were approved 
by the local animal ethics committee of Wageningen University. 
Plasma measurements
Plasma was collected in EDTA-coated tubes and spun down for 15 minutes at 3000 rpm to 
obtain plasma. Plasma concentration of serum amyloid A was measured with a kit from Life 
technologies (Bleiswijk, Netherlands). Plasma triglyceride concentrations were determined 
according to the manufacturer’s instructions using a commercially available kit (HUMAN 
Diagnostics, Wiesbaden, Germany). The commercially available Limulus Amebocyte Lysate 
assay (Lonza, Walkerville, USA) was used to quantify plasma endotoxin levels.
Intraperitoneal glucose tolerance test
A glucose tolerance test was performed one week before the mice were euthanized. Mice 
were placed in clean cages without food and fructose water was replaced by tap water with 
or without the antibiotic mixture at 8.00h. After 5 hours of fasting, mice were weighed and 
a blood sample was drawn. Mice were injected intraperitoneally with glucose (0.8 g/kg 
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bodyweight) and blood was drawn at specific time points for measurement of glucose using 
Accu-chek Compact (study 1) or Glucofix Tech (study 2). 
In study 1, plasma concentrations of insulin were measured after 5 hours of fasting and 
in study 2 after 5 hours of fasting and 20 and 60 minutes after glucose injection. The insulin 
measurement was done according to manufacturer’s instructions (Crystal Chem, Downers 
Grove, USA). 
Insulin tolerance test
In study 2, an insulin tolerance test was performed 2 weeks before the mice were euthanized. 
Mice were fasted for 5 hours prior to the insulin tolerance test. During this period fructose 
water was replaced by tap water with or without the antibiotic mixture. Blood samples were 
collected from the tail vein immediately before (t=0 min) and at selected time points after 
insulin injection (0.75U/kg bodyweight). Glucose was measured using Glucofix Tech.
RNA isolation and qPCR
Total RNA was extracted using TRIzol reagent (Life technologies, Bleiswijk, Netherlands). 
RNA from mesenteric fat depots and pancreatic islets was purified using the RNeasy minikit 
(Qiagen, Venlo, The Netherlands). RNA was reverse transcribed to cDNA using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Veenendaal, the Netherlands). Changes in gene 
expression were determined by real-time PCR on a CFX384 Real-Time PCR detection system 
(Bio-Rad) by using SensiMix (Bioline, GC biotech, Alphen aan den Rijn, the Netherlands). 
The data were analyzed using the Bio-Rad CFX Manager 3.0. The housekeeping genes 36b4 
was used for normalization. Sequences of the used primers are listed in Supplemental Table 
1. 
Intestinal permeability assay
In study 2, an intestinal permeability assay was performed 3 weeks before the mice were 
euthanized. To correct for autofluorescence, blood was drawn from the tail vein prior to 
administration of fluorescein isothiocyanate (FITC)-dextran (4 kilodaltons) by oral gavage 
(600mg/kg bodyweight, 40mg/ml). After 1 hour blood was drawn, stored on ice in the dark 
and centrifuged for 15 minutes at 3000 rpm to obtain plasma. Plasma was diluted in PBS and 
fluorescent intensity was measured using a Fluorescence Spectrophotometer (Fluoroskan 
Ascent, Thermo Fisher Scientific, λex 485nm and λem 538nm). FITC-dextran concentrations 
were determined from a standard curve generated by diluting FITC-dextran in PBS. 
Cell culture
Mouse β-TC6 cell were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
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supplemented with 15% heat-inactivated FCS and 1% penicillin/streptomycin (Lonza, 
Verviers, Belgium) under 5% CO2 at 37˚C. RNA isolation was performed from cells that 
were seeded in a 24-wells plate. 
Mouse pancreatic islet isolation
Pancreatic islets were isolated from C57Bl/6 mice using Liberase TL Research Grade (Roche) 
as previously described (22). Briefly, Liberase TL was dissolved in low glucose DMEM 
(Gibco) and 2-3ml was injected into the bile duct. After incubation of the perfused pancreas 
at 37°C, the digestion was stopped by adding DMEM containing FCS. The islet suspension 
was subsequently filtered (420 μm mesh) and centrifuged using Histopaque 1077 (Sigma-
Aldrich). Islets were collected from the interphase between Histopaque 1077 and DMEM, 
and washed twice with CMRL medium (Gibco) containing 15% heat-inactivated FCS, 
11mM glucose, 0.15% NaHCO3,50 μM β-mercaptoethanol and 1% penicillin/streptomycin. 
Subsequently, pancreatic islets were collected for RNA isolation. 
LPL activity measurements 
LPL activity in mesenteric white adipose tissue was quantified using a 3H-oleic acid-labelled 
triolein substrate as previously described (23).
1H NMR spectroscopy
Short-chain fatty acids levels in the content of the cecum were measured in an Avance III 
NMR spectrometer, as previously described (24).
Western blot
Mesenteric fat pads were lysed in ice-cold Pierce IP lysis buffer (ThermoScientific) containing 
protease and phosphatase inhibitors (Roche). Lysates were centrifuged 4 times for 10min at 
13000g to remove fat droplets. 15ug of protein were loaded on a Criterion TGX gel, 8-16% 
and subsequently transferred onto a PVDF membrane using a Transblot Turbo system (Bio-
Rad). After blocking in TBS, 0.1% Tween-20 and 5% nonfat dry milk, the membranes were 
incubated overnight with a goat anti-mouse LPL antibody (25) or a rabbit anti-goat HSP90 
(Cell Signalling, #4874) antibody, both at 1:2000 dilutions. Finally, the blots were exposed to 
Enhanced Chemiluminescent substrate (Bio-Rad) for the visualization of the protein bands 
by using the ChemiDoc MP Imaging System (Bio-Rad). 
DNA extraction
In study 1, fecal samples derived from the second part of the colon were suspended in 10 
mM Tris, 1mM EDTA, 0.5% SDS and 0.2mg/ml Proteinase K (ThermoScientific, Rockford, 
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USA). After addition of 0.1-0.25mm and 4mm glass beads, buffered phenol (Invitrogen, 
Carlsbad, USA) was added and cells were lysed by mechanical disruption using a bead beater 
(MP biomedicals, Santa Ana, USA) for 3 minutes. DNA was subsequently extracted using 
phenol:chloroform:isoamylalcohol [25:24:1] (Invitrogen, Carlsbad, USA), precipitated with 
isopropanol and washed with 70% ethanol. 
In study 2, fecal samples (~15-60mg) derived from the second part of the colon were 
suspended in 500μL S.T.A.R. buffer (Roche). After addition of 0.1mm zirconia and 2.5mm 
glass beads (BioSpec, Bartlesville, USA), cells were lysed by mechanical disruption using 
a bead beater (MP biomedicals, Santa Ana, USA) for 3x1 minute. DNA was subsequently 
extracted and purified using Maxwell 16 System (Promega). In brief, homogenates (250 
μL) were transferred to a prefilled reagent cartridge (Maxwell® 16 Tissue LEV Total RNA 
Purification Kit, Custom-made, Promega). Sixteen samples were processed at the same time. 
After 30 minutes the purification process was completed and DNA was eluted in 50 μL of 
water (Nuclease free)(Promega).
16S rRNA gene sequencing 
For 16S rRNA gene sequencing DNA samples were send to the Broad Institute of MIT and 
Harvard (Cambridge, USA). Microbial 16S rRNA gene was amplified targeting the hyper-
variable region V4 using forward primer 515F (5’-GTGCCAGCMGCCGCGGTAA-3’) and 
the reverse primer 806R (5’- GGACTACHVGGGTWTCTAAT-3’). The cycling conditions 
consisted of an initial denaturation of 94°C for 3 min, followed by 25 cycles of denaturation 
at 94°C for 45 sec, annealing at 50 °C for 60 sec, extension at 72°C for 5 min, and a final 
extension at 72°C for 10 min. Sequencing was performed using the Illumina MiSeq platform 
generating paired-end reads of 175 bp in length in each direction. Overlapping paired-end 
reads were subsequently aligned. Detailed of this protocol are as previously described (26).
Raw sequence data quality was assessed using FastQC, version: 0.11.2 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Reads quality was checked with Sickle, 
version: 1.33 (https://github.com/najoshi/sickle) and low quality reads were removed. For 
visualising the taxonomic composition of the fecal microbiota and further beta diversity 
analysis, QIIME, version: 1.9.0 was used(27). In brief, closed reference OTU picking with 
97% sequence similarity against GreenGenes 13.8 reference database was done. Jackknifed 
beta-diversity of unweighted UniFrac distances with 10 jackknife replicates was measured 
at rarefaction depth of 22000 reads/sample. For statistical significance, biological relevance 
and visualisation we used linear discriminant analysis (LDA) effect size (LEfSe) method 
(https://bitbucket.org/biobakery/biobakery/wiki/lefse) (28).
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Bacterial 16S rRNA gene quantification 
Standard curves were constructed by amplifying 16S rRNA gene using fecal DNA of the 
control group using the universal 16S primers 27F (5’-GTTTGATCCTGGCTCAG-3’) and 
1492R (5’-CGGCTACCTTGTTACGAC-3’). The cycling conditions consisted of an initial 
denaturation of 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 sec, 
annealing at 52°C for 40 sec and extension at 72°C for 90 sec and a final extension at 72°C for 
7 min. Amplicon size was verified by agarose gel electrophoresis and amplicon was purified 
using a commercial available PCR purification kit (ThermoScientific). After the DNA 
concentration was quantitated and copy number was calculated, a serial dilution ranging 
from 108 to 101 16S rRNA gene copies/μl was generated. 
Real-time PCR for the 16S rRNA gene was performed using fecal DNA samples 
from study 2 and standards on a CFX384 Real-Time PCR detection system (Bio-
Rad Laboratories, Veenendaal, Netherlands) with SensiMix (Bioline, GC biotech, 
Alphen aan den Rijn, Netherlands). 16S rRNA gene was amplified using the forward 
primer 1369F (5’-CGGTGAATACGTTCYCGG-3’)(29) and the reverse primer 1492R 
(5’-GGWTACCTTGTTACGACTT-3’)(30). The cycling conditions consisted of an initial 
denaturation of 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 15 sec, 
annealing at 60 °C for 30 sec and extension at 72°C for 30 sec. The data were analyzed using 
the Bio-Rad CFX Manager 3.0.
Statistics
Data are presented as mean ± SEM, unless otherwise indicated. Statistical analysis were 
performed using an unpaired Student’s t-test or two-way analysis of variance followed by a 
Bonferroni test for post-hoc analysis. (GraphPad Software, Inc., La Jolla, USA). P<0.05 was 
considered as statistically significant. 
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Results
To elicit a phenotype that includes (visceral) obesity, insulin resistance and NAFLD/
NASH, wild-type and Angptl4-/- mice were fed a high fat diet rich in unsaturated fatty acids 
complemented with fructose and cholesterol (24, 31, 32). In contrast to feeding Angptl4-/- 
mice a diet rich in saturated fatty acids, feeding a diet rich in unsaturated fatty acids did 
not significantly raise plasma serum amyloid A concentrations (Figure 1A). Angptl4-/- mice 
gained more weight and had a higher visceral (mesenteric) fat mass compared to wild-type 
mice, despite having a similar level of food intake (Figure 1B-C). In accordance with the 
function of ANGPTL4 as LPL inhibitor, LPL activity and the amount of LPL was significantly 
higher in the mesenteric white adipose tissue of Angptl4-/- mice as compared to wild-type 
mice (Figure 1E, F). In addition, plasma triglyceride levels were significantly lower in 
the Angptl4-/- mice than in the wild-type mice (Figure 1G). Consistent with the increased 
bodyweight and elevated mesenteric fat pad weight, Angptl4-/- mice displayed increased 
inflammation in mesenteric adipose tissue as compared to wildtype mice, as revealed by the 
higher expression of several inflammatory genes (Figure 1H). 
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Figure 1. ANGPTL4 protects against diet-induced obesity and reduces adipose tissue inflammation 
(A) Plasma serum amyloid A concentration. (B) Bodyweight gain of wild-type (WT) and Angptl4-/- mice 
at the end of the dietary intervention. (C) Mesenteric white adipose tissue (mWAT) weight. (D) Average 
food intake per mouse per day during dietary intervention. (E) LPL activity and (F) LPL protein levels 
in mWAT homogenates. (G) Plasma triglyceride levels. (H) Relative expression of inflammatory genes in 
mWAT. Gene expression levels of WT mice were set at 1. Data are presented as mean ± SEM. Asterisks 
indicate significant differences according to a Student’s t-test. *p<0.05 **p<0.001. 
Loss of ANGPTL4 uncouples visceral obesity from glucose intolerance
247
9
Loss of ANGPTL4 leads to improved glucose tolerance
Strikingly, despite the higher visceral adipose tissue mass and inflammation, blood glucose 
levels during a glucose tolerance test were markedly lower in the Angptl4-/- mice than in wild-
type mice (Figure 2A). The lower glucose levels in the Angptl4-/- mice were accompanied 
by elevated fasting plasma insulin levels (Figure 2B). These data suggest Angptl4-/- mice are 
more glucose tolerant than wild-type mice, possibly due to higher plasma insulin levels. 
When exploring the potential origin of the elevated plasma insulin levels in the Angptl4-/- 
mice, we considered the possibility that ANGPTL4 may be expressed in pancreatic islets, 
together with LPL, and thereby influence insulin secretion. LPL has been proposed as a 
mediator of the effect of dietary lipids on insulin secretion (33). However, whereas the 
expression of Lpl was relatively high in primary pancreatic islets and in the β-cell line beta-
TC6, with Ct values of ~21-22, Angptl4 expression was very low, showing Ct values of ~30.5-
32 (Figure 2C). Hence, the effect of ANGPTL4 on glucose tolerance is unlikely to be mediated 
via ANGPTL4 produced in β-cells. BIOGPS supports the minimal expression of Angptl4 in 
the mouse pancreas (http://biogps.org/) . Furthermore, analysis of a number of microarray 
datasets of mouse pancreatic islets (GSE43620), the β-cell line bTC3 (GSE31102), β-cells from 
adult mice (GSE54374), and human islets (Dr. Eelco de Koning, personal communication) 
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(A) Intraperitoneal glucose tolerance and areas under the curve (AUC) of wild-type (WT) and Angptl4-/- 
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verified the minimal expression of ANGPTL4 in pancreatic islets and β-cells. 
The above data do not exclude a role of circulating ANGPTL4 in the regulation 
of islet LPL. However, upregulation of LPL activity in β-cells has been shown to lead to 
hyperglycemia during a glucose tolerance test (34). Accordingly, it is unlikely that the 
observed hypoglycaemia and hyperinsulinemia in Angptl4-/- mice are linked to loss of 
inhibition of LPL activity in islet cells, whether via ANGPTL4 produced in the pancreas 
or elsewhere. Together, these findings suggest that ANGPTL4 probably does not influence 
plasma insulin levels via a direct effect on insulin secretion in pancreatic islets.
Loss of ANGPTL4 alters levels of gut-derived metabolites and changes gut 
microbial composition
Considering that the gut microbiota have been suggested to influence insulin secretion (35–
37), and since ANGPTL4 has been suggested to link changes in gut microbial composition 
to host metabolism (38, 39), we hypothesized a potential role of the gut microbiota. To 
explore the possibility that Angptl4-/- mice may carry a different gut microbiota, we first 
measured the levels of several gut-derived metabolites, including luminal short-chain fatty 
acids and succinate and plasma LPS. In the cecum, the concentration of the short-chain 
fatty acid butyrate was significantly lower in the Angptl4-/- mice as compared to the wild-
type mice (Figure 3A). Moreover, in the colon, levels of both propionate and butyrate were 
significantly lower and levels of succinate were significantly higher in the Angptl4-/- mice 
(Figure 3A). Also, plasma LPS levels were higher in the Angptl4-/- mice than in the wild-
type mice, even though intestinal permeability measured using FITC-dextran was similar 
(Figure 3B-C). Together, these alterations in gut-derived metabolites suggest a potential 
difference in gut microbiota composition between the Angptl4-/- and wild-type mice.
To further examine the gut microbiota in the wild-type and Angptl4-/- mice, we performed 
16S rRNA sequencing. Principle coordinate analysis of unweighted UniFrac distance 
demonstrated a significant clustering of microbiome sequences of Angptl4-/- and wild-type 
mice (Figure 3D). The majority of the difference in bacterial community between Angptl4-/- 
and wild-type mice can be explained by the phyla Actinobacteria and Firmicutes. Indeed, only 
small non-significant differences were observed within the phyla Bacteroidetes, Deferribacteres 
and Proteobacteria. The phylum Actinobacteria was 2.5-fold more abundant in the Angptl4-/- 
mice, which was mainly accounted for by a significant increase in the genus Adlercreutzia. 
Although the relative abundance of the phylum Firmicutes was comparable between the 
genotypes, the genera Lactobacillus and SMB53 were overrepresented in the Angptl4-/- mice, 
whereas the genus Allobaculum was more abundant in the wild-type mice (Figure 3E-G, 
Supplemental Table 2). Overall, these data indicate that the gut bacterial composition is 
significantly different between Angptl4-/- and wild-type mice.
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Figure 3. ANGPTL4 alters levels of gut-derived metabolites and changes gut microbial composition
(A) Concentration of acetate, propionate, butyrate and succinate in the cecum and colon of wild-type 
(WT) and Angptl4-/- mice. (B) LPS levels in plasma of WT and Angptl4-/- mice. (C) Intestinal permeability 
as assessed by plasma FITC-dextran concentration 1 hour after oral administration. (D) Principle 
coordinates analysis plot and boxplots of unweighted UniFrac distances of the intestinal microbiota. Mean 
relative abundance of the colonic bacteria (E) at phylum level and (F) to the lowest identifiable level. The 
letter preceding the underscore indicates the taxonomic level: o, order; f, family; g, genus; s, species. (G) 
Cladogram generated from LEfSe analysis displaying bacterial taxa significantly enriched in WT (green) or 
Angptl4-/- (red) mice. The domain bacteria is depicted by the central point and each ring represents the next 
lower taxonomic level (phylum to genus). Data are presented as mean ± SEM. Asterisks indicate significant 
differences according to a Student’s t-test. *p<0.05 **p<0.001. 
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Suppression of the gut bacteria abolishes the increase in glucose tolerance in 
Angptl4-/- mice
To further study the role of the gut microbiota in mediating the effect of loss of ANGPTL4 on 
glucose tolerance, we repeated the diet-induced obesity study in wild-type and Angptl4-/- mice 
with or without the addition of antibiotics in their drinking water. As shown previously (24), 
antibiotic supplementation significantly reduced the number of 16S rRNA gene copies in the 
feces (Figure 4A) and caused a marked increase in cecum weight (Figure 4B), indicating an 
effective suppression of the gut bacteria. 
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Figure 4. Antibiotics largely abolish the difference in adipose tissue inflammation between wild-type 
and Angptl4-/- mice
(A) 16S rRNA gene copies per gram feces of wild-type (WT) and Angptl4-/- mice fed the high fat/high 
cholesterol/high fructose diet with or without antibiotics supplementation. (B) Weight of the cecum and 
representative pictures of the cecum. (C) Bodyweight gain of wild-type (WT) and Angptl4-/- mice at the end 
of the dietary intervention. (D) Mesenteric white adipose tissue (mWAT) weight. Relative mRNA levels 
of Angptl4 in the (E) ileum or (F) mWAT. (G) Relative expression of inflammatory genes in mWAT. Gene 
expression levels of WT mice fed the CTRL diet were set at 1. Data are presented as mean ± SEM. Asterisks 
indicate significant differences compared to WT or between groups as indicated by bars according to two-
way ANOVA with Bonferroni post-hoc test. *p<0.05 **p<0.001. 
Loss of ANGPTL4 uncouples visceral obesity from glucose intolerance
251
9
Although antibiotic supplementation reduced overall bodyweight gain, Angptl4-/- mice 
still gained more bodyweight as compared to wild-type mice (Figure 4C). In agreement 
with the first study, in the absence of antibiotics, Angptl4-/- mice had elevated mesenteric 
fat pad weight at the end of the dietary intervention. Surprisingly, after antibiotic treatment 
mesenteric fat mass was not significantly different anymore between Angptl4-/- mice and wild-
type mice (Figure 4D). Interestingly, in the wild-type mice, antibiotics treatment increased 
Angptl4 mRNA levels in the ileum but not the mesenteric adipose tissue, suggesting a 
suppressive effect of the gut bacteria on intestinal Angptl4 expression (Figure 4E-F).
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Figure 5. Antibiotics largely abolish the difference in glucose tolerance between wild-type and Angptl4-/- 
mice
(A) Intraperitoneal glucose tolerance and areas under the curve (AUC) of wild-type (WT) and Angptl4-/- 
mice fed the high fat/high cholesterol/high fructose diet with or without antibiotics supplementation. (B) 
Plasma insulin levels and corresponding AUC during the glucose tolerance test. (C) Blood glucose levels 
as percentage of baseline during an insulin tolerance test. Data are presented as mean ± SEM. Asterisks 
indicate significant differences compared to WT or between groups as indicated by bars according to a 
Student’s t-test or two-way ANOVA with Bonferroni post-hoc test. *p<0.05 **p<0.001.
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Concurrent with the elevated fat mass, the expression of several inflammatory genes, 
including Cd68, Mcp-1, Il-6 and Il-1ra, was elevated in Angptl4-/- mice as compared to 
wild-type mice in the absence of antibiotics. However, in the presence of antibiotics these 
differences in adipose tissue inflammation between the genotypes were largely abolished 
(Figure 4G), suggesting that the elevated fat mass and subsequent increase in adipose tissue 
inflammation in Angptl4-/- mice is partly dependent on the gut bacteria.
Consistent with the data presented in Figure 2A, blood glucose levels during a glucose 
tolerance test were significantly lower in  Angptl4-/- mice than in wild-type mice (Figure 
5A). Suppression of the gut bacteria using antibiotics in part abolished the differences in 
blood glucose levels between the two sets of mice, suggesting a role for the gut microbiota 
in mediating the effect of loss of ANGPTL4 on glucose tolerance. The lower glucose levels in 
the Angptl4-/- mice were accompanied by higher plasma insulin levels (Figure 5B). However, 
an insulin tolerance test did not reveal any difference between Angptl4-/- and wild-type mice 
(Figure 5C), irrespective of the antibiotics treatment (Figure 5C). Overall, our findings 
suggest that loss of ANGPTL4 promotes (visceral) obesity but, by raising insulin levels, 
improves glucose intolerance, which is partly mediated via a mechanism dependent on the 
gut bacteria. 
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Discussion
In the present study we investigated the role of ANGPTL4 in metabolic dysfunction in diet-
induced obese mice. Consistent with the known biological functions of ANGPTL4 (13, 14, 17, 
20), Angptl4-/- mice gained more weight, had elevated fat mass, displayed increased adipose 
LPL activity and LPL protein abundance, and had lower plasma triglyceride levels compared 
to wild-type mice. Unexpectedly, despite these changes, mice lacking ANGPTL4 had 
improved glucose tolerance. Interestingly, suppression of the gut bacteria using antibiotics 
largely abolished the increased glucose tolerance in Angptl4-/- mice as compared to wild-type 
mice. Together, our results indicate that loss of ANGPTL4 uncouples visceral obesity from 
glucose intolerance partly via a mechanism dependent on the gut microbiota. 
In contrast to the well-established role of ANGPTL4 in lipid metabolism, much less is 
known about the impact of ANGPTL4 on glucose metabolism. Previously, we found that 
mice overexpressing Angptl4 have impaired glucose tolerance and reduced peripheral insulin 
sensitivity (15). Conversely, Angptl4-/- mice fed a high (saturated) fat diet were reported to 
have improved glucose tolerance (40), although these data were likely confounded by the 
development of an acute phase response and chylous ascites and peritonitis (20). Our present 
data indicate that, despite being heavier, mice lacking ANGPTL4 also have improved glucose 
tolerance when fed a high fat diet rich in unsaturated fatty acids, which does not trigger a 
pro-inflammatory response, as shown by the lack of elevation of plasma serum amyloid A in 
the Angptl4-/- mice. Interestingly, recently it was reported that Angptl4-/- mice fed chow have 
impaired glucose tolerance (41). Similarly, in a previous study, we found that Angptl4-/- mice 
fed a low fat diet have impaired glucose tolerance ((20), unpublished data). However, in the 
latter study, the impaired glucose tolerance was probably due to the more rapid weight gain 
in the Angptl4-/- mice. In human subjects, plasma ANGPTL4 levels appear to be positively 
correlated with fasting blood glucose levels (42), which may hint at a detrimental effect of 
ANGPTL4 on glucose tolerance in humans.
We found that the improvement in glucose tolerance in the Angptl4-/- mice was 
accompanied by elevated insulin levels and not by increased insulin sensitivity, suggesting 
that the lower plasma glucose levels are probably caused by increased insulin secretion. Since 
lipids can potentiate insulin secretion of pancreatic β-cells (33, 43, 44), we hypothesized that 
the increased insulin levels in the Angptl4-/- mice may be due to increased lipid uptake in 
β-cells as a result of loss of LPL inhibition. Interestingly, LPL does not appear to be localized 
on the cell surface but primarily within the pancreatic β-cells (45),  implying that β-cell LPL 
may not be involved in lipid uptake. Furthermore, mice with β-cell-specific overexpression 
of LPL and a concomitant increase in LPL activity were hyperglycemic during a glucose 
tolerance test (34). Paradoxically, a similar phenotype was observed in β-cell-specific LPL 
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knock-out mice (34). Accordingly, it is difficult to assess the potential role of β-cell LPL in 
conferring the effect of loss of ANGPTL4 on glucose tolerance and insulin secretion. In any 
case, the effects of loss of ANGPTL4 on glucose tolerance are unlikely to be mediated by 
ANGPTL4 produced in β-cells, as we and others found that Angptl4 is minimally expressed 
in pancreatic islets and β-cells (41). 
Intriguingly, human genetic studies do suggest a link between LPL and glucose 
metabolism. Specifically, a gain-of-function variant in LPL in humans was found to be 
associated with higher insulin sensitivity, lower fasting glucose, and lower risk of type 2 
diabetes (46). Conversely, a loss-of-function variant in LPL was found to be associated with 
a higher risk of type 2 diabetes (46). Whether these effects are specifically connected to LPL 
in β-cells, the hypothalamus, or elsewhere, remains unclear. 
Our data suggest that the effects of loss of ANGPTL4 on glucose tolerance are at least 
partly dependent on the gut microbiota. There is growing evidence that alterations in the gut 
microbiota composition can modulate insulin sensitivity (38, 47–49) and insulin secretion 
(35–37). For example, it has been shown that germ-free mice and mice treated with antibiotics 
have an improved insulin sensitivity as compared to conventionally-raised or untreated 
mice (47–49). Furthermore, it has been demonstrated that the difference in insulin secretion 
between different mouse strains could largely be recapitulated via microbial transfer (35). 
In human subjects, transfer of the fecal microbiota from lean donors to recipients with the 
metabolic syndrome was found to increase insulin sensitivity (50). 
One microbial family that has been shown to have a strong positive correlation with plasma 
insulin levels is Clostridiaceae (35). Interestingly, we found a higher relative abundance 
of Clostridiaceae in the colon of Angptl4-/- mice, concurrent with elevated plasma insulin 
levels. However, because certain Clostridiaceae family members also positively correlate 
with obesity and other metabolic perturbations (51, 52), it is difficult to link Clostridiaceae 
specifically to insulin secretion in our study. Interestingly, in human subjects ingestion of 
a specific Lactobacillus strain, L. reuteri, for four weeks improved glucose-induced insulin 
secretion (37). In our study, Lactobacillus was—with a relative abundance of 15.82%—almost 
2-fold more abundant in the colon of the Angptl4-/- mice as compared with the wild-type 
mice. It can thus be speculated that the increase in Lactobacillus might contribute to the 
elevated insulin levels in Angptl4-/- mice. 
Several mechanisms have been suggested by which the gut microbiota may affect glucose 
metabolism, including via altered production of short-chain fatty acids and LPS. Short-
chain fatty acids have been suggested to promote insulin secretion via several mechanisms, 
including the intestinal GPCR43 receptor, either dependent (53) or independent of GLP-1 
secretion (54). In addition, evidence was provided that acetate produced by the gut microbiota 
may increase glucose-stimulated insulin secretion via activation of the parasympathetic 
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nervous system (55). We observed that the improved glucose tolerance in Angptl4-/- mice was 
associated with lower short-chain fatty acids levels, suggesting that the improved glucose-
stimulated insulin secretion can probably not be attributed to short-chain fatty acids. Of 
note, short-chain fatty acid fluxes, rather than concentrations, have been found to correlate 
with several metabolic markers. For this reason, measurement of short-chain fatty acid 
fluxes is more valuable to understand the role of short-chain fatty acids in host metabolism 
(56). 
Another potential candidate that may link the gut microbiota to glucose tolerance is LPS. 
In our study, elevated plasma insulin levels in the Angptl4-/- mice were associated with higher 
levels of circulating LPS. However, conflicting results have been reported regarding the 
role of LPS in insulin secretion. Whereas Amyot et al. reported that LPS attenuates insulin 
secretion (57), Nguyen et al. found that LPS stimulates insulin secretion (58). Another study 
reported that LPS does not affect plasma insulin levels (47), rendering it difficult to link 
the higher LPS levels in the Angptl4-/- mice to the elevated plasma insulin levels. Hence, 
short-chain fatty acids and LPS are probably not involved in conferring the effect of the gut 
bacteria on insulin levels in Angptl4-/- mice. 
Interestingly, in our study we found an increased abundance of equol-producing bacteria, 
including Adlercreutzia, Lactobacillus and Coriobacteriaceae (59). As equol improves 
glucose tolerance (60), it may be hypothesized that the improved glucose tolerance in the 
Angptl4-/- mice may be related to altered production of equol. However, future studies should 
investigate the role of equol and other potential candidates that may mediated the effects of 
the gut microbiota on insulin levels and glucose tolerance. 
In our study, we suppressed the gut bacteria by adding broad-spectrum antibiotics to 
the drinking water. Although treating mice with antibiotics is a commonly used strategy 
to investigate whether the gut bacteria influence host metabolism, it is important to note 
that antibiotics also possess direct immunomodulatory properties and may influence 
mitochondrial function (61, 62). 
Bäckhed and colleagues suggested that intestinal ANGPTL4 mediates the stimulatory 
effects of the gut microbiota on fat storage (38, 39). Although our results are consistent with 
their studies showing that the gut bacteria suppress Angptl4 expression in the intestine but 
not in the adipose tissue (38, 39), we did not observe that the effect of the microbiota on 
mesenteric fat storage is mediated by ANGPTL4. Specifically, we only observed a stimulatory 
effect of the gut microbes on mesenteric fat mass in mice lacking ANPGTL4. Future studies 
using intestinal-specific Angptl4-/- mice should shed more light on the link between intestinal 
ANGPTL4 and fat storage. 
In conclusion, we show that loss of ANGPTL4 in diet-induced obese mice promotes 
visceral obesity, while improving glucose tolerance. Suppression of the gut bacteria by 
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antibiotics largely abolished the difference in glucose tolerance between the wild-type 
and Angptl4-/- mice, suggesting that ANGPTL4 influences glucose tolerance partly via a 
mechanism dependent on the gut bacteria. 
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Supplemental tables
Supplemental table 1. Primer sequences used for qPCR
 Primer Sequence  
Name Forward Reverse 
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mCd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
mF4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
mMcp-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
mIl-6 CTTCCATCCAGTTGCCTTCTTG AATTAAGCCTCCGACTTGTGAAG 
mIl-1ra AAATCTGCTGGGGACCCTAC TGAGCTGGTTGTTTCTCAGG 
mLPL CAGCTGGGCCTAACTTTGAG GACCCCCTGGTAAATGTGTG 
mAngptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG 
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Supplemental table 2. Relative abundance of microbiota in colonic luminal content
 
Phylum Class Order Family Genus Species Wild-type (%) Angptl4 -/-  (%) FC P-value*
Actinobacteria 0.67 1.68 2.5 0.004
Coriobacteriia 0.67 1.68 2.5 0.004
Coriobacteriales 0.67 1.68 2.5 0.004
Coriobacteriaceae 0.67 1.68 2.5 0.004
Adlercreutzia 0.67 1.68 2.5 0.004
Bacteroidetes 4.61 5.86 1.3 ns
Bacteroidia 4.61 5.86 1.3 ns
Bacteriodales 4.61 5.86 1.3 ns
Unidentified 2.04 2.46 1.2 ns
Bacteroidaceae 0.95 1.14 1.2 ns
Bacteroides 0.95 1.14 1.2 ns
S24-7 1.61 2.26 1.4 ns
Unidentified 1.61 2.26 1.4 ns
Deferribacteres 4.67 4.26 -1.1 ns
Deferiibacteres 4.67 4.26 -1.1 ns
Deferribacterales 4.67 4.26 -1.1 ns
Deferribacteraceae 4.67 4.26 -1.1 ns
Mucispirillum 4.67 4.26 -1.1 ns
Mucispirillum schaedleri 4.67 4.26 -1.1 ns
Firmicutes 84.95 82.24 -1.0 ns 
Bacilli 8.82 15.82 1.8 0.023
Lactobacillales 8.82 15.82 1.8 0.023
Lactobacillaceae 8.82 15.82 1.8 0.023
Lactobacillus 8.82 15.82 1.8 0.023
Clostridia 29.88 46.49 1.6 0.011
Clostridiales 29.88 46.49 1.6 0.011
Unidentified 19.04 23.21 1.2 ns
Clostridiaceae 3.84 14.19 3.7 0.001
Unidentified 0.00 1.97 >2000 <0,001
SMB53 3.84 12.22 3.2 0.001
Lachnospiraceae 2.22 1.61 -1.4 ns
Unidentified 2.22 1.61 -1.4 ns
Ruminococcaceae 4.78 7.49 1.6 ns
Unidentified 0.90 3.67 4.1 ns
Oscillospira 3.23 3.15 1.0 ns
Ruminococcus 0.64 0.66 1.0 ns
Erysipelotrichi 46.25 19.93 -2.3 0.016
Erysipelotricales 46.25 19.93 -2.3 0.016
Erysipelotrichaceae 46.25 19.93 -2.3 0.016
Allobaculum 46.25 19.93 -2.3 0.016
Proteobacteria 5.09 5.96 1.2 ns
Deltaproteobacteria 5.09 5.96 1.2 ns
Desulfovibrionales 5.09 5.96 1.2 ns
Desulfovibrionaceae 5.09 5.96 1.2 ns
Bilophila 2.84 4.09 1.4 ns
Desulfovibrio 2.26 1.87 -1.2 ns
Abundance treshold for presentation in the table >0.5% in at least one of the two genotypes
* significance according to unpaired Wilcoxon rank-sum test 
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Everyday researchers are looking for potential mechanisms to reduce or at least stop the 
increasing prevalence of obesity and related metabolic diseases. To be able to develop effective 
treatment and prevention strategies, better understanding the underlying mechanisms and 
factors contributing to these metabolic diseases is of utmost importance. 
Therefore, the aim of this thesis was to increase our understanding regarding the role of 
various mediators in metabolic health, with a special focus on the gut microbiota, bile acids, 
and ANGPTL4. To comprehensively elucidate the role of these mediators, we pursued a 
number of approaches, including the use of mice with an altered gut microbial composition, 
mice lacking Angptl4, and an ex vivo model to study the liver. In the previous chapters we 
demonstrated that the gut microbiota, bile acids, and ANGPTL4 influence various aspects 
of metabolic health. 
The main outcomes of this thesis were:
• In Chapter 4, we showed that the gut microbiota are causally involved in the pathogenesis 
of non-alcoholic fatty liver disease (NAFLD), likely mediated by alterations in portal 
delivery of bile acids.
• In Chapter 5, we demonstrated that the mucin-degrading bacteria A. muciniphila and 
B. thetaiotaomicron do not influence features of NAFLD in an obese model of NAFLD. 
• In Chapter 6 and Chapter 7, we demonstrated the suitability of precision-cut liver slices 
to study the human liver by using agonists of the nuclear receptors PPARα and FXR. 
• In Chapter 8, we switched to ANGPTL4 and investigated whether ANGPTL4 may be 
responsible for the triglyceride-lowering effect of bile acids. Although we find that the 
triglyceride-lowering effect of bile acids is not mediated by ANGPTL4, we uncover a 
novel function of ANGPTL4 in regulating bile acid reabsorption.
• In Chapter 9 we studied the effects of ANGPTL4 in diet-induced obesity, where we 
reveal a new role for ANGPTL4 in regulating glucose metabolism. 
The role of intestinal microbiota in metabolic disorders
In the last two decades, the intestinal microbiota have been increasingly linked to obesity 
and metabolic diseases, such as type 2 diabetes, NAFLD, and cardiovascular disease (1–5). 
However, as discussed in Chapter 2 and Chapter 3, many of these studies are associative 
and do not discriminate whether changes in gut microbiota causally contribute to metabolic 
disease or are merely a consequence of the metabolic disturbances. 
Intestinal microbiota and NAFLD
The liver receives about 70% of its blood supply from the gut via the portal vein and is 
therefore the first organ that is exposed to potential harmful gut-derived factors. Alterations 
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in gut microbial composition and function may therefore also influence liver physiology. 
Indeed, many studies hint at the possibility that disturbances in the gut microbiota are 
linked to NAFLD (6–9). However, the number of studies providing direct causal evidence is 
limited and use methods to induce liver injury that do not encompass all features of NAFLD 
in humans, including obesity, insulin resistance, steatohepatitis and fibrosis (10–16). In 
Chapter 4, we show that feeding mice a diet rich in fat, cholesterol and fructose induces all 
features of NAFLD and therefore represents a suitable model to study NAFLD. Accordingly, 
we show that stimulation of the gut microbiota promotes the progression of NAFLD, while 
suppression of the gut microbiota using antibiotics attenuates hepatic inflammation and 
fibrosis. The effects of the gut microbiota on NAFLD were found to be mediated by changes 
in the portal delivery of bile acids (Figure 1). Although these data clearly point to a causal 
role of the gut microbiota in NAFLD, several aspects require further investigation. 
Hepatic inammation
and brosis
Guar gum
Altered 
intestinal microbial
composition
Portal delivery 
of bile acids
Hepatic inammation
and steatosis
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Suppression
of the intestinal
bacteria
Portal delivery 
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Figure 1. The intestinal microbiota impacts hepatic inflammation and fibrosis via changes in the portal 
delivery of bile acids
Stimulation of the gut microbiota using the highly fermentable dietary fiber guar gum enhanced hepatic 
inflammation and fibrosis, concurrent with elevated portal delivery of bile acids. By contrast, suppression of 
the gut bacteria using antibiotics reduced portal delivery of bile acids and attenuated hepatic inflammation 
and fibrosis. Suppression of the intestinal bacteria did not influence hepatic steatosis. 
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First, the lack of an effect of the antibiotics treatment on hepatic steatosis is highly 
intriguing (Chapter 4). Although we did find that the stimulation of the gut microbiota 
using guar gum reduced hepatic steatosis, this effect is likely a consequence of the lower 
bodyweight and is not due to changes in the gut microbiota. These data therefore imply 
that the gut microbiota are only involved in the more advanced stages of NAFLD, including 
hepatic inflammation and fibrosis, but not in hepatic steatosis perse. However, several 
studies do report an effect of the gut microbiota in hepatic steatosis (12, 15, 17). One 
possibility for this discrepancy may be the difference in intestinal microbial composition 
and/or function between the different studies. Indeed, the composition of the gut microbiota 
is influenced by many factors, including diet, age, gender, and genome (18–20), and can also 
vary substantially between different animal facilities (21). Consequently, the metabolites 
produced and released by the microbiota may be different, resulting in different effect on 
the liver. For example, Bergheim et al. found that hepatic steatosis was associated with an 
increased translocation of lipopolysaccharide (LPS) to the portal vein (12), whereas in our 
study plasma LPS levels were not different upon antibiotic treatment or guar gum feeding. 
Additionally, a difference is intestinal microbial composition may also indirectly influence 
hepatic steatosis, as the gut microbiota have also been reported to influence hepatic steatosis 
via intestinal FXR-mediated induction of ceramides (14). Despite the difference in microbial 
composition, it would be of great interest to identify the bacterial species responsible for 
the effects on NAFLD, which would allow for a better comparison of studies with different 
outcomes. Moreover, apart from the colonic microbiota, the study of the bacteria located 
in the small intestine in NALFD also warrants further investigation, as small intestinal 
bacterial overgrowth is increasingly linked to the pathogenesis of NAFLD (22, 23). 
Secondly, of particular importance is the mechanism by which the microbiota-mediated 
changes in bile acids induce NAFLD. In three independent studies we have demonstrated 
that bile acids influence the pathogenesis of NAFLD, but the mechanism underlying this 
effect is not exactly clear (Chapter 4). While we hypothesize that the increased portal 
delivery of bile acids promotes liver injury and subsequently hepatic inflammation and 
fibrosis, we cannot exclude a role for the nuclear receptor FXR. FXR is abundantly expressed 
in the liver and intestine and is thought to be the master regulator of bile acid metabolism. 
Indeed, mice lacking FXR have impaired bile acid synthesis, biliary bile acid secretion, and 
intestinal and hepatic uptake of bile acids (24, 25). Interestingly, FXR knockout mice also 
display hepatic inflammation and spontaneously develop hepatocellular carcinomas (26–
28). Consistent with a suppressive effect of FXR on inflammation, activation of the FXR 
receptor using synthetic FXR ligands, including bile acid derivatives, was demonstrated to 
attenuate hepatic inflammation and fibrosis in animal models of NASH (29, 30). In fact, 
FXR agonists are currently under investigation in several clinical trials for the treatment 
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of patients with NAFLD (31). In our study, based on the expression of FXR-target genes in 
the liver and ileum, the increase hepatic inflammation and fibrosis upon guar gum feeding, 
was associated with increased FXR activation in the liver but reduced FXR activation in 
the ileum (Chapter 4). It could therefore be hypothesized that hepatic inflammation and 
fibrosis in mice fed guar gum is linked to the reduced activation of FXR specifically in the 
ileum. Indeed, inhibition of intestinal FXR by Tβ-MCA has been suggested to promote 
NAFLD (14). If the stimulation of NAFLD by bile acids is independent of FXR, then the 
question remains whether one bile acid in particular induces liver injury or whether the liver 
injury may be caused by the hepatic accumulation of the bile acids as a group. However, it is 
possible that the mechanism underlying the bile-acid induced NAFLD involves both FXR 
and intrahepatic accumulation of cytotoxic bile acids. To gain further insight, ideally an 
elaborate experiment should be performed using targeted deletion of enzymes involved in 
the production of the different bile acids species in the liver and the gut. In addition, studies 
using FXR knockout mice may also be helpful to understand underlying mechanisms.
 
Administration of specific bacterial species to treat NAFLD 
The observation that the gut microbiota are causally involved in the development of NAFLD 
led us to hypothesize that targeting the gut microbiota may provide therapeutic tools to treat 
NAFLD (Chapter 4). In addition to bile acids, impairment of the intestinal barrier is also 
suggested to mediate the effects of the gut microbiota on NAFLD (9, 32). Recently, Rahman 
et al. demonstrated that mice with an impaired intestinal barrier develop more severe 
non-alcoholic steatohepatitis. Importantly, depletion of the gut bacteria using antibiotics 
abolished the difference in hepatic inflammation and fibrosis (33), further confirming an 
important role for the gut microbiota and their metabolites in NAFLD. 
Therefore, in Chapter 5, we aimed to attenuate NAFLD in an obese mouse model of 
NAFLD by administrating bacterial species that have been suggested to improve the 
intestinal barrier, namely Akkermansia muciniphila and Bacteroides thetaiotaomicron. A. 
muciniphila and B. thetaiotaomicron are both gram-negative anaerobic bacteria that are 
able to degrade mucins in the mucus layer. As a result, mucin synthesis is stimulated and 
thinning of the mucus layer may be prevented (34–36). We found that daily administration 
of A. muciniphila and B. thetaiotaomicron for 5 weeks to mice with NAFLD did not alter 
intestinal permeability or features of NAFLD (Chapter 5). Although these data imply that 
A.muciniphila and B. thetaiotaomicron are not promising therapeutics to treat NAFLD, 
several aspects of this study merit consideration.
First of all, B. thetaiotaomicron was not able to colonize the colon after five weeks 
daily B. thetaiotaomicron administration (Chapter 5). Since B. thetaiotaomicron has been 
shown to very efficiently colonize the gastrointestinal tract of germ-free mice (37), it may 
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be hypothesized that B. thetaiotaomicron is rejected by the commensal microbiota, thereby 
limiting the effect of B. thetaiotaomicron on intestinal permeability. Developing strategies 
to improve the establishment of B. thetaiotaomicron in the recipients’ gastrointestinal 
tract, should clarify whether B. thetaiotaomicron indeed has no effect on at least intestinal 
permeability or whether the results are explained by lack of effective colonization. 
Secondly, in contrast to the standard high fat diet, the diet that we used also contains 
cholesterol and fructose, leading to a more advanced form of NAFLD (Chapter 4). Although 
A. muciniphila effectively colonized the colon, it is conceivable that the effect of diet on 
NAFLD overrules the potential effect of A. muciniphila on NAFLD. Alternatively, as the 
abundance of A. muciniphila increases upon bodyweight loss (38, 39), the decrease in 
bodyweight of all groups upon the start of the oral gavages (Chapter 5) might already have 
caused an increase in the abundance of A. muciniphila. Consequently, it may be possible that 
the relatively small increase in A. muciniphila abundance in the control group during the 
first week of oral gavages already influenced metabolic health of the host and that a further 
increase in A. muciniphila abundance did not have an additional effect. To avoid the potential 
interference caused by the frequent oral gavages, future studies should investigate how often 
A. muciniphila needs to be administered to effectively colonize the colon. Additionally, one 
could start with weekly oral gavages containing PBS at the start of the dietary intervention, 
in order to avoid a stress response at the start of the A. muciniphila administration. 
Limitations and future perspectives of studying the gut microbiota
As already briefly mentioned, there is considerable controversy with respect to whether 
and how the gut microbiota influence metabolic health. For example, several studies have 
provided evidence that the gut microbiota are causally involved in the development of obesity 
(40–42), but there are also studies reporting no effect (43–45). Although it was not our initial 
research question, in Chapter 4 and Chapter 9 we also investigated the effect of the gut 
bacteria on the development of obesity. Interestingly, it was observed that suppression of the 
gut microbiota using antibiotics resulted in a lower final bodyweight than mice that were 
not treated with antibiotics. However, this effect was mainly accounted for by a reduction in 
food intake during the first two weeks of the dietary intervention, when the mice have to get 
used to the antibiotics. Subsequently, after these two weeks, the rate of bodyweight gain was 
not different between the mice that received or did not receive antibiotics, indicating that in 
our study the absence of bacteria does not protect against diet-induced obesity. With regard 
to glucose metabolism, many studies also suggest that gut microbiota influence glucose 
metabolism (40, 46, 47). For example, compared to conventionally-raised mice, germ-free 
mice were found to have an improved glucose tolerance, likely due to an improvement 
in insulin sensitivity (48). However, since many of these studies also report an effect on 
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bodyweight, it is unclear whether the effects on glucose metabolism are directly mediated 
by the gut microbiota, or indirectly via the difference in bodyweight. To circumvent effects 
of bodyweight on glucose metabolism, Carvalho et al. (49) and Membrez et al. (50) pair-fed 
mice and treated them with and without antibiotics. They found that suppression of the 
gut bacteria improved glucose tolerance. In Chapter 9, we also investigated the effect of gut 
bacteria on glucose tolerance. In our study we found that depletion of the gut bacteria using 
antibiotics reduced bodyweight gain, but surprisingly worsened glucose tolerance (Chapter 
9).
A reasonable explanation for the apparent discrepancies between the various studies is 
the variation in gut bacterial composition and function between different mouse strains 
(51) and between different animal facilities (21, 52). Although differences in genotype 
explain some bacterial variation, it turns out that diet has a dominant role in shaping the gut 
microbial composition (53, 54). Yet even within the same facility, the bacterial community 
of the same mouse strains consuming identical diets may differ over subsequent generations 
(55). It can be hypothesized that these differences in bacterial communities may translate 
into different experimental outcomes. Indeed, two mice strains with the same genetic 
background from two different breeders were shown to either protect or to promote obesity, 
depending on their gut microbial composition (56). Furthermore, even with a similar gut 
microbial composition, the function of the microbiota may be different. 
While animal studies point to a causal role for the gut microbiota in obesity-related 
metabolic disturbances, current causal evidence from human studies is limited. The 
advantage of animal studies is that multiple factors that may influence the gut microbiota 
can be controlled for. In humans, the bacterial community is influenced by a plethora of 
environmental factors. Indeed, recently 126 intrinsic and extrinsic factors were found to be 
associated with inter-individual variation of the gut microbiome (57). Interestingly, in four 
independent cross-sectional studies, an association between metabolic syndrome and the 
gut microbiota was found (2, 41, 58, 59). Strikingly, however, when these four studies were 
pooled and examined, no associations between BMI and bacterial composition could be 
observed. A possible explanation for the lack of an association may be the large difference 
in research design and methodology between the different studies, including the study 
populations, as well as the methodology used, including the DNA extraction method, the 16S 
region that is sequenced, and the sequencing platform used (60). In fact, it is estimated that 
to adequately assess a relationship between metabolic disease and the intestinal microbiota 
while correcting for confounding factors, a study should contain at least 1700 subjects (61). 
A powerful method to study the potential causal relationship between microbiota and 
metabolic health in humans is fecal microbiota transplantation. To date, only one human 
study has performed fecal microbial transplantations to assess the relationship between 
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microbiota and metabolic syndrome. It was found that infusion of gut microbiota from 
lean subjects into individuals with metabolic syndrome significantly improved peripheral 
insulin sensitivity (62). Careful examination of the individual responses indicates that some 
individuals benefit from the treatment while others do not (62). These so-called responders 
and non-responders have also been observed in probiotic interventions (63). Because it has 
been suggested that the success of colonization increases if the bacterial species already 
exists in the recipient (64), one possible explanation might be that the individuals who 
do not respond to the treatment do not harbour some of the infused bacterial species and 
therefore have limited colonization. However, it should be realized that without proper 
replication studies in the same individuals, the concept of responders and non-responders is 
methodologically questionable.  
To overcome the above mentioned limitations, it is critical that existing studies are 
repeated. This will help to determine whether the overall effects, such as induced by human 
fecal microbial transplantations, are consistent. As with the animals studies, repeating the 
human studies may help to identify bacterial species that are causally involved in or are 
beneficial to metabolic diseases. Subsequent targeted approaches involving modification of 
only one strain might give useful insight into the role of specific gut bacteria in obesity 
and related disturbances. Identification of these important bacterial strains might benefit 
from the quantification of the absolute abundance of bacterial species, instead of the relative 
abundance.
In addition to the bacteria, the gastrointestinal tract also harbours fungi, protozoa, viruses 
and archaea. In Chapter 4 we observed an outgrowth of fungi upon antibiotic treatment. 
Accordingly, the observation that antibiotic treatment protects against features of NAFLD 
might not only be related to the gut bacteria but also to changes in the mycobiome. Moreover, 
the intestinal mycobiome has been found to be different between lean and obese individuals, 
which implies that at least the fungi may also have a modulating role in metabolic health 
(65). Therefore, future studies should also focus on these less prevalent inhabitants of the 
gastrointestinal tract. 
Nevertheless, an important step in further elucidating the role of the gut microbiota in 
metabolic health would be to not solely look at the presence or absence of microbiota but also 
to determine their function. One approach would be to identify and isolate intestine-derived 
metabolites from portal blood of patients and rodents with various metabolic diseases 
and determine which metabolites have detrimental effects on host health, for example by 
adding these metabolites to in vitro cell culture systems and ex vivo models. Accordingly, 
targeted inhibition of the bacterial enzymes responsible for the production of these harmful 
metabolites might reveal novel targets for the treatment of metabolic diseases. 
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Liver slices as a model to study human liver
As mentioned in the previous sections, intestine-derived metabolites represent an important 
link between disturbances in the gut microbiota and NAFLD. Hence, the identification of 
these harmful metabolites might reveal novel therapeutic targets for NAFLD. To investigate 
if certain metabolites are harmful to the liver, an in vivo or ex vivo system that reflects the 
human liver is essential. In Chapter 6, we demonstrate the suitability and superiority of 
human liver slices over primary hepatocytes to study the human liver. By comparing whole 
genome expression profiles of human liver slices with the expression profiles of primary 
hepatocytes in response to activation of the nuclear receptor PPARα, we reveal that the 
induction of gene expression by PPARα is in general well captured by the two model system. 
One the contrary, downregulation of gene expression was almost exclusively observed in 
human PCLS, which was largely connected to cells of the immune system. These cells are 
present in PCLS, but absent in primary human hepatocytes (Chapter 6). Because the multi-
cellular and structural organization is very well reflected in liver slices, this ex vivo model 
may provide a suitable ex vivo model for the screening of harmful and beneficial intestine-
derived metabolites, but also to test pharmacological agents in liver diseases. 
One disadvantage of liver slices, however, is that hepatic functionality declines quite 
rapidly once they are taken into culture. Hence, liver slices can be cultured for only a 
maximum of five days (66), which precludes the use of liver slices for long-term functional 
and toxicological studies. Alternatively, a novel technique that is increasingly used over 
the past few years are hepatic 3D spheroids, in which primary human hepatocytes are 
cultured as 3D microtissues (67). Based on whole proteome analysis, these primary human 
hepatocyte spheroids were shown to more closely resemble the donors’ in vivo liver than 
primary human hepatocytes spheroids obtained from another donor, indicating that inter-
individual variability is maintained (68). Importantly, as compared to liver slices, primary 
human hepatocytes spheroids have been shown to remain functional and viable for at least 
five weeks in culture (68, 69). Accordingly, co-culturing these primary human hepatocyte 
spheroids with non-parenchymal cells, including Kupffer cells, stellate cells and biliary cells 
allows for the study of complex diseases such as hepatic steatosis (68). However, the limited 
availability of primary human hepatocytes and non-parenchymal cells remains a problem. 
Therefore, current approaches attempt to generate hepatocytes from induced pluripotent 
stem cells (iPSC) (70, 71). The advantage of iPSC over primary human hepatocytes is that 
iPSC can be obtained from nearly any somatic cell including renal tubular cells from urine 
(72), keratinocytes (73) and hair follicle cell (74), all sources that are easily accessible and 
available. However, currently the differentiation of iPSC into hepatocytes is not optimal as 
the generated hepatocytes more closely resemble fetal-like hepatocytes than mature adult 
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hepatocytes (75, 76) and also have features of colon and fibroblast lineages (76). Despite 
current advances made in the development of 3D liver model systems, co-culturing 
hepatocytes with non-parenchymal cells in 3D spheroids probably does not very well 
resemble the architecture and ratio of hepatocytes to non-parenchymal cells of human liver 
in vivo. It is expected that the architecture and cell ratio will be better captured in liver slices. 
Accordingly, also disease states such as NAFLD are probably better reflected in liver slices 
obtained from patients with NAFLD than co-cultured primary cells obtained from NAFLD 
patients in 3D spheroids. Overall, human liver slices provide the closest representation of the 
in vivo human liver with all relevant cell types in the appropriate structural organization. 
PPARα and FXR as therapeutic targets for NAFLD
Approximately 25% of the patients with NAFLD have non-alcoholic steatohepatitis, of 
which approximately 20% will progress to cirrhosis (77). Weight loss and exercise are the 
most effective treatments for NAFLD. A large prospective study with biopsy-proven NASH 
showed that already a bodyweight loss of more than 5% significantly improved NAFLD 
activity score, whereas of the patients who lost more than 10% of their bodyweight 90% had 
NASH resolution and 45% had regression of fibrosis (78). However, lifestyle modifications 
are often very challenging and maintaining weight loss is difficult, which increases the need 
for pharmacological interventions. Although there are currently no approved drugs for 
NAFLD, several therapeutic targets, including PPARα and FXR appear to be very promising. 
In Chapter 6, we treated precision cut liver slices with the PPARα agonist Wy14643 to 
gain insight into the molecular function of PPARα in human liver. We provide evidence that 
the response of the liver to activation of the nuclear receptor PPARα is highly dependent on 
the interaction between hepatocytes and non-parenchymal cells. Since PPARα is very weakly 
expressed in non-parenchymal cells (79, 80), and activation of PPARα hepatocytes reduces 
the expression of immune-related genes in liver slices but not in primary hepatocytes, 
we hypothesized that the interaction between hepatocytes and non-parenchymal cells 
is essential for regulation of the immune response (Chapter 6). It remains, however, 
questionable how PPARα activation in hepatocytes regulates gene expression in non-
parenchymal cells. As PPARα is a potent inducer of fatty acid oxidation (81, 82) and multiple 
genes involved in lipid metabolism were upregulated upon PPARα activation (Chapter 6), 
one possible scenario is that PPARα-induced fatty acid oxidation in hepatocytes reduced 
lipotoxicity which, together with induction of the unfolded protein response, reduces ER 
stress and consequently suppresses the immune response in non-parenchymal cells (83). 
Indeed, deletion of PPARα in mice was shown to induce hepatic ER stress and promote fat 
storage in the liver upon high-fat feeding (84–86). Conversely, PPARα activation in wild-
type mice prevented ER stress and reduced hepatic steatosis and inflammation (86, 87). 
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Irrespective of the underlying mechanism, the marked immunosuppressive effect of PPARα 
in human liver indicates that PPARα may be a therapeutic target for NAFLD. To date, 
several clinical pilot studies have been conducted to assess the impact of PPARα activation 
on NAFLD. Unfortunately, the activation of PPARα using fibrates showed only mild effects 
on hepatic steatosis, inflammation and fibrosis (88, 89), which may likely be explained by 
reduced expression of PPARα upon the progression of NAFLD in humans (90). Therefore 
current efforts attempt to develop novel synthetic PPARα agonists with greater potency 
(91). In spite of solely activating PPARα, activation of multiple PPAR isotypes may also be 
promising in the treatment of NAFLD. For example, the dual PPARα/δ agonist GFT505 
(Elafibranor), which is currently in phase II clinical trials, has been demonstrated to inhibit 
hepatic steatosis, inflammation and fibrosis in animal models and to lower dyslipidemia, 
liver function tests, and hepatic and peripheral insulin sensitivity in human subjects (92, 93). 
In addition to PPAR agonists, activation of FXR also holds promise as novel therapeutic 
target for NAFLD. One FXR ligand that is especially promising is obeticholic acid (OCA). 
OCA is a semisynthetic derivative of the primary bile acid chenodeoxycholic acid (CDCA) 
that is 100-fold more potent in activating FXR than CDCA, the most potent natural FXR 
agonist (94). In animals models of diabetes and NAFLD, activation of FXR by OCA was 
shown to reverse insulin resistance and to improve liver dysfunction markers, hepatic 
steatosis and inflammation (95–98). In 2013, Mudaliar et al. performed the first proof of 
concept study in patients with NAFLD and type 2 diabetes and showed that OCA treatment 
improved insulin sensitivity and reduced markers of liver inflammation and fibrosis (99). 
More recently in the FLINT trial, administration of OCA to patients with NASH improved all 
histological features of NASH, including hepatic fibrosis, whereas improvement in NAFLD 
activity score occurred in only 21% of the patients treated with placebo, with no effect on 
fibrosis (100). OCA is currently being tested in phase III clinical trials, which hopefully 
will provide more evidence on the efficacy of OCA (NCT02548351, clinicaltrials.gov). In 
Chapter 7, we have for the first time investigated the effect of OCA on whole genome gene 
expression in human liver. It was found that human liver slices do maintain their ability to 
respond to FXR activation. More recently, OCA was shown to induce FXR-target genes in an 
in vitro model system of the human liver as well, but also activated anti-inflammatory and 
anti-fibrotic pathways (101). Although all these results are very promising, OCA treatment 
was also found to cause a striking increase in LDL cholesterol levels and a decrease in 
HDL cholesterol in both healthy subjects and patients with NASH (100, 102). It has been 
hypothesized that the increase in LDL cholesterol is related to downregulation of the LDL 
receptor and that the lower HDL cholesterol levels are mediated by the upregulation of 
the HDL scavenger receptor SR-B1 or a decrease in ApoA1 (102). However, in our study 
no difference in the expression of SR-B1 or APOA1 was found upon OCA treatment, while 
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expression of LDLR was induced (Chapter 7). Conversely, it may be possible that the lower 
LDLR mRNA levels are related to the elevated HDL cholesterol levels, as mice lacking Ldlr 
have elevated HDL levels (103). Irrespective of the underlying mechanism by which OCA 
influences plasma lipoprotein levels, long term studies are needed to investigate whether 
this dyslipidemia results in an increased cardiovascular disease risk, but also whether OCA 
treatment can reverse NASH-related cirrhosis. 
Angptl4 and metabolic health
Angptl4 as regulator of bile acid metabolism
Disturbed lipid metabolism is an important risk factor for several metabolic diseases, 
including NAFLD and cardiovascular diseases (104). Hence, lipid metabolism is tightly 
regulated by a number of proteins, including ANGPTL4 (105, 106). ANGPTL4 regulates 
plasma triglyceride levels by inhibiting the activity of the enzyme lipoprotein lipase (107–
111). Interestingly, bile acids and bile acid resins also have been shown to influence plasma 
triglyceride levels (112–116). Because we have observed that bile acids lower ANGPTL4 
secretion by intestinal cells, in Chapter 8, we propose that the triglyceride-lowering effect 
of bile acids may be mediated by ANGPTL4. Although we found that ANGPTL4 is not 
required for the plasma triglyceride lowering action of bile acids, we unexpectedly observed 
that ANGPTL4 promotes bile acid uptake during taurocholic acid feeding concomitant with 
changes in the gut microbial composition (Chapter 8). In fact, we found that suppression of 
the gut microbiota using antibiotics abolished the difference in bile acid absorption between 
wild-type and Angptl4-/- mice, indicating that ANGPTL4 reduces bile acid absorption via a 
mechanism that is dependent on the gut microbiota (Chapter 8). 
Although it can be hypothesized that changes in the gut microbial composition caused 
by loss of ANGPTL4 directly impacts bile acid metabolism, it cannot be excluded that 
ANGPTL4 directly influences bile acid absorption via a mechanism that is dependent on the 
gut microbiota. Similarly, it is currently also unknown whether Angptl4 locally produced in 
the intestine is responsible for the altered bile acid metabolism or whether the effect on bile 
acid uptake is related to ANGPTL4 produced elsewhere. Indeed, it has been suggested that 
intestinal- and liver-derived ANGPTL4 may have an endocrine function (40, 111, 117, 118). 
Downregulation of intestinal Angptl4 expression by the gut microbiota has been proposed 
to promote peripheral fat storage by increasing adipose tissue lipoprotein lipase activity (40, 
117). However, although we and others have observed that gut bacteria decreased intestinal 
Angptl4 expression, this finding did not translate into an increased fat mass (43) (Chapter 
9). Currently it is still unclear to what extent ANGPTL4 has an endocrine function, which 
is also hampered by the absence of proper functioning antibodies for murine ANGPTL4. 
Nonetheless, there is growing evidence that ANGPTL4 acts more locally than systemically 
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(119). In fact, it has been suggested that intestinal ANGPTL4 primarily targets pancreatic 
lipase to reduce fat absorption (120). Whether intestinal ANGPTL4 also locally targets the 
bile acid transporter SLC10A2 (ASBT) would merit further investigation using intestinal-
specific Angptl4-/- mice. 
Additionally, it would be interesting to investigate whether ANGPTL4 also regulates bile 
acid absorption under other physiological conditions or during feeding of other primary 
bile acids. The majority of the difference in bile acid absorption between wild-type and 
Angptl4-/- mice could be related to differences in the classical bile acid synthesis pathway, as 
the bile acids cholic acid and deoxycholic acid, and the expression of the bile acid synthesis 
enzymes Cyp7a1 and Cyp8b1, were specifically altered between wild-type and Angptl4-/- mice 
upon taurocholic acid feeding (Chapter 8). Accordingly, to gain further insight into the 
regulation of bile acid absorption by ANGPTL4 it would be interesting to know if feeding 
wild-type and Angptl4-/- mice a bile acid synthesized by the alternative pathway, such as 
chenodeoxycholic acid, also leads to differences in bile acid absorption. 
An intriguing question concerns the differences in bile acid levels in the presence and 
absence of the gut microbiota. In Chapter 4 and Chapter 8 we observed that antibiotic 
treatment reduced total level of plasma bile acids upon high fat feeding and during 
taurocholic acid supplementation, respectively. As expected, this decrease was mainly 
related to a decrease in deconjugated primary bile acids and secondary bile acids, as a 
consequence of the absence of intestinal microbes to metabolize primary bile acids. By 
contrast, there are also studies reporting an increase in plasma bile acids upon antibiotic 
treatment (121, 122). These differences may be explained by the different types of antibiotics 
used, which in turn differentially impact gut microbiota and bile acid metabolism, resulting 
in altered expression of the ileal bile acid transporter Slc10a2 (Asbt) or hepatic bile acid 
transporter Slc10a1 (Ntcp) (121–123). To gain further insight into underlying mechanism, 
it will be important to elucidate how the intestinal microbes affect ileal and hepatic bile 
acids transporters, as also differences in microbial composition in mice not treated with 
antibiotics could be responsible for the apparent differences in plasma bile acid levels. 
Angptl4 as regulator of glucose metabolism
In Chapter 9 we investigated the influence of ANGPTL4 on diet-induced obesity and 
metabolic dysfunction and reveal another novel function of ANGPTL4 in regulating glucose 
metabolism. Although we convincingly demonstrated that ANPGTL4 improved glucose 
metabolism by elevating plasma insulin levels via a mechanism that is partly dependent on 
the gut microbiota, our data did not shed light on the mechanism by which alterations in the 
gut microbiota composition elevated plasma insulin levels. Although glucose is the primary 
stimuli for pancreatic β-cells to secrete insulin (124), there are various factors that can 
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influence insulin secretion, including amino acids (125), fatty acids (126), gastrointestinal 
hormones (127), but also microbial-derived factors such as LPS (128, 129), short chain fatty 
acids (130, 131) and bile acids (132, 133). In Chapter 9, we propose that short chain fatty acids 
and LPS are probably not involved in conferring the effect of the gut microbiota on insulin 
levels in Angptl4-/- mice. As bile acids are influenced by ANGPTL4 (Chapter 8), but also 
by the intestinal microbes (Chapter 4), it might be possible that bile acids link changes in 
gut microbiota to the elevated insulin secretion. In addition, many other bacterial-derived 
metabolites that were not quantified in our study or that are still unknown could play a role 
in mediating the effect of the gut microbiota on glucose metabolism. To study how changes 
in the gut microbiota composition and/or function may relate to an improved insulin 
secretion, it would be worthwhile to assess the functional profile of the intestinal microbes 
in wild-type and Angptl4-/- mice. This can be achieved by predicting the bacterial function 
from 16s rRNA gene sequences using PICRUSt or by performing bacterial transcriptomics 
using RNA-seq. Combining one of these approaches with portal blood metabolomics of 
wild-type and Angptl4-/- mice may reveal novel metabolites that are potentially involved in 
insulin secretion. 
Angptl4 as modulator of gut microbial composition
An interesting question based on the data in Chapter 8 and Chapter 9 concerns the 
mechanism by which ANGPTL4 modifies the gut bacterial composition. One possibility is 
that the difference in host genotype shapes the gut microbial composition (134). Indeed, in 
our studies we found that mice lacking Angptl4 had a lower relative abundance of the genus 
Allobaculum than wild-type mice, irrespective of whether the mice were fed a high fat diet, 
chow, or chow supplemented with taurocholic acid (Chapter 8 and Chapter 9). However, 
the majority of the bacterial taxa that were different between wild-type and Angptl4-/- mice 
was not consistently changed in the two studies (Chapter 8 and Chapter 9), indicating that 
the effect of loss of ANGPTL4 on the gut microbiota is dependent on the diet. Given the 
established role of ANGPTL4 in intestinal lipid digestion (120) and the observation that 
elevated levels of lipids can markedly influence gut microbial composition (135, 136), it 
can be hypothesized that the origin of the difference in gut microbial composition between 
wild-type and Angptl4-/- mice may be during suckling when the pups receive high amounts 
of lipid-containing milk. Alternatively, since we showed that ANGPTL4 impacts bile acid 
metabolism (Chapter 8), the difference in fecal bile acids may also have impacted the gut 
microbiota composition. Indeed, recently Watanabe et al. demonstrated that each free bile 
acid has a different bactericidal activity (137), indicating that different fecal bile acid levels 
result in a different bacterial composition. Alternatively, bile acids may also impact the gut 
microbiota indirectly through the intestinal immune system via the induction of ileal FXR-
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mediated antimicrobial genes (138). Although we did not quantify fecal bile acid levels 
in Chapter 9, high fat diets are known to elevate bile secretion. It is thus possible that 
ANGPTL4 also regulates bile acid metabolism during high fat feeding and subsequently 
alters gut bacterial composition. Interestingly, not only bile acids, but also ANGPTL4 may 
influence microbial composition via differences in intestinal immunity. Recently, it was 
shown that Angptl4-/- mice have increased leukocyte infiltration and inflammation in the 
colon upon DSS treatment, concurrent with differences in gut microbial composition (139). 
Future studies should clarify how ANGPTL4 influences the gut microbiota composition, for 
example by using intestine-specific Angptl4-/- mice.
Gut microbiota, bile acids and Angptl4: a complex interplay
In this thesis, we have investigated the role of various mediators of metabolic health, 
including the gut microbiota, bile acids and ANGPTL4. We demonstrated that the gut 
microbiota likely plays an important role in the pathogenesis of NAFLD. Modulation of 
the gut microbiota was found to worsen features of NAFLD, whereas suppression of the 
gut bacteria protected against NAFLD, which was likely mediated via changes in the portal 
delivery of bile acids. Accordingly, we investigated whether it would be possible to treat 
Metabolic health
including 
lipid & glucose metabolism
Intestinal 
microbiota
Bile acids ANGPTL4
Figure 2. Model of the interaction between the intestinal microbiota, bile acids and ANGPTL4 and 
their influence on metabolic health
An intricate relationship exists between the intestinal microbiota, bile acids and ANGPTL4. Data presented 
in this thesis demonstrated that the intestinal microbiota influence bile acid metabolism but also vice versa 
as bile acids were also shown to alter the intestinal microbiota composition. In addition, we showed that 
the gut microbiota and bile acids alter intestinal Angptl4 expression, but also that ANGPTL4 influences bile 
acid metabolism and intestinal microbial composition. Furthermore, previous studies and data presented 
in this manuscript have shown that all these three factors also influence metabolic health, including lipid 
and glucose metabolism and vice versa. 
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NAFLD by administrating specific bacteria to obese mice with NAFLD. It was found that, 
in our experimental setup, the bacteria A. muciniphila and B. thetaiotaomicron did not affect 
features of non-alcoholic fatty liver disease. Subsequently, we demonstrate the suitability of 
precision-cut liver slices to study the human liver. These studies highlight the possibility 
to study the response of the human liver to various gut-derived metabolites. Furthermore, 
we show that the triglyceride-lowering effects of bile acids is not mediated by ANGPTL4. 
Finally, we uncover two novel functions of ANGPTL4 in mediating bile acids absorption 
and glucose metabolism. Taken together, our studies have clarified and strengthened the 
role of the intestinal microbiota, bile acids and ANGPTL4 in metabolic health. 
Moreover, we provide evidence for an intricate relationship between the intestinal 
microbiota, bile acids and ANGPTL4 (Figure 2). While intestinal Angptl4 expression was 
found to be influenced by bile acids and the gut microbiota, we showed that ANPGTL4 also 
influences bile acid metabolism and the intestinal microbial composition (Chapter 8 and 
Chapter 9). In addition, we showed that the gut microbiota influence bile acid metabolism 
(Chapter 4 and Chapter 8), while vice versa bile acids are able to alter the gut microbial 
composition (Chapter 8). Although our studies have expanded our knowledge of the role 
of these mediators in metabolic diseases, there are still questions that need to be addressed. 
Since the intestinal microbiota, bile acids and ANGPTL4 are all interconnected and all have 
a role in lipid and glucose metabolism, it is important to realize that modulation of one of 
the three mediators likely also affects the other two mediators, including their metabolic 
responses (Figure 2). 
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The global prevalence of obesity has increased substantially over the past decades. As 
a consequence, there has been a rise in obesity-related comorbidities, such as diabetes 
mellitus, non-alcoholic fatty liver disease (NAFLD), and dyslipidemia, each of which serves 
as an independent risk factor for cardiovascular diseases. While the increase in obesity 
rates and related metabolic diseases are believed to be primarily the result of an increased 
consumption of calorie-dense foods in combination with reduced levels of physical activity, 
various factors have been suggested to influence the progression of these metabolic diseases, 
including the gut microbiota, bile acids and angiopoietin-like protein 4 (ANGPTL4). 
The gut microbiota live in a close relationship with the host and have an essential 
role in several aspects of host physiology, such as conferring protection against invading 
pathogens and facilitating the digestion of complex carbohydrates. The composition of 
the gut microbiota varies greatly between individuals, which is caused by differences 
in host genome and environmental factors, and may also be affected by specific disease 
states. Emerging evidence suggests that changes in intestinal microbiota are not merely a 
consequence of metabolic health, but may in fact contribute to certain diseases. To link 
changes in gut microbiota to metabolic health, several mechanisms have been proposed, 
including lipopolysaccharides, short-chain fatty acids, bile acids and ANGPTL4, which 
are extensively described in Chapter 2 and Chapter 3. Bile acids are primarily known for 
their role in lipid absorption. By emulsifying triglycerides and stimulating pancreatic lipase 
activity, bile acids facilitate the digestion of dietary lipids and promote their absorption, 
although it is becoming increasingly apparent that bile acids also have major regulatory 
roles in the control of lipid, glucose and energy metabolism. Another important mediator of 
metabolic health is ANGPTL4. ANGPTL4 is a potent inhibitor of lipoprotein lipase (LPL), 
and is active under various physiological conditions, including fasting, exercise and cold 
exposure, thereby ensuring the proper distribution of plasma triglycerides over different 
tissues. In addition to inhibiting LPL, ANGPTL4 is also able to inhibit intestinal pancreatic 
lipase, thereby limiting dietary lipid absorption. Next to its role in lipid metabolism, 
ANGPTL4 has also been suggested to influence glucose metabolism. Although it is well-
established that the gut microbiota, bile acids and ANGPTL4 influence metabolic health, 
the exact mechanisms are far from being completely understood. Therefore, the main of this 
thesis is to increase our understanding regarding the role of these mediators in metabolic 
health.
The first part of this thesis focuses on the role of the gut microbiota in NAFLD. NAFLD 
describes a spectrum of liver diseases ranging from simple steatosis to non-alcoholic 
steatohepatitis, liver fibrosis and cirrhosis. In Chapter 4 we studied the influence of 
modulation of the gut microbiota in the development of NAFLD. To that end, in a mouse 
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model of NAFLD, we stimulated the gut bacteria by feeding mice the highly fermentable 
fiber guar gum (GG) and suppressed the gut bacteria via oral administration of antibiotics. 
We found that stimulation of the gut microbiota using GG enhanced hepatic inflammation 
and fibrosis, concurrent with elevated plasma and hepatic bile acid levels. In contrast, 
suppression of the gut bacteria using antibiotics decreased portal secondary bile acid levels 
and attenuated hepatic inflammation and fibrosis. Together, these data suggest a causal link 
between disturbances in gut microbial community and NAFLD. To investigate if bile acids 
are causally involved in the progression of NAFLD upon GG feeding, we fed mice chow 
supplemented with the primary bile acid taurocholic acid. Provision of taurocholic acid raised 
plasma bile acid levels and stimulated hepatic inflammation and fibrosis. Taken together, our 
data indicate that the gut microbiota have a marked impact on NAFLD, possibly via changes 
in the portal delivery of bile acids. Accordingly, in Chapter 5, we hypothesized that targeting 
the gut microbiota may provide therapeutic tools to treat NAFLD. As impairments of the 
intestinal barrier are also suggested to mediate the effect of the gut microbiota on NAFLD, 
we administrated Akkermansia muciniphila and Bacteroides thetaiotaomicron to obese mice 
with NAFLD, which have both been suggested to improve the intestinal barrier. It was found 
that daily administration of A. muciniphila or B. thetaiotaomicron for 5 weeks to obese mice 
with NAFLD did not influence hepatic steatosis, inflammation or fibrosis. Importantly, we 
also found no difference in intestinal permeability as well as portal lipopolysaccharide levels. 
In conclusion, although we demonstrate that the gut microbiota have a marked impact on 
NAFLD, in our experimental setup, administration of A. muciniphila or B. thetaiotaomicron 
to obese mice with NAFLD did not improve features of NAFLD. 
The liver receives about 70% of its blood supply from the intestine via the portal vein and is 
therefore the first organ that may be exposed to potentially harmful metabolites released by 
the intestinal microbiota. Identification of these harmful metabolites are very important as 
it might reveal novel therapeutic targets for NAFLD. To investigate if certain metabolites are 
harmful to the liver, it is important to utilize in vivo or ex vivo systems that reflect the human 
liver. In the second part of this thesis, we investigated whether precision-cut liver slices 
(PCLS) may be a suitable ex vivo model to study the human liver. Accordingly, in Chapter 
6, we used whole genome gene expression profiling to compare the effect of activation of 
the nuclear receptor PPARα between human PCLS and primary human hepatocytes. We 
show that the induction of gene expression by PPARα is in general well captured by both 
the human primary hepatocytes and human PCLS, as activation of PPARα consistently 
upregulates genes involved in lipid and xenobiotic metabolism in both models. By contrast, 
downregulation of gene expression by PPARα activation was almost exclusively observed 
in human PCLS, which was largely connected to cells of the immune system, which are 
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present in PCLS but absent in the primary hepatocytes. Taken together, we show that human 
PCLS are a suitable and superior model over primary hepatocytes to study PPARα activation 
in human liver. Subsequently, in Chapter 7, we show, for the first time, the response of 
the human liver to FXR activation by obeticholic acid (OCA), a promising drug for the 
treatment of non-alcoholic steatohepatitis that is now in phase 3 clinical trials. It was found 
that human PCLS are highly and consistently responsive to FXR activation. In addition, by 
comparing the response of human PCLS to wild-type and FXR-/- mice receiving obeticholic 
acid, we were also able to identify putative novel FXR target genes. Taken together, these 
results indicate that human PCLS are a suitable model to study human liver and represent 
a very useful tool for testing the response of human liver to intestinal-derived metabolites. 
In the third part of this thesis, we focused on the metabolic effects of ANGPTL4. ANGPTL4 
raises plasma triglyceride levels by inhibiting the enzyme lipoprotein lipase. Interestingly, 
bile acids and bile acids resins also have been shown to influence plasma triglyceride levels. 
Because we previously observed that bile acids lower ANGPTL4 secretion by intestinal 
cells, in Chapter 8, we hypothesized that the triglyceride-lowering effect of bile acids is 
mediated by ANGPTL4. To test this hypothesis, wild-type and Angptl4-/- mice were fed chow 
supplemented with the primary bile acid taurocholic acid. It was found that the triglyceride-
lowering effect of bile acids was not mediated by ANGPTL4, but may be mediated by 
downregulation of the LPL inhibitors ANGPTL3 and APOC3. Intriguingly, plasma and 
hepatic BA concentrations were significantly lower in TCA-supplemented Angptl4-/- mice 
than in TCA-supplemented wild-type mice, suggesting that loss of ANGPTL4 impairs 
intestinal bile acid absorption. Since the gut microbiota converts primary bile acids into 
secondary bile acids, we hypothesized that the elevated excretion of primary bile acids and 
decreased bile acid absorption in Angptl4-/- mice may be dependent on the gut microbiota. 
Indeed, suppression of the gut bacteria using antibiotics abolished the differences in bile 
acid absorption. In conclusion, our data indicate that ANGPTL4 is not involved in the 
triglyceride-lowering effect of bile acids but promotes bile acid absorption during taurocholic 
acid supplementation via a mechanism dependent on the gut microbiota. 
The observation that Angptl4-/- mice develop a massive acute phase response, lethal 
chylous ascites and peritonitis when fed a high fat diet rich in saturated fat, has hampered 
the study of ANGPTL4 in diet-induced obesity and related metabolic dysfunction. To 
overcome that obstacle, in Chapter 9, we investigated the influence of ANGPTL4 on diet-
induced obesity and metabolic dysfunction by feeding wild-type and Angptl4-/- mice a high 
fat diet rich in unsaturated fat, combined with fructose and cholesterol. It was found that 
Angptl4-/- mice displayed increased bodyweight gain, adipose tissue mass and adipose tissue 
inflammation, but unexpectedly had markedly improved glucose tolerance, which was 
Summary 
293
accompanied by elevated plasma insulin levels. Inasmuch as the gut microbiota has been 
suggested to influence insulin secretion and as ANGPTL4 has been proposed to link the gut 
microbiota to host metabolism, we hypothesized a potential role for the gut bacteria. Indeed, 
the gut bacterial composition was profoundly different between wild-type and Angptl4-/- 
mice. Furthermore, suppression of the gut bacteria using antibiotics largely abolished the 
differences in glucose tolerance and insulin levels between wild-type and Angptl4-/- mice. 
Taken together, loss of ANGPTL4 improves glucose tolerance at least partly via changes in 
the gut microbiota. Nevertheless, future studies are warranted to investigate how ANGPTL4 
alters the gut bacterial composition and how this may influence insulin levels and glucose 
tolerance. 
In summary, the studies presented in this thesis have clarified and strengthened our 
understanding regarding the role of the gut microbiota, bile acids and ANGPTL4 in 
metabolic health. We showed that the gut microbiota have an important role in the 
pathogenesis of NAFLD, which is likely mediated via changes in portal delivery of bile 
acids. Subsequently, we demonstrated that human PCLS provide a suitable model to study 
the human liver and provide a pivotal tool for testing the effect of intestinal metabolites 
on human liver. Finally, we show that the triglyceride-lowering effects of bile acids is not 
mediated by ANGPTL4 and reveal two novel functions of ANGPTL4 in mediating bile acids 
absorption and glucose metabolism. Although our studies extended our knowledge of the 
role of these mediators in metabolic diseases, several questions remain. Since the intestinal 
microbiota, bile acids and ANGPTL4 are all interconnected and are all involved in lipid 
and glucose metabolism, it is important to realize that modulation of one of these three 
mediators likely also affects the other two mediators, including their metabolic responses, 
reflecting a strong interdependence.
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Zo, en dan (ineens) schrijf ik de eerste woorden van mijn dankwoord op papier. Hiermee 
komt de afsluiting van een belangrijke periode in mijn leven toch opeens heel dichtbij. 
Ik kan terugkijken op vier zeer plezierige jaren waarin ik enorm veel heb geleerd met als 
resultaat mijn naam pronkend op de voorkant van dit proefschrift. Echter, zonder hulp van 
velen zou dit boekje er niet zijn. Daarom wil ik graag alle mensen bedanken die, elk op hun 
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taalkundig perfectionisme. Enorm bedankt voor al je hulp en vertrouwen. Ik had me geen 
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I also thank the committee, Jerry Wells, Erwin Zoetendal, Max Nieuwdorp and Hans 
Jonker for the critical review and judgement of my thesis. 
Lily, al vanaf dag één zijn we kamergenootjes en hebben we alle ups en downs van het leven 
als PhD student met elkaar gedeeld. Zonder jou zou dit promotietraject een stuk minder 
gezellig zijn geweest. Ik bewonder je creativiteit, je doorzettingsvermogen en je brede 
interesse. Heel erg bedankt voor je gezelligheid, je deskundig advies, je luisterend oor en je 
(sarcastische) humor de afgelopen vier jaar. Met jou is het nooit saai :-). Ik wens je heel veel 
succes met het afronden van je PhD. Ik zal je missen!
Wieneke, het was wel even wennen toen je ons had verlaten voor het zonnige Frankrijk. 
Door je enorm goede geheugen en kennis kon ik altijd bij je terecht voor hulp of advies, maar 
ook gewoon voor een gezellig praatje. Gelukkig hebben we dit na je vertrek in stand kunnen 
houden door regelmatig met elkaar te bellen. Ik wil je bedanken voor al je hulp tijdens mijn 
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nodig, kwam jij mij helpen. Bedankt daarvoor. Ik wens je heel veel succes met je toekomstige 
onderzoek!
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bedankt voor je deskundig commentaar op mijn manuscripten. 
Naast mijn tijd op het lab heb ik ook flink wat tijd doorgebracht in het CKP. Rene, Bert 
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alle NMR-metingen en het identificeren van onbekende pieken. Steven en Clara, het was erg 
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het niet gelukt :-). Lydia, je enthousiasme werkt erg aanstekelijk. Bedankt voor je interesse en 
gezellige gesprekken. Mark, bedankt voor al je hulp bij de array analyses. Jocelijn, Klaske, 
Marco en Michiel, bedankt voor jullie interesse in mijn onderzoek! Shohreh, despite your 
busy schedule you were always willing to help me. Thank you for all the help with histology 
and mouse experiments, it is much appreciated. Jenny, Mechteld, Mieke, Carolien en Karin, 
jullie werk is onmisbaar op het lab. Bedankt voor de gezelligheid, de leuke gesprekken en 
het plaatsen van mijn (soms last minute) bestellingen! Merel, bedankt voor je vrolijkheid, 
betrokkenheid en grappige Belgische uitspraken :-). Je bent ook al weer over de helft van je 
promotietraject en ik weet zeker dat je het geweldig gaat afronden. Sophie, heel veel succes 
met de laatste loodjes, er gaat ongetwijfeld een mooi eindresultaat uitkomen! Frits, ik ben 
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met je verdere carrière. Inge, Katja en Juri bedankt voor alle gezellige praatjes in het lab of 
zomaar even op de gang. Roland and Neeraj, you’re almost there. I wish you all the best! 
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etentjes, dat er nog velen mogen volgen :-). Michaela en Nalia, hoewel ik jullie 4 jaar geleden 
als collega bij Burgers’ Zoo moest verlaten, is onze vriendschap gelukkig niet verloren gegaan. 
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